

EXHIBIT 1

ASSET AND EQUITY PURCHASE AGREEMENT

by and among

CYTORI THERAPEUTICS, INC.

CYTORI THERAPEUTICS, K.K. (with respect to SECTION 6.06 only)

and

LOREM VASCULAR PTE. LTD

Dated as of March 29, 2019

TABLE OF CONTENTS

	Page
ARTICLE I DEFINITIONS	1
SECTION 1.01 Certain Defined Terms.....	1
SECTION 1.02 Interpretation and Rules of Construction	11
ARTICLE II PURCHASE AND SALE	12
SECTION 2.01 Purchase and Sale of the Equity Interests	12
SECTION 2.02 Purchase and Sale of Purchased Assets	13
SECTION 2.03 Assumption and Exclusion of Liabilities	15
SECTION 2.04 Closing	16
SECTION 2.05 Closing Deliveries by Seller	16
SECTION 2.06 Closing Deliveries by Buyer	18
SECTION 2.07 Tax Withholding	18
ARTICLE III REPRESENTATIONS AND WARRANTIES OF SELLER.....	18
SECTION 3.01 Organization, Authority and Qualification of Seller.....	18
SECTION 3.02 No Conflict.....	19
SECTION 3.03 Ownership of the Equity Interests.....	20
SECTION 3.04 Governmental Consents and Approvals.....	20
SECTION 3.05 Financial Information.....	20
SECTION 3.06 Books and Records; Controls.....	20
SECTION 3.07 Absence of Undisclosed Material Liabilities	20
SECTION 3.08 Conduct in the Ordinary Course	21
SECTION 3.09 Litigation.....	22
SECTION 3.10 Compliance with Laws.....	22
SECTION 3.11 Intellectual Property	24
SECTION 3.12 Insurance	27
SECTION 3.13 Real Property.....	27
SECTION 3.14 Purchased Assets.....	28
SECTION 3.15 Sufficiency of Assets	28
SECTION 3.16 Condition of Assets	28
SECTION 3.17 Inventories.....	28
SECTION 3.18 Employees and Employee Benefit Matters	29
SECTION 3.19 Environmental Matters.....	32
SECTION 3.20 Taxes	32
SECTION 3.21 Material Contracts.....	35
SECTION 3.22 Products.....	35
SECTION 3.23 Relationships with Suppliers, Customers and Distributors.....	36
SECTION 3.24 Relationships with Affiliates.....	36
SECTION 3.25 Brokers	37
SECTION 3.26 Capitalization	37

ARTICLE IV REPRESENTATIONS AND WARRANTIES OF BUYER.....38

SECTION 4.01 Organization and Authority of Buyer	38
SECTION 4.02 No Conflict.....	38
SECTION 4.03 Governmental Consents and Approvals.....	39
SECTION 4.04 Litigation.....	39
SECTION 4.05 Brokers	39
SECTION 4.06 Financial Capacity; Solvency.....	39

ARTICLE V ACTIONS PRIOR TO THE CLOSING DATE.....39

SECTION 5.01 Third-Party Consents	39
SECTION 5.02 Conduct of Business Prior to the Closing	39
SECTION 5.03 Best Efforts	40
SECTION 5.04 Confidentiality	40
SECTION 5.05 Notification of Certain Events	40
SECTION 5.06 Exclusivity	40
SECTION 5.07 Access to Information	40
SECTION 5.08 Crossed Books and Records and Software	41
SECTION 5.09 Termination of Affiliate Contracts.....	41

ARTICLE VI ADDITIONAL AGREEMENTS41

SECTION 6.01 Confidentiality	41
SECTION 6.02 Business Relationships.....	41
SECTION 6.03 Crossed Payments	42
SECTION 6.04 Further Assurances.....	42
SECTION 6.05 Bulk Transfer Laws.....	42
SECTION 6.06 Non-Competition	42
SECTION 6.07 Cooperation.....	44
SECTION 6.08 Termination of Current License Agreement	44
SECTION 6.09 Employees and Employee Benefits.....	44
SECTION 6.10 Third Party Consents.....	45
SECTION 6.11 Intercompany Indebtedness.....	45

ARTICLE VII TAX MATTERS46

SECTION 7.01 Conveyance Taxes	46
SECTION 7.02 Tax Allocation.....	46
SECTION 7.03 Tax Cooperation.....	46
SECTION 7.04 Tax Returns	46
SECTION 7.05 Purchase Price Allocation	47

ARTICLE VIII CONDITIONS TO CLOSING.....48

SECTION 8.01 Buyer Closing Conditions.....	48
SECTION 8.02 Seller Closing Conditions	49

ARTICLE IX INDEMNIFICATION.....	50
SECTION 9.01 Survival of Representations and Warranties	50
SECTION 9.02 Indemnification by Seller.....	50
SECTION 9.03 Indemnification by Buyer	51
SECTION 9.04 Limits on Indemnification.....	51
SECTION 9.05 Notice of Loss; Third Party Claims	52
SECTION 9.06 Tax Treatment of Indemnification Payments.....	53
SECTION 9.07 Effect of Investigation; Effect on Indemnity	53
SECTION 9.08 No Double Recovery	54
SECTION 9.09 Remedies	54
ARTICLE X TERMINATION.....	54
SECTION 10.01 Termination.....	54
SECTION 10.02 Effect of Termination.....	55
ARTICLE XI GENERAL PROVISIONS	55
SECTION 11.01 Expenses.....	55
SECTION 11.02 Notices	55
SECTION 11.03 Public Announcements	56
SECTION 11.04 Severability	57
SECTION 11.05 Entire Agreement	57
SECTION 11.06 Assignment.....	57
SECTION 11.07 Amendment; Remedies Cumulative	57
SECTION 11.08 Waiver	58
SECTION 11.09 No Third-Party Beneficiaries	58
SECTION 11.10 Currency	58
SECTION 11.11 Governing Law	58
SECTION 11.12 Waiver of Jury Trial.....	58
SECTION 11.13 Attorneys’ Fees	59
SECTION 11.14 Time of Essence	59
SECTION 11.15 Counterparts	59
SECTION 11.16 Specific Performance	59

EXHIBITS

Exhibit A	Form of Seller License Agreement
Exhibit B	Form of Buyer License Agreement
Exhibit C	Supply Agreement Terms

INDEX OF DEFINED TERMS

<u>Defined Term</u>	<u>Page</u>	<u>Defined Term</u>	<u>Page</u>
Accountant	47	Equity Interests	1
Action	1	ERISA	30
Affiliate	1	Excluded Assets	14
Agreement	1	Excluded Liabilities	15
Allocations	47	FDA	23
Ancillary Agreements	1	FDCA	4
Assigned Contracts	13	Fundamental Representations	4
Assignment and Assumption Agreement	2	GAAP	4
Assignment of Lease	2	Governmental Authority	4
Assumed Liabilities	15	Governmental Order	4
Books and Records	2	Hazardous Material	4
Business	2	Indebtedness	4
Business Day	2	Indemnified Party	5
Business Employees	29	Indemnified Taxes	5
Business Intellectual Property	2	Indemnifying Party	5
Buyer	1	Intellectual Property	5
Buyer Income Tax Return	46	Intellectual Property Assignment	6
Buyer Indemnified Party	50	Intercompany Indebtedness	45
Buyer License Agreement	2	Inventories	6
Buyer Returns	46	IP Participant	26
Capital Stock	2	IRS	6
CERCLA	4	Japan Intellectual Property	14
Cleanup	4	Japan Inventory	14
Clinical Files	2	Knowledge of Seller	10
Closing	16	Law	6
Closing Date	16	Lease	6
Code	3	Leased Real Property	6
Confidentiality Agreement	39	Liabilities	6
Contract	3	Licensed Intellectual Property	7
Control	3	Loss	50
Conveyance Taxes	3	Material Adverse Effect	7
Copyrights	6	Neutral Accounting Firm	7
Current Good Manufacturing Practice	3	Notice	54
Cytori Japan	3	Objection Notice	47
Cytori UK	1	Occupational Safety and Health Law	7
Disclosure Schedule	3	Off-the-Shelf Software	24
Domain Names	6	Open Source Software	7
Encumbrance	3	Ordinary Course of Business	7
Enforceability Exceptions	19	Organizational Documents	8
Environment	3	Owned Real Property	8
Environmental Laws	3	Parties	1
Environmental Liabilities	4	Party	1

Patents	6	Seller Indemnified Party	50
Permit	8	Seller License Agreement	10
Permitted Encumbrances	8	Seller Returns	46
Person	8	Seller's Knowledge	10
Plans	31	Software	10
Post-Closing Tax Period	9	Straddle Period	10
Pre-Closing Tax Period	9	Supply Agreement	10
Purchase Price	9	Tangible Personal Property	10
Purchased Assets	13	Tax	10
Purchased Permits	9	Tax Return	11
RCRA	3	Taxes	10
Real Property	9	Taxing Authority	11
Reference Date	9	Termination of the Affiliate Contracts	41
Registered Intellectual Property	9	Territory	11
Release	9	Third Party Claim	51
Required Consents	48	Trade Secrets	6
Resolution Period	47	Trademarks	6
Restricted Business	42	Transaction Expenses	11
Restricted Parties	42	Transferred Employees	44
Review Period	47	Transition Services Agreement	9, 11
SEC	9	Treasury Regulations	11
Securities Transfer Agreement	9	WARN Act	44
Seller	1		

This **ASSET AND EQUITY PURCHASE AGREEMENT** (this “Agreement”), dated as of March 29, 2019, is by and among Cytori Therapeutics, Inc., a Delaware corporation (“Seller”), Lorem Vascular Pte. Ltd., a company incorporated in Singapore (“Buyer”), and with respect to Section 6.06 only, Cytori Therapeutics, K.K., a kabushiki kaisha organized under the laws of Japan.

Seller and Buyer are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

RECITALS

WHEREAS, Seller owns all of the issued and outstanding equity interests of Cytori Ltd., a private limited company registered in the United Kingdom (“Cytori UK”);

WHEREAS, Seller and Cytori UK are engaged in the Business;

WHEREAS, Seller desires to sell to Buyer, and Buyer desires to purchase from Seller, the Purchased Assets, and in connection therewith, Buyer is willing to assume from Seller the Assumed Liabilities, all upon the terms and subject to the conditions set forth herein;

WHEREAS, Seller desires to sell to Buyer, and Buyer desires to purchase from Seller, all of the issued and outstanding equity interests of Cytori UK (such equity interests, collectively, the “Equity Interests”) and

WHEREAS, concurrently with the Closing, the Parties (or Cytori UK, as applicable) shall enter into the Ancillary Agreements.

NOW, THEREFORE, in consideration of the mutual benefits to be derived from this Agreement, the representations, warranties, conditions, agreements and promises contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

ARTICLE I

DEFINITIONS

SECTION 1.01 Certain Defined Terms. For purposes of this Agreement:

“Action” means any claim, action, grievance, suit, arbitration, inquiry, proceeding, investigation, audit, hearing or litigation by or before any Governmental Authority or arbitrator.

“Affiliate” means, with respect to a Person, any other Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with such first Person, for so long as such Person controls, is controlled by or is under common control with such first Person.

“Ancillary Agreements” means the Buyer License Agreement, the Seller License Agreement, the Supply Agreement, the Transition Services Agreement, the Reverse Transition Services Agreement, the Assignment and Assumption Agreement, the Assignment of Lease, the Intellectual Property Assignment, and Securities Transfer Agreement.

“Assignment and Assumption Agreement” means the Bill of Sale and Assignment and Assumption Agreement to be executed by Seller and Buyer at the Closing, in form and substance reasonably acceptable to Buyer.

“Assignment of Lease” means the Assignment of Lease to be executed by Seller at the Closing with respect to the Leased Real Property (other than such Leased Real Property of Cytori UK, which will be indirectly transferred to Buyer through the sale of Cytori UK), in form and substance reasonably acceptable to Buyer.

“Books and Records”) means the books of account, general, financial records, invoices, shipping records, supplier, correspondence and other documents, records and files, sales and promotional literature, customer lists and other sales related materials, electronic mail, electronic records, all other books and records of Seller and any rights thereto, in each case, excluding the Clinical Files, any Contracts and any Plans.

“Business” means Seller’s cell therapy business of extracting a unique mixed population of stem, progenitor and regenerative cells from human and/or animal adipose tissue for the treatment of disease and for other purposes utilizing proprietary hardware and software-based devices and single-use reagents and consumable sets, including but not limited to Seller’s cell banking expertise and technology.

“Business Day” means any day that is not a Saturday, a Sunday or other day on which banks are closed in San Diego, California.

“Business Intellectual Property” means all Intellectual Property owned by, or filed by or on behalf of, Seller or any of its Affiliates that is being or has been used in or created for use in the Business in the Territory.

“Buyer License Agreement” means the License Agreement to be executed by Cytori Japan and Buyer at the Closing whereby Buyer will license certain Intellectual Property to Cytori Japan, in form attached hereto as Exhibit A.

“Capital Stock” means (a) any shares, interests, participations or other equivalents (however designated) of capital stock of a corporation; (b) any ownership interests in a Person other than a corporation, including membership interests, partnership interests, joint venture interests and beneficial interests; and (c) any warrants, options, convertible or exchangeable securities, subscriptions, rights (including any preemptive or similar rights), calls or other rights to purchase or acquire any of the foregoing.

“Clinical Files” means (a) all clinical and regulatory files, filings, correspondences and reports (including submission information) with any Governmental Authority; (b) all preclinical research, testing, validations and data; and (c) all clinical trial or

study documents, protocols, reports, trial data (including complete master files, clinical summary reports, data listings, data tables, and all raw data used to generate such tables and listings).

“Code” means the United States Internal Revenue Code of 1986, as amended.

“Contract” means any agreement, contract, Lease, obligation, promise or undertaking (whether written or oral and whether express or implied).

“Control” (including the terms “controlled by” and “under common control with”), with respect to the relationship between or among two or more Persons, means the possession, directly or indirectly or as trustee, personal representative or executor, of the power to direct or cause the direction of the affairs or management of a Person, whether through the ownership of voting securities, as trustee, personal representative or executor, by Contract, credit arrangement or otherwise.

“Conveyance Taxes” means any and all sales, use, value added, goods and services, transfer, documentary, stamp, recording and similar taxes, fees and charges, together with any interest, penalties, or additions to tax with respect thereto.

“Current Good Manufacturing Practice” means current good manufacturing practice for the methods used in, and the facilities and controls used for, the manufacture of Seller’s products, all as set forth from time to time by the FDA pursuant to the FDCA (including regulations, rules, guidance, and policies), and similar regulations, rules, standards, and policies as prescribed by Governmental Authorities in other jurisdictions.

“Cytori Japan” means Cytori Therapeutics, K.K., a *kabushiki kaisha* organized under the laws of Japan.

“Disclosure Schedule” means the Disclosure Schedule attached hereto, dated as of the date hereof, delivered by Seller to Buyer in connection with this Agreement.

“Encumbrance” means any security interest, pledge, hypothecation, mortgage, lien, encumbrance, charge, claim, community or other marital property interest, condition, equitable interest, option, right of way, easement, encroachment, servitude, right of first option, right of first refusal or similar restriction, including any restriction on use, voting (in the case of any security or equity interest), transfer, right to receipt of income or right to exercise of any other attribute of ownership.

“Environment” means soil, land surface or subsurface strata, surface waters (including navigable waters and ocean waters), groundwaters, drinking water supply, stream sediments, ambient air (including indoor air), plant and animal life and any other environmental medium or natural resource.

“Environmental Laws” shall mean any Law relating to pollution, protection or cleanup of the Environment, including, CERCLA, the Resources Conservation and Recovery Act of 1976, as amended (“RCRA”), and any other federal, state, and local legal requirements relating to: (a) a Release or the Cleanup of a Hazardous Material; (b) the manufacture, generation, formulation, processing, labeling, distribution, introduction into commerce, use,

treatment, handling, storage, or transportation of a Hazardous Material; and (c) exposure of Persons, including employees, to a Hazardous Material, including, without limitation, those relating to the management, use, storage, disposal, cleanup or removal of asbestos, asbestos-containing materials, polychlorinated biphenyls or any other Hazardous Material.

“Environmental Liabilities” means any Liabilities or losses arising from or under any Environmental Law, including, without limitation, those consisting of or relating to: (a) any fine, penalty, judgment, award, settlement, legal or administrative proceeding, Loss, claim, demand or response, remedial or inspection cost or expense arising under any Environmental Law; (b) financial responsibility under any Environmental Law for cleanup costs or corrective action, including any cleanup, removal, abatement, containment or other remediation or response actions (“Cleanup”) required by any Environmental Law (whether or not such Cleanup has been required or requested by any Governmental Authority or any other Person); or (c) any other compliance, corrective or remedial measure required under any Environmental Law. The terms “removal,” “remedial” and “response action” include the types of activities covered by the United States Comprehensive Environmental Response, Compensation and Liability Act of 1980 (“CERCLA”).

“FDCA” means the Federal Food, Drug, and Cosmetic Act and FDA regulations promulgated pursuant thereto.

“Fundamental Representations” means the representations and warranties set forth in Section 3.01 (Organization, Authority and Qualification of Seller), Section 3.03 (Ownership of the Equity Interests), Section 3.14 (Purchased Assets), Section 3.19 (Environmental Matters), Section 3.20 (Taxes), Section 3.25 (Brokers), Section 3.26 (Capitalization), Section 4.01 (Organization and Authority of Buyer), Section 4.05 (Brokers), and Section 4.06 (Financial Capacity; Solvency).

“GAAP” means United States generally accepted accounting principles as in effect from time to time and applied consistently throughout the periods involved.

“Governmental Authority” means any foreign, domestic, federal, territorial, national, supranational, state, provincial, local or other government, governmental, regulatory, self-regulatory or administrative authority, notified body, agency or commission or any court, tribunal, board, bureau or judicial or arbitral body.

“Governmental Order” means any order, writ, judgment, injunction, decree, assessment, stipulation, determination or award entered by or with any Governmental Authority or arbitrator.

“Hazardous Material” shall mean any toxic substance or hazardous waste, pollutant, or substance, contaminant, or any toxic or hazardous constituent of any such substance or waste, including any substance regulated under or defined by Environmental Laws.

“Indebtedness” of any Person means, without duplication, (a) all obligations of such Person for borrowed money, (b) all obligations of such Person evidenced by, or which customarily would be evidenced by, bonds, debentures, notes or similar instruments, (c) all reimbursement obligations of such Person with respect to letters of credit and similar

instruments, (d) all obligations of such Person under conditional sale or other title retention agreements relating to property or assets purchased by such Person, (e) all obligations of such Person incurred, issued or assumed as the deferred purchase price of property other than accounts payable incurred and paid on terms customary in the business of such Person (it being understood that the “deferred purchase price” in connection with any purchase of property or assets shall include only that portion of the purchase price which is deferred beyond the date on which the purchase is actually consummated), (f) all obligations secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any lien on property owned or acquired by such Person, whether or not the obligations secured thereby have been assumed, (g) all obligations of such Person under forward sales, futures, options and other similar hedging arrangements (including interest rate hedging or protection agreements), (h) all obligations of such Person to purchase or otherwise pay for merchandise, materials, supplies, services or other property under an arrangement which provides that payment for such merchandise, materials, supplies, services or other property shall be made regardless of whether delivery of such merchandise, materials, supplies, services or other property is ever made or tendered, (i) all capitalized lease obligations of such Person, (j) accrued but unpaid Taxes, and (k) all guaranties by such Person of any obligation mentioned in the foregoing clauses (a) through (j).

“Indemnified Party” means a Buyer Indemnified Party or a Seller Indemnified Party, as the case may be.

“Indemnified Taxes” means (a) all Taxes (or the non-payment thereof) imposed on or with respect to the Seller, (b) all Taxes (or the non-payment thereof) imposed on or with respect to Cytori UK with respect to any Pre-Closing Tax Period (as determined, with respect to any Straddle Period, in accordance with the provisions of Section 7.02); (c) all Taxes of any affiliated, consolidated, combined or unitary group of which the Seller or Cytori UK is or was a member on or prior to the Closing Date, including pursuant to Treasury Regulations Section 1.1502-6 or any analogous or similar state, local, or non-U.S. Law; (d) all Taxes imposed upon the Seller or Cytori UK as a transferee or successor, or by contract, Law or otherwise which Taxes relate to an event or transaction occurring before the Closing; (e) the cost of preparing, filing, amending and defending any Tax Return for a Pre-Closing Tax Period or Straddle Period; (f) all Taxes attributable to any inclusion under Section 951 or Section 951A of the Code by Buyer or its Affiliates at the end of the taxable year of Cytori UK that includes, but does not end on the Closing Date, arising out of income accrued or transactions undertaken by Cytori UK on or prior to the Closing Date, (g) any Tax imposed on the Seller or Cytori UK as a result of an election made by such Seller or Cytori UK on or before the Closing Date under Section 108(i) of the Code; and (h) any Taxes for a Post-Closing Tax Period with respect to any adjustment to income under Code Section 481 of the Code (or any similar provision of Law) or otherwise as a result of any change in method of accounting of Cytori UK to the accrual method of accounting from the cash receipts and disbursements method of accounting.

“Indemnifying Party” means Seller pursuant to Section 9.02 and Buyer pursuant to Section 9.03, as the case may be.

“Intellectual Property” means all worldwide intellectual property and all right, title and interest therein, including, without limitation, (a) all patents and patent applications,

utility models, design registrations and certificates of invention and other governmental grants for the protection of inventions or industrial designs (including all related continuations, continuations-in-part, divisionals, reissues and reexaminations), invention disclosures, utility models, invention disclosures, inventions and discoveries, whether or not patented or patentable and whether or not reduced to practice, improvements thereto, and other rights of invention (the items in clause (a), collectively, “Patents”); (b) registered and unregistered trademarks, service marks, trade names, trade dress, brand marks, brand names, logos, product names and slogans, including any common law rights, registrations and applications for the foregoing (the items in clause (b), collectively, “Trademarks”); (c) all registered and unregistered copyrights, in both published and unpublished works including copyrights in computer software, copyrightable works, website content, other rights of authorship and exploitation, and any applications, registrations and renewals in connection therewith (the items in clause (c), collectively, “Copyrights”); (d) all rights in mask works; (e) all know-how, trade secrets, confidential or proprietary information, customer lists, technical information, data, confidential or proprietary process technology, plans, drawings and blue prints (the items in clause (e), collectively, “Trade Secrets”); (f) all Software; (g) all rights in internet web sites and internet domain names (such web sites and internet domain names collectively referred to as “Domain Names”) ; and (h) rights to exclude others from appropriating any of such Intellectual Property, including the right to sue for an remedies against past, present and future infringements of any or all of the foregoing and rights of priority and protection of interests therein, and any other proprietary, intellectual property and other rights relating to any or all of the foregoing anywhere in the world.

“Intellectual Property Assignment” means the assignment(s) transferring all of Seller’s right, title and interest in and to the Business Intellectual Property of Seller, in form and substance reasonably acceptable to Buyer.

“Inventories” means any and all product inventories of the Business, wherever located, including all finished goods, work-in-process, raw materials, spare parts and all other materials and supplies to be used or consumed by Seller or its Affiliates in the production of finished goods for the Business.

“IRS” means the Internal Revenue Service of the United States.

“Law” means any applicable foreign, international, federal, national, supranational, state, provincial, local, municipal or similar statute, law, ordinance, regulation, rule, code, order, requirement or rule of law (including common law), in each of the foregoing cases, as amended or may be amended.

“Lease” means any lease of Real Property or other lease or rental agreement, or license, right to use or installment and conditional sale agreement to which Seller is a party and any other Contract pertaining to the leasing or use of any Tangible Personal Property.

“Leased Real Property” means (i) the Real Property leased by Seller or Cytro UK, as tenant, described on Section 3.13(a) of the Disclosure Schedule, and (ii) all easements, licenses, rights and appurtenances relating to the foregoing.

“Liabilities” means any and all debts, liabilities and obligations, whether accrued or fixed, absolute or contingent, known or unknown, disputed or undisputed, matured or unmatured or determined or determinable, including those arising under any Law, Action or Governmental Order and those arising under any Contract, agreement, arrangement, commitment or undertaking.

“Licensed Intellectual Property” means all Intellectual Property licensed by a Person to Seller or any its Affiliates that is being or has been used by Seller or any of its Affiliates in the Business in the Territory.

“Material Adverse Effect” means (a) with respect to Seller, any circumstance, change in or effect on the Business in the Territory that is materially adverse to the results of operations, assets, Liabilities or the financial condition of the Business in the Territory; provided, however, that “Material Adverse Effect” shall not include the following, and none of the following, either alone or in combination, shall be considered in determining whether there has been a “Material Adverse Effect”: (i) events, circumstances, changes or effects that generally affect the industries in which the Business operates in the Territory (including legal and regulatory changes) to the extent such conditions do not disproportionately impact the Business in the Territory compared to other businesses that operate in the same industry or industries as the Business in the Territory and as compared to the industry as a whole; (ii) general economic or political conditions or events, circumstances, changes or effects affecting the securities markets or credit markets generally; (iii) changes arising from the consummation of the transactions contemplated by, or the announcement of the execution of, this Agreement; (iv) any circumstance, change or effect that results from any action taken pursuant to or in accordance with this Agreement or at request of Buyer; (v) changes caused by a material worsening of current conditions caused by acts of terrorism or war (whether or not declared) occurring after the date hereof or any natural or man-made disaster or acts of God; and (vi) any matter of which Buyer is aware on the date hereof solely to the extent set forth on the Disclosure Schedule and (b) with respect to Buyer, any circumstance, change or effect that is materially adverse to the ability of Buyer to consummate timely the transactions contemplated by this Agreement.

“Neutral Accounting Firm” means an independent accounting firm of nationally recognized standing that is not at the time it is to be engaged hereunder rendering services to any Party, or any Affiliate of either, and has not done so within the two year period prior thereto.

“Occupational Safety and Health Law” means any Law designed to provide safe and healthful working conditions and to reduce occupational safety and health hazards, including the Occupational Safety and Health Act, and any program, whether governmental or private (such as those promulgated or sponsored by industry associations and insurance companies), designed to provide safe and healthful working conditions.

“Open Source Software” means any Software that is subject to, distributed, transmitted, licensed or otherwise made available under any so-called “public license,” “open source license,” “free license,” “industry standard license,” “intellectual property pool license” or similar license that requires, as a condition of use, modification and/or distribution of such Software that other Software incorporated into, derived from or distributed with such Software be (a) disclosed or distributed in source code form, (b) licensed for the purpose of making

derivative works, or (c) be redistributable at no charge, including any version of any of the following licenses: GNU General Public License, GNU Library or “Lesser” Public License, or any substantially similar license.

“Ordinary Course of Business” means, with respect to an action taken by a Person, that such action (a) is consistent in nature, scope and magnitude with the past practices of such Person and is taken in the ordinary course of the normal, day-to-day operations of such Person; (b) does not require authorization by the board of directors or shareholders of such Person (or by any Person or group of Persons exercising similar authority) and does not require any other separate or special authorization of any nature; and (c) is similar in nature, scope and magnitude to actions customarily taken, without any separate or special authorization, in the ordinary course of the normal, day-to-day operations of other Persons that are in the same line of business as such Person. No violation of law or contractual obligations shall be deemed in the Ordinary Course of Business.

“Organizational Documents” of a Person means its articles of incorporation, articles of organization, bylaws and/or other organizational documents, as applicable.

“Owned Real Property” means the Real Property in which Seller or its Affiliates (to the extent related to the Business in the Territory) has fee title (or equivalent) interest, together with all buildings and other structures, facilities or improvements currently or hereafter located thereon, all fixtures, systems, equipment and items of personal property of Seller (to the extent related to the Business in the Territory) attached or appurtenant thereto and all easements, licenses, rights and appurtenances relating to the foregoing.

“Permit” means all approvals, authorizations, clearances, notifications, consents, licenses, registrations, permits, permit applications, and other rights issued, granted, given or otherwise made available by or under the authority of any Governmental Authority or pursuant to any Law.

“Permitted Encumbrances” means (a) statutory liens for current Taxes not yet due and payable or the validity or amount of which is being contested in good faith by appropriate proceedings and for which adequate reserves have been established in accordance with GAAP, (b) mechanics’, carriers’, workers’, repairers’ and other similar liens arising or incurred in the Ordinary Course of Business relating to obligations as to which there is no default on the part of Seller, as the case may be, or the validity or amount of which is being contested in good faith by appropriate proceedings, or workers’ or unemployment compensation liens arising in the Ordinary Course of Business, (c) zoning, entitlement, conservation restriction and other land use and environmental regulations by Governmental Authorities which do not materially interfere with the present use of the Purchased Assets, (d) all covenants, conditions, restrictions, easements, charges, rights-of-way, other Encumbrances and similar matters of record set forth in any state, provincial, local or municipal franchise of Seller, which do not materially interfere with the present use of the Purchased Assets, and (e) matters which would be disclosed by an accurate survey or inspection of the Real Property which do not materially impair the occupancy or current use of such Real Property which they encumber.

“Person” means any individual, partnership, firm, corporation, limited liability company, association, trust, unincorporated organization or other entity, as well as any syndicate or group that would be deemed to be a person under Section 13(d)(3) of the Securities Exchange Act of 1934, as amended.

“Post-Closing Tax Period” means any taxable period beginning after the Closing Date, and, with respect to any Straddle Period, the portion of such Straddle Period beginning after the Closing Date.

“Pre-Closing Tax Period” means any taxable period ending on or before the Closing Date, and, with respect to any Straddle Period, the portion of such Straddle Period ending on the Closing Date.

“Purchased Permits” means all Permits used in, or necessary to, the operation of the Business in the Territory, including, to test, manufacture, market, supply or distribute the products of the Business in the Territory, including, but not limited to, all Premarket Approval Applications, 510(k) notifications, Investigational Device Exemptions, quality and other certificates issued by notified bodies and all other marketing authorizations issued by Governmental Authorities which are used by Seller or its Affiliates to test, sell, manufacture and distribute the products of the Business in the Territory.

“Purchase Price” means \$3,000,000.

“Real Property” means all land, buildings, improvements and fixtures erected thereon and all appurtenances related thereto.

“Reference Date” means December 31, 2018.

“Registered Intellectual Property” means all Intellectual Property consisting of federal, state, international, and other: (a) Patents; (b) Trademarks; (c) Copyrights; (d) mask work registrations and applications to register mask works; (e) Domain Names; and (f) other Intellectual Property assets that are the subject of an application, certificate, filing, registration or other document issued by, filed with, or recorded by, any Governmental Authority owned, or filed by or on behalf of, or purported to be owned by Seller or its Affiliates and used in the conduct of the Business in the Territory.

“Release” shall mean any spilling, leaking, pumping, pouring, emitting, emptying, discharging, escaping, leaching, dumping or disposing of a Hazardous Material into the Environment of any kind whatsoever, including the abandonment or discarding of barrels, containers, tanks or other receptacles containing or previously containing Hazardous Material.

“Reverse Transition Services Agreement” means the Reverse Transition Services Agreement to be executed by Seller and Buyer at the Closing, in a form and substance reasonably acceptable to Buyer.

“SEC” means the United States Securities and Exchange Commission.

“Securities Transfer Agreement” means the instrument of transfer transferring all of Seller’s right, title and interest in and to Equity Interests to Buyer, in form and substance reasonably acceptable to Buyer.

“Seller’s Knowledge” “Knowledge of Seller” or similar terms used in this Agreement means the actual or constructive knowledge of each of Marc Hedrick, Tiago Girao, John Fraser, and Cheri Rice, after due inquiry.

“Seller License Agreement” means the License Agreement to be executed by Cytori Japan and Buyer at the Closing whereby Cytori Japan will license certain Intellectual Property to Buyer, in form attached hereto as Exhibit B.

“Software” means any and all computer programs, whether in source code or object code; databases and compilations, whether machine readable or otherwise; descriptions, flow-charts and other work product used to design, plan, organize and develop any of the foregoing; and all documentation including user manuals and other training documentation related to any of the foregoing. For clarity, Software does not include emails.

“Straddle Period” means any taxable period beginning on or before the Closing Date and ending after the Closing Date.

“Supply Agreement” means the Supply Agreement to be executed by Seller and Buyer at the Closing, in form and substance reasonably acceptable to Buyer and consistent with the terms summarized in Exhibit C.

“Tangible Personal Property” means all furniture, fixtures, machinery, equipment, tools, computer hardware, supplies, materials, lab equipment, manufacturing, testing, storage and shipping related equipment, and other items of tangible personal property of every kind (in each case other than Inventory, Books and Records, Software and Clinical Files) owned or leased by Seller or any of its Affiliates and used in, or necessary to, the Business in the Territory (wherever located and whether or not carried on Seller’s books), together with any express or implied warranty by the manufacturers, sellers or lessors of any item or component part of Tangible Personal Property (as otherwise defined) and all maintenance records and other documents relating thereto.

“Tax” or “Taxes” means any and all income, gross receipts, sales, use, production, ad valorem, transfer, franchise, registration, profits, license, lease, service, service use, withholding, payroll, employment, unemployment, estimated, excise, severance, escheat, abandoned or unclaimed property, environmental, stamp, occupation, premium, property (real or personal), Real Property gains, windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatsoever, together with any interest, additions or penalties with respect thereto and any interest in respect of such additions or penalties, imposed, assessed or collected by or under the authority of any Taxing Authority or payable pursuant to any Tax-sharing agreement or other agreement relating to the payment of any such tax, fee, assessment or charge, whether imposed directly, under Treasury Regulations Section 1.1502-6 (or any similar provision of state, local or foreign law), as a result of being a transferee, successor or member of an affiliated, consolidated, unitary or combined group, by Contract (other than commercial

Contracts entered into in the Ordinary Course of Business that do not primarily relate to Taxes), pursuant to Law or otherwise.

“Tax Return” means any return, report, form, statement or claim for refund (including elections, declarations, schedules, information returns or attachments thereto) filed or required to be filed with a Taxing Authority with respect to Taxes, including any amendment thereof.

“Taxing Authority” means, with respect to any Tax, the Governmental Authority that imposes such Tax or is charged with the collection of such Tax.

“Territory” means the entire world, other than Japan.

“Transaction Expenses” means the aggregate (i) amount of fees and expenses incurred by Seller, Cytore UK and their Affiliates incident to the negotiation, preparation and execution of this Agreement, the Ancillary Agreements and the consummation of the transactions contemplated hereby and thereby (other than Conveyance Taxes, which are separately allocated in accordance with Section 7.01), and (ii) amount payable under any employment agreement, severance plan or any other arrangement, in effect at any time prior to the Closing, under which certain rights are triggered solely by a change in control or as a result of the transactions contemplated herein.

“Transition Services Agreement” means the Transition Services Agreement to be executed by Seller and Buyer at the Closing, in form and substance reasonably acceptable to Buyer.

“Treasury Regulations” means the regulations (including temporary regulations) promulgated by the United States Department of Treasury with respect to the Code or other federal Tax statutes.

SECTION 1.02 Interpretation and Rules of Construction. In this Agreement:

(a) except to the extent otherwise provided or that the context otherwise requires, wherever used, the singular includes the plural, the plural includes the singular, the use of any gender shall be applicable to all genders;

(b) the word “or” is used in the inclusive sense (and/or);

(c) the table of contents and captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement;

(d) the term “including” or its variations as used herein does not limit the generality of any description preceding such term and shall be construed as “including, without limitation”;

(e) the language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party;

(f) unless otherwise specified or where the context otherwise requires,

(i) references in this Agreement to any Article, Section, Schedule or Exhibit are references to such Article, Section, Schedule or Exhibit of this Agreement, and references to this “Agreement” are references to this Agreement and all exhibits and schedules hereto;

(ii) references in any Section to any clause are references to such clause of such Section;

(iii) “hereof,” “hereto,” “hereby,” “herein” and “hereunder” and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement;

(iv) references to a Person are also to its permitted successors and assigns;

(v) references to a Law include any amendment or modification to such Law and any rules, regulations or legally binding guidelines issued thereunder, in each case, as in effect at the relevant time of reference thereto;

(vi) references to any agreement, instrument or other document in this Agreement refer to such agreement, instrument or other document as originally executed or, if subsequently amended, replaced or supplemented from time to time, as so amended, replaced or supplemented and in effect at the relevant time of reference thereto;

(vii) “extent” in the phrase “to the extent” means the degree to which a subject or other thing extends, and such phrase does not mean simply “if”;

(viii) references to monetary amounts are denominated in United States Dollars; and

(ix) references to days (excluding Business Days) or months shall be deemed references to calendar days or months.

ARTICLE II

PURCHASE AND SALE

SECTION 2.01 Purchase and Sale of the Equity Interests. Upon the terms and subject to the conditions set forth in this Agreement, at the Closing, Seller shall sell, convey, assign, transfer and deliver to Buyer, and Buyer shall purchase and acquire from Seller, the Equity Interests, free and clear of any Encumbrances other than restrictions imposed under applicable securities Laws, as partial consideration for the Purchase Price.

SECTION 2.02 Purchase and Sale of Purchased Assets.

(a) Upon the terms and subject to the conditions of this Agreement (including Section 2.02(b)), at the Closing, Seller shall sell, assign, transfer, convey and deliver, or cause to be sold, assigned, transferred, conveyed and delivered, to Buyer, and Buyer shall purchase and acquire from Seller, free and clear of any Encumbrances, all of Seller's right, title and interest in the assets, properties and rights listed below (collectively, the "Purchased Assets"):

(i) all rights in respect of the Leased Real Property and Leases, in each case listed on Section 2.02(a)(i) of the Disclosure Schedule;

(ii) all Tangible Personal Property other than Tangible Personal Property set forth in Section 2.02(b)(vi) below;

(iii) all Inventories of Seller and its Affiliates (other than the Japan Inventory), including, but not limited to, the Inventories set forth on Section 2.02(a)(iii) of the Disclosure Schedule;

(iv) all Books and Records relating to the Business in the Territory, including personnel Books and Records relating to any Transferred Employees, but excluding the Books and Records set forth on Section 2.02(b)(v) below and provided that Seller may keep a copy of such Books and Records to the extent they do not solely relate to the Business in the Territory;

(v) the goodwill of Seller in the Business in the Territory;

(vi) the rights of Seller under the following Contracts (the "Assigned Contracts"); (a) the Contracts listed on Section 2.02(a)(vi)(a) of the Disclosure Schedule that Buyer, in its sole discretion, elects to assume at Closing by giving written notice to Seller of such assumption, and (b) all Contracts listed on Section 2.02(a)(vi)(b) of the Disclosure Schedule;

(vii) all Purchased Permits, to the extent transferable;

(viii) all Business Intellectual Property, including the assets set forth on Section 2.02(a)(viii) of the Disclosure Schedule, other than the Japanese Intellectual Property;

(ix) all unfilled purchased orders to Seller for products sold and services rendered by the Business in the Territory set forth on Section 2.02(a)(ix) of the Disclosure Schedule;

(x) all insurance benefits, including rights and proceeds, arising from or relating to the Purchased Assets or the Assumed Liabilities and not arising from an Excluded Liability;

(xi) all of Seller's claims, causes of Action, choses in Action, rights of recovery and rights of offset of any kind, against third parties relating to the Purchased Assets and not arising from an Excluded Liability, whether choate or inchoate, known or unknown, or contingent or noncontingent and whether or not liquidated;

(xii) all of Seller's rights under warranties, indemnities and all similar rights against third parties to the extent related to any Purchased Assets or Assumed Liability and not arising from an Excluded Liability with respect to matters occurring prior to the Closing;

(xiii) all Clinical Files relating to the Business in the Territory;

(xiv) all Software relating to the Business in the Territory, other than the Software set forth in Section 2.02(b)(x) below; and

(xv) any other assets, properties and rights of Seller that are not specifically allocated in this Agreement and that are used in the Business in the Territory.

For clarity, the Purchased Assets shall not include any right, title and interest in the assets, properties and rights of Cytori UK, which shall instead be acquired indirectly through the purchase of the Equity Interests pursuant to Section 2.01.

(b) Notwithstanding anything in Section 2.02(a) to the contrary, Seller shall not sell, convey, assign, transfer or deliver, nor cause to be sold, conveyed, assigned, transferred or delivered, to Buyer, and Buyer shall not purchase, and the Purchased Assets shall not include, Seller's right, title and interest in or to any of the following assets (the "Excluded Assets"), which Excluded Assets, for purposes of clarity, shall not include any asset owned by Cytori UK:

(i) all cash and cash equivalents, securities, and negotiable instruments of Seller or on hand, in lock boxes, in financial institutions or elsewhere, including all cash residing in any collateral cash account securing any obligation or contingent obligation of Seller;

(ii) (a) all billed and unbilled accounts receivable and other rights to payment from customers of the Seller or its Affiliates and the full benefit of all security for such accounts or rights to payment, including all accounts receivable representing amounts receivable in respect of goods shipped or products sold or services rendered to customers of the Seller or its Affiliates and (b) any claim, remedy or other right related to any of the foregoing;

(iii) all Inventories of Seller and its Affiliates set forth on Section 2.02(b)(iii) of the Disclosure Schedule (the "Japan Inventory");

(iv) all deposits (including, without limitation, lease, vendor and customer deposits), prepayments (except to the extent relating to an assumed obligation of Buyer to perform), and refunds set forth on Section 2.02(b)(iv) of the Disclosure Schedule;

(v) the company seal, minute books, charter documents, stock or equity record books and such other Books and Records as pertain to the organization, existence or capitalization of Seller, as well as any other records or materials relating to Seller generally and not involving or related to the Purchased Assets or the operations of the Business in the Territory;

(vi) all Tangible Personal Property set forth on Section 2.02(b)(vi);

(vii) the goodwill of Seller in the Business in Japan and outside of the Business;

(viii) the Patents, Trademarks, and Domain Names relating to the Business in Japan that are listed on Section 2.02(b)(viii) of the Disclosure Schedule and Software in the computers or servers or other electronic storage medium contained in Tangible Personal Property located in Japan (the “Japanese Intellectual Property”);

(ix) the Intellectual Property that is not related to the Business;

(x) the Software set forth on Section 2.02(b)(x) of the Disclosure Schedule;

(xi) all Clinical Files relating to studies or trials performed primarily in Japan;

(xii) all rights of Seller under this Agreement and the Ancillary Agreements, and all correspondence, emails, and Books and Records relating thereto to the extent not used in the Business in the Territory;

(xiii) all Contracts and agreements of Seller other than the Assigned Contracts;

(xiv) all Plans and trusts or other assets attributable thereto;

(xv) all Tax Returns and related work papers and documents of Seller and all Tax assets of the Seller, including Tax refunds and prepayments;

(xvi) all current and prior insurance policies of Seller;

(xvii) all intercompany, related party receivables;

(xviii) the property and assets owned directly by Cytori Japan and not used in the Business in the Territory, other than Inventory that is not Japan Inventory; and

(xix) all assets that are unrelated to the Business.

SECTION 2.03 Assumption and Exclusion of Liabilities.

(a) Upon the terms and subject to the conditions set forth in this Agreement, Buyer shall, by executing and delivering, at the Closing, the Assignment and Assumption Agreement, assume, and agree to pay, perform and discharge when due, notwithstanding anything to the contrary herein or in any Assigned Contract, only (i) the executory obligations under the Assigned Contracts arising with respect to matters occurring after the Closing Date and required to be performed after the Closing Date and (ii) the accounts payable described in Section 2.03(a) of the Disclosure Schedule (collectively, the “Assumed Liabilities”); provided, however, that the Assumed Liabilities shall not include (i) any Liability arising under the Assigned Contracts as a result of any pre-Closing conduct or condition, or (ii) any Liability of

Seller with respect to any Tax for any Pre-Closing Period. Buyer shall not assume or have any responsibility for any Liability of Seller or its Affiliates other than the Assumed Liabilities.

(b) Seller shall retain and be solely (as with respect to the Buyer) responsible for paying, performing and discharging, and Buyer shall not assume or have any responsibility for, all Liabilities of Seller and its Affiliates, including those listed below, other than the Assumed Liabilities and Liabilities of Cytori UK (the “Excluded Liabilities”):

(i) all Liabilities for any accounts payable of Seller, including accounts payable in respect of the Business as of the Closing Date;

(ii) all Indemnified Taxes;

(iii) all Liabilities relating to or arising out of the Excluded Assets;

(iv) all Liabilities relating to or arising out of product liability, indemnity, warranty, infringement, misappropriation or similar claims by any Person in connection with any tangible or intangible products or services used, sold or licensed by Seller that arise out of or relate to Seller’s ownership and operation of the Purchased Assets prior to the Closing;

(v) all Liabilities arising out of or relating to Indebtedness incurred by Seller;

(vi) any Liabilities with respect to the employment, or termination of employment, of the employees of Seller (which shall include, but not be limited to, benefit and Plan-related Liabilities, severance, accrued but unused vacation, payroll Taxes and related expenses);

(vii) all Transaction Expenses;

(viii) all Liabilities of Cytori Japan; and

(ix) Seller’s obligations under this Agreement.

SECTION 2.04 Closing. Pursuant to the terms and subject to the conditions of this Agreement, the closing of the transactions contemplated hereby (the “Closing”) shall take place remotely via the exchange of documents and signatures by facsimile or electronic mail on the Business Day immediately following the satisfaction or waiver of the conditions to Closing contained in ARTICLE VIII. The date of the Closing is referred to herein as the “Closing Date”. Legal title, equitable title, and risk of loss with respect to the Purchased Assets will pass to Buyer at the Closing, which will be deemed for tax, accounting and other computational purposes as of 11:59 p.m. on the Closing Date.

SECTION 2.05 Closing Deliveries by Seller. At the Closing, Seller or its Affiliates shall deliver or cause to be delivered to Buyer:

- (a) certificates representing such Seller's interests in the Equity Interests, duly endorsed (or accompanied by duly executed stock powers), for transfer to Buyer;
- (b) a good standing certificate (or its equivalent) as of a recent date issued by the applicable Governmental Authority of Seller's and Cytori UK's jurisdictions of organization;
- (c) a resignation letter from each officer, director or manager (as applicable) of Cytori UK as requested by Buyer, in form and substance reasonably satisfactory to Buyer;
- (d) the Ancillary Agreements, in each case, duly executed by Seller and/or Cytori UK, as applicable;
- (e) such other deeds, bills of sale, assignments, certificates of title, documents and other instruments of transfer and conveyance as may reasonably be requested by Buyer, each in form and substance to be reasonably agreed upon by Buyer and Seller and duly executed by Seller or Cytori UK, as applicable;
- (f) evidence, in a form reasonably acceptable to Buyer, of (i) the release of all Encumbrances on the Purchased Assets, and (ii) the payoff of all Transaction Expenses of the Seller, the Business and Cytori UK;
- (g) evidence reasonably satisfactory to Buyer of the receipt of all filings required to be made and consents required from third parties (including Governmental Authorities), in each case, listed on Section 2.05(g) of the Disclosure Schedule;
- (h) a true and complete copy, certified by the Secretary or an Assistant Secretary of Seller, of the resolutions duly and validly adopted by the Board of Directors of Seller, evidencing its authorization of the execution and delivery of this Agreement and the Ancillary Agreements and the consummation of the transactions contemplated hereby and thereby;
- (i) a certificate of the President or Chief Financial Officer of Seller, dated as of the Closing Date, certifying that the conditions set forth in Sections 8.01(a) and 8.01(b) have been satisfied and certifying the names and signatures of the officers of Seller authorized to sign this Agreement and the Ancillary Agreements and the other documents to be delivered hereunder and thereunder;
- (j) a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Cytori UK any, in form and substance reasonably satisfactory to Buyer, certifying the Organizational Documents of Cytori UK as then in effect;
- (k) a certificate as to the non-foreign status of Seller pursuant to Treasury Regulations Section 1.1445-2(b)(2), in a form reasonably acceptable to Buyer; and
- (l) any other documents as Buyer may reasonably request for the purpose of otherwise facilitating the consummation or performance of any the transactions contemplated by this Agreement.

SECTION 2.06 Closing Deliveries by Buyer. At the Closing, Buyer shall deliver or cause to be delivered to Seller:

- (a) an amount equal to the Purchase Price, by wire transfer in immediately available funds to the bank accounts specified in writing by Seller to Buyer no less than three (3) Business Days prior to the Closing;
- (b) executed counterparts of each Ancillary Agreement;
- (c) a true and complete copy, certified by the Secretary or an Assistant Secretary of Buyer, of the resolutions duly and validly adopted by the board of directors of Buyer evidencing its authorization of the execution and delivery of this Agreement and the Ancillary Agreements to which it is a party and the consummation of the transactions contemplated hereby and thereby; and
- (d) a certificate of the President or an Chief Financial Officer of Buyer, dated as of the Closing Date, certifying that the conditions set forth in Sections 8.02(a) and 8.02(b) have been satisfied and certifying the names and signatures of the officers of Buyer authorized to sign this Agreement and the Ancillary Agreements and the other documents to be delivered hereunder and thereunder.

SECTION 2.07 Tax Withholding. Each of Seller and Buyer shall be entitled to deduct and withhold from an amount otherwise payable to the other party in connection with this Agreement such Taxes as the payer is required to deduct and withhold under the Code or any other Law with respect to the making of such payment. To the extent that amounts are so withheld by Buyer or Seller, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of which such deduction and withholding was made, and Buyer or Seller, as applicable, shall disburse such withheld amounts to the applicable Taxing Authority. The Parties shall cooperate to minimize or avoid any such deduction or withholding of such Taxes that might be imposed to the extent permitted by Law.

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF SELLER

Seller represents and warrants, in each case as of the date hereof and as of the Closing or, if a representation or warranty is made as of a specified date, as of such date, to Buyer as follows, with each such representation and warranty subject to such exceptions, if any, as are set forth in the Disclosure Schedule. Disclosures in any section or paragraph of the Disclosure Schedule are made generally and shall not only address the corresponding section or paragraph of this Agreement, but also other sections or paragraphs of this Agreement to the extent that it is readily apparent from the face of such disclosure that such disclosure is applicable to such other sections or paragraphs.

SECTION 3.01 Organization, Authority and Qualification of Seller. Each of Seller and Cytori UK is an entity duly incorporated, validly existing and, where applicable, in good standing under the laws of the jurisdiction of its incorporation and has all necessary corporate

power and authority to enter into this Agreement and the Ancillary Agreements, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby and to conduct its business as it is now being conducted, to own or use the properties and assets that it purports to own or use, and to perform all of its obligations in the Business. Each of Seller and Cytori UK is duly licensed or qualified to do business and is in good standing in each jurisdiction in which the properties owned or leased by it or the operation of its business makes such licensing or qualification necessary, except to the extent that the failure to be so licensed, qualified or in good standing would not (a) adversely affect the ability of Seller to carry out its obligations under, and to consummate the transactions contemplated by, this Agreement and the Ancillary Agreements, or (b) otherwise have a Material Adverse Effect. Except as set forth in Section 3.01 of the Disclosure Schedule, no part of the Business is currently operated through any entity other than Seller or Cytori UK. The execution and delivery of this Agreement and the Ancillary Agreements by Seller (or, as applicable, Cytori UK), the performance by Seller (or, as applicable, Cytori UK) of its obligations hereunder and thereunder and the consummation by Seller (or, as applicable, Cytori UK) of the transactions contemplated hereby and thereby have been duly authorized by all requisite corporate action on the part of Seller and Cytori UK. This Agreement has been duly executed and delivered by Seller and upon their execution the Ancillary Agreements shall have been, duly executed and delivered by Seller and Cytori UK, and (assuming due authorization, execution and delivery by Buyer, where applicable) this Agreement constitutes, and upon their execution the Ancillary Agreements shall constitute, legal, valid and binding obligations of Seller and Cytori UK, enforceable against Seller (or, as applicable, Cytori UK) in accordance with their respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium or similar Laws of general application affecting or relating to the enforcement of creditors' rights generally, and subject to equitable principles of general applicability, whether considered in a proceeding at law or in equity (the "Enforceability Exceptions").

SECTION 3.02 No Conflict. Assuming that all consents, approvals, authorizations and other actions described in Section 3.04 have been obtained, all filings and notifications listed in Section 3.02 of the Disclosure Schedule have been made, and any applicable waiting period has expired or been terminated, and except as may result from any facts or circumstances relating solely to Buyer, the execution, delivery and performance of this Agreement and the Ancillary Agreements by Seller (or, as applicable, Cytori UK) do not and will not, directly or indirectly (with or without notice or lapse of time) (a) violate, conflict with or result in the breach of the certificate of incorporation or bylaws (or similar Organizational Documents) of Seller or Cytori UK or any resolutions adopted by the Board of Directors or the stockholders of Seller or the governing body of Cytori UK, (b) conflict with or violate any Law or Governmental Order applicable to Seller or Cytori UK or give any Governmental Authority or other Person the right to challenge any of the transactions contemplated by this Agreement or to exercise any remedy or obtain any relief under any Law or Governmental Order applicable to Seller or Cytori UK, (c) except as set forth in Section 3.02(c) of the Disclosure Schedule, conflict with, result in any breach of, constitute a default (or event which with the giving of notice or lapse of time, or both, would become a default) under, require any consent under, or give to others any rights of termination, amendment, acceleration, suspension, revocation or cancellation of, any note, bond, mortgage or indenture, Contract, lease, sublease, license, Permit, franchise or other instrument or arrangement to which Seller or Cytori UK is a party, or (d) result in the imposition or creation of any Encumbrance upon or with respect to any of the Purchased Assets or the Equity Interests,

except, in the case of clauses (b) and (c), as would not materially and adversely affect the ability of Seller (or, as applicable, Cytori UK) to carry out its obligations under, and to consummate the transactions contemplated by, this Agreement and the Ancillary Agreements.

SECTION 3.03 Ownership of the Equity Interests. Seller is, and Buyer will at the Closing be, the owner of the Equity Interests, free and clear of Encumbrances or any other restrictions on transfer other than any restrictions on transfers imposed under federal, state and provincial securities laws or as otherwise set forth on Section 3.03 of the Disclosure Schedule. At the Closing, Buyer will acquire good and valid title to the Equity Interests, free and clear of all Encumbrances (other than any restrictions on transfers imposed under federal, state and provincial securities laws).

SECTION 3.04 Governmental Consents and Approvals. The execution, delivery and performance of this Agreement and each Ancillary Agreement by Seller (or, as applicable, Cytori UK) do not and will not require any consent, approval, authorization, or other order of, action by, filing with, or notification to, any Governmental Authority and no registrations or declarations are required to be filed in connection therewith, except (a) as described in Section 3.04 of the Disclosure Schedule, (b) where failure to obtain such consent, approval, authorization or action, or to make such filing, notification, declaration or registration, would not prevent or materially delay the consummation by Seller of the transactions contemplated by this Agreement and the Ancillary Agreements or (c) as may be necessary as a result of any facts or circumstances relating solely to Buyer or any of its Affiliates.

SECTION 3.05 Financial Information. The information relating to the Business presented in the audited annual financial statements filed by Seller with the SEC on Form 10-K for the 2018 fiscal year (i) was derived from the Books and Records of Seller and prepared in accordance with GAAP on a consistent basis throughout the periods covered thereby and (ii) presented fairly, in all material respects, the revenues of the Business at the respective dates thereof.

SECTION 3.06 Books and Records; Controls. The Books and Records relating to the Business in the Territory, all of which have been made available to Buyer as of the date hereof, are complete and correct in all material respects and represent actual, bona fide transactions and have been maintained in accordance with sound business practices. Seller maintains a system of internal accounting controls sufficient to provide reasonable assurances that (a) transactions are executed in accordance with management's general or specific authorization, (b) transactions are recorded as necessary to (i) permit preparation of financial statements in conformity with GAAP, and (ii) maintain accountability for assets, (c) access to assets is permitted only in accordance with management's general or specific authorization and (d) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Seller's internal accounting controls, as in effect during all periods commencing after the Reference Date, did not contain any material weaknesses.

SECTION 3.07 Absence of Undisclosed Material Liabilities. There are no material Liabilities of the Business relating to the Territory or Cytori UK of any nature that would be required to be reflected on a consolidated balance sheet of the Business for the Territory prepared in accordance with GAAP or the financial statements of Seller or Cytori UK, other than

Liabilities that (a) are set forth in Section 3.07 of the Disclosure Schedule, (b) were incurred since the Reference Date in the Ordinary Course of Business, (c) have been incurred pursuant to this Agreement or (d) are set forth in the financial statements described in Section 3.05. Other than obligations of Cytori UK for the Leased Property and the Intercompany Indebtedness, Cytori UK has no Liabilities of any nature.

SECTION 3.08 Conduct in the Ordinary Course.

(a) Since the Reference Date, except as set forth in Section 3.08(a) of the Disclosure Schedule, the Business and the business of Cytori UK has been conducted in the Ordinary Course of Business and there has not occurred any (i) Material Adverse Effect, (ii) transfer, assignment, sale or other disposition of any asset that would be a Purchased Asset shown or reflected in the financial statements of Seller and Cytori UK, except for the sale of Inventory in the Ordinary Course of Business, or (iii) material damage, destruction or loss, or any material interruption in use, of any Purchased Assets, whether or not covered by insurance, or any changes in the amount or scope of insurance coverage.

(b) Since the Reference Date, except as set forth in Section 3.08(b) of the Disclosure Schedule, neither Seller (to the extent related to the conduct of the Business) nor Cytori UK has:

(i) entered into any material Contract outside the Ordinary Course of Business, with respect to Seller, relating to the Business or the Purchased Assets or amended, terminated or waived any material right under any material Contract, with respect to Seller, related to the Business or the Purchased Assets;

(ii) made any loans or advances of money;

(iii) made any material capital expenditures outside the Ordinary Course of Business;

(iv) placed any Encumbrance on any Purchased Asset;

(v) suffered the loss of employment of any key employee or group of employees of Cytori UK or of the Business or been notified that any such Person or group of Persons intends to terminate employment;

(vi) entered into or terminated any employment Contract or collective bargaining agreement, written or oral, or modified the terms of any existing such Contract or agreement, or entered into any collective bargaining relationship, with respect to the Business Employees;

(vii) granted (A) any increase in the base compensation of, (B) any bonus to, or (C) any other change in employment terms for any of the Business Employees outside the Ordinary Course of Business;

(viii) adopted, amended, modified, or terminated any bonus, profit sharing, incentive, severance, or other plan, Contract, or commitment for the benefit of any of the Business Employees (or taken any such action with respect to any other Plan);

(ix) entered into any material settlement, conciliation or similar agreement, with respect to Seller, related to the Business or the Purchased Assets;

(x) made or changed any election, changed any annual accounting period, adopted or changed any accounting method, filed any amended Tax Return for Taxes, entered into any closing agreement, settled any Tax claim or assessment, surrendered any right to claim a refund of Taxes, consented to any extension or waiver of the limitation period applicable to any Tax claim or assessment, or taken any other similar action relating to the filing of any Tax Return or the payment of any Tax, if such election, adoption, change, amendment, agreement, settlement, surrender, consent or other action would have had the effect of increasing the Tax Liability for any Post-Closing Tax Period or decreasing any Tax attribute existing on the Closing Date; or

(xi) agreed, whether orally or in writing, to do any of the foregoing or agreed to take any action, that if taken prior to the date of this Agreement, would have made any representation or warranty in this ARTICLE III untrue or incorrect.

SECTION 3.09 Litigation. Except as set forth in Section 3.09 of the Disclosure Schedule, as of the date hereof, there is no Action by or against Seller (which Action relates to the Business) or Cytori UK pending before any Governmental Authority, or to Seller's Knowledge, threatened. Neither Cytori UK, the Business nor the Purchased Assets is subject to any order, injunction, judgment, decree, ruling, assessment or arbitration award of any Governmental Authority or arbitrator.

SECTION 3.10 Compliance with Laws.

(a) Except as set forth in Section 3.10(a) of the Disclosure Schedule, each of Seller and Cytori UK (i) has conducted and continues to conduct its business in accordance with all Laws and Governmental Orders applicable to the Business in all material respects, (ii) neither Seller nor Cytori UK is in material violation of any such Law or Governmental Order, including, all applicable Laws (including regulations, rules, guidance, and policies) promulgated by the FDA or any other Governmental Authority relating to Current Good Manufacturing Practice, quality systems, medical device reporting, device design, establishment registration and product listing, tracking (as applicable), product export, unique device identification, and post market surveillance regulations, and (iii) no event has occurred or circumstance exists that (with or without notice or lapse of time) may constitute or result in a material violation by Seller or Cytori UK of, or a material failure of Seller or Cytori UK to comply with, any Law with respect to the Purchased Assets or the Business, and (iv) neither Seller nor Cytori UK has received any notice or other communication (whether oral or written) with respect to the Business or the Purchased Assets from any Governmental Authority or any other Person regarding any actual, alleged, possible or potential violation of, or failure to comply with, any Law which is material to the Business in the Territory.

(b) Section 3.10(b) of the Disclosure Schedule contains a complete and accurate list of each Permit relating to the Business held by Seller and Cytori UK. Seller has made available to Buyer complete copies of all such Permits. Each Permit listed or required to be listed in Section 3.10(b) of the Disclosure Schedule is valid and in full force and effect. Except as set forth in Section 3.10(b) of the Disclosure Schedule, (i) Seller (or, as applicable, Cytori UK) is and has been since the Reference Date, in full compliance with all of the material terms and requirements of each Permit identified or required to be identified in Section 3.10(b) of the Disclosure Schedule, (ii) no event has occurred or circumstance exists that may (with or without notice or lapse of time) (A) constitute or result directly or indirectly in a violation of or a failure to comply with any material term or requirement of any Permit listed or required to be listed in Section 3.10(b) of the Disclosure Schedule or (B) result directly or indirectly in the revocation, withdrawal, suspension, cancellation or termination of, or any modification to, any Permit listed or required to be listed in Section 3.10(b) of the Disclosure Schedule; (iii) neither Seller nor Cytori UK has received any notice or other communication from any Governmental Authority or any other Person regarding (A) any actual, alleged, possible or potential violation of or failure to comply with any material term or requirement of any Permit listed or required to be listed in Section 3.10(b) of the Disclosure Schedule or (B) any actual, proposed, possible or potential revocation, withdrawal, suspension, cancellation, termination of or modification to any Permit listed or required to be listed in Section 3.10(b) of the Disclosure Schedule, (iv) Seller and Cytori UK have paid any and all site registration fees, medical device excise taxes and other fees relating to such Permits, (v) all applications required to have been filed for the renewal of the Permits listed or required to be listed in Section 3.10(b) of the Disclosure Schedule have been duly filed on a timely basis with the appropriate Governmental Authorities, and (vi) all other filings required to have been made with respect to such Permits have been duly made on a timely basis with the appropriate Governmental Authorities. The Purchased Permits listed in Section 3.10(b) of the Disclosure Schedule collectively constitute all of the Permits used by Seller (or, as applicable, Cytori UK) to lawfully conduct and operate the Business in the Territory in the manner in which it currently is conducted.

(c) All applications, notifications, submissions, information, claims, reports and statistics, and other data and conclusions derived therefrom, utilized as the basis for or submitted in connection with any and all requests to obtain or maintain any Purchased Permits from, or otherwise submitted to, the U.S. Food and Drug Administration (the “FDA”) or other Governmental Authority, when submitted to the FDA or other Governmental Authority were (to the Knowledge of Seller in the case of any such materials prepared by a third party) true, complete and correct in all material respects as of the date of submission and any legally necessary or required updates, changes, corrections or modifications to such applications, submissions, information, claims, reports or statistics have been submitted to the FDA and other Governmental Authorities.

(d) Other than as set forth in Section 3.10(d) of the Disclosure Schedule, neither Seller nor Cytori UK is aware, nor has it received notice, of any Action pending with respect to a violation by Seller or Cytori UK of the FDCA or other Law, and, to the Knowledge of Seller, there are no facts or circumstances existing that would reasonably be expected to serve as a basis for such an Action. Other than as set forth in Section 3.10(d) of the Disclosure Schedule, neither Seller nor Cytori UK is subject to an FDA consent decree or warning letter or any similar order of a Governmental Authority. Except as would not be material to the business

in the Territory, any preclinical and clinical studies or tests sponsored by the Company and its Subsidiaries relating to the Business in the Territory, have been conducted in compliance with standard medical and scientific research procedures and applicable Laws (including Good Clinical Practices requirements and Laws restricting the use and disclosure of individually identifiable health information) and (ii) the Company and its Subsidiaries have not received written notice from (A) the FDA or any other Governmental Authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination, suspension or material modification of such studies or tests or (B) any Person regarding any breach or alleged breach with respect to individually identifiable health information.

(e) No Governmental Authority has commenced or, to the Knowledge of Seller, threatened to initiate any action to request the recall of any products produced thereunder, nor has Seller or Cytori UK received any notice to such effect and, to the Knowledge of Seller, there are no grounds for such action. Except as noted on Section 3.10(e) of the Disclosure Schedule, there are no ongoing recalls/field correction on any lack of compliance with Laws by Seller or Cytori UK which could require a recall/field correction.

(f) Neither Seller, Cytori UK, nor, to the Knowledge of Seller, any of their employees or agents, in their capacities as such, have been disqualified or debarred by the FDA, pursuant to 21 U.S.C. §§ 335(a) or (b), or been charged with or convicted under the Laws of the United States for conduct relating to the development or approval, or otherwise relating to the regulation of, any product under the Generic Drug Enforcement Act of 1992, or any other relevant Law or been debarred, disqualified or convicted under or for any equivalent or similar applicable foreign Law.

SECTION 3.11 Intellectual Property.

(a) Section 3.11(a) of the Disclosure Schedule sets forth a true and complete list of all Business Intellectual Property and Licensed Intellectual Property. With respect to each item of Business Intellectual Property, Seller (or, as applicable, Cytori UK) is the owner of the entire right, title and interest in and to such item, and has the right to sell, convey, assign, transfer and deliver, the Business Intellectual Property, free and clear of any Encumbrances.

(b) Section 3.11(b) of the Disclosure Schedule sets forth a true and complete list of all Contracts, except for licenses of Software generally publicly available for an annual or one-time license fee of no more than \$10,000 ("Off-the-Shelf Software"), pursuant to which Seller (or, as applicable, Cytori UK) licenses in or otherwise is authorized to use any Intellectual Property of any Person in the conduct of the Business (including all contracts for Licensed Intellectual Property). Section 3.11(b) of the Disclosure Schedule further includes, for each Contract set forth therein, the date of such Contract and any amendments, and the parties thereto. As of the date hereof, Seller has made available to Purchaser true, correct and complete copies of each Contract set forth on Section 3.11(b) of the Disclosure Schedule, together with all amendments, modifications or supplements thereto.

(c) Except as set forth on Section 3.11(c) of the Disclosure Schedule, no licensing fees, royalties or payments are due or payable in connection with any Business

Intellectual Property, other than standard maintenance fees and annuities payable to Governmental Authorities for the Registered Intellectual Property.

(d) Except for the Contracts listed in Section 3.11(b) of the Disclosure Schedule and Off-the-Shelf Software properly licensed by Seller, there are no Intellectual Property rights of third parties that are included in the Intellectual Property used in the Business. Except as set forth on Section 3.11(d) of the Disclosure Schedule, the consummation of the transactions contemplated by this Agreement will not result in a default under or termination of any of the Contracts set forth on Section 3.11(b) of the Disclosure Schedule. Neither Seller nor Cytori UK is, nor has it received any notice that it is in default or (with the giving of notice or lapse of time or both) would be in default under any Contract that comprises Licensed Intellectual Property. There are no outstanding or, to Seller's Knowledge, threatened, Actions with respect to any Contract that comprises Licensed Intellectual Property. All Off-the-Shelf Software used in the operation of the Business, has been properly licensed from the owner of such Software.

(e) Section 3.11(e)(i) of the Disclosure Schedule sets forth a true and complete list of all Contracts pursuant to which Seller (or, as applicable, Cytori UK) has licensed any Business Intellectual Property to any Person for any purpose. Except as set forth on Section 3.11(e)(ii) of the Disclosure Schedule, no Contract to which Seller (or, as applicable, Cytori UK) is a party (i) contains a covenant not to compete or otherwise limits its ability to use or exploit fully any Business Intellectual Property; or (ii) contains an agreement to indemnify any other Person against any claim of infringement, misappropriation, unauthorized use or other violation of any Intellectual Property of a Person.

(f) The operation of the Business does not interfere with, infringe upon, misappropriate, or otherwise violate the Intellectual Property rights of any Person. Except as set forth on Section 3.11(f) of the Disclosure Schedule, there is no Action pending or, to Seller's Knowledge, threatened, against Seller (or, as applicable, Cytori UK) relating to any Intellectual Property used or allegedly used in the conduct of Business. Except as set forth on Section 3.11(f) of the Disclosure Schedule, neither Seller nor Cytori UK has, since the Reference Date, received any written charge, complaint, claim, demand or notice alleging any past, present or future infringement, misappropriation or violation of any Intellectual Property rights of any Person (including any claim that Seller or Cytori UK must license or refrain from using any Intellectual Property rights of any Person).

(g) To the Knowledge of Seller, no Person is infringing upon, misappropriating or otherwise violating any Business Intellectual Property. Except as set forth on Section 3.11(g) of the Disclosure Schedule, neither Seller nor Cytori UK has not brought any Action against any Person alleging interference with, or infringement, misappropriation or violation of any Business Intellectual Property. Except as set forth in Section 3.11(g) of the Disclosure Schedule, (i) the Business Intellectual Property is not subject to any outstanding injunction, judgment, order, decree, ruling, charge, or settlement agreement or stipulation, and (ii) there is no Action pending or threatened by any Person before any court or tribunal (including, without limitation, the United States Patent and Trademark Office or equivalent authority anywhere in the world) relating to any of the Business Intellectual Property (other than office actions and other *ex parte* prosecution of Registered Intellectual Property), including any

claim that challenges the validity, enforceability, registration, scope, use or exclusive ownership of any Business Intellectual Property, nor is Seller or Cytori UK aware of any reasonable basis for any such claim or demand.

(h) Section 3.11(h) of the Disclosure Schedule lists all Registered Intellectual Property. To the Knowledge of Seller, all Registered Intellectual Property is valid, enforceable and subsisting. All necessary registration and renewal fees in connection with applications and registrations for Registered Intellectual Property have been timely made, and all necessary documents and certificates in connection with such applications and registrations have been filed with the relevant Governmental Authority in all applicable jurisdictions.

(i) All employees and contractors of Seller (or, as applicable, Cytori UK) who have authored, co-authored or otherwise contributed to or participated in the conception or development of any Intellectual Property relating to the Business on behalf of Seller (or, as applicable, Cytori UK) ("IP Participant") have executed and delivered to Seller (or, as applicable, Cytori UK) a proprietary information agreement, pursuant to which, *inter alia*, such IP Participant has assigned any and all of such IP Participant's rights in such Intellectual Property to Seller (or, as applicable, Cytori UK) and has agreed to keep such Intellectual Property confidential and not use such Intellectual Property for any purpose unrelated to his or her work for Seller (or, as applicable, Cytori UK), and to Seller's Knowledge no IP Participant is in default of any such agreement. No current or former IP Participant has filed, asserted in writing, or threatened in writing any claim against Seller in connection with his or her involvement with such Intellectual Property.

(j) Seller (or, as applicable, Cytori UK) has taken all commercially reasonable measures to maintain the confidentiality of Trade Secrets used in the Business, including, *inter alia*, requiring all current and former employees, consultants and contractors of Seller (or, as applicable, Cytori UK) and any other Persons with access to such information to execute a confidentiality or similar agreement, and, to the Knowledge of Seller, there has not been any breach by any such party to any such agreement.

(k) The Software contained in the Business Intellectual Property performs in accordance with the documentation and other written materials related to such Software, and is free from all viruses, worms, Trojan horses, and other defects in programming and operations, is in machine readable form, and contains all current revisions of such Software. All Software, other than Commercial Off-the-Shelf Software, included in the Business Intellectual Property was developed: (i) by employees of Seller (or, as applicable, Cytori UK) within the scope of such employee's employment duties; (ii) by independent contractors as "works-made-for-hire," as that term is defined under the United States Copyright Act, 17 U.S.C. § 101, pursuant to a written agreement between Seller and each such independent contractor; or (iii) by Persons who have assigned all of their rights therein to Seller (or, as applicable, Cytori UK) pursuant to a written agreement with Seller (or, as applicable, Cytori UK). Seller (or, as applicable, Cytori UK) has kept secret and has not disclosed the source code for the Software included in the Business Intellectual Property to any Person other than certain employees of Seller who are subject to the terms of a binding confidentiality agreement with respect thereto, and to Seller's Knowledge all such employees are in compliance with such confidentiality agreements.

(l) Neither Seller nor Cytori UK has used any Open Source Software in a way that (i) creates or imposes any obligation on Seller (or, as applicable, Cytori UK) with respect to Open Source Software; or (ii) grants, or purports to grant, to any third party, any rights or immunities under any of the Business Intellectual Property or Licensed Intellectual Property of Seller or Cytori UK (including by using any Open Source Software that requires, as a condition of use, modification and/or distribution of such Open Source Software that other Software incorporated into, derived from or distributed with such Open Source Software be (A) disclosed or distributed in source code form, (B) licensed for the purpose of making derivative works, or (C) be redistributable at no charge.

(m) Seller and Cytori UK has complied in all material respects with all Laws relating to privacy, data protection and the collection, use and security of personal information gathered or accessed in the course of the operations of the Business, and have complied with all Contracts established by Seller or Cytori UK, as applicable, from time to time with respect to the foregoing. No written notice has been received from and no Action is threatened by, any Person alleging a violation of such Person's rights: (i) under any such Laws, or (ii) as a result of any breach by Seller or Cytori UK of any of its Contracts relating to privacy, data protection, use and security of personal information. Seller and Cytori UK have taken commercially reasonable steps in accordance with applicable industry standards and practices to ensure that the personal information gathered or accessed in the course of the operations of Seller or Cytori UK is protected against loss and against unauthorized access, use, modification or disclosure. Since the Reference Date, there has been no material unauthorized access to or use, modification or disclosure of such information. Seller has not experienced the cancellation, termination or revocation of any privacy or security certification.

(n) No government funding, facilities of a university or other educational institution or research center or funding from third parties was used in the development of the Business Intellectual Property, and no such entity has any claim or right to or in such Business Intellectual Property.

SECTION 3.12 Insurance. All policies of insurance that provide coverage with respect to the Business or Purchased Assets are sufficient for compliance with all Laws and Contracts in all material respects.

SECTION 3.13 Real Property.

(a) Cytori UK does not own any Real Property. Section 3.13(a) of the Disclosure Schedule lists the street address of each parcel of Leased Real Property and the identity of the lessor, lessee and current occupant of each such parcel, and all of the Leases relating to such Leased Real Property. Except as set forth on Section 3.13(a) of the Disclosure Schedule, (i) Seller has made available to Buyer, true and complete a copy of the Leases in effect at the date hereof relating to the Leased Real Property, (ii) all such Leases relating to the Leased Real Property are in full force and effect, (iii) Seller (or, as applicable, Cytori UK) is not in breach of or in default of its obligations thereunder, and no event has occurred which, with notice or lapse of time, or both would constitute a breach or default or permit termination, modification or acceleration thereunder, (iv) no Leases relating to the Leased Real Property are subject to any Encumbrance or other restriction that impairs, in any material respect, the use of the property to

which it relates in the Business as now conducted and (v) there has not been any sublease or assignment entered into by Seller (or, as applicable, Cytori UK) in respect of the Leases relating to the Leased Real Property.

(b) Neither the whole nor any portion of the Leased Real Property has been condemned, requisitioned or otherwise taken by any Governmental Authority, and neither Seller nor Cytori UK has received any notice that any such condemnation, requisition or taking is threatened, which condemnation, requisition or taking would preclude or materially impair the current use thereof. All buildings, structures and appurtenances comprising any part of the Leased Real Property that are currently being used in the conduct of the Business are in satisfactory condition and have been well maintained, normal wear and tear excepted. The Leased Real Property has received all required Permits (including, without limitation, a certificate of occupancy or other similar certificate permitting lawful occupancy of the Leased Real Property) required in connection with the operation thereof and have been operated and maintained in accordance with Law. The Leased Real Property is supplied with utilities (including, without limitation, water, sewage, disposal, electricity, gas and telephone) and other services necessary for the operation of such facility as currently operated.

(c) Except as set forth in Section 3.13(c) of the Disclosure Schedule, neither Seller nor Cytori UK has received any notice that it is in violation of any zoning, use, occupancy, building, wetlands or environmental regulation, ordinance or other Law or requirement relating to the Leased Real Property. Seller has not received notice of any, and, to the Knowledge of Seller, there is no threatened, eminent domain proceeding or proceeding to change or redefine the zoning classification with respect to the Leased Real Property.

SECTION 3.14 Purchased Assets. Seller owns, and will transfer, at the Closing, good and transferable title to all of the Purchased Assets free and clear of all Encumbrances, except as set forth in Section 3.14 of the Disclosure Schedule. Except as disclosed in Section 3.14 of the Disclosure Schedule, all Tangible Personal Property and Inventory included in the Purchased Assets is in the possession of Seller (or, as applicable, Cytori UK) at the Leased Real Property.

SECTION 3.15 Sufficiency of Assets. Except as set forth in Section 3.15 of the Disclosure Schedule, the Purchased Assets and the assets of Cytori UK (a) constitute all of the assets, tangible and intangible, of any nature whatsoever, used to operate (and to the Knowledge of Seller, necessary to operate) the Business in the Territory in the manner presently operated by Seller and Cytori UK, and as has been conducted in the past year, in the Territory, (b) include all of the operating assets of the Business in the Territory owned, used or Controlled by Seller or any of its Affiliates, and (c) other than changes in assets in the Ordinary Course of Business, include all of the assets of the Business used in the Territory.

SECTION 3.16 Condition of Assets. Each item of Tangible Personal Property included in the Purchased Assets has been recorded in the Books and Records of the Seller in accordance with GAAP. All items of Tangible Personal Property and Inventory included in the Purchased Assets have been maintained in accordance with normal industry practice.

SECTION 3.17 Inventories. Except for Inventories owned by Cytori Japan, neither Seller nor Cytori UK is in possession of any Inventories not owned by Seller (or, as applicable, Cytori

UK), including goods already sold, and no other Person holds any Inventories on consignment from Seller. All Inventories are saleable at prevailing market prices not less than the book value thereof, and are not obsolete, damaged, slow-moving or defective. The value at which Inventories are carried on the balance sheets of Seller and Cytori UK reflects the customary inventory valuation of Seller (which fairly reflects the value of obsolete or excess inventory) for stating Inventories in accordance with GAAP and there has been no change to the method of such inventory valuation in the prior three (3) years. Inventories on hand that were purchased after the Reference Date were purchased in the Ordinary Course of Business at a cost not exceeding market prices prevailing at the time of purchase. The quantities of each item of Inventories (whether raw materials, work-in-process or finished goods) are not excessive but are reasonable in the present circumstances of Seller (or, as applicable, Cytori UK). Work-in-process Inventories are valued according to GAAP. There are no blanket purchase orders for any Inventories.

SECTION 3.18 Employees and Employee Benefit Matters.

(a) Section 3.18(a) of the Disclosure Schedule contains a complete and accurate list of all employees of Cytori UK and all employees of Seller associated with the Business in the Territory as of the date hereof (the “Business Employees”). All Business Employees are legally entitled to work in the United States or the United Kingdom, as applicable, and, to Seller’s Knowledge, all Persons employed by Seller (or, as applicable, Cytori UK) during the past three (3) years were at the time of their employment, legally entitled to work in the United States or the United Kingdom, as applicable. Other than the Business Employees set forth in Section 3.18(a) of the Disclosure Schedule, no other employees of Seller or Cytori UK are involved in the Business in the Territory.

(b) Except as set forth in Section 3.18(b) of the Disclosure Schedule, each Business Employee is an “at will” employee of Seller (or, as applicable, Cytori UK) and may terminate his or her employment or be terminated from such employment at any time for any reason with or without prior notice. Section 3.18(b) of the Disclosure Schedule lists each Contract for the employment of any Business Employee on a full-time or part-time basis, any severance agreement or any agreement of any Business Employee requiring any payment upon a change of control of the Business.

(c) Seller and Cytori UK have complied with all Laws relating to the employment of the Business Employees, including, without limitation, Title VII of the Federal Civil Rights Act of 1964, as amended, Occupational Safety and Health Laws, and those relating to hours, wages, collective bargaining, hiring, promotion, demotion and termination.

(d) There are no management, employment, consulting, non-compete, confidentiality, severance, change of control, retention or guaranteed bonus contracts, or similar Contracts or arrangements of any nature between Seller, Cytori UK, and any Person providing services for or on behalf of the Business, which by their terms or operation of law will be binding upon Buyer or result in Liabilities to Buyer.

(e) To the Knowledge of Seller, no Business Employee or agent, consultant, or contractor of the Business is bound by any Contract that purports to limit the ability of such

Business Employee or agent, consultant, or contractor (i) to engage in or continue or perform any conduct, activity, duties or practice relating to the Business or (ii) to assign to Seller, Cytori UK, or to any other Person any rights to any invention, improvement, or discovery. To the Knowledge of Seller, no former or current Business Employee is a party to, or is otherwise bound by, any Contract that in any way adversely affected, affects, or will affect the ability of Buyer to conduct the Business in the Territory as heretofore carried on by Seller or Cytori UK.

(f) There is no labor strike, dispute, corporate campaign, slowdown, stoppage or lockout or other labor dispute pending or, to the Knowledge of Seller, threatened against or affecting the Business in the Territory.

(g) None of Seller nor Cytori UK is a party to or bound by any collective bargaining or similar agreement, or other agreement or understanding, with any labor organization employee association or other similar organization with respect to any Business Employee. No Business Employee is represented by any labor organization and, to the Knowledge of Seller, there have been no union organizing activities involving any Business Employee pending or threatened at any time since the Reference Date. Since the Reference Date, (i) no labor union has been certified by the National Labor Relations Board as bargaining agent for any Business Employee, (ii) no notice has been received by Seller or Cytori UK from any labor union stating that it has been, or is demanding to be, designated or otherwise recognized as the bargaining agent for any Business Employee, (iii) no representation proceeding or petition seeking a representation proceeding has been filed (or threatened to be filed) with respect to any Business Employee and (iv) neither Seller nor Cytori UK is or has been negotiating, or has been asked to negotiate, any collective bargaining agreement or other agreement or understanding with any labor organization with respect to any Business Employee.

(h) There is no, and since the Reference Date, has not been any, unfair labor practice charge or complaint involving the Business Employees pending or, to the Knowledge of Seller, threatened, before the National Labor Relations Board or any similar Governmental Authority.

(i) There are no, and since the Reference Date, there have not been any, charges involving any Business Employee pending before the federal Equal Employment Opportunity Commission, the federal Department of Labor or any other Governmental Authority responsible for receiving employment or labor-related claims or the prevention of unlawful employment or wage and hour practices, nor, to the Knowledge of Seller, is there any basis for any of the same.

(j) Neither Seller nor Cytori UK has received notice from any Governmental Authority seeking to conduct an investigation, audit or other inquiry specifically with respect to the Business Employees and to Seller's Knowledge no such investigation, audit or inquiry is in progress.

(k) There are no Actions pending in any forum (including internal investigations or complaints) or to Seller's Knowledge threatened, by or on behalf of any present or former Business Employee, or any applicant for employment for the Business alleging breach of any express or implied contract of employment, violation of any Laws governing wage and

hour requirements of any kind (including claims for unpaid overtime or any other wage and hour violations referenced in this Section 3.18), violation of any Laws governing employment or the termination thereof or other discriminatory, wrongful or tortious conduct in connection with the employment relationship, nor, to the Knowledge of Seller, is there any basis for any of the same.

(l) Section 3.18(l) of the Disclosure Schedule lists all employee benefit plans (as defined in Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”) and all bonus, stock option, stock purchase, restricted stock, incentive, deferred compensation, retiree medical or life insurance, supplemental retirement, severance or other benefit plans, programs or arrangements, and all employment, termination, severance or other Contracts or agreements, to which Seller or Cytori UK is a party, with respect to which Seller (or, as applicable, Cytori UK) has any obligation or which are maintained, contributed to or sponsored by Seller for the benefit of any Business Employee, other than any statutory or government-sponsored plan to which Seller (or, as applicable, Cytori UK) is required to contribute or with which any of them is required to comply pursuant to Laws (collectively, the “Plans”). Each Plan is in writing, and Seller has made available to Buyer a true and complete copy of each Plan.

(m) Each Plan has been operated in all material respects in accordance with its terms and is in compliance in all material respects with the requirements of all Laws, including ERISA and the Code. Seller (or, as applicable, Cytori UK) has performed all material obligations required to be performed by it under, is not in any material respect in default under or in material violation of, and to the Knowledge of Seller there are no material defaults or violations by any party to, any Plan. No Action that could have a Material Adverse Effect is pending or threatened with respect to any Plan (other than claims for benefits in the ordinary course) and, to the Knowledge of Seller, no fact or event exists that could give rise to any such Action.

(n) Each Plan that is intended to be qualified under Section 401(a) of the Code or Section 401(k) of the Code has timely received a favorable determination letter from the IRS covering all of the provisions applicable to the Plan for which determination letters are currently available that the Plan is so qualified and each trust established in connection with any Plan which is intended to be exempt from federal income taxation under Section 501(a) of the Code has received a determination letter from the IRS that it is so exempt, and no fact or event has occurred since the date of such determination letter or letters from the IRS to adversely affect the qualified status of any such Plan or the exempt status of any such trust.

(o) No Plan is (i) a “multiemployer plan” within the meaning of Section 3(37) of ERISA; or (ii) a defined benefit pension plan (as defined in Section 3(35) of ERISA) or plan subject to Section 412 of the Code or Section 302 of ERISA. None of the Purchased Assets is subject to any lien or encumbrance imposed under ERISA or Section 430(k) of the Code. Neither Seller nor Cytori UK has any liability regarding any “employee benefit plan,” as defined in Section 3(3) of ERISA, solely because of being treated as a single employer under Section 414 of the Code with any other trade or business.

(p) Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated by this Agreement (in each case, either alone or

in combination with any other event) will (i) result in any Business Employee becoming entitled to any unemployment compensation, deferred compensation, bonus or severance pay, materially increase or otherwise enhance any benefits otherwise payable by Seller or Cytori UK; (ii) result in the acceleration of time of payment or vesting, or an increase in the amount of any compensation due to any Business Employee; (iii) result in forgiveness, in whole or in part, of any outstanding loans made by Seller (or, as applicable, Cytori UK) to any Business Employee; or (iv) result in a payment or provision of any benefit to any Business Employee that would be considered an “excess parachute payment” within the meaning of Section 280G of the Code.

SECTION 3.19 Environmental Matters. Except as disclosed in Section 3.19 of the Disclosure Schedule:

(a) The Business is, and at all times has been, conducted and operated in full compliance with, and has not been and is not in violation of or liable under, any Environmental Law. Neither Seller nor Cytori UK has any basis to expect, nor has it or any other Person for whose conduct it is or may be held to be responsible received, any actual or threatened order, notice or other communication of any actual or potential violation or failure by Seller or Cytori UK to comply with any Environmental Law, or of any actual or threatened obligation to undertake or bear the cost of any Environmental Liabilities with respect to the Business or the Purchased Assets, or with respect to any Leased Real Property at or to which Hazardous Materials were generated, manufactured, refined, transferred, imported, used or processed by Seller or Cytori UK (or any other Person for whose conduct it is or may be held responsible) in connection with the Business, or from which Hazardous Materials have been transported, treated, stored, handled, transferred, disposed, recycled or received in connection with the Business.

(b) There are no pending, threatened in writing or, to Seller’s Knowledge, otherwise threatened claims, Encumbrances, or other restrictions of any nature resulting from any Environmental Liabilities or arising under or pursuant to any Environmental Law with respect to Cytori UK or affecting any operations of the Business or the Purchased Assets.

(c) Neither Seller nor Cytori UK has treated, stored, disposed of, arranged for or permitted the disposal of, transported, handled, manufactured, distributed, exposed any person to, or released any substance, including without limitation any hazardous substance, or owned or operated any property or facility (and no such property or facility is contaminated by any such substance) so as to give rise to any Environmental Liabilities, including any liability for fines, penalties, response costs, corrective action costs, personal injury, property damage, natural resources damages or attorneys’ fees, pursuant to CERCLA or RCRA, as amended or any other Environmental Laws.

SECTION 3.20 Taxes.

(a) All Tax Returns required to have been filed by the Seller (solely with respect to the Purchased Assets, the Assumed Liabilities, or the Business) or by Cytori UK have been timely filed (taking into account any extension of time to file granted or obtained) and all Taxes (whether or not shown to be payable on such Tax Returns) have been timely paid. All Tax Returns filed by the Seller (solely with respect to the Purchased Assets, the Assumed Liabilities, or the Business) or by Cytori UK are true, complete, and correct in all material respects.

(b) Each of the Seller (solely with respect to the Purchased Assets, the Assumed Liabilities, or the Business) and Cytori UK has withheld and paid all Taxes and paid all Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder, or other third party, and all IRS Forms W-2 and 1099 or other forms required with respect thereto have been properly completed in all material respects and timely filed.

(c) Seller has made available to Buyer true, correct and complete copies of all Tax Returns of Cytori UK, and examination reports and statements of deficiencies assessed against or agreed to by the Seller (solely with respect to the Purchased Assets, the Assumed Liabilities, or the Business) or by Cytori UK, since January 1, 2015.

(d) Neither the Seller (solely with respect to the Purchased Assets, the Assumed Liabilities, or the Business) nor Cytori UK is currently the subject of a Tax audit or examination and neither the Seller (solely with respect to the Purchased Assets, the Assumed Liabilities, or the Business) nor Cytori UK has received any written notice from a Taxing Authority indicating an intent to open an audit, examination, Action or other review or a request for information related to Tax matters.

(e) Neither the Seller (solely with respect to the Purchased Assets, the Assumed Liabilities, or the Business) nor Cytori UK has consented to extend the time, or is the beneficiary of any extension of time, in which any Tax may be assessed or collected by any Taxing Authority.

(f) Neither the Seller (solely with respect to the Purchased Assets, the Assumed Liabilities, or the Business) nor Cytori UK has received from any Taxing Authority any written notice of proposed adjustment, deficiency, underpayment of Taxes or any other such written notice which has not been satisfied by payment or been withdrawn.

(g) No claim has been made by any Taxing Authority in writing in a jurisdiction where the Seller (solely with respect to the Purchased Assets, the Assumed Liabilities, or the Business) or Cytori UK does not file Tax Returns that such Person is or may be subject to taxation by that jurisdiction.

(h) Neither the Seller (solely with respect to the Purchased Assets, the Assumed Liabilities, or the Business) nor Cytori UK has any Tax Return filing obligation in any jurisdiction outside the United States or has a permanent establishment or other fixed place of business in any country other than the United States.

(i) There are no Encumbrances for Taxes upon any asset of the Seller (solely with respect to the Purchased Assets, the Assumed Liabilities, or the Business) or Cytori UK (other than Encumbrances for Taxes not yet delinquent).

(j) Neither the Seller (solely with respect to the Purchased Assets or the Business) nor Cytori UK has requested or received a ruling, technical advice memorandum, or similar ruling or memorandum from any Taxing Authority or signed a closing or other agreement with any Taxing Authority.

(k) Neither the Seller (solely with respect to the Purchased Assets or the Business) nor Cytori UK has ever been a party to any “listed transaction” within the meaning of Section 6707A(c)(1) of the Code or Treasury Regulation Section 1.6011-4(b).

(l) Neither the Seller (solely with respect to the Purchased Assets or the Business) nor Cytori UK is a party to any Tax allocation or Tax sharing agreement.

(m) The entity classification of Cytori UK for U.S. federal income Tax purposes is set forth on Section 3.20(m) of the Disclosure Schedule.

(n) Cytori UK is not a successor for Tax purposes to any other Person or has any liability for Taxes of any Person under Treasury Regulation Section 1.1502-6 (or any comparable provision of local, state or foreign Law), as a transferee or successor, by Contract (other than commercial Contracts entered into in the ordinary course of business the primary purpose of which does not relate to Taxes) or otherwise.

(o) Neither the Buyer, Cytori UK, nor any Affiliate thereof after the Closing Date, will be required to include an item of income, or exclude an item of deduction, for any period after the Closing Date as a result of (in each case, with respect to Cytori UK) (i) an installment sale transaction occurring on or before the Closing Date governed by Section 453 of the Code (or any corresponding or similar provision of state, local or non-U.S. Tax Laws); (ii) a transaction occurring on or before the Closing Date reported as an open transaction for federal income Tax purposes (or any similar doctrine under state, local or non-U.S. Laws); (iii) any prepaid amounts received on or prior to the Closing Date; (iv) a change in method of accounting requested or occurring on or prior to the Closing Date; (v) an agreement entered into with any Taxing Authority (including a “closing agreement” under Section 7121 of the Code) on or prior to the Closing Date; (vi) an election (including a protective election) pursuant to Section 108(i) or Section 965 of the Code (or any corresponding or similar provision of state, local or non-U.S. Tax Law); or (vii) an intercompany transaction or excess loss account described in the Treasury Regulations under Section 1502 of the Code (or any corresponding or similar provision of state, local or non-U.S. Tax Law) with respect to a transaction occurring on or prior to the Closing Date.

(p) At no time during the two-year period ending on the date hereof was Cytori UK a “distributing corporation” or a “controlled corporation” in a distribution of stock to which Section 355 of the Code applied or was intended to apply.

(q) There are no joint ventures, partnerships, limited liability companies, or other arrangements or Contracts to which Cytori UK is a party that could be treated as a partnership for federal income tax purposes.

(r) Cytori UK has not agreed to, nor is it required to, include in income any adjustment pursuant to Section 482 of the Code (or any similar provision of state, local, or non-U.S. Tax Law), nor has any written claim been made by a Taxing Authority proposing any such adjustment.

SECTION 3.21 Material Contracts.

(a) Section 3.21(a) of the Disclosure Schedule lists each of the following Contracts of Seller (to the extent related to and necessary for the Business) or Cytori UK, all of which have been delivered by Seller to Buyer: (i) all Contracts involving total annual payments in excess of \$50,000 that are not cancelable without penalty or further payment and without more than 30 days' notice; (ii) each Contract involving \$50,000 or more per year in revenue to the Business or to Cytori UK; (iii) all Contracts relating to Indebtedness for borrowed money, in each case having an outstanding principal amount in excess of \$100,000; (iv) each Contract with a distributor, consignor, sales representative or sales agent; (v) all material Contracts that limit or purport to limit the ability of Seller, with respect to the Business, or Cytori UK to compete in any line of business or with any Person or in any geographic area or during any period of time or that contain "most favored nations" restrictions; (vi) all Contracts under which Seller or Cytori UK have advanced or loaned monies to any other Person; (vii) each settlement, conciliation or similar Contract with any Governmental Authority; (viii) all Contracts for capital expenditures in excess of \$50,000; (ix) all material Contracts between Seller (in respect of the Business) or Cytori UK, on the one hand, and any Affiliate of Seller, on the other hand; (x) each written warranty, guaranty and/or other similar undertaking with respect to contractual performance extended by Seller relating to the Business or by Cytori UK, other than in the Ordinary Course of Business; and (xi) each other Contract material to the Business, whether or not entered into in the Ordinary Course of Business. Section 3.21(a) of the Disclosure Schedule also describes any current negotiations regarding entering into or amending, supplementing or modifying any Contract listed or required to be listed in such section. Except as disclosed in Section 3.21(a) of the Disclosure Schedule, each Material Contract (i) is valid and binding on Seller (or, as applicable, Cytori UK) and, to the Knowledge of Seller, the counterparties thereto, and is in full force and effect and (ii) upon consummation of the transactions contemplated by this Agreement, except to the extent that any consents set forth in Section 3.02(d) of the Disclosure Schedule are not obtained, shall continue in full force and effect without penalty or other adverse consequence. Except as disclosed in of the Disclosure Schedule, neither Seller nor Cytori UK is in breach of, or default under, any Material Contract to which it is a party.

(b) There are no renegotiations of, attempts to renegotiate or outstanding rights to renegotiate any material amounts paid or payable to Seller (or, as applicable, Cytori UK) under any of the Contracts listed or required to be listed on Section 3.21(a) of the Disclosure Schedule. No Person has a Contractual or statutory right to demand or require such renegotiation and no such Person has made demand for such renegotiation.

SECTION 3.22 Products. Each product related to the Business and designed, manufactured, sold or delivered by Seller (or, as applicable, Cytori UK) was designed, manufactured, sold or delivered, as applicable, in conformity with all Laws, Contracts, and all express and implied warranties. No product related to the Business that is designed, manufactured, sold or delivered by Seller (or, as applicable, Cytori UK) is subject to any guaranty, warranty, or other indemnity or similar Liability beyond the applicable standard terms and conditions of sale, which have been made available to Buyer. Seller and Cytori UK have no Liability arising out of any injury to Persons or property as a result of the ownership, possession, or use of any product designed, manufactured, sold or delivered by Seller (or, as applicable, Cytori UK) in connection with the Business. No product designed, manufactured, sold or

delivered by Seller (or, as applicable, Cytori UK) in connection with the Business has been subject to a recall by Seller or its affiliates, any Governmental Authority or, to the Knowledge of Seller, any third Person.

SECTION 3.23 Relationships with Suppliers, Customers and Distributors.

(a) Section 3.23(a) of the Disclosure Schedule sets forth a list of the five largest suppliers for products and supplies of the Business in the Territory (including the combined business of Cytori UK), including dollar volume, for each of calendar years 2017 and 2018 and for 2019 year to date through the date hereof. Neither Seller nor Cytori UK has received any notice from any such supplier to the effect that, and, to the Knowledge of Seller, there is no reason to believe that, any such supplier will stop, materially decrease the rate of, or materially change the terms (whether related to payment, price or otherwise) with respect to, supplying materials, products or services to Seller for purposes of, or in connection with, the Business (including the combined business of Cytori UK).

(b) Section 3.23(b) of the Disclosure Schedule sets forth a list of the five largest customers of the Business in the Territory (including the combined business of Cytori UK), including dollar volume, for each of calendar years 2017 and 2018 and for 2019 year to date through the date hereof. Neither Seller nor Cytori UK has received notice from any such customer to the effect that, and, to the Knowledge of Seller, there is no reason to believe that, any such customer will stop, materially decrease the rate of, or change the terms (whether related to payment, price or otherwise) with respect to, buying products or services from the Business (including the combined business of Cytori UK).

(c) Section 3.23(c) of the Disclosure Schedule sets forth a list of the five largest distributors of the Business in the Territory (including the combined business of Cytori UK), including dollar volume, for each of calendar years 2017 and 2018 and for 2019 year to date through the date hereof. Neither Seller nor Cytori UK has received notice from any such distributor to the effect that, and, to the Knowledge of Seller, there is no reason to believe that, any such distributor will stop, materially decrease the rate of, or materially change the terms (whether related to payment, price or otherwise) with respect to, distributing products of the Business (including the combined business of Cytori UK).

(d) Neither Seller, Cytori UK, nor to Seller's Knowledge any of their representatives nor any Person acting on behalf of any of the foregoing (including through one or more intermediaries such as a consultant or other third party) has: (i) made, paid or received any bribes, kickbacks, or other similar payments to or from any Person (including any customer or supplier); (ii) made or paid any contributions, directly or indirectly, in exchange directly or indirectly for business or business opportunities; (iii) made any payment directly or indirectly, in exchange directly or indirectly for business or business opportunities; or (iv) agreed to do any of the foregoing in the immediately foregoing clauses (i) through (iii).

SECTION 3.24 Relationships with Affiliates. Except as disclosed in Section 3.24 of the Disclosure Schedule, no Affiliate (other than Cytori UK) of Seller has, or since the Reference Date has had, any interest in any property (whether real, personal or mixed and whether tangible or intangible) used in or pertaining to the Business in the Territory. Neither Seller nor any

Affiliate thereof (other than Cytori UK) owns, or since the Reference Date has owned, of record or as a beneficial owner, an equity interest or any other financial or profit interest in any Person that has (a) had business dealings or a material financial interest in any transaction with the Business other than business dealings or transactions disclosed in Section 3.24 of the Disclosure Schedule, each of which has been conducted in the Ordinary Course of Business with Seller (or, as applicable, Cytori UK) at substantially prevailing market prices and on substantially prevailing market terms or (b) engaged in competition with the Business with respect to any line of the products or services of the Business in any market presently served by the Business, except for ownership of less than one percent (1%) of the outstanding capital stock of any such competing business that is publicly traded on any recognized exchange or in the over-the-counter market. Except as set forth in Section 3.24 of the Disclosure Schedule, no Affiliate of Seller (other than Cytori UK) is a party to any Contract with, has any claim or right against, or is indebted to, the Business. The Business is not indebted or otherwise obligated to any other businesses of Seller or its Affiliates (other than Cytori UK), except for amounts due under normal arrangements applicable to all employees generally as to salary or reimbursement of ordinary business expenses not unusual in amount or significance.

SECTION 3.25 Brokers. No broker, finder or investment banker is entitled to any brokerage, finder's or other fee or commission in connection with the transactions contemplated by this Agreement or the Ancillary Agreements based upon arrangements made by or on behalf of Seller or Cytori UK.

SECTION 3.26 Capitalization. As of the date of this Agreement, the entire authorized Capital Stock of Cytori UK is as set forth set forth in Section 3.26 of the Disclosure Schedule. All of the outstanding shares of Capital Stock and equity interests of Cytori UK have been duly authorized, validly issued, and are fully paid and non-assessable. All of the outstanding equity interests of Cytori UK (including, without limitation, any and all options, warrants, subscriptions, or other securities convertible into or exchangeable or exercisable for equity interests of Seller) are held of record and beneficially owned by Seller. All of the outstanding equity interests in Cytori UK are set forth in Section 3.26 of the Disclosure Schedule and are validly issued, fully paid and non-assessable. There are no preemptive rights or other similar rights in respect of any equity interests in Cytori UK, except as imposed by applicable securities laws, there are no Encumbrances on, or other Contracts relating to, the ownership, transfer or voting of any equity interests in Cytori UK, or otherwise affecting the rights of any holder of the equity interests in Cytori UK. There are outstanding (i) no Capital Stock of Cytori UK, and no Capital Stock of Cytori UK is authorized (to the extent applicable), issued or reserved for issuance, other than as set forth in Section 3.26 of the Disclosure Schedule, (ii) no Capital Stock of Cytori UK convertible into or exchangeable for Capital Stock of Cytori UK, (iii) no options, warrants or other rights to acquire any Capital Stock from Cytori UK, (iv) no obligations of Cytori UK to issue any Capital Stock or securities convertible into or exchangeable for Capital Stock of Cytori UK, or (v) no equity appreciation, phantom equity, profit participation or similar rights with respect to any Capital Stock of Cytori UK. Cytori UK has not any authorized or outstanding bonds, debentures, notes or other indebtedness the holders of which have the right to vote (or are convertible into, exchangeable for or evidencing the right to subscribe for or acquire securities having the right to vote) with the equityholders of Cytori UK on any matter. There are no Contracts to which Cytori UK is a party or by which it is bound to (i) repurchase, redeem or otherwise acquire any Capital Stock of Cytori UK or (ii) vote or dispose of any Capital Stock of

Cytori UK. No Person has any right of first offer, right of first refusal or preemptive right in connection with any future offer, sale or issuance of Capital Stock of Cytori UK.

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF BUYER

Buyer hereby represents and warrants to Seller as follows:

SECTION 4.01 Organization and Authority of Buyer. Buyer is an entity duly incorporated, validly existing and, where applicable, in good standing under the laws of the jurisdiction of its incorporation and has all necessary corporate power and authority to enter into this Agreement and the Ancillary Agreements to which it is a party, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby and to conduct its business as it is now being conducted, to own or use the properties and assets that it purports to own or use, and to perform all of its obligations in its business. Buyer is duly licensed or qualified to do business and is in good standing in each jurisdiction in which the properties owned or leased by it or the operation of its business makes such licensing or qualification necessary, except to the extent that the failure to be so licensed, qualified or in good standing would not (a) adversely affect the ability of Buyer to carry out its obligations under, and to consummate the transactions contemplated by, this Agreement and the Ancillary Agreements, or (b) otherwise have a Material Adverse Effect. The execution and delivery of this Agreement and the Ancillary Agreements to which it is a party by Buyer, the performance by Buyer of its obligations hereunder and thereunder and the consummation by Buyer of the transactions contemplated hereby and thereby have been duly authorized by all requisite corporate action on the part of Buyer. This Agreement has been duly executed and delivered by Buyer and upon their execution the Ancillary Agreements to which Buyer is a party shall have been, duly executed and delivered by Buyer, and (assuming due authorization, execution and delivery by Seller (or, as applicable, Cytori UK)) this Agreement constitutes, and upon their execution the Ancillary Agreements to which Buyer is a party shall constitute, legal, valid and binding obligations of Buyer, enforceable against Buyer in accordance with their respective terms, subject to the Enforceability Exceptions.

SECTION 4.02 No Conflict. Assuming that all consents, approvals, authorizations and other actions described in Section 3.04 have been obtained, all filings and notifications listed in Section 3.04 of the Disclosure Schedule have been made, and any applicable waiting period has expired or been terminated, and except as may result from any facts or circumstances relating solely to Seller (or, as applicable, Cytori UK), the execution, delivery and performance of this Agreement and the Ancillary Agreements to which it is a party by Buyer do not and will not, directly or indirectly (with or without notice or lapse of time) (a) violate, conflict with or result in the breach of the certificate of incorporation or bylaws (or similar Organizational Documents) of Buyer or any resolutions adopted by the Board of Directors or the stockholders of Buyer, (b) conflict with or violate any Law or Governmental Order applicable to Buyer or give any Governmental Authority or other Person the right to challenge any of the transactions contemplated by this Agreement or to exercise any remedy or obtain any relief under any Law or Governmental Order applicable to Buyer, except, in the case of clause (b), as would not

materially and adversely affect the ability of Buyer to carry out its obligations under, and to consummate the transactions contemplated by, this Agreement and the Ancillary Agreements.

SECTION 4.03 Governmental Consents and Approvals. The execution, delivery and performance by Buyer of this Agreement and each Ancillary Agreement to which Buyer is a party do not and will not require any consent, approval, authorization or other order of, action by, filing with, or notification to, any Governmental Authority, except (a) where failure to obtain such consent, approval, authorization or action, or to make such filing or notification, would not prevent or materially delay the consummation by Buyer of the transactions contemplated by this Agreement and the Ancillary Agreements or (b) as may be necessary as a result of any facts or circumstances relating solely to Seller or any of its Affiliates.

SECTION 4.04 Litigation. As of the date hereof, no Action by or against Buyer is pending or, to the best knowledge of Buyer, threatened, which could affect the legality, validity or enforceability of this Agreement, any Ancillary Agreement or the consummation of the transactions contemplated hereby or thereby.

SECTION 4.05 Brokers. No broker, finder or investment banker is entitled to any brokerage, finder's or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Buyer.

SECTION 4.06 Financial Capacity; Solvency. Immediately prior to and at the Closing, Buyer will have immediately available cash that is sufficient to enable it to pay the full consideration payable hereunder and to make all other payments required to be made by Buyer in connection with the transactions contemplated hereby.

ARTICLE V

ACTIONS PRIOR TO THE CLOSING DATE

SECTION 5.01 Third-Party Consents. Buyer and Seller shall take, or cause to be taken by its respective Affiliates (including Cytori UK), all commercially reasonable steps to obtain and satisfy, at the earliest practicable date, all Required Consents and all other consents of all Governmental Authorities and other Persons that may be required to consummate the transactions contemplated by this Agreement; provided, however, that neither Buyer nor Seller shall be required to incur any financial or other obligation in connection therewith (other than transaction costs and filing fees that are normal and customary or otherwise required hereby to be incurred by such Party).

SECTION 5.02 Conduct of Business Prior to the Closing. From the date hereof until the Closing, except as otherwise provided in this Agreement or consented to in writing by Buyer (which consent shall not be unreasonably withheld, conditioned or delayed), Seller shall and shall cause Cytori UK to (x) conduct the Business in the Territory in the Ordinary Course of Business; and (y) use commercially reasonable efforts to maintain and preserve intact their current Business organization, operations and franchise in the Territory and to preserve the rights, franchises, goodwill and relationships of its employees, customers, lenders, suppliers, regulators and others having relationships with the Business in the Territory. Without limiting

the foregoing, from the date hereof until the Closing Date, Seller shall not take or permit any action listed on Section 3.08(b).

SECTION 5.03 Best Efforts. Subject to the terms and conditions of this Agreement, each Party will use best efforts to cause the Closing to occur (including, without limitation, the best efforts to execute any documents reasonably requested by either Party hereto and to satisfy such Party's conditions to Closing set forth herein).

SECTION 5.04 Confidentiality. The terms of the Mutual Nondisclosure Agreement by and between Buyer and Seller dated January 23, 2019 (the "Confidentiality Agreement") are hereby incorporated herein by reference and shall continue in full force and effect until the Closing, at which time the Confidentiality Agreement and the obligations of Buyer under this Section 5.04 shall terminate. If this Agreement is, for any reason, terminated prior to the Closing, the Confidentiality Agreement shall continue in full force and effect in accordance with its terms.

SECTION 5.05 Notification of Certain Events. From the date hereof until the earlier to occur of (a) the Closing Date or (b) termination of this Agreement, Seller shall give prompt written notice to Buyer of (i) the occurrence of any event that, individually or in combination with any other events, has had a Material Adverse Effect, (ii) any failure of Seller or Cytori UK to comply with or satisfy any covenant or agreement to be complied with or satisfied by it hereunder, (iii) any notice or other communication from any Person alleging that the consent of such Person is or may be required in connection with the consummation of the transactions contemplated by this Agreement or the Ancillary Agreements, or (iv) any Action pending or, to the Knowledge of Seller, threatened against a Party or the Parties relating to the transactions contemplated by this Agreement or the Ancillary Agreements.

SECTION 5.06 Exclusivity. Until the earlier of the Closing and such time as this Agreement is terminated in accordance its terms, except for the transactions contemplated by this Agreement or the sale of the Business outside of the Territory (provided such sale shall not include any Purchased Assets nor impair or inhibit Seller's ability to consummate the transaction on the terms set forth in this Agreement, including the Ancillary Agreements), Seller and its Affiliates (including Cytori UK) will not, and will cause their respective representatives not to, directly or indirectly, solicit, encourage or enter into any negotiation, discussion, contract, agreement, instrument, arrangement or understanding with any party, with respect to the sale of the Equity Interests or all or substantially all the assets of Cytori UK or the Business in the Territory, or any merger, recapitalization or similar transaction with respect to Cytori UK or the Business in the Territory.

SECTION 5.07 Access to Information. From the date hereof until the earlier to occur of (i) one year after the Closing or (ii) termination of this Agreement, Seller shall to the extent permitted by applicable Law (A) give, and shall cause its Affiliates to give, Buyer, its personnel, counsel, financial advisors, auditors and other authorized representatives reasonable access to its offices, properties, officers, employees, Contracts and Books and Records to the extent relating to the Business in the Territory or the Purchased Assets, (B) furnish, and shall cause its Affiliates to furnish, to Buyer, its personnel, counsel, financial advisors, auditors and other authorized representatives such financial and operating data and other information relating to Cytori UK as

such Persons may reasonably request, and (C) instruct the employees, counsel and financial advisors of Seller or its Affiliates to reasonably cooperate with Buyer in its investigation of Cytori UK. Any investigation pursuant to this Section shall be conducted in such manner as not to unreasonably interfere with the conduct of the Business.

SECTION 5.08 Crossed Books and Records and Software. Prior to, and for one year after, the Closing, the Parties shall cooperate in good faith to transfer any Books and Records or Software which has been allocated to either Party hereunder, but which is stored in the computers or servers or other electronic storage medium contained in Tangible Personal Property that has been allocated to the other Party hereunder, to the proper Party.

SECTION 5.09 Termination of Affiliate Contracts. Prior to the Closing Date, except as set forth on Section 5.09 of the Disclosure Schedule and except for the Intercompany Indebtedness, Seller shall, and shall cause Cytori UK to cause, all Liabilities between Cytori UK or, with respect to the Business in the Territory, Seller, on the one hand, and one or more of its Affiliates (including Seller but not including Cytori UK) on the other hand, including (i) any and all Indebtedness between Cytori UK, on the one hand, and one or more of its Affiliates (including Seller but not including Cytori UK), on the other hand, and (ii) any and all Contracts (other than this Agreement and any Ancillary Agreement) between Cytori UK or, with respect to the Business in the Territory, Seller, on the one hand, and one or more of its Affiliates (including Seller but not including Cytori UK), on the other hand, including all contracts listed on Section 3.24 of the Disclosure Schedule, to be paid in full and settled prior to the Closing without any Liabilities (including Liabilities arising from such termination) on the part of Buyer or any of its Affiliates (including, after the Closing, Cytori UK), except for this Agreement, the Ancillary Agreements, and those contracts or other transactions set forth on Section 5.09 of the Disclosure Schedule (the “Termination of the Affiliate Contracts”).

ARTICLE VI

ADDITIONAL AGREEMENTS

SECTION 6.01 Confidentiality. After the Closing, Seller shall hold and shall cause each of its Affiliates to hold, and Seller shall use its reasonable efforts to cause its and its Affiliates’ respective officers, directors, employees, accountants, counsel, consultants, advisors and agents to hold, in confidence, unless compelled to disclose by Law, all confidential documents and information concerning Cytori UK or the Business in the Territory, except to the extent that such information is (a) in the public domain through no fault of Seller or its Affiliate or (b) later lawfully acquired by Seller following the Closing Date from sources other than those related to its prior ownership of Cytori UK and the Business. The obligation of Seller to hold and to cause its Affiliates to hold any such information in confidence shall be satisfied if it exercises at least the same care with respect to such information as it would take to preserve the confidentiality of its own similar information.

SECTION 6.02 Business Relationships. For a period of 1 year after the Closing, Seller shall cooperate with Buyer in its efforts to continue and maintain for the benefit of Buyer those business relationships of Seller and Cytori UK existing prior to the Closing and relating to the Business in the Territory, including relationships with lessors, employees, Governmental

Authorities, licensors, customers, suppliers and others. Seller shall refer to Buyer all inquiries relating to the Business in the Territory.

SECTION 6.03 Crossed Payments. If, after the Closing Date, either Party shall receive any payments or other funds due to the other Party pursuant to the terms of this Agreement or any Ancillary Agreement, then the Party receiving such funds shall, within 30 days after receipt of such funds, forward such funds to the proper Party. The Parties acknowledge and agree there is no right of offset regarding such payments and a Party may not withhold funds received from Third Parties for the account of the other Party in the event there is a dispute regarding any other issue under this Agreement or any of the Ancillary Agreements.

SECTION 6.04 Further Assurances. Each of Seller and Buyer shall, at any time or from time to time after the Closing, at the request and expense of the other, execute and deliver to the other all such instruments and documents or further assurances as the other may reasonably request in order to (i) vest in Buyer all of Seller's (or Seller's Affiliates') right, title and interest in and to the Purchased Assets as contemplated hereby, (ii) effectuate Buyer's assumption of the Assumed Liabilities and (iii) grant to each Party all rights contemplated herein to be granted to such Party under this Agreement or the Ancillary Agreements; provided, that after the Closing, apart from such foregoing customary further assurances, neither Seller nor Buyer shall have any other obligations except as specifically set forth and described herein or in the Ancillary Agreements.

SECTION 6.05 Bulk Transfer Laws. Buyer hereby waives compliance by Seller with any applicable bulk sale or bulk transfer laws of any jurisdiction in connection with the sale of the Purchased Assets to Buyer.

SECTION 6.06 Non-Competition.

(a) For a period of five (5) years commencing on the Closing Date, Seller and Cytori Japan shall not, and shall not permit any of their Affiliates, successors or assigns to (Seller, Cytori Japan, or their Affiliates and their successors and assigns, the "Seller Restricted Parties"), directly or indirectly (including through one or more intermediaries) (i) own, manage, operate, control, be employed by or participate in the ownership, management, operation or control of, or otherwise engage in or assist others in engaging in any business competitive with the Business in the Territory (the "Seller Restricted Business"); (ii) take any action that would or would reasonably be expected to assist any third party to compete with the Business in the Territory, or (iii) have an interest in any Person that engages directly or indirectly in the Seller Restricted Business. Notwithstanding the foregoing, (x) Seller, Cytori, Japan, and their Affiliates may own, directly or indirectly, solely as an investment, securities of any company in the Seller Restricted Business traded on any national securities exchange if Seller, Cytori Japan, and their Affiliates do not control, and are not members of a group which controls, such company and do not, directly or indirectly, own 5% or more of any class of securities of such company; (y) Seller, Cytori Japan, and their Affiliates may, directly or indirectly, acquire, carry on, manage, engage, take part in, render services to, own, share in the earnings of or invest in the securities of any business or entity 10% or less of whose gross revenues for the preceding calendar year were not, and for the calendar year in question are not reasonably expected to be, derived from being engaged in the Seller Restricted Business and (z) Cytori Japan (and its

successors or assigns) may continue to operate the Business in Japan, as currently conducted by Cytori Japan; provided Seller, Cytori Japan, or any successors or assigns of the Cytori Japan business or assets may not manufacture, market, or sell products or otherwise conduct any part of the Business in the Territory.

(b) For a period of five (5) years commencing on the Closing Date, Buyer shall not, and shall not permit any of its Affiliates, successors or assigns to (Buyer or its Affiliates and their successors and assigns, the “Buyer Restricted Parties”), directly or indirectly (including through one or more intermediaries) (i) own, manage, operate, control, be employed by or participate in the ownership, management, operation or control of, or otherwise engage in or assist others (other than the Seller Restricted Parties) in engaging in any business competitive with the Business in Japan (the “Buyer Restricted Business”); (ii) take any action that would or would reasonably be expected to assist any third party (other than a Seller Restricted Party) to compete with the Business in Japan, or (iii) have an interest in any Person (other than a Seller Restricted Party) that engages directly or indirectly in the Buyer Restricted Business. Notwithstanding the foregoing, (x) Buyer and its Affiliates may own, directly or indirectly, solely as an investment, securities of any company in the Buyer Restricted Business traded on any national securities exchange if Buyer and its Affiliates do not control, and are not members of a group which controls, such company and do not, directly or indirectly, own 5% or more of any class of securities of such company; (y) Buyer and its Affiliates may, directly or indirectly, acquire, carry on, manage, engage, take part in, render services to, own, share in the earnings of or invest in the securities of any business or entity 10% or less of whose gross revenues for the preceding calendar year were not, and for the calendar year in question are not reasonably expected to be, derived from being engaged in the Buyer Restricted Business. For purposes of clarity, nothing in this Section 6.06(b) shall prevent Buyer or any of its Affiliates from owning any interest in, or engaging in any transaction with, a Seller Restricted Party.

(c) It is the desire and intent of the Parties that the provisions of this Section 6.06 shall be enforced to the fullest extent permissible under the Laws and public policies applied in each jurisdiction in which enforcement is sought. If any particular provision of this Section 6.06 is adjudicated to be invalid or unenforceable, then this Section 6.06 shall be deemed amended to delete therefrom such provision or portion adjudicated to be invalid or unenforceable; such amendment to apply only with respect to the operation of this Section 6.06 in the particular jurisdiction in which such adjudication is made.

(d) The Parties recognize that the performance of the obligations under this Section 6.06 by the Restricted Parties is special, unique and extraordinary in character. Each Restricted Party acknowledges and agrees that irreparable injury will result to Buyer, Cytori UK and the Business in the Territory in the event of a breach of any of the provisions of this Section 6.06 and that Buyer, Cytori UK and the Business will have no adequate remedy at law with respect thereto. Accordingly, in the event of the breach by a Restricted Party of any of the terms and conditions of this Section 6.06, in addition to any other legal or equitable remedy that Buyer may have, (i) Buyer shall be entitled to obtain damages for any breach of this Section 6.06 and (ii) without having to demonstrate (A) the inadequacy of money damages, (B) the likelihood of success on the merits, (C) damages, or (D) irreparable harm and (to the extent permitted by Law) without posting a bond or other security, Buyer shall be entitled to (1) enforce the specific performance of each provision of this Section 6.06 by the Restricted Parties or (2) enjoin the

Restricted Parties from violating the terms of this Section 6.06, including through entry of a preliminary injunction or a permanent injunction by a court of competent jurisdiction. Each Restricted Party agrees, on behalf of itself and its Affiliates, to submit to the jurisdiction of such court in any such Action.

(e) In the event that a Restricted Party violates any provision of this Section 6.06, the Restricted Period shall be automatically tolled to account for the period of violation (including until all appeals, if any, are resolved).

SECTION 6.07 Cooperation. If a Party to this Agreement or any of their respective Affiliates shall become engaged or participate in any other legal or regulatory proceeding involving or relating to (a) the transactions contemplated by this Agreement and the Ancillary Agreements or (b) any action, activity, circumstance, condition, conduct, event, fact, failure to act, incident, occurrence, plan, practice, situation, status or transaction on or before the Closing Date involving Seller, Buyer, Cytos UK, or the Business in the Territory, then the other Party shall cooperate with such Party in connection therewith, including, making available to such Party, without cost, all relevant records and using its commercially reasonable efforts to make available the employees of such Party or its Affiliates who are reasonably expected by the Party engaged in such legal or regulatory proceeding to be helpful with respect to such legal or regulatory proceeding and who may, from time to time, be requested to make themselves available to provide depositions, testimony and other discovery in connection with any such legal or regulatory proceeding or to provide other information in connection with the defense of such matters. Notwithstanding the foregoing, Seller shall control and conduct the prosecution of, and defense against, any such legal proceeding that may constitute an Excluded Liability. For the avoidance of doubt, in no instance shall the obligations set forth under this Section 6.07 cause or create any Liability under any provision of this Agreement or any Ancillary Agreement for any damages.

SECTION 6.08 Termination of Current License Agreement. Buyer and Seller acknowledge and agree that upon the Closing, without any further action on the part of any Person, the Amended and Restated License and Supply Agreement dated January 30, 2014 and any and all outstanding invoices related thereto will be terminated and cease to have any further force or effect.

SECTION 6.09 Employees and Employee Benefits.

(a) On the Closing Date, Seller shall terminate all employees identified on Section 6.09(a)(i) of the Disclosure Schedule who are actively at work on the Closing Date (the “Transferred Employees”) and Buyer, or an Affiliate of Buyer, shall offer employment, on an “at will” basis, to such Transferred Employees. Seller shall fully comply with any obligations under the Worker Adjustment and Retraining Notification Act, as amended and any state law counterpart (collectively, the “WARN Act”) with respect to the employment losses pursuant to this Section 6.09 and shall bear any and all obligations and liability under resulting such employment losses.

(b) Seller shall be solely responsible, and Buyer shall have no obligations whatsoever for, any compensation or other amounts payable to any current or former employee,

officer, director, independent contractor or consultant of Seller, including, without limitation, hourly pay, commission, bonus, salary, accrued vacation, fringe, pension or profit sharing benefits or severance pay for any period relating to the service with Seller at any time on or prior to the Closing Date and Seller shall pay all such amounts to all entitled persons on or prior to the Closing Date.

(c) Seller shall remain solely responsible for the satisfaction of all claims for medical, dental, life insurance, health accident or disability benefits brought by or in respect of current or former employees, officers, directors, independent contractors or consultants of Seller or the spouses, dependents or beneficiaries thereof, which claims relate to events occurring on or prior to the Closing Date. Seller also shall remain solely responsible for all worker's compensation claims of any current or former employees, officers, directors, independent contractors or consultants of Seller which relate to events occurring on or prior to the Closing Date. Seller shall pay, or cause to be paid, all such amounts to the appropriate persons as and when due. Seller shall remain solely responsible for maintaining a group health plan that will have the obligation to make group health plan continuation coverage available to any "M&A qualified beneficiaries" (within the meaning of Treasury Regulation Section 54-4980B-9, Q&A-4) with respect to the transaction contemplated under this Agreement.

(d) Notwithstanding anything herein to the contrary, this Section 6.09 shall not apply to any employees of Cytori UK or Cytori Japan.

SECTION 6.10 Third Party Consents. To the extent that Seller's rights under any Contract or Purchased Permit constituting a Purchased Asset, or any other Purchased Asset, may not be assigned to Buyer without the consent of another Person which has not been obtained, this Agreement shall not constitute an agreement to assign the same if an attempted assignment would constitute a breach thereof or be unlawful, and Seller, at its expense, shall use its commercially reasonable efforts to obtain any such required consent(s) as promptly as practicable. If any such consent shall not be obtained or if any attempted assignment would be ineffective or would impair Buyer's rights under the Purchased Asset in question so that Buyer would not in effect acquire the benefit of all such rights, then for a period of 12 months after the Closing, Seller, to the maximum extent permitted by law and the Purchased Asset, shall act after the Closing as Buyer's agent in order to obtain for it the benefits thereunder and shall cooperate, to the maximum extent permitted by Law and the Purchased Asset, with Buyer in any other reasonable arrangement designed to provide such benefits to Buyer. Notwithstanding any provision in this Section 6.10 to the contrary, (a) Buyer shall not be deemed to have waived its rights under Section 8.01 hereof unless and until Buyer provides written waivers thereof and (b) nothing in this Section 6.10 shall be deemed to relieve Seller of its liability for breach of Section 3.02.

SECTION 6.11 Intercompany Indebtedness. The Parties acknowledge and agree that as of the date hereof, Cytori UK owes Seller \$1,000,000 of Indebtedness (the "Intercompany Indebtedness"). Immediately after the Closing, Buyer shall cause Cytori UK to repay Seller the Intercompany Indebtedness by wire transfer in immediately available funds to the bank accounts specified in writing by Seller to Buyer no less than three (3) Business Days prior to the Closing. In the event, Cytori UK has any Indebtedness to any Person as of the Closing, other than the

Intercompany Indebtedness, Seller shall within (5) days written notice by Buyer pay the amount of such Indebtedness to Cytori UK in immediately available funds.

ARTICLE VII

TAX MATTERS

SECTION 7.01 Conveyance Taxes. All Conveyance Taxes shall be borne and paid 50% by Buyer and 50% by Seller. With respect to the preparation and filing of Tax Returns for such Conveyance Taxes, (i) the party legally responsible for filing any Tax Return relating to such Conveyance Taxes shall timely file such Tax Return; (ii) the party legally responsible for filing such Tax Return will use commercially reasonable efforts to provide such Tax Return to the other party at least five (5) Business Days prior to the due date for such Tax Return for such party's review and comments (which shall be considered in good faith), and (iii) at least two (2) Business Days prior to the due date for filing such Tax Return, the non-filing party shall, pay to the filing party (or any of its Affiliates, as applicable), 50% of the amount of any Conveyance Taxes required to be paid with respect to such Tax Return. The Parties shall cooperate to minimize or avoid any Conveyance Taxes that might be imposed to the extent permitted by Law.

SECTION 7.02 Tax Allocation. Taxes for any Straddle Period shall be allocated to the Pre-Closing Tax Period and the Post-Closing Tax Period as follows: any allocation of (a) Taxes, other than those referred to in the succeeding clause (b), shall be made by means of an interim closing of the books and records of Seller and Cytori UK as of the end of the Closing Date; provided, however, that exemptions, allowances or deductions that are calculated on an annual basis (including depreciation and amortization deductions) shall be allocated between the Pre-Closing Tax Period and the Post-Closing Tax Period in proportion to the relative number of days in each such period, and (b) property Taxes and ad valorem Taxes shall be allocated between such two periods in proportion to the relative number of days in each such period.

SECTION 7.03 Tax Cooperation. Buyer and Seller agree to provide all reasonable assistance to, and to cooperate with, each other to the extent reasonably requested from and after the Closing Date in connection with any and all matters which may arise with respect to Tax documents or any Tax issues related to the Purchased Assets, the Business or Cytori UK, including providing reasonable access to books and records reasonably necessary for preparation of Tax Returns. Any expenses incurred in furnishing such information or assistance shall be borne by the Party requesting it.

SECTION 7.04 Tax Returns.

(a) At the sole expense of Seller, Seller shall cause to be prepared and filed all federal and state income Tax Returns required to be filed by Cytori UK for taxable periods ending prior to or on the Closing Date which are to be filed after the Closing Date (the "Seller Returns"). Each such Seller Return shall be prepared in a manner consistent with Cytori UK's past practice except as otherwise required by Law. Seller shall provide Buyer with a copy of any such Seller Return for its review and comment at least thirty (30) days prior to its filing due date and Seller shall make any changes reasonably requested by Buyer to such Seller Return. After such review, Seller will submit such Seller Returns to Buyer for filing on behalf of Cytori UK.

(b) Buyer shall cause Cytori UK to cause to be prepared and filed all Tax Returns, other than the Seller Returns, for a Pre-Closing Tax Period (at Seller's sole expense) or a Straddle Period (at Buyer's sole expense) which are required to be filed by Cytori UK after the Closing Date (the "Buyer Returns"). Each such Buyer Return shall be prepared in a manner consistent with Cytori UK's past practice except as otherwise required by Law. Buyer shall submit a copy of each such Buyer Return relating to income Taxes ("Buyer Income Tax Return") to Seller at least thirty (30) days prior to the due date for the filing of such Buyer Income Tax Return (taking into account any valid extensions of time to file) and Buyer shall make any changes reasonably requested by Seller to such Buyer Income Tax Return.

(c) At least five (5) Business Days prior to the due date for filing any Seller Return or Buyer Return, Seller shall promptly pay to Buyer all Indemnified Taxes (to the extent such Taxes were not reflected as a liability in the calculation of Indebtedness) shown to be due on any Tax Return to be filed by or with respect to Cytori UK for any Pre-Closing Tax Periods which are due after the Closing Date and for any Straddle Periods.

SECTION 7.05 Purchase Price Allocation.

(a) Buyer will prepare and deliver to Seller, within sixty (60) days after the Closing Date, an allocation of the Purchase Price (as finally adjusted pursuant to this Agreement, and including any Assumed Liabilities treated as consideration for the Purchased Assets and the Equity Interests for Tax purposes) first among the Purchased Assets and the Equity Interests, then, the amount allocated to the Purchased Assets shall be further allocated among such Purchased Assets (the "Allocations"). In each case, the aforementioned Allocations shall be prepared in accordance with Section 1060 of the Code. The Allocations shall be deemed final unless Seller notifies Buyer in writing (such written notice, an "Objection Notice") that Seller objects to one or more items reflected in the Allocations within twenty (20) days after delivery of the Allocations to Seller (the "Review Period"). In the event of any such objection, Seller and Buyer shall negotiate in good faith to resolve such dispute; *provided, however*, that if Seller and buyer are unable to resolve any dispute with respect to the Allocations within thirty (30) days after deliver of the Allocations to Seller, such dispute shall be resolved as set forth on Sections 7.05(b) and 7.05(c). Seller and Buyer agree to file their respective IRS Forms 8594 and all federal, state, and local Tax Returns in accordance with the Allocation.

(b) With respect to any disputed amounts, Seller and Buyer will negotiate in good faith during the 30-day period (the "Resolution Period") after the Review Period to resolve any such disputes. If Seller and Buyer are unable to resolve all such disputes within the Resolution Period, then either Party may submit the disputes to a Neutral Accounting Firm that is mutually agreed upon by Buyer and Seller (the "Accountant"), who will be engaged by both parties to provide a final and conclusive resolution of all unresolved disputes in accordance with this Section 7.05.

(c) The Accountant will act as an expert to determine only those issues identified in the Objection Notice, and such determination will be based solely on a review of the factual materials presented by Seller and Buyer, either on their own initiative or at the specific request of the Accountant, and the applicable provisions of this Agreement. Seller and Buyer each shall be permitted to present a supporting brief to the Accountant (which supporting brief

shall also be concurrently provided to the other party) within ten (10) days of the appointment of the Accountant. Within ten (10) days of receipt of a supporting brief, the receiving party may present a responsive brief to the Accountant (which responsive brief shall also be concurrently provided to the other party). Each party may make an oral presentation to the Accountant (in which case, such presenting party shall notify the other party of such presentation, and the other party shall have the right to be present (but not speak) at such presentation) within forty-five (45) days of the appointment of the Accountant. The parties will instruct the Accountant to not assign a value to any item in dispute greater than the greatest value for such item assigned by Buyer in the Allocation, on the one hand, or Seller in the Objection Notice, on the other hand, or less than the smallest value for such item assigned by Buyer in the Allocation, on the one hand, or Seller in the Objection Notice, on the other hand. The Accountant shall deliver to Buyer and Seller, as promptly as practicable and in any event within sixty (60) days after its appointment, a written report setting forth the resolution of any such disagreement determined in accordance with the terms of this Agreement. The determination of the Accountant will be final and binding on the parties absent manifest error, and the Allocation as adjusted by such determination will be final. The fees and expenses of the Accountant will be borne by each party in the proportion that the aggregate dollar amount of items submitted to the Accountant that are unsuccessfully disputed by such party bears to the aggregate dollar amount of all items submitted to the Accountant.

ARTICLE VIII

CONDITIONS TO CLOSING

SECTION 8.01 Buyer Closing Conditions. The obligations of Buyer to consummate the transactions contemplated herein shall be subject to the fulfillment, at or prior to the Closing, of each of the following conditions:

(a) Other than the Fundamental Representations of Seller, the representations and warranties of Seller contained in this Agreement, the Ancillary Documents and any certificate or other writing delivered pursuant hereto shall be true and correct in all respects (in the case of any representation or warranty qualified by materiality or Material Adverse Effect) or in all material respects (in the case of any representation or warranty not qualified by materiality or Material Adverse Effect) on and as of the date hereof and on and as of the Closing Date with the same effect as though made at and as of such date (except those representations and warranties that address matters only as of a specified date, the accuracy of which shall be determined as of that specified date in all respects). The Fundamental Representations of Seller shall be true and correct in all respects on and as of the date hereof and on and as of the Closing Date with the same effect as though made at and as of such date (except those representations and warranties that address matters only as of a specified date, the accuracy of which shall be determined as of that specified date in all respects).

(b) Seller shall have duly performed and complied in all material respects with all agreements, covenants and conditions required by this Agreement and each of the Ancillary Documents to be performed or complied with by it prior to or on the Closing Date.

(c) Since the date of this Agreement, there shall not have occurred any change, circumstance or effect that, individually or in the aggregate, has had a Material Adverse Effect.

(d) Seller shall have delivered to Buyer all the items specified to be delivered in Section 2.05.

(e) There shall not be in effect on the Closing Date any Law or Governmental Order restraining or enjoining the carrying out of this Agreement or the consummation of the transactions contemplated by this Agreement.

(f) The consents, approvals, waivers, and notices set forth on Section 8.01(f) of the Disclosure Schedule shall have been obtained in form and substance reasonably acceptable to Buyer (the “Required Consents”).

(g) Seller shall have delivered to Buyer true and complete copies of all payoff letters in form and substance reasonably satisfactory to Buyer, evidencing the release of all Encumbrances other than Permitted Liens upon payment of the Indebtedness of the Business and Cytori UK.

(h) All approvals, consents, waivers, amendments, and Permits that are listed on Section 8.01(h) of the Disclosure Schedule shall have been received in form and substance reasonably acceptable to Buyer.

(i) The Termination of the Affiliate Contracts shall have been consummated in form and substance reasonably acceptable to Buyer.

SECTION 8.02 Seller Closing Conditions. The obligations of Seller to consummate the transactions contemplated herein shall be subject to the fulfillment, at or prior to the Closing, of each of the following conditions:

(a) Other than the Fundamental Representations of Buyer, the representations and warranties of Buyer contained in this Agreement, the Ancillary Documents and any certificate or other writing delivered pursuant hereto shall be true and correct in all respects (in the case of any representation or warranty qualified by materiality or Material Adverse Effect) or in all material respects (in the case of any representation or warranty not qualified by materiality or Material Adverse Effect) on and as of the date hereof and on and as of the Closing Date with the same effect as though made at and as of such date (except those representations and warranties that address matters only as of a specified date, the accuracy of which shall be determined as of that specified date in all respects). The Fundamental Representations of Buyer shall be true and correct in all respects on and as of the date hereof and on and as of the Closing Date with the same effect as though made at and as of such date).

(b) Buyer shall have duly performed and complied in all material respects with all agreements, covenants and conditions required by this Agreement and each of the Ancillary Documents to be performed or complied with by it prior to or on the Closing Date.

(c) Seller shall have duly performed and complied in all material respects with all agreements, covenants and conditions required by this Agreement and each of the Ancillary Documents to be performed or complied with by it prior to or on the Closing Date

(d) Since the date of this Agreement, there shall not have occurred any change, circumstance or effect that, individually or in the aggregate, has had a Material Adverse Effect.

ARTICLE IX

INDEMNIFICATION

SECTION 9.01 Survival of Representations and Warranties. The representations and warranties of Seller and Buyer shall survive until the eighteen (18) month anniversary of the Closing Date; provided, however, that (a) the Fundamental Representations shall survive until sixty (60) days after the expiration of the applicable statutes of limitations (taking into account any extensions or waivers thereof) and (b) there shall be no limitations with respect to claims relating to fraud, intentional misrepresentation or willful misconduct; and provided further, that any claim made in good faith and with reasonable specificity by the party seeking to be indemnified within the time periods set forth in this Section 9.01 shall survive until such claim is finally and fully resolved. The covenants and other agreements of the Parties contained in this Agreement and the Ancillary Agreements shall survive the Closing Date until they are otherwise terminated by their terms.

SECTION 9.02 Indemnification by Seller. Buyer and its Affiliates, officers, directors, employees, agents, successors and assigns and their respective shareholders, directors, officers and employees (each, a "Buyer Indemnified Party") shall be indemnified, reimbursed and held harmless by Seller for and against all losses, damages, claims, costs, Taxes and expenses, interest, awards, judgments and penalties (including reasonable attorneys' and consultants' fees and expenses) suffered or incurred by them (hereinafter, a "Loss"), arising out of or resulting from:

(a) any inaccuracy in or any breach of any representation or warranty made by Seller contained in this Agreement, other than breaches of Fundamental Representations;

(b) any inaccuracy in or any breach of any representation or warranty made by Seller in any Fundamental Representation;

(c) the breach of any covenant or agreement by Seller (or, as applicable, Cytos UK) contained in this Agreement or any Ancillary Agreement;

(d) any Excluded Liability or Excluded Asset;

(e) any Liability imposed upon Buyer by reason of Buyer's status as transferee of the Business or the Purchased Assets or by reason of non-compliance with applicable bulk transfer provisions of Law in connection with the transactions contemplated by this Agreement;

(f) Indemnified Taxes; and

(g) any Liability imposed upon Buyer by any shareholder of Seller in their capacity as such.

SECTION 9.03 Indemnification by Buyer. Seller and its Affiliates, officers, directors, employees, agents, successors and assigns (each, a “Seller Indemnified Party”) shall be indemnified, reimbursed and held harmless by Buyer for and against any and all Losses, arising out of or resulting from:

(a) any inaccuracy in or any breach of any representation or warranty made by Buyer contained in this Agreement;

(b) the breach of any covenant or agreement by Buyer contained in this Agreement or any Ancillary Agreement;

(c) any Liabilities first arising out of Buyer’s operation of the Business in the Territory after the Closing, other than Excluded Liabilities; or

(d) any Assumed Liability.

SECTION 9.04 Limits on Indemnification.

(a) No claim may be asserted nor shall any Action be commenced against any party hereto for breach of any representation, warranty, covenant or agreement contained herein, unless written notice of such claim or Action is received by such party describing in reasonable detail the facts and circumstances with respect to the subject matter of such claim or Action, to the extent known by the Indemnified Party, on or prior to the date on which the representation, warranty, covenant or agreement on which such claim or Action is based ceases to survive as set forth in Section 9.01, irrespective of whether the subject matter of such claim or Action shall have occurred before or after such date.

(b) Other than for claims relating to fraud, intentional misrepresentation or willful misconduct or for breaches of the Fundamental Representations (which shall not be subject to any limitations herein), the indemnification provided for in this Agreement shall be subject to the following limitations:

(i) Seller shall not have any obligation to indemnify any Buyer Indemnified Party under Section 9.02(a) unless and until the aggregate amount of all Losses of Buyer Indemnified Parties exceed \$20,000, in which event Seller shall be liable for the full amount of such Losses from the first dollar;

(ii) The aggregate amount required to be paid by Seller under Section 9.02(a) shall not exceed \$1,145,000; and

(iii) neither party hereto shall have any Liability under any provision of this Agreement or any Ancillary Agreement for any (i) punitive damages or (ii) special, indirect, or consequential damages that are not reasonably foreseeable as of the date of this Agreement,

except to the extent that such damages are paid by an Indemnified Party to a Third Party in a Third Party Claim.

(c) For all purposes of this ARTICLE IX, Losses shall be reduced by the net proceeds such Indemnified Party actually recovers from any third party or insurance provider resulting from making a claim thereunder less the costs of recovering such amounts, costs of investigation, any applicable deductibles and premiums.

(d) No Buyer Indemnified Party shall be entitled to indemnification under Section 9.02 for any Losses with respect to Tax attributes of Seller or any Losses attributable to Post-Closing Tax Periods (other than Losses arising in a Post-Closing Tax Period as a result of a breach of the representations in Section 3.20(o)).

SECTION 9.05 Notice of Loss; Third Party Claims. An Indemnified Party shall give the Indemnifying Party prompt notice (within 30 days of the incurrence of the related Loss) of any matter which an Indemnified Party has determined has given or could reasonably be expected to give rise to a right of indemnification under this Agreement, stating the amount of the Loss, if known, and method of computation thereof, and containing a reference to the specific provisions of this Agreement in respect of which such right of indemnification is claimed or arises; provided, however, that the failure to provide such notice shall not release the Indemnifying Party from any of its obligations under this ARTICLE IX except to the extent that such failure results in a detriment to the Indemnifying Party and shall not relieve the Indemnifying Party from any other Liability that it may have to any Indemnified Party other than under this ARTICLE IX.

(a) If an Indemnified Party shall receive notice of any Action, audit, claim, demand or assessment (each, a “Third Party Claim”) against it which may give rise to a claim for Loss under this ARTICLE IX, within thirty (30) days of the receipt of such notice, the Indemnified Party shall give the Indemnifying Party notice of such Third Party Claim; provided, however, that the failure to provide such notice shall not release the Indemnifying Party from any of its obligations under this ARTICLE IX except to the extent that such failure results in a detriment to the Indemnifying Party and shall not relieve the Indemnifying Party from any other Liability that it may have to any Indemnified Party other than under this ARTICLE IX. The Indemnifying Party shall be entitled to assume and control the defense of such Third Party Claim at its expense and through counsel of its choice if it gives notice of its intention to do so to the Indemnified Party within fifteen (15) days of the receipt of such notice from the Indemnified Party; provided, that the Indemnifying Party shall not have the right to assume the defense of such Third Party Claim if (i) the Indemnifying Party fails to conduct the defense of the claim actively and diligently, (ii) any applicable limitation herein would serve to limit the obligation of the Indemnifying Party to indemnify the Indemnified Party for all of the Losses which would be reasonably anticipated to result from such claim were it successful, (iii) the claim for indemnification relates to or arises in connection with any criminal Action, indictment or allegation against the Indemnified Party, (iv) the Indemnified Party reasonably concludes in good faith that, in light of any actual or potential conflict of interest which would be reasonably likely to occur, it would be inappropriate for legal counsel selected by the Indemnifying Party to represent the Indemnified Party, (v) the Indemnified Party believes in good faith that an adverse determination with respect to the Action giving rise to such claim for indemnification would be

materially detrimental to or materially injure the Indemnified Party's reputation or future business prospects, (vi) the Indemnifying Party is not reasonably anticipated to have the financial resources to indemnify the Indemnified Party if the claim is successful, or (vii) the claim for indemnification relates to or arises in connection with a Tax which is assessed or proposed to be assessed against Buyer or any of its Affiliates. If the Indemnifying Party elects to undertake the defense of a Third Party Claim, the Indemnified Party may participate in such defense at its own expense, other than reasonable costs of investigation, and the Indemnified Party shall cooperate with the Indemnifying Party in such defense and make available to the Indemnifying Party, at the Indemnifying Party's expense, all witnesses, pertinent records, materials and information in the Indemnified Party's possession or under the Indemnified Party's control relating thereto as is reasonably required by the Indemnifying Party. If the Indemnifying Party assumes the defense of a Third Party Claim, then no compromise or settlement of such Third Party Claims may be effected by the Indemnifying Party without the Indemnified Party's consent (not to be unreasonably withheld, conditioned or delayed) unless (A) there is no finding or admission of any violation of Law or any violation of the rights of any Person; (B) the sole relief provided is monetary damages that are paid in full by the Indemnifying Party; and (C) the Indemnified Party has no Liability with respect to such compromise or settlement. If notice is given to an Indemnifying Party of the assertion of any Third Party Claim and the Indemnifying Party does not, within fifteen (15) days after the Indemnified Party's notice is given, give notice to the Indemnified Party of the Indemnifying Party's election to assume the defense of such Third Party Claim, then the Indemnified Party may assume defense of such Third Party Claim. If the Indemnified Party assumes the defense of such Third Party Claim, then the Indemnifying Party shall have the right to participate in the settlement or assume or reassume the defense of such claims or proceeding.

(b) With respect to any Third Party Claim subject to indemnification under this ARTICLE IX: (i) both the Indemnified Party and the Indemnifying Party, as the case may be, shall keep the other Person fully informed of the status of such Third Party Claim and any related Actions at all stages thereof (it being understood that if both Parties are being represented by their own counsel with respect to any such Third Party Claim, then this clause (i) will be deemed to have been met, and (ii) the Parties agree (each at its own expense) to render to each other such assistance as they may reasonably require of each other and to cooperate in good faith with each other in order to ensure the proper and adequate defense of any Third Party Claim.

SECTION 9.06 Tax Treatment of Indemnification Payments. All indemnification payments made under this Agreement shall be treated by the Parties as an adjustment to the Purchase Price for tax purposes, unless otherwise required by Law.

SECTION 9.07 Effect of Investigation; Effect on Indemnity.

(a) The representations, warranties and covenants of the Indemnifying Party, and the Indemnified Party's right to indemnification with respect thereto, shall not be affected or deemed waived by reason of any investigation made by or on behalf of the Indemnified Party (including by any of its representatives) or by reason of the fact that the Indemnified Party or any of its representatives knew or should have known that any such representation or warranty is, was or might be inaccurate.

(b) For purposes of calculating the amount of Losses incurred by a party seeking indemnification hereunder arising out of or resulting from any breach of a representation, warranty covenant or agreement contained herein, references to Material Adverse Effect or materiality (or other similar terms) shall be disregarded.

SECTION 9.08 No Double Recovery. No Party is entitled to recover any Losses pursuant to this **ARTICLE IX** to the extent such Party previously actually recovered the full cash amount of such Losses pursuant to another provision of this Agreement.

SECTION 9.09 Remedies. Buyer and Seller acknowledge and agree that other than in the case of claims relating to fraud, intentional misrepresentation or willful misconduct (a) following the Closing, the indemnification provisions of **Section 9.02** and **Section 9.03** shall be the sole and exclusive remedies of Buyer and Seller for any breach by the other party of the representations and warranties in this Agreement and for any failure by the other party to perform and comply with any covenants and agreements in this Agreement, except that if any of the provisions of this Agreement are not performed in accordance with their terms or are otherwise breached, the parties shall be entitled to injunctive relief or specific performance of the terms thereof in addition to any other remedy at law or equity, and (b) anything herein to the contrary notwithstanding, no breach of any representation, warranty, covenant or agreement contained herein shall give rise to any right on the part of Buyer or Seller, after the consummation of the purchase and sale of the Purchased Assets and the Equity Interests contemplated by this Agreement, to rescind this Agreement or any of the transactions contemplated hereby. Each party hereto shall take reasonable steps as required by law to mitigate its Losses upon and after becoming aware of any event which could reasonably be expected to give rise to any Losses.

ARTICLE X

TERMINATION

SECTION 10.01 Termination. This Agreement may be terminated at any time prior to the Closing:

(a) by the mutual written consent of Seller and Buyer;

(b) by Buyer by written notice to Seller if (i) Buyer is not then in material breach of any provision of this Agreement and there has been a breach, inaccuracy in or failure to perform any representation, warranty, covenant or agreement made by Seller pursuant to this Agreement that would give rise to the failure of any of the conditions specified in **Section 8.01** and such breach, inaccuracy or failure has not been cured within ten days of Seller's receipt of written notice of such breach from Buyer; or (ii) any of the conditions set forth in **Section 8.01** shall not have been fulfilled by the 30th day hereafter, unless due to the failure of Buyer to perform or comply with any of the covenants, agreements or conditions hereof to be performed or complied with by it prior to the Closing;

(c) by Seller by written notice to Buyer if (i) Seller is not then in material breach of any provision of this Agreement and there has been a breach, inaccuracy in or failure

to perform any representation, warranty, covenant or agreement made by Buyer pursuant to this Agreement that would give rise to the failure of any of the conditions specified in Section 8.02 and such breach, inaccuracy or failure has not been cured within ten days of Buyer's receipt of written notice of such breach from Seller; or (ii) any of the conditions set forth in Section 8.02 shall not have been, or if it becomes apparent that any of such conditions will not be, fulfilled by the 30th day hereafter, unless due to the failure of Seller to perform or comply with any of the covenants, agreements or conditions hereof to be performed or complied with by it prior to the Closing; or

(d) by Buyer or Seller in the event that (i) there shall be any Law that makes consummation of the transactions contemplated by this Agreement illegal or otherwise prohibited, or (ii) any Governmental Authority shall have issued a Governmental Order restraining or enjoining the transactions contemplated by this Agreement, and such Governmental Order shall have become final and non-appealable.

SECTION 10.02 Effect of Termination. In the event of the termination of this Agreement in accordance with this ARTICLE X, this Agreement shall forthwith become void (other than the provisions of Section 11.03, ARTICLE XI and this ARTICLE X) provided that nothing herein shall relieve any party from liability for any breach of any provision hereof.

ARTICLE XI

GENERAL PROVISIONS

SECTION 11.01 Expenses. Except as otherwise specified in this Agreement, all costs and expenses, including, fees and disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement and the transactions contemplated by this Agreement shall be borne by the party incurring such costs and expenses, whether or not the Closing shall have occurred.

SECTION 11.02 Notices. Any notice, request, demand, waiver, consent, approval or other communication permitted or required under this Agreement (each, a "Notice") shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if delivered by hand, sent by internationally recognized overnight delivery service that maintains records of delivery, or sent by facsimile or e-mail addressed to the Parties, as applicable, at their respective addresses specified in this Section 11.02 or to such other address as the party to whom notice is to be given may have provided to the other Party at least five (5) Business Days prior to such address taking effect in accordance with this Section 11.02. Such Notice shall be deemed to have been given as of the date delivered by hand or internationally recognized overnight delivery service or when transmitted if transmitted without indication of delivery failure prior to 5:00 p.m. local time for the recipient (and if transmitted without indication of delivery failure after 5:00 p.m. local time for the recipient, then delivery will be deemed duly given at 9:00 a.m. local time for the recipient on the subsequent Business Day):

(a) if to Seller:

Cytori Therapeutics, Inc.

3020 Callan Road
San Diego, CA 92121
Telephone: (858) 458-0999
Attention: Marc Hedrick
Email: mhedrick@cytori.com

and, in each case, a copy (which shall not constitute effective notice) to:

Latham & Watkins LLP
650 Town Center Drive, 20th floor
Costa Mesa, CA 92626

Telephone: (714) 755-8069
Attention: David Lee; Cheston Larson
Email: david.lee@lw.com; cheston.larson@lw.com

(b) if to Buyer:

Lorem Vascular Pte. Ltd.
Level 12
2 Queen Street
Melbourne VIC Australia 3000

Telephone: +61 4 0888 6633
Attention: K.T. Lim, Chairman
Email: ktlim@loremvascular.com

and, in each case, a copy (which shall not constitute effective notice) to:

Sheppard Mullin Richter & Hampton LLP
12275 El Camino Real, Suite 200
San Diego, CA 92130-4092
Telephone: (858) 720-7470; (650) 815-2674
Attention: Michael S. Umansky; Tobin M. Dommer
Email: mumansky@sheppardmullin.com; tdommer@sheppardmullin.com

SECTION 11.03 Public Announcements. Neither Party to this Agreement shall make, or cause to be made, any press release or public announcement in respect of this Agreement or the transactions contemplated by this Agreement or otherwise communicate with any news media without the prior written consent of the other party unless otherwise required by Law or applicable stock exchange regulation, and the parties to this Agreement shall reasonably cooperate as to the timing and contents of any such press release, public announcement or communication; provided, that Seller or its Affiliates may make an announcement to any stock exchange on which such entity's shares are registered or otherwise to its shareholders regarding

the entry into the transaction pursuant to this Agreement; provided, further, that Buyer may make an announcement without the consent of Seller so long as such announcement does not disclose the financial terms hereof or any confidential information of Seller.

SECTION 11.04 Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any Law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect for so long as the economic or legal substance of the transactions contemplated by this Agreement is not affected in any manner materially adverse to either party hereto. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that the transactions contemplated by this Agreement are consummated as originally contemplated to the greatest extent possible.

SECTION 11.05 Entire Agreement. This Agreement, the Ancillary Agreements and the Confidentiality Agreement constitute the entire agreement of the parties hereto with respect to the subject matter hereof and thereof and supersede all prior agreements and undertakings, both written and oral, between Seller and Buyer with respect to the subject matter hereof and thereof.

SECTION 11.06 Assignment. Neither this Agreement nor any right, interest or obligation hereunder may be assigned by either party without the express written consent of other party hereto (which consent may be granted or withheld in the sole discretion of Seller or Buyer), except for assignments and transfers by operation of law; provided, that Buyer may assign or transfer any or all of their rights and obligations hereunder, without consent, to (a) any one or more of its Affiliates (whether by way of assignment, merger or otherwise), (b) any financial institution providing purchase money or other financing to Buyer from time to time as collateral security for such financing, or (c) to any post-Closing purchaser of the Business or a substantial part of the Purchased Assets or the Equity Interests. No assignment of any obligations hereunder shall relieve the parties hereto of any such obligations. Upon any such permitted assignment, the references in this Agreement to the assigning party shall also apply to any such assignee unless the context otherwise requires.

SECTION 11.07 Amendment; Remedies Cumulative. This Agreement may not be amended or modified except (a) by an instrument in writing signed by, or on behalf of, Seller and Buyer or (b) by a waiver in accordance with Section 11.08. The rights and remedies of the parties hereunder are cumulative and not alternative. Neither any failure nor any delay by any party in exercising any right, power or privilege under this Agreement or any of the documents referred to in this Agreement will operate as a waiver of such right, power or privilege, and no single or partial exercise of any such right, power or privilege will preclude any other or further exercise of such right, power or privilege or the exercise of any other right, power or privilege. To the maximum extent permitted by Law, (a) no waiver that may be given by a party will be applicable except in the specific instance for which it is given, and (b) no notice to or demand on one party will be deemed to be a waiver of any obligation of that party or of the right of the party giving such notice or demand to take further action without notice or demand as provided in this Agreement or the Ancillary Agreements.

SECTION 11.08 Waiver. Either Party to this Agreement may (a) extend the time for the performance of any of the obligations or other acts of the other party, (b) waive any inaccuracies in the representations and warranties of the other party contained herein or in any document delivered by the other party pursuant hereto or (c) waive compliance with any of the agreements of the other party or conditions to such party's obligations contained herein. Any such extension or waiver shall be valid only if set forth in an instrument in writing signed by the Party to be bound thereby. Any waiver of any term or condition shall not be construed as a waiver of any subsequent breach or a subsequent waiver of the same term or condition, or a waiver of any other term or condition of this Agreement. The failure of either Party hereto to assert any of its rights hereunder shall not constitute a waiver of any of such rights.

SECTION 11.09 No Third-Party Beneficiaries. This Agreement shall be binding upon and inure solely to the benefit of the Parties hereto and their respective successors and permitted assigns and nothing herein, express or implied (other than the provisions of ARTICLE IX relating to Indemnified Parties), is intended to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever, including any rights of employment for any specified period, under or by reason of this Agreement.

SECTION 11.10 Currency. Unless otherwise specified in this Agreement, all references to currency, monetary values and dollars set forth herein shall mean United States (U.S.) dollars and all payments hereunder shall be made in United States dollars.

SECTION 11.11 Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware. All Actions arising out of or relating to this Agreement shall be heard and determined exclusively in any federal court sitting in the Delaware; provided, however, if such federal court does not have jurisdiction over such Action, such Action shall be heard and determined exclusively in any Delaware court sitting in Delaware. Consistent with the preceding sentence, the parties hereto hereby (a) submit to the exclusive jurisdiction of any federal or state court sitting in the Delaware for the purpose of any Action arising out of or relating to this Agreement brought by any party hereto and (b) irrevocably waive, and agree not to assert by way of motion, defense, or otherwise, in any such Action, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the Action is brought in an inconvenient forum, that the venue of the Action is improper, or that this Agreement or the transactions contemplated by this Agreement may not be enforced in or by any of the above-named courts.

SECTION 11.12 Waiver of Jury Trial. EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH OF THE PARTIES HERETO HEREBY (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT HAS BEEN INDUCED TO ENTER INTO THIS

AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 11.12.

SECTION 11.13 Attorneys' Fees. If any Action is brought for the enforcement of this Agreement, or because of an alleged dispute, breach, default or misrepresentation in connection with any of the provisions of this Agreement, the successful or prevailing party shall be entitled to recover reasonable attorneys' fees and other costs incurred in that Action, in addition to any other relief to which it may be entitled.

SECTION 11.14 Time of Essence. With regard to all dates and time periods set forth or referred to in this Agreement, time is of the essence.

SECTION 11.15 Counterparts. This Agreement may be executed in any number of counterparts, and each such counterpart hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement. This Agreement and each Ancillary Agreement, and any amendments hereto or thereto, to the extent signed and delivered by means of a facsimile machine or scanned pages via electronic mail in "portable document format" form or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, shall be treated in all manner and respects as an original Contract and shall be considered to have the same binding legal effects as physical delivery of the paper document bearing the original signature. At the request of any party to this Agreement or any Ancillary Agreement, each other party shall re-execute original forms hereof or thereof, as the case may be, and deliver them to each other such party. No party to this Agreement or any Ancillary Agreement shall raise the use of a facsimile machine or email to deliver a signature or the fact that any signature or Contract was transmitted or communicated through the use of facsimile machine or email as a defense to the formation of a Contract, and each party to this Agreement or any such Ancillary Agreement forever waives any such defense.

SECTION 11.16 Specific Performance. The parties hereto agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that the parties hereto do not perform the provisions of this Agreement (including failing to take such actions as are required of it hereunder in order to consummate this Agreement) in accordance with its specified terms or otherwise breach such provisions. The parties hereto acknowledge and agree that the parties hereto shall be entitled to an injunction, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof, including with respect to the making of required regulatory filings in connection with the transactions contemplated hereby, this being in addition to any other remedy to which they are entitled at Law or in equity.

[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, Seller and Buyer have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.

CYTORI THERAPEUTICS, INC.


By: Marc H. Hedrick

Name: Marc H. Hedrick

Title: President and CEO

IN WITNESS WHEREOF, Seller and Buyer have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.

LOREM VASCULAR PTE. LTD.

By:  DocuSigned by:
Name: _____
Title: _____

ACKNOWLEDGED AND AGREED WITH RESPECT TO SECTION 6.06 ONLY

CYTORI THERAPEUTICS, K.K. .

By: Man H. Hedrick

Name:

Title:

Signature Page

EXHIBIT A

FORM OF SELLER LICENSE AGREEMENT

SELLER LICENSE AGREEMENT

This SELLER LICENSE AGREEMENT ("Agreement") is made as of this _____, 2019 ("Effective Date"), by and between Lorem Vascular Pte. Ltd., a _____ ("Licensee"), and Cytori Therapeutics, K.K., a kabushiki kaisha organized under the laws of Japan ("Licensor"). Licensor and Licensee are each referred to individually as a "Party" and together as the "Parties."

RECITALS

WHEREAS, pursuant to the Asset and Equity Purchase Agreement, dated as of March __, 2019 by and between Licensee and Cytori Therapeutics, Inc., a Delaware corporation (the "Purchase Agreement"), Cytori Therapeutics, Inc. sold to Licensee and Licensee purchased the Purchased Assets (as defined in the Purchase Agreement);

WHEREAS, pursuant to the Purchase Agreement, the Parties have agreed to deliver, or cause to be delivered, executed copies of this Agreement at the Closing;

WHEREAS, concurrently with this Agreement, the Parties have entered into a Manufacturing and Supply Agreement of even date herewith (the "Supply Agreement"); and

WHEREAS, Licensee wishes to obtain, and Licensor wishes to grant to Licensee effective upon the Effective Date, the exclusive license to use and sell Celution Products in the Hair Field worldwide, and to use Historic Data outside of the Territory (each as defined below), as further provided herein.

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, the Parties agree as follows:

ARTICLE 1

DEFINITIONS

Capitalized terms used but not defined herein have the meanings set out in the Purchase Agreement. As used herein, the following terms have the following meanings:

1.1 "ADRC" means adipose-derived regenerative cells.

1.2 "Bimini" is defined in Section 2.1(a).

1.3 "Bimini Agreement" is defined in Section 2.1(a).

1.4 "Celution Products" means Celution® devices and consumable products including all future generations, comparable derivatives, successors or alternative adipose derived regenerative cell devices.

1.5 "Confidential Information" means any and all information or materials disclosed or otherwise made available by either Party to the other Party hereunder, including information

or materials concerning the manufacture, supply, distribution, marketing, use or sale of the Products, the Party's business affairs and other confidential, sensitive or proprietary information or materials.

1.6 “Control” or “Controlled” means the possession of a Party of the ability to grant a license or sublicense as provided for herein without violating the terms of any arrangement or agreement between such Party and any Third Party.

1.7 “Hair Field” means sale and use of the Celution Product derived ADRC's applied “Locally” to the affected skin to reverse, stop or slow hair loss and/or re-grow lost or removed hair and/or improve existing hair follicle thickness, hair color, texture or form, whether alone or in combination with Puregraft processed fat and/or scaffolds or matrices and/or any other additive or combination of additives and alone or in combination with other procedures and treatments. “Locally” is defined as the delivery of cells into the skin and/or epicutaneous and /or subcutaneous space at or adjacent to an affected area. This field of use may not be used or marketed to treat the underlying systemic conditions that may be the causes of hair loss, such as thyroid or hormone regulation, or immune disorders, though in such cases it may be used as a localized treatment into the skin or subcutaneous space at or adjacent to an affected area. This Hair Field specifically excludes any and all marketing and use of the Celution Products for the treatment of thermal and radiation burns to the skin, as well as any systemic (such as intravascular, blood vessel) delivery of cells.

1.8 “Historic Data” means any clinical trial or study documents, protocols, reports, study and trial data (including complete master files, clinical summary reports, data listings, data tables, and all raw data used to generate such tables and listings) owned or Controlled by Licensor relating to the Business generated from clinical trials and studies inside the Territory that were completed prior to the Effective Date or that are currently being conducted as of the Effective Date.

1.9 “Licensed IP” means all Intellectual Property owned or Controlled by Licensor related to the Celution Products.

1.10 “Person” means any individual, partnership, limited liability company, firm, corporation, association, trust, unincorporated organization or other entity.

1.11 “Products” shall have the meaning given to such term in the Supply Agreement.

1.12 “Receiving Party” is defined in Section 4.2.

1.13 “Territory” means Japan.

1.14 “Third Party” means any Person other than a Party or an Affiliate of a Party.

1.15 “Transaction Documents” is defined in Section 4.1.

ARTICLE 2

LICENSE TO TECHNOLOGY AND DATA

2.1 Grant.

(a) Pursuant to and subject to the terms and conditions of this Agreement, Licensors hereby grants Licensee a worldwide, irrevocable, perpetual, exclusive, paid-up, royalty-free license under its rights in the Licensed IP to use, sell, offer for sale, have sold, lease, import, export, and otherwise exploit the Celution Products in the Hair Field, and to sublicense such rights to Bimini Technologies LLC (“Bimini”), its successors, assigns and sublicensees under that certain Sales and Exclusive License/Supply Agreement between Bimini and Licensee (by assignment from Cytos Therapeutics, Inc.) dated July 30, 2013 (the “Bimini Agreement”). Except as provided in the immediately preceding sentence, Licensee shall not grant sublicenses under this Agreement without the prior written consent of Licensors, which consent shall not be unreasonably withheld, conditioned or delayed. Any permitted sublicense shall be in writing, and shall be materially consistent with and subject to the terms of this Agreement and shall in no case grant any rights broader than those granted herein. Licensee shall be responsible for any breach of this Agreement that is caused (directly or indirectly) by the performance (or failure to perform) of any sublicensee.

(b) Pursuant to and subject to the terms and conditions of this Agreement, Licensors hereby grants Licensee an irrevocable, perpetual, exclusive, paid-up, royalty-free, transferrable (subject to Section 5.8), sublicenseable (subject to the conditions herein) license under its rights in the Historic Data, to use and reference such Historic Data solely outside of the Territory for Business research, development and in support of regulatory filings and other business purposes outside of the Territory with respect to the Business. Copies of all Historic Data generated prior to the Effective Date shall be provided to Licensee within ten (10) days after the Effective Date together with a list of all current trials and studies related to the Business in the Territory. Any Historic Data generated after the Effective Date shall be provided to Licensee within thirty (30) days following Licensee’s written request. Any sublicense of the foregoing rights shall be in writing, and shall be materially consistent with and subject to the terms of this Agreement and shall in no case grant any rights broader than those granted herein. Licensee shall be responsible for any breach of this Agreement that is caused (directly or indirectly) by the performance (or failure to perform) of any sublicensee.

2.2 No Implied Licenses. Except as expressly set forth in this Agreement, no licenses, sublicenses or other rights are granted to Licensee (whether implied, by estoppel or otherwise) and Licensors reserves all right, title and interest in and to its intellectual property.

2.3 Licensee Covenants. Licensee shall use reasonable efforts to ensure that Bimini complies with the trademark usage and quality control provisions of the Bimini Agreement related to Licensors’ trademarks licensed to Licensee under Section 2.1(a).

2.4 Licensors Covenants. Licensors acknowledges that the Supply Agreement contains certain obligations of Licensors with respect to the purchase and supply of Celution Products and Licensors agrees that in connection with granting the rights under this Agreement it shall comply

with all such obligations. In the event of a “Failure of Supply” under the Bimini Agreement with respect to the Territory directly resulting from the acts or omissions of Licensor or its Affiliates or their respective employees, agents, contractors or representatives, and resulting in the right of Bimini to manufacture the Celution Product, the license in Section 2.1(a) shall include the right of Bimini to make and have made Celution Products in the Hair Field to the extent provided in the Bimini Agreement.

2.5 Section 365(n). All licenses granted under this Agreement are deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code (“Code”), licenses of right to “intellectual property” as defined in Section 101 of such Code. The Parties agree that Licensee may fully exercise all of its rights and elections under the Code, regardless of whether either Party files for bankruptcy in the United States or other jurisdiction. The Parties further agree that, in the event Licensee elects to retain its rights as a licensee under such Code, Licensee shall be entitled to complete access to any technology licensed to it hereunder and all embodiments of such technology.

2.6 Intellectual Property.

2.6.1 Ownership. Ownership of inventions arising during and in the course of the Parties’ performance under the Agreement, and related intellectual property rights (“Inventions”) will be determined in accordance with U.S. rules of inventorship.

2.6.2 Prosecution and Maintenance; Enforcement and Defense. Licensor shall have the sole right to file, prosecute, register and maintain the Licensed IP, to enforce the Licensed IP against infringement or misappropriation by third parties, and to defend the Licensed IP against third party claims of infringement or misappropriation, and Licensee shall cooperate with Licensor, at Licensor’s request and at Licensor’s cost and expense, with respect to the foregoing.

ARTICLE 3

REPRESENTATIONS, WARRANTIES, AND INDEMNITIES

3.1 Representations and Warranties. Each Party represents and warrants to the other Party as of the Effective Date that:

(a) it is duly organized, validly existing, and in good standing under the Laws of its jurisdiction of formation;

(b) it has full power and authority to execute, deliver, and perform its obligations under this Agreement; and

(c) this Agreement constitutes a valid and binding agreement enforceable against it in accordance with its terms, subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, rehabilitation, liquidation, preferential transfer, moratorium and similar Laws.

3.2 Representations, Warranties and Covenants of Licensee. Licensee represents, warrants and covenants to Licensors that, as of the Effective Date and through the term of this Agreement:

(a) Licensee shall comply with all applicable Law with respect to the performance of rights and its obligations hereunder; and

(b) Without limiting the generality of Section 3.2(a), Licensee shall comply with the U.S. Foreign Corrupt Practices Act of 1977 (as modified or amended) or its equivalent in the Territory. Licensee represents and warrants that it has not and will not directly or indirectly offer or pay, or authorize such offer or payment of, any money, or transfer anything of value, to improperly seek to influence any government official.

3.3 No Other Warranties. EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE 3, (A) NO REPRESENTATION, CONDITION OR WARRANTY WHATSOEVER IS MADE OR GIVEN BY OR ON BEHALF OF LICENSOR; AND (B) ALL OTHER CONDITIONS AND WARRANTIES WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE ARE HEREBY EXPRESSLY EXCLUDED, INCLUDING ANY CONDITIONS AND WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT.

3.4 Special, Indirect and Other Losses. EXCEPT FOR BREACHES OF ARTICLE 4, NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR FOR ANY ECONOMIC LOSS OR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY.

3.5 Indemnification. Licensee shall indemnify and hold harmless Licensors and its permitted assignees, and their respective Affiliates and its and their respective officers, directors, employees, agents, contractors and representatives from and against all Loss suffered or incurred by them, in connection with any claims by Third Parties arising out of or resulting from Licensee's breach of this Agreement or its exercise of the licenses granted herein.

ARTICLE 4

CONFIDENTIAL INFORMATION

4.1 Confidentiality Obligations. Each Party shall treat the other Party's Confidential Information as strictly confidential. Except as expressly provided herein, neither Party shall use or disclose to any Third Party the other Party's Confidential Information. Each Party may only use the other Party's Confidential Information as is necessary to exercise their respective rights granted or reserved to it under this Agreement, except to the extent expressly permitted in the Purchase Agreement and any Ancillary Agreement (collectively, the "Transaction Documents"). Without limiting the foregoing provisions, each Party may only disclose the other Party's Confidential Information to its employees, contractors and agents who need to know the Confidential Information for the purposes of performing under this Agreement or in connection

with the Transaction Documents and who are subject to confidentiality obligations no less stringent than those herein. In protecting the other Party's Confidential Information, each Party agrees to exercise at least the same degree of care as it uses for its own Confidential Information, but in no event less than a reasonable degree of care. The Historic Data is deemed to be the Confidential Information of both Parties and shall only be used in compliance with this Agreement and applicable Law.

4.2 Exceptions. The foregoing obligations shall not apply to the extent the recipient of Confidential Information (the "Receiving Party") can demonstrate that such information or materials:

(a) are (at the time of initial disclosure) or become (after the time of initial disclosure) known to the public or part of the public domain through no breach of this Agreement by the Receiving Party;

(b) were known to, or were otherwise in the possession of, the Receiving Party prior to the time of initial disclosure by the disclosing Party (except for any information or materials exclusively related to or included in the Purchased Assets assigned to Licensor under the Purchase Agreement);

(c) were disclosed to the Receiving Party on a non-confidential basis by a Third Party who is entitled to disclose it without breaching any confidentiality obligation; or

(d) were independently developed by or on behalf of the Receiving Party, as evidenced by its written records, without reference to the Confidential Information disclosed by the disclosing Party under this Agreement

4.3 Compelled Disclosure. The Receiving Party may disclose Confidential Information of the disclosing Party to the extent required by any applicable Law (including under a proper discovery request or court or government order). In such a case, the Receiving Party must use reasonable efforts to prevent disclosure of the Confidential Information, and cooperate with the disclosing Party, if requested, to obtain a protective order or otherwise limit the disclosure.

4.4 Confidential Terms. Each Party shall treat the terms and existence of this Agreement as the Confidential Information of the other Party. Notwithstanding anything to the contrary herein, each Party may disclose the terms and existence of this Agreement (a) to professional advisors and actual or potential investors or acquirers bound by obligations of confidentiality and (b) as required by securities or other Law, provided that such Party seeks confidential treatment thereof. In the event that such disclosure is required by Law, the disclosing Party shall provide the other Party with notice beforehand and reasonably coordinate with the other Party with respect to the wording, content, scope and timing of any such disclosure.

ARTICLE 5

GENERAL PROVISIONS

5.1 Counterparts. This Agreement may be executed in any number of counterparts, and each such counterpart hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement. This Agreement and any amendments hereto, to the extent signed and delivered by means of a facsimile machine or scanned pages via electronic mail in “portable document format” form or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, shall be treated in all manner and respects as an original and shall be considered to have the same binding legal effects as physical delivery of the paper document bearing the original signature. At the request of either Party, the non-requesting Party shall re-execute original forms hereof or thereof, as the case may be, and deliver them to the requesting Party. No Party to this Agreement shall raise the use of a facsimile machine or email to deliver a signature or the fact that any signature was transmitted or communicated through the use of facsimile machine or email as a defense to the formation of this Agreement, and each Party to this Agreement forever waives any such defense.

5.2 Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any Law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect for so long as the economic or legal substance of the transactions contemplated by this Agreement is not affected in any manner materially adverse to either Party hereto. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order that the transactions contemplated by this Agreement are consummated as originally contemplated to the greatest extent possible.

5.3 Successors and Assigns. This Agreement shall be binding upon and inure solely to the benefit of the Parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever, under or by reason of this Agreement.

5.4 Notices. All notices or other communications required or permitted hereunder shall be in writing and shall be deemed given or delivered (a) when delivered personally, against written receipt, (b) if sent by registered or certified mail, return receipt requested, postage prepaid, when received, (c) when received by email or facsimile transmission, if confirmation of receipt is received and (d) when delivered by a nationally recognized overnight courier service, prepaid, and shall be addressed to the address of such Party specified in the Purchase Agreement (and with respect to Licensor, to the address of Cytori Therapeutics, Inc. specified in the Purchase Agreement, or to such other address as Licensor has provided to Licensee in accordance with the foregoing).

5.5 Entire Agreement. This Agreement and the Supply Agreement, constitute the entire agreement among the Parties and supersede any other undertakings and agreements, whether written or oral, that may have been made or entered into by or among any of the Parties

or any of their respective Affiliates relating to the subject matter hereof and thereof including the transactions contemplated hereby and thereby.

5.6 Amendments. This Agreement may not be amended or modified except (a) by an instrument in writing signed by each of the Parties hereto, or (b) by a waiver in accordance with Section 5.7.

5.7 Waiver. Failure of a Party to enforce performance of the terms, conditions or other provisions of this Agreement or to exercise any option or rights hereunder shall not be construed to be a waiver or relinquishment of any right granted under this Agreement to such Party nor to, in any way, affect the validity of this Agreement or such Party's right thereafter to enforce each and every provision of this Agreement, nor to preclude such Party from taking any other action at any time which it would legally be entitled to take. No waiver on the part of any Party of any right, power or privilege, nor any single or partial exercise of any such right, power or privilege, shall preclude any further exercise thereof or the exercise of any other such right, power or privilege.

5.8 Assignment. Neither this Agreement nor any right, interest or obligation hereunder may be assigned by either Party without the express written consent of other Party hereto (which consent may be granted or withheld in the sole discretion of each of the Parties), except for assignments and transfers by operation of law. Notwithstanding the foregoing, either Party may, without the other Party's written consent, assign this Agreement and its rights and obligations hereunder in whole or in part to (i) an Affiliate of such Party, or (ii) a Third Party that acquires, by or otherwise in connection with, merger, sale of assets or otherwise, all or substantially all of the business of the assigning Party to which the subject matter of this Agreement relates. No assignment of any obligations hereunder shall relieve the Parties hereto of any such obligations. Upon any such permitted assignment, the references in this Agreement to the assigning Party shall also apply to any such assignee unless the context otherwise requires.

5.9 Specific Performance. The Parties acknowledge that it will be impossible to measure the damages that would be suffered by the other Party if a Party fails to comply with this Agreement and that in the event of any such failure, there may not be an adequate remedy at law. It is accordingly agreed that the Parties will be entitled to seek injunctive relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, in each case without posting a bond or undertaking, this being in addition to any other remedy to which they are entitled at law or in equity.

5.10 Further Assurances. Each of the Parties covenants and agrees that, without any additional consideration, it shall execute and deliver, or shall cause its Affiliates to execute and deliver, such documents and other papers and shall take, or shall cause its Affiliates to take, such further actions as may be reasonably required to carry out the provisions of this Agreement and give effect to the transactions contemplated by this Agreement.

5.11 Rights of Third Parties. Nothing expressed or implied in this Agreement is intended or shall be construed to confer upon or give any Person, other than the Parties and their permitted successors and assigns, any legal or equitable right, benefits or remedy of any nature whatsoever under or by reason of this Agreement.

5.12 Remedies Cumulative. The rights and remedies provided herein shall be cumulative and not exclusive of any rights or remedies provided by Law or otherwise hereunder.

5.13 Independent Contractors. The Parties and each of their respective Affiliates shall each be an independent contractor in the performance of its obligations hereunder and nothing in this Agreement and no action taken by the Parties under this Agreement shall constitute a partnership, agency, relationship, association, joint venture or other co-operative entity between any of the Parties and no Third Party, including any employee of any Party or any of such Party's Affiliates, shall have or acquire any rights by reason of this Agreement.

5.14 English Language. The Parties have requested that this Agreement and the documents relating hereto be drawn up in the English language. The English language text and usage thereof in the United States of America shall control the interpretation and construction of this Agreement and all other writings between the Parties, even if this Agreement is translated into any other language. Any notice given under or in connection with this Agreement shall be given in the English language. Each Party agrees and acknowledges that it fully understands all of the terms and consequences of this Agreement and that it has had the opportunity to consult with an attorney of its own choosing regarding this Agreement.

5.15 Governing Law and Arbitration. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without reference to its conflict rules. Any dispute, controversy or claim arising out of or in connection with this Agreement, including any question regarding its existence, validity or termination shall be exclusively submitted to binding arbitration under the Rules of Arbitration (the "Rules") of the International Chamber of Commerce ("ICC"). The place and location of the arbitration shall be in San Diego, California. The arbitration proceeding shall be conducted in the English language. The arbitration shall be conducted by a tribunal of arbitrators with life science experience, selected within thirty (30) days after initiation of arbitration. The tribunal shall be comprised of three (3) arbitrators, one of whom shall be nominated by each Party and a third of whom, who shall serve as the presiding arbitrator, shall be nominated by mutual agreement of the two party-nominated arbitrators. If the Party-selected arbitrators are unable to agree upon the third arbitrator, or if either Party fails to select an arbitrator, then the International Court of Arbitration shall choose the arbitrator. If the issues in dispute involve scientific, technical or commercial matters, the arbitrators shall engage experts with sufficient education, industry experience and knowledge as necessary to resolve the dispute. The arbitration award shall be final and binding on the parties to this Agreement and the parties agree to be bound thereby and to act accordingly, and the parties hereby waive any right of appeal on the merits and/or any point of law. Either Party to this Agreement may request any competent judicial or other authority to order any provisional or conservatory measure (including any injunction), either prior to the institution of the arbitration proceeding or during such proceeding, for the preservation of its rights and interests. Each Party shall cooperate with the other Party in making full disclosure of and providing complete access to all information and documents requested by the other Party in connection with such proceedings, subject only to any confidentiality obligations binding on such Party. Judgment on a binding arbitration award may be entered in any court of competent jurisdiction. In any arbitration, the cost of arbitration and attorneys' fees and disbursements shall be borne by the losing Party, unless otherwise determined by the arbitration award.

[Signature Page Follows]

IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by each Party as of the Effective Date.

CYTORI THERAPEUTICS, K.K.

By: _____

Name:

Title:

IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by each Party as of the Effective Date.

LOREM VASCULAR PTE. LTD

By: _____

Name:

Title:

EXHIBIT B

FORM OF BUYER LICENSE AGREEMENT

BUYER LICENSE AGREEMENT

This BUYER LICENSE AGREEMENT ("Agreement") is made as of this _____, 2019 ("Effective Date"), by and between Lorem Vascular Pte. Ltd., a _____ ("Licensor"), on the one hand, and Cytori Therapeutics, K.K., a kabushiki kaisha organized under the laws of Japan ("Licensee"), and Cytori Therapeutics, Inc., a Delaware corporation ("Cytori US"), on the other hand. Licensor, Licensee and Cytori US are each referred to individually as a "Party" and together as the "Parties."

RECITALS

WHEREAS, pursuant to the Asset and Equity Purchase Agreement, dated as of March __, 2019, by and between Licensor and Cytori US (the "Purchase Agreement"), Cytori US sold to Licensor, and Licensor purchased the Purchased Assets (as defined in the Purchase Agreement);

WHEREAS, pursuant to the Purchase Agreement, the Parties have agreed to deliver, or cause to be delivered, executed copies of this Agreement at the Closing;

WHEREAS, concurrently with this Agreement, the Parties have entered into a Manufacturing and Supply Agreement of even date herewith (the "Supply Agreement"); and

WHEREAS, Licensee wishes to obtain, and Licensor wishes to grant to Licensee, effective upon the Effective Date, a non-exclusive license under the Manufacturing Technology to make and have made the Products in the Territory, and to use Historic Data in the Territory (each as defined below), as further provided herein.

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, the Parties agree as follows:

ARTICLE 1

DEFINITIONS

Capitalized terms used but not defined herein have the meanings set out in the Purchase Agreement. As used herein, the following terms have the following meanings:

- 1.1 "ADRC" means adipose-derived regenerative cells.
- 1.2 "BARDA Contract" is defined in Section 2.1(c).
- 1.3 "Bimini" means Bimini Technologies, LLC.
- 1.4 "Bimini Agreement" means that certain Sales and Exclusive License/Supply Agreement between Bimini and Licensor (by assignment from Cytori US) dated July 30, 2013.

1.5 “Celution Products” means Celution® devices and consumable products including all future generations, comparable derivatives, successors or alternative adipose derived regenerative cell devices.

1.6 “Confidential Information” means any and all information or materials disclosed or otherwise made available (a) by Licensor to Licensee or Cytori US or (b) by Licensee or Cytori US to Licensor, including information or materials concerning the manufacture, supply, distribution, marketing, use or sale of the Products, the Party’s business affairs and other confidential, sensitive or proprietary information or materials.

1.7 “Control” or “Controlled” means the possession of a Party of the ability to grant a license or sublicense as provided for herein without violating the terms of any arrangement or agreement between such Party and any Third Party.

1.8 “Hair Field” means sale and use of the Celution Product derived ADRC’s applied “Locally” to the affected skin to reverse, stop or slow hair loss and/or re-grow lost or removed hair and/or improve existing hair follicle thickness, hair color, texture or form, whether alone or in combination with Puregraft processed fat and/or scaffolds or matrices and/or any other additive or combination of additives and alone or in combination with other procedures and treatments. “Locally” is defined as the delivery of cells into the skin and/or epicutaneous and /or subcutaneous space at or adjacent to an affected area. This field of use may not be used or marketed to treat the underlying systemic conditions that may be the causes of hair loss, such as thyroid or hormone regulation, or immune disorders, though in such cases it may be used as a localized treatment into the skin or subcutaneous space at or adjacent to an affected area. This Hair Field specifically excludes any and all marketing and use of the Celution Products for the treatment of thermal and radiation burns to the skin, as well as any systemic (such as intravascular, blood vessel) delivery of cells.

1.9 “Historic Data” means any clinical trial or study documents, protocols, reports, study and trial data (including complete master files, clinical summary reports, data listings, data tables, and all raw data used to generate such tables and listings) owned or Controlled by Licensor relating to the Business generated from clinical trials and studies outside of the Territory that were completed prior to the Effective Date or that are currently being conducted as of the Effective Date.

1.10 “Licensed IP” means the Intellectual Property licensed by Licensor to Licensee or Cytori US, as applicable, pursuant to Section 2.1 of this Agreement.

1.11 “Manufacturing Technology” means all patented or unpatented, proprietary inventions, designs, specifications, trade secrets, methods, processes, Software, technical information and know-how included in the Business Intellectual Property that is owned or Controlled by Licensor as of the Effective Date and necessary or useful to manufacture the Products.

1.12 “Person” means any individual, partnership, limited liability company, firm, corporation, association, trust, unincorporated organization or other entity.

1.13 “Products” shall have the meaning given to such term in the Supply Agreement.

1.14 “Receiving Party” is defined in Section 4.2.

1.15 “Software” means the object code and source code versions of the software owned or Controlled by Licenser as of the Effective Date that form part of the Products.

1.16 “Tangible Technology” is defined in Section 2.4.

1.17 “Territory” means Japan.

1.18 “Third Party” means any Person other than a Party or an Affiliate of a Party.

1.19 “Transaction Documents” is defined in Section 4.1.

ARTICLE 2

LICENSE TO TECHNOLOGY AND DATA

2.1 Grant.

(a) Pursuant to and subject to the terms and conditions of this Agreement and the applicable terms and conditions of the Supply Agreement, Licenser hereby grants Licensee an irrevocable, perpetual, non-exclusive, paid-up, royalty-free license under its rights in the Manufacturing Technology, to:

(1) manufacture or have manufactured Products inside of or for the Territory, solely to the extent that such Products are sold and marketed inside of the Territory outside of the Hair Field; and

(2) use, copy, compile, integrate, access, display, distribute, perform, modify, enhance and create derivative works of, any instruction manuals and related documentation and Software solely as part of the Products manufactured, sold and marketed in the Territory outside of the Hair Field pursuant to Section 2.1(a)(1) above. Any Software will only be distributed to end users of such Products in object code form.

(b) Pursuant to and subject to the terms and conditions of this Agreement, Licenser hereby grants Licensee an irrevocable, perpetual, exclusive, paid-up, royalty-free, transferrable (subject to Section 5.8), sublicenseable (subject to Section 2.2) license under its rights in the Historic Data, to use and reference such Historic Data solely in the Territory for Business research, development and in support of regulatory filings and other business purposes inside of the Territory with respect to the Business. Copies of all Historic Data generated prior to the Effective Date shall be made available to Licensee within thirty (30) days after Licensee’s written request together with a list of all current trials and studies as of the Effective Date related to the Business outside of the Territory. Any Historic Data generated after the Effective Date shall be provided to Licensee within thirty (30) days following Licensee’s written request.

(c) Pursuant to and subject to the terms and conditions of this Agreement, Licenser hereby grants Cytos US during the term of the BARDA Contract, a non-exclusive,

fully paid-up, royalty-free, irrevocable license under its rights in the Business Intellectual Property (other than Trademarks), solely to the extent necessary for Cytori US to perform research and development services and clinical trials related to burn and radiation injury studies for the United States Government under Contract No. HHS0100201200008C dated [REDACTED] (the “BARDA Contract”).

2.2 Sublicense Rights.

(a) Licensee shall have the right to grant sublicenses of its rights under Section 2.1(a) or (b) to one or more Affiliates or Third Parties, but only to the extent required for such Affiliate or Third Party to manufacture Products (or any component thereof) in or for the Territory on behalf of Licensee or any of its Affiliates or their respective permitted assignees or sublicensees. Cytori US shall have the right to grant sublicenses of its rights under Section 2.1(c) to one or more Affiliates or Third Parties with Licensor’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed.

(b) Any such sublicense shall be in writing, and shall be materially consistent with and subject to the terms of this Agreement and shall in no case grant any rights broader than those granted herein. Licensee shall be responsible for any breach of this Agreement that is caused (directly or indirectly) by the performance (or failure to perform) of any sublicensee.

2.3 No Implied Licenses. Except as expressly set forth in this Agreement, no licenses, sublicenses or other rights are granted to Licensee (whether implied, by estoppel or otherwise) and Licensor reserves all right, title and interest in and to its intellectual property, including the rights to manufacture and supply the Products to Licensee in accordance with the terms of the Supply Agreement.

2.4 Protection of Technology. In addition to the license limitations and confidentiality obligations set forth elsewhere in this Agreement or the Supply Agreement, with respect to any source code version of the Software or other sensitive Manufacturing Technology in a fixed medium of expression (“Tangible Technology”), (a) Licensee will not place, or make available, the Tangible Technology on any computer network (including the Internet, company intranet, or peer-to-peer network) except for Licensee’s or its Affiliates’ or permitted sublicensees’ protected corporate network; (b) the Tangible Technology will be installed only on computer systems that are password protected, and access to the Tangible Technology files must be restricted to necessary personnel; and (c) Licensee must ensure that any physical copies of the Tangible Technology are protected on its premises.

2.5 Proprietary Rights Notices. For each item of Software, Licensee must not remove, alter, obscure, or destroy any proprietary rights notices in the code, including any copyright notices of Licensor.

2.6 Licensee Covenants. Licensee acknowledges that the Supply Agreement contains various restrictions, covenants and obligations with respect to the manufacture, use and distribution of Products and Licensee agrees that in exercising its rights under this Agreement it shall comply with all such restrictions, covenants and obligations.

2.7 Transfer of Manufacturing Technology. Licensors shall disclose the Manufacturing Technology to Licensee in accordance with the terms of the Supply Agreement.

2.8 Section 365(n). All licenses granted under this Agreement are deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to “intellectual property” as defined in Section 101 of such Code. The Parties agree that Licensee may fully exercise all of its rights and elections under the U.S. Bankruptcy Code, regardless of whether either Party files for bankruptcy in the United States or other jurisdiction. The Parties further agree that, in the event Licensee elects to retain its rights as a licensee under such Code, Licensee shall be entitled to complete access to any technology licensed to it hereunder and all embodiments of such technology.

2.9 Intellectual Property.

2.9.1 Ownership. Ownership of inventions arising during and in the course of the Parties’ performance under the Agreement, and related intellectual property rights (“Inventions”) will be determined in accordance with U.S. rules of inventorship.

2.9.2 Prosecution and Maintenance; Enforcement and Defense. Licensors shall have the sole right to file, prosecute, register and maintain the Licensed IP, to enforce the Licensed IP against infringement or misappropriation by third parties, and to defend the Licensed IP against third party claims of infringement or misappropriation, and Licensee and Cytos US shall cooperate with Licensors, at Licensors’ request and at Licensors’ cost and expense, with respect to the foregoing.

ARTICLE 3

REPRESENTATIONS, WARRANTIES, AND INDEMNITIES

3.1 Representations and Warranties. Each Party represents and warrants to the other Parties as of the Effective Date that:

(a) it is duly organized, validly existing, and in good standing under the Laws of its jurisdiction of formation;

(b) it has full power and authority to execute, deliver, and perform its obligations under this Agreement; and

(c) this Agreement constitutes a valid and binding agreement enforceable against it in accordance with its terms, subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, rehabilitation, liquidation, preferential transfer, moratorium and similar Laws.

3.2 Representations, Warranties and Covenants of Licensee and Cytos US. Licensee and Cytos US each represents, warrants and covenants to Licensors that, as of the Effective Date and through the term of this Agreement:

(a) it shall comply with all applicable Law with respect to the performance of rights and its obligations hereunder; and

(b) Without limiting the generality of Section 3.2(a), it shall comply with the U.S. Foreign Corrupt Practices Act of 1977 (as modified or amended) or its equivalent in the Territory. Licensee represents and warrants that it has not and will not directly or indirectly offer or pay, or authorize such offer or payment of, any money, or transfer anything of value, to improperly seek to influence any government official.

3.3 No Other Warranties. EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE 3, (A) NO REPRESENTATION, CONDITION OR WARRANTY WHATSOEVER IS MADE OR GIVEN BY OR ON BEHALF OF LICENSOR; AND (B) ALL OTHER CONDITIONS AND WARRANTIES WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE ARE HEREBY EXPRESSLY EXCLUDED, INCLUDING ANY CONDITIONS AND WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT.

3.4 Special, Indirect and Other Losses. EXCEPT FOR BREACH OF ARTICLE 4, NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR FOR ANY ECONOMIC LOSS OR LOSS OF PROFITS SUFFERED BY ANY OTHER PARTY.

3.5 Indemnification. Licensee and Cytori US shall each severally indemnify and hold harmless Licensor and its permitted assignees, and their respective Affiliates and its and their respective officers, directors, employees, agents, contractors and representatives from and against all Loss suffered or incurred by them, in connection with any claims by Third Parties arising out of or resulting from the breach of this Agreement by Licensee or Cytori US, as applicable, or from Licensee's or Cytori US's (as applicable) exercise of the licenses granted to such Party herein.

ARTICLE 4

CONFIDENTIAL INFORMATION

4.1 Confidentiality Obligations. Each Party shall treat another Party's Confidential Information as strictly confidential. Except as expressly provided herein, no Party shall use or disclose to any Third Party another Party's Confidential Information. Each Party may only use another Party's Confidential Information as is necessary to exercise their respective rights granted or reserved to it under this Agreement, except to the extent expressly permitted in the Purchase Agreement and any Ancillary Agreement (collectively, the "Transaction Documents"). Without limiting the foregoing provisions, each Party may only disclose another Party's Confidential Information to its employees, contractors and agents who need to know the Confidential Information for the purposes of performing under this Agreement or in connection with the Transaction Documents and who are subject to confidentiality obligations no less stringent than those herein. In protecting another Party's Confidential Information, each Party

agrees to exercise at least the same degree of care as it uses for its own Confidential Information, but in no event less than a reasonable degree of care. The Manufacturing Technology and Business Intellectual Property are owned by and constitute the Confidential Information of Licensor. The Historic Data is deemed to be the Confidential Information of both Parties and shall only be used in compliance with this Agreement and applicable Law.

4.2 Exceptions. The foregoing obligations shall not apply to the extent the recipient of Confidential Information (the “Receiving Party”) can demonstrate that such information or materials:

(a) are (at the time of initial disclosure) or become (after the time of initial disclosure) known to the public or part of the public domain through no breach of this Agreement by the Receiving Party;

(b) were known to, or were otherwise in the possession of, the Receiving Party prior to the time of initial disclosure by the disclosing Party (except for any information or materials exclusively related to or included in the Purchased Assets assigned to Licensor under the Purchase Agreement);

(c) were disclosed to the Receiving Party on a non-confidential basis by a Third Party who is entitled to disclose it without breaching any confidentiality obligation; or

(d) were independently developed by or on behalf of the Receiving Party, as evidenced by its written records, without reference to the Confidential Information disclosed by the disclosing Party under this Agreement

4.3 Compelled Disclosure. The Receiving Party may disclose Confidential Information of the disclosing Party to the extent required by any applicable Law (including under a proper discovery request or court or government order). In such a case, the Receiving Party must use reasonable efforts to prevent disclosure of the Confidential Information, and cooperate with the disclosing Party, if requested, to obtain a protective order or otherwise limit the disclosure.

4.4 Confidential Terms. Each Party shall treat the terms and existence of this Agreement as the Confidential Information of each other Party. Notwithstanding anything to the contrary herein, each Party may disclose the terms and existence of this Agreement (a) to professional advisors and actual or potential investors or acquirers bound by obligations of confidentiality and (b) as required by securities or other Law, provided that such Party seeks confidential treatment thereof. In the event that such disclosure is required by Law, the disclosing Party shall provide the other Party with notice beforehand and reasonably coordinate with each other Party with respect to the wording, content, scope and timing of any such disclosure.

ARTICLE 5

GENERAL PROVISIONS

5.1 Counterparts. This Agreement may be executed in any number of counterparts, and each such counterpart hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement. This Agreement and any amendments hereto, to the extent signed and delivered by means of a facsimile machine or scanned pages via electronic mail in “portable document format” form or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, shall be treated in all manner and respects as an original and shall be considered to have the same binding legal effects as physical delivery of the paper document bearing the original signature. At the request of another Party, each non-requesting Party shall re-execute original forms hereof or thereof, as the case may be, and deliver them to the requesting Party. No Party to this Agreement shall raise the use of a facsimile machine or email to deliver a signature or the fact that any signature was transmitted or communicated through the use of facsimile machine or email as a defense to the formation of this Agreement, and each Party to this Agreement forever waives any such defense.

5.2 Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any Law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect for so long as the economic or legal substance of the transactions contemplated by this Agreement is not affected in any manner materially adverse to each Party hereto. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order that the transactions contemplated by this Agreement are consummated as originally contemplated to the greatest extent possible.

5.3 Successors and Assigns. This Agreement shall be binding upon and inure solely to the benefit of the Parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever, under or by reason of this Agreement.

5.4 Notices. All notices or other communications required or permitted hereunder shall be in writing and shall be deemed given or delivered (a) when delivered personally, against written receipt, (b) if sent by registered or certified mail, return receipt requested, postage prepaid, when received, (c) when received by email or facsimile transmission, if confirmation of receipt is received and (d) when delivered by a nationally recognized overnight courier service, prepaid, and shall be addressed to the address of such Party specified in the Purchase Agreement (and with respect to Licensee, to the address of Cytori US specified in the Purchase Agreement, or to such other address as Licensee has provided to Licensors in accordance with the foregoing).

5.5 Entire Agreement. This Agreement and the Supply Agreement constitute the entire agreement among the Parties and supersede any other undertakings and agreements, whether written or oral, that may have been made or entered into by or among any of the Parties

or any of their respective Affiliates relating to the subject matter hereof and thereof including the transactions contemplated hereby and thereby.

5.6 Amendments. This Agreement may not be amended or modified except (a) by an instrument in writing signed by each of the Parties hereto, or (b) by a waiver in accordance with Section 5.7.

5.7 Waiver. Failure of a Party to enforce performance of the terms, conditions or other provisions of this Agreement or to exercise any option or rights hereunder shall not be construed to be a waiver or relinquishment of any right granted under this Agreement to such Party nor to, in any way, affect the validity of this Agreement or such Party's right thereafter to enforce each and every provision of this Agreement, nor to preclude such Party from taking any other action at any time which it would legally be entitled to take. No waiver on the part of any Party of any right, power or privilege, nor any single or partial exercise of any such right, power or privilege, shall preclude any further exercise thereof or the exercise of any other such right, power or privilege.

5.8 Assignment. Neither this Agreement nor any right, interest or obligation hereunder may be assigned by any Party without the express written consent of each other Party hereto (which consent may be granted or withheld in the sole discretion of each of the Parties), except for assignments and transfers by operation of law. Notwithstanding the foregoing, a Party may, without the other Parties' written consent, assign this Agreement and its rights and obligations hereunder in whole or in part to (i) an Affiliate of such Party, or (ii) a Third Party that acquires, by or otherwise in connection with, merger, sale of assets or otherwise, all or substantially all of the business of the assigning Party to which the subject matter of this Agreement relates. No assignment of any obligations hereunder shall relieve the Parties hereto of any such obligations. Upon any such permitted assignment, the references in this Agreement to the assigning Party shall also apply to any such assignee unless the context otherwise requires.

5.9 Specific Performance. The Parties acknowledge that it will be impossible to measure the damages that would be suffered by another Party if a Party fails to comply with this Agreement and that in the event of any such failure, there may not be an adequate remedy at law. It is accordingly agreed that the Parties will be entitled to seek injunctive relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, in each case without posting a bond or undertaking, this being in addition to any other remedy to which they are entitled at law or in equity.

5.10 Further Assurances. Each of the Parties covenants and agrees that, without any additional consideration, it shall execute and deliver, or shall cause its Affiliates to execute and deliver, such documents and other papers and shall take, or shall cause its Affiliates to take, such further actions as may be reasonably required to carry out the provisions of this Agreement and give effect to the transactions contemplated by this Agreement.

5.11 Rights of Third Parties. Nothing expressed or implied in this Agreement is intended or shall be construed to confer upon or give any Person, other than the Parties and their permitted successors and assigns, any legal or equitable right, benefits or remedy of any nature whatsoever under or by reason of this Agreement.

5.12 Remedies Cumulative. The rights and remedies provided herein shall be cumulative and not exclusive of any rights or remedies provided by Law or otherwise hereunder.

5.13 Independent Contractors. The Parties and each of their respective Affiliates shall each be an independent contractor in the performance of its obligations hereunder and nothing in this Agreement and no action taken by the Parties under this Agreement shall constitute a partnership, agency, relationship, association, joint venture or other co-operative entity between any of the Parties and no Third Party, including any employee of any Party or any of such Party's Affiliates, shall have or acquire any rights by reason of this Agreement.

5.14 English Language. The Parties have requested that this Agreement and the documents relating hereto be drawn up in the English language. The English language text and usage thereof in the United States of America shall control the interpretation and construction of this Agreement and all other writings between the Parties, even if this Agreement is translated into any other language. Any notice given under or in connection with this Agreement shall be given in the English language. Each Party agrees and acknowledges that it fully understands all of the terms and consequences of this Agreement and that it has had the opportunity to consult with an attorney of its own choosing regarding this Agreement.

5.15 Governing Law and Arbitration. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without reference to its conflict rules. Any dispute, controversy or claim arising out of or in connection with this Agreement, including any question regarding its existence, validity or termination shall be exclusively submitted to binding arbitration under the Rules of Arbitration (the "Rules") of the International Chamber of Commerce ("ICC"). The place and location of the arbitration shall be in San Diego, California. The arbitration proceeding shall be conducted in the English language. The arbitration shall be conducted by a tribunal of arbitrators with life science experience, selected within thirty (30) days after initiation of arbitration. The tribunal shall be comprised of three (3) arbitrators, one of whom shall be nominated by each Party (Cytori US and Licensee, as applicable, together selecting one, and Licensors selecting one) and a third of whom, who shall serve as the presiding arbitrator, shall be nominated by mutual agreement of the two Party-nominated arbitrators. If the Party-selected arbitrators are unable to agree upon the third arbitrator, or if either Party fails to select an arbitrator, then the International Court of Arbitration shall choose the arbitrator. If the issues in dispute involve scientific, technical or commercial matters, the arbitrators shall engage experts with sufficient education, industry experience and knowledge as necessary to resolve the dispute. The arbitration award shall be final and binding on the parties to this Agreement and the parties agree to be bound thereby and to act accordingly, and the parties hereby waive any right of appeal on the merits and/or any point of law. Either Party to this Agreement may request any competent judicial or other authority to order any provisional or conservatory measure (including any injunction), either prior to the institution of the arbitration proceeding or during such proceeding, for the preservation of its rights and interests. Each Party shall cooperate with the other Party in making full disclosure of and providing complete access to all information and documents requested by the other Party in connection with such proceedings, subject only to any confidentiality obligations binding on such Party. Judgment on a binding arbitration award may be entered in any court of competent jurisdiction. In any arbitration, the cost of arbitration and attorneys' fees and disbursements shall be borne by the losing Party, unless otherwise determined by the arbitration award.

[Signature Pages Follow]

IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by each Party as of the Effective Date.

CYTORI THERAPEUTICS, K.K.

By: _____

Name:

Title:

IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by each Party as of the Effective Date.

CYTORI THERAPEUTICS, INC.

By: _____

Name:

Title:

IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by each Party as of the Effective Date.

LOREM VASCULAR PTE. LTD

By: _____
Name:
Title

EXHIBIT C

SUPPLY AGREEMENT TERMS

Proposed Key Terms for Manufacturing and Supply Agreement (“MSA”)

Clarification of Parties (all shipments Ship FIFO – all Ex Works (Incoterms 2010) San Diego / Germany/ San Antonio

- - LV is supplier
 - Cytori KK is purchaser for Japan;
 - MSA can be assigned by either party in connection with a merger, sale of assets or otherwise of all or substantially all of the business of the assigning party to which the subject matter of the MSA relates.
- Term of supply agreement is 36 months, thereafter, likely should have ability to negotiate in good faith language to extend by mutual agreement recognizing transfer price will increase for such periods.
- Manufacturing Technology sharing provision ,
 - Any time after six months following the Closing, At Cytori KK’s request, Supplier will proceed expeditiously to share all necessary technology and support implementation of technology sharing to make devices, consumables to be completed in 18 months AT KK’S EXPENSE. (Note: we do not make enzyme).
- Forecasting, Minimums & Ordering
 - KK will provide quarterly rolling 12 month forecast to supplier with 3 month binding period
 - Full batch for consumables is 1000 units however consumable shipments may be broken down 350 units, min orders for devices (1)
- Japan Pricing for ‘Japan’ (CRS) products
 - Consumables
 - 0-12 month- cogs plus 20%
 - 13-24 month- cogs plus 50%
 - 25 to 36 months- cogs plus 80%
 - OVER 36 MONTHS PRICE WILL INCREASE
 - New Devices
 - 0-18 month- cogs plus 50% (ESTIMATES BY CYTORI \$60,000)
 - 19-36 month- cogs plus 80% (ESTIMATES BY CYTORI \$72,000)
 - Enzymes- Ship FIFO – all Ex Works (Incoterms 2010) San Diego/Germany
 - Celase (Enzymes to be sourced exclusively from Lorem for the duration of this Agreement on a minimum of a 1 to 1 ratio with consumables)
 - \$125 vial/ 1st 1600.
 - \$100 vial thereafter until exhausted
 - Intravase (Enzymes to be sourced exclusively from Lorem for the duration of this Agreement on a minimum of a 1 to 1 ratio with consumables)
 - \$200 vial
- BARDA Pricing for ‘BARDA’ products
 - Consumables (IV consumable set)
 - 0-12 month- cogs plus 20%
 - 13-24 month- cogs plus 50%

- 25 to 36 months- cogs plus 80%
- Devices
 - 0-12 month- cogs plus 20%
 - 13-24 month- cogs plus 50%
 - 25 to 36 months- cogs plus 80%
- Enzymes
 - Celase
 - \$200 vial
 - Intravase
 - \$275 vial

Payment Terms- 50% at order and 50% just prior to delivery, provided that after the first two order cycles have been completed and paid for according to these terms, the parties shall work together in good faith to establish a credit relationship (in full or in part) to reduce the up front payment required herein.

Enzyme pricing is only applicable to inventory remaining from Cytori at Closing. Future supply is Cogs + 80%.

DISCLOSURE SCHEDULE TO THE

ASSET AND EQUITY PURCHASE AGREEMENT

by and among

CYTORI THERAPEUTICS, INC.

CYTORI THERAPEUTICS, K.K. (with respect to SECTION 6.06 only)

and

LOREM VASCULAR PTE. LTD

Dated as of March 29, 2019

DISCLOSURE SCHEDULES

Reference is hereby made to that certain Asset and Equity Purchase Agreement (the “Agreement”), dated as of March 29, 2019 by and among (i) Cytori Therapeutics, Inc., a Delaware corporation (the “Company”), (ii) Lorem Vascular Pte. Ltd., a company incorporated in Singapore (“Buyer”), and with respect to Section 6.06 of the Agreement only, Cytori Therapeutics, K.K. Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Agreement. Section references herein are to sections of the Agreement. These Disclosure Schedules are provided in confidence on the terms and subject to the conditions of the Agreement and the Confidentiality Agreement. The information set forth in these Disclosure Schedules, which relates to the representations, warranties, covenants and agreements of the Company in the Agreement, is subject to the following qualifications:

Matters reflected in these Disclosure Schedules are not necessarily limited to matters required by the Agreement to be reflected in these Disclosure Schedules; these Disclosure Schedules may contain items that are not material (or otherwise required to be disclosed) in order to avoid any misunderstanding, or otherwise for informational purposes. Accordingly, the disclosure or inclusion of information in these Disclosure Schedules (including the specification of any dollar amount herein or in the Agreement, or the inclusion of any specific item herein) is not intended as and shall not be deemed to be an acknowledgement or admission that any such information is required to be disclosed or is material for purposes of the representations and warranties set forth in the Agreement. The disclosure of any matter or item in these Disclosure Schedules shall not be construed as an admission of liability or fault with respect to the matters covered by such disclosure or constitute, or be deemed to be, an admission to any third party concerning such matter or item.

Disclosures in any section or paragraph of the Disclosure Schedule are made generally and shall not only address the corresponding section or paragraph of this Agreement, but also other sections or paragraphs of this Agreement to the extent that it is readily apparent from the face of such disclosure that such disclosure is applicable to such other sections or paragraphs.

Disclosure of any allegations with respect to any alleged breach, violation or default under any contractual or other obligation, or any Law, is not an admission that such breach, violation or default has occurred. The information contained in these Disclosure Schedules is disclosed solely for purposes of the Agreement, and no information contained herein (including any disclosure relating to any possible breach or violation of, or conflict with, any Law or contract, and any statements with respect to the enforceability of contracts, or the existence or non-existence of third-party rights) shall be deemed to be an admission by any party to the Agreement to any third party of any matter whatsoever, or otherwise give rise to any claim or benefit to any third party.

The information provided in these Disclosure Schedules is being provided solely for the purpose of making disclosures to Buyer under the Agreement. In disclosing this information, neither the Company nor any Seller waives, and each of them expressly reserves any rights under, any attorney-client privilege associated with such information or any protection afforded by the work-product doctrine with respect to any of the matters disclosed or discussed herein.

The headings and introductions used in these Disclosure Schedules have been included for convenience only, and are not intended to limit the effect of the disclosures contained herein or to expand the scope of the information required to be disclosed herein.

SECTION 2.02
PURCHASE AND SALE OF PURCHASE ASSETS

(a)(i)

Leased Real Property and Leases

- Lease, dated as of February 26, 2010, by and between Cytori Therapeutics, Inc., and HCP Callan Road, LLC, as amended by the First Amendment to Lease, dated as of September 30, 2011, as amended by the Second Amendment to Lease, dated as of October 13, 2017, as amended by the Third Amendment to Lease, dated as of November 3, 2017, as amended by the Fourth Amendment to Lease, dated as of February 23, 2018, and as further amended by the Fifth Amendment to Lease, dated as of December 21, 2018 (the “San Diego Lease”).
- Sublease Agreement, dated as of November 1, 2017, by and between Synthetic Genomics, Inc., and Cytori Therapeutics, Inc., as amended by the Amendment to Sublease, dated as of February 5, 2018, and as further amended by that Second Amendment to Sublease, dated as of December 31, 2018. (the “San Diego Sublease”).
- Lease, dated as of March 30, 2010, by and between Starkey Investment Company, and Cytori Therapeutics, Inc., as amended by the First Amendment to Lease, dated as of February 20, 2013 (the “Storage Lease”).

(a)(iii)

Inventories Included in the Purchased Assets

- Each of the pieces of inventory listed in Exhibit 2.02(a)(iii)-1 to these schedules.
- Please also refer to Exhibit 2.02(a)(iii)-2 to these schedules.

This list is as of February 28, 2019, and subject to changes in the Ordinary Course of Business between the date hereof and Closing. The final Inventory to be delivered will be no less than 95%, measured by value, of the amount disclosed herein in Exhibit 2.02(a)(iii)-1 and in Exhibit 2.02(a)(iii)-2 to these schedules.

(a)(vi)(a)

Assigned Contracts (To the extent that Buyer, in its sole discretion, elects to assume at Closing by giving written notice to Seller of such assumption)

Contracts relating to the following:

- Settlement Agreement, dated as of November 12, 2018 by and between Bimini Technologies LLC, and Cytori Therapeutics, Inc.
- Henke-Sass, Wolf, GmbH: Exclusive Manufacture and Supply Agreement (FOR CELLBRUSH)

- Centurion
- Cardinal Health (Monoject 60 mL Toomey Syringe)
- Sterigenics
- BSI
- DEKRA
- Best Roads
- CPA Global – IP maintenance
- EIP US - IP
- RSQR: Authorized Representative for EU (in process of changing to non-UK source due to Brexit)
- Sephno – Network/Server/IT support
- Accense – Freezer Monitoring
- Anmar – Calibration and Preventative Maintenance
- GL Technologies – Calibration and Preventative Maintenance
- Apple Tree – Customer Service
- OSI – Safety and Permitting
- Waste Management– Chemicals handling
- Intertek – Safety Testing and Certification of device
- Namsa – Biocompatibility and Analytical Testing - consumable
- Nelson – Biocompatibility and Analytical Testing - consumable
- Westpak – Aging Chambers and Testing
- Philip Medisize – CTX2 Tooling (\$0 NBV as of 2/28/19)
- Molecular Devices LLC (Microplate reader, and calibration service)
- Rainin (calibration and repair services for pipettes)
- Clinical Network Services (CNS) Pty Ltd (scleroderma Orphan drug designation to CNS Netherlands)
- Cogen Korea: Non-Exclusive Distribution Agreement (Celase GMP)
- Worthington Biochemical Corporation: Non-Exclusive Distribution Agreement
- Mira Corporation: Exclusive Distribution Non-Binding Term Sheet
- Sharon James – Office support UK
- Celution 800 Systems
 - Mayo Clinic, Rochester, MN

- Winthrop University Hospital, Mineola, NY
- Okyanos Operating Company Ltd (“Emergency” device provided at no cost under Supply Agreement Amendment 2
- FacesPlus – we can’t find a record of a Loaner Agreement
- Hospital de la Conception, Marseille, France
- Hospital Saint Louis, Paris, France
- Hospital General La Paz, Madrid, Spain
- Hospital Miguel Dominguez, Pontevedra, Spain
- Fundacion Jimenez Diaz, Madrid, Spain
- Hospital Quiron, Barcelona, Spain
- Glasgow Royal Infirmary, Glasgow, Scotland, UK
- Queen Elizabeth University Hospital, Glasgow, Scotland, UK
- Mira Corporation
- Dr. Joel Aronowitz
- Nucleocounter 100 Devices
 - Hospital de la Conception, Marseille, France
 - CHU Rouen, Rouen, France
 - Hospital Miguel Dominguez, Pontevedra, Spain
 - Hospital Quiron, Barcelona, Spain

Other than the Cardinal Health PO (as defined below), the open purchase orders in Exhibit 2.02(a)(vi)(a) are incorporated herein by reference.

An informal warehousing arrangement in Germany for which there is no written agreement.

(a)(vi)(b)

Assigned Contract

- Bimini Technologies LLC: Sale and Exclusive License/Supply Agreement (the “Bimini Agreement”).
- Contract Manufacturing Agreement, dated as of March 21, 2018, by and between Coastal Life Technologies, Inc., and Cytori Therapeutics, Inc. (the “Coastal Agreement”).
- Each of the leases set forth in Section 2.02(a)(i) hereof.
- The prepaid purchase order with Cardinal Health in the amount \$67,554 (the “Cardinal Health PO”), which for purpose of clarity, shall not require any reimbursement to Seller or additional payment to Cardinal Health with respect to same.

(a)(viii)

Business Intellectual Property

- The intellectual property listed in Exhibit 2.02(a)(viii) to these schedules.

(a)(ix)

Unfilled Purchase Orders

- Bimini – 250 consumables + celase, expected delivery in May 2019
- Ambrose – 70 consumables + celase + intravase, expected delivery over the balance of 2019
- Cytori Japan (intercompany) – 210 consumables and celases, expected delivery by end of April 2019.
- The purchase orders in Exhibit 2.02(a)(vi)(a) are incorporated herein by reference to the extent such contracts are assumed by the Buyer in accordance with Section 2.02(a)(vi)(a) of the Agreement. For purposes of clarity, unfilled, but prepaid, Cardinal Health PO shall be assumed by Buyer and shall not require any reimbursement to Seller or additional payment to Cardinal Health with respect to same.

(b)(iii)

Japan Inventory

- Each of the pieces of inventory listed in Exhibit 2.02(b)(iii) to these schedules.

This list is as of February 28, 2019, and subject to changes in the Ordinary Course of Business between the date hereof and Closing. The final Inventory to be retained as Japan Inventory will be no less than 95%, measured by value, of the amount disclosed herein in this Exhibit 2.02(b)(iii).

(b)(iv)

Deposits

- A deposit for approximately £20,000 pursuant to the UK Lease (as defined in Section 3.02(c) herein).
- A Wells Fargo Letter of Credit for approximately \$40,000 pursuant to the San Diego Lease.
- A deposit for approximately \$7,000 pursuant to the San Diego Sublease.
- A deposit for approximately \$2,000 pursuant to the Storage Lease.

(b)(vi)

Excluded Tangible Personal Property

- Tangible Personal Property located in Seller's Texas office or located in Japan
- All personal computers used by any employee of Seller, other than the Transferred Employees; provided that all data contained on such personal computers relating to Business in the Territory shall not be an Excluded Asset and shall be transferred to servers or computers included in the Purchased Assets prior to the Closing.
- All employee owned, personal items located on or in the desks and cabinets used by any employee of Seller, other than the Transferred Employees
- All copy machines and printers located in San Diego
- All phones, other than the phones of the Transferred Employees
- Each of the pieces of equipment listed in Exhibit 2.02(b)(vi) to these schedules.

(b)(viii)

Japanese Intellectual Property

Patents (solely those patent applications and patents filed with the Japan Patent Office)

Cytori Reference:	Knobbe Reference:	Title of Invention:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9673JP	CYTH.001VJP	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	Issued	2006-503755	2/20/2004	4971787	4/13/2012	2/20/2024

MA9889JP	CYTH.002Q3JP	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	Issued	2008-513441	5/25/2005	5210155	3/1/2013	5/25/2025
MA9889JPDIV1	CYTH.002Q3JPD1	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	Issued	2011-229609	5/25/2005	5628131	10/10/2014	5/25/2025
MA9778JP	CYTH.002Q5JP	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	Abandoned	2007-503885	7/1/2004			
MA9796JP	CYTH.002QJP	SYSTEMS AND METHODS FOR ISOLATING AND USING CLINICALLY SAFE ADIPOSE DERIVED REGENERATIVE CELLS	Issued	2007-519184	7/2/2004	4731556	4/28/2011	7/2/2024
MA9790JP	CYTH.002QJP4	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	Issued	2007-519186	7/1/2004	4937119	3/2/2012	7/1/2024
MA9793JP	CYTH.002QJP6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	Issued	2007-519185	7/1/2004	4733699	4/28/2011	7/1/2024
	CYTH.002QJP6D1	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	Unfiled					
MA9658JP	CYTH.002VJP	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	Issued	2003-554106	12/9/2002	4653952	12/24/2010	12/9/2022
MA9658JPDV1	CYTH.002VJPD1	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	Issued	2010-001420	12/9/2002	5883553	2/12/2016	12/9/2022
MA9658JPDIV2	CYTH.002VJPD2	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	Issued	2012-091080	12/9/2002	5575174	7/11/2014	12/9/2022
MA9658JPDIV3	CYTH.002VJPD3	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	Issued	2013-242179	11/22/2013	5938029	5/20/2016	12/9/2022

MA9684JP	CYTH.003QJP	SYSTEMS AND METHODS FOR SEPARATING AND CONCENTRATING REGENERATIVE CELLS FROM TISSUE	Abandoned	2006-517708	6/25/2004			
MA9684JPDIV1A	CYTH.003QJPD1	SYSTEMS AND METHODS FOR SEPARATING AND CONCENTRATING REGENERATIVE CELLS FROM TISSUE	Issued	2011-217918	6/25/2004	5604397	8/29/2014	6/25/2024
MA9794JP	CYTH.004QJP	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	Issued	2006-526870	7/1/2004	5019511	6/22/2012	7/1/2024
MA9685JP	CYTH.005QJP	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	Issued	2006-517438	6/18/2004	4722041	4/15/2011	6/18/2024
MA9661JP	CYTH.017VJP	PRESERVATION OF NON EMBRYONIC CELLS FROM NON HEMATOPOIETIC TISSUES	Abandoned	2003-528119	9/13/2002			
MA9661JPDIV	CYTH.017VRJP	PRESERVATION OF NON EMBRYONIC CELLS FROM NON HEMATOPOIETIC TISSUES	Abandoned	2009-189198	9/13/2002			
MA9659JP	CYTH.019VJP	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH COLLAGEN-RICH MATERIAL EXTRACTED FROM ADIPOSE TISSUE	Abandoned	2003-554122	12/20/2002			
MA9976JP	CYTH.075JP	SYSTEMS, METHODS AND COMPOSITIONS FOR OPTIMIZING TISSUE AND CELL ENRICHED GRAFTS	Transferred	2012-508801	4/30/2010			
MA112JP	CYTH.112JP	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	Published	2016-515549	3/18/2016			
MA118JP	CYTH.118JP	USE OF REGENERATIVE CELLS IN MITIGATING BURN PROGRESSION AND IMPROVING SKIN GRAFT INCORPORATION AND HEALING	Published	2017-517678	3/31/2017			
MA124JP	CYTH.124JP	REGENERATIVE CELL THERAPY FOR MUSCULOSKELETAL DISORDERS	To be filed					

MA132JP	CYTH.132JP	PROTEIN-STABILIZED LIPOSOMAL FORMULATIONS OF PHARMACEUTICAL AGENTS	Abandoned	2004-551766	11/6/2003			
MA9843JP	CYTH.2Q12JP	DEVICES AND METHODS FOR MONITORING, MANAGING, AND SERVICING MEDICAL DEVICES	Issued	2007-550348	1/12/2005	5138384	11/22/2012	1/12/2025

For IP there is one patent that is still in the PCT International Phase (it was filed earlier this year). Consequently, rights under this patent application to pursue a patent in Japan will not transfer under this agreement but all rights under this application outside of Japan are hereby assigned. The information for this patent application is as follows:

Cytori Reference:	Knobbe Reference:	Title of Invention:	Application No.	Filing Date:
MA123WO	CYTH.123WO3	IMPROVEMENT OF ENDOTHELIAL CELL FUNCTION	PCT/US2019/018176	2/15/19

Trademarks (solely those trademark applications and registered trademarks filed with the Japan Patent Office)

Case No.	Title:	Status:	Application No.	Filing Date:	Reg Date:	Reg No:	Next Renewal:
CYTH.032WJP	STEMSOURCE	Renewed	2007-117034	11/20/2007	2/27/2009	5208354	2/27/2029
CYTH.035WJP	STEMBANK	Renewed	2003-017657	3/6/2003	3/17/2006		
CYTH.042WJP	CELUTION	Renewed	2004-106453	11/19/2004	3/16/2007	5033248	3/16/2027
CYTH.043IJP	CYTORI THERAPEUTICS	Renewed	899295	12/14/2005	12/14/2005	899295	12/14/2025
CYTH.051IJP	CELA SE	Renewed	968466	5/28/2008	5/28/2008	968466	5/28/2028
CYTH.060WJP	CYTORI and Design	Registered	2008-070808	8/28/2008	8/28/2009	5260767	8/28/2019
CYTH.061WJP	CELUTION and Design	Registered	2008-070809	8/28/2008	8/28/2009	5260768	8/28/2019
CYTH.070WJP	INTRAVASE	Registered	2009-014722	3/2/2009	11/6/2009	5278525	11/6/2019
CYTH.082IJP	CELBRUSH	Registered	1040124	5/19/2010	5/19/2010	1040124	5/19/2020
CYTH.122WJP	HABEO	Published	2017-58573	4/25/2017	4/20/2018	6037735	4/20/2028
CYTH.138WJP	SAME DAY REGENERATIVE MEDICINE	Registered	2017-091900	7/7/2017	7/6/2018	6059611	7/6/2028

Domain Names

- BIOREGENERATION.JP
- CELUTION.JP
- CELUTIONSYSTEM.JP
- CYTORI.JP

- CYTORIINC.JP
- CYTORITHERAPEUTICS.JP
- CYTORITX.JP
- KANSAIBOBANK.JP
- CYTORIJAPAN.COM
- STEMSOURCE.JP

(b)(ix)

Non-Business Intellectual Property

Patents

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA132JP	CYTH.132JP	PROTEIN-STABILIZED LIPOSOMAL FORMULATIONS OF PHARMACEUTICAL AGENTS	JP	Abandoned	2004-551766	11/6/2003			
MA127PR	CYTH.127PR	LIPOSOMAL REGENERATIVE CELL SECRETIONS	US	Expired	62/436260	12/19/2016			12/19/2017
MA127PR2	CYTH.127PR2	LIPOSOMAL REGENERATIVE CELL SECRETIONS	US	Abandoned	62/608243	12/20/2017			12/20/2018
MA132A	CYTH.132A	PROTEIN-STABILIZED LIPOSOMAL FORMULATIONS OF PHARMACEUTICAL AGENTS	US	Issued	10/703187	11/6/2003	7179484	2/20/2007	4/22/2024
MA132CA	CYTH.132CA	PROTEIN-STABILIZED LIPOSOMAL FORMULATIONS OF PHARMACEUTICAL AGENTS	CA	Issued	2505520	11/6/2003	2505520	7/17/2012	11/6/2023
MA132EP	CYTH.132EP	PROTEIN-STABILIZED LIPOSOMAL FORMULATIONS OF PHARMACEUTICAL AGENTS	EP	Published	3781768.1	11/6/2003			
MA133PR	CYTH.133PR	LIPOSOMAL TAXANES FOR TREATMENT OF SCLC	US	Expired	62/542993	8/9/2017			8/9/2018
MA133PCT	CYTH.133WO	LIPOSOMAL TAXANES FOR	WO	Published	PCT/US2018/045339	8/6/2018			4/9/2020

		TREATMENT OF SCLC						
--	--	----------------------	--	--	--	--	--	--

Trademarks

Case No.	Title:	Country:	Status:	Application No.	Filing Date:	Reg Date:	Reg No:	Next Renewal:
CYTH.128T	CYTORI NANOMEDICINE	US	Allowed	87/363762	3/8/2017			

Domain Names

- CYTORINANOMEDICINE.COM
- CYTORINANOMEDICINE.INFO
- CYTORINANOMEDICINE.NET
- CYTORINANOMEDICINE.ORG

(b)(x)*Excluded Software*

- SolidWorks, solid modeling computer-aided design and engineering software
- ProEngineering, product development software
- Microsoft Office
- SAGE, inventory management software

SECTION 2.03
ASSUMPTION AND EXCLUSION OF LIABILITIES

(a)

The following Liabilities will be Assumed Liabilities solely to the extent the underlying products or services are received by the Buyer.

Vendor	Invoice Number	Due Date	US\$
Viant San Antonio, Inc.	15972-22	4/14/2019	\$134,859.55
CPA Global North America LLC	U18577	4/29/2019	\$34,372.58

**SECTION 2.05
REQUIRED CONSENTS**

(g)

- Each of the leases listed in Section 2.02(a)(i) herein.
- Lease, dated as of August 15, 2014, by and between Cytori Ltd., and British Overseas Bank Nominees Limited and WGTC Nominees Limited (the “UK Lease”).
- The Coastal Agreement.
- The Bimini Agreement
- Loan and Security Agreement, dated as of May 29, 2015, by and among Oxford Finance LLC, Cytori Therapeutics, Inc., and those certain lenders listed therein, as amended by the First Amendment to Loan and Security Agreement, dated as of September 20, 2017 (the “Oxford Agreement”).

SECTION 3.01
ORGANIZATION, AUTHORITY AND QUALIFICATION OF SELLER

No disclosure.

**SECTION 3.02
NO CONFLICT**

(c)

No Conflict

- Each of the items listed on Section 2.05 herein.

(d)

- No disclosure.

SECTION 3.03
OWNERSHIP OF THE EQUITY INTERESTS

No disclosure.

SECTION 3.04
GOVERNMENTAL CONSENTS AND APPROVALS

No disclosure.

SECTION 3.07
ABSENCE OF UNDISCLOSED MATERIAL LIABILITIES

No disclosure.

SECTION 3.08
CONDUCT IN THE ORDINARY COURSE

(a)(i)

- The Company has been in financial distress since the Reference Date and has been winding down the Business operations.
- Each of the Current Reports on Form 8-K filed by the Company on January 2, 2019, February 1, 2019, February 14, 2019, February 27, 2019, March 5, 2019, and March 18, 2019, are incorporated herein by reference.

(a)(ii)

- No disclosure.

(a)(iii)

- Enzymes have reached their expiration date in the Ordinary Course of Business.

(b)(ii)

- The Company has pre-paid Cardinal Health \$67,000 for Toomey syringes.

(b)(v)

- Tiago Girao, the Company's CFO resigned effective March 31, 2019
- Terrie Heidemann, Quality Assurance and Regulatory Associate Director, termination effective January 4, 2019.

(b)(viii)

Employee	Retention Bonus (due May 15, 2019)	2018 Bonus (due May 31, 2019)	Total
Cidean Koeut	\$7,500	\$3,000	\$10,5000
Janice Valenciano	\$5,000	\$2,000	\$7,000

SECTION 3.09 LITIGATION

- On April 27, 2018, Lorem Vascular (“Lorem”) filed suit against the Company in the U.S. District Court for the Southern District of California alleging the Company breached an oral agreement made in 2013 to purchase 5% of Lorem’s common stock for an aggregate amount of \$5.0 million, and seeking specific performance of the alleged oral agreement and damages in an amount to be determined at trial. The Company filed a motion to dismiss all of Lorem’s claims, and on July 11, 2018 the Court granted the Company’s motion to dismiss. Lorem filed an amended complaint on August 3, 2018, advancing similar causes of action and seeking similar relief. Cytori filed a renewed motion to dismiss on August 27, 2018, and on October 1, 2018, Lorem voluntarily dismissed its amended complaint in its entirety.
- On August 31, 2018, we filed a Demand for Arbitration with the American Arbitration Association in San Diego, California, against Bimini Technologies LLC (“Bimini”) for fraud and breach of a Sale and Exclusive License/Supply Agreement made in 2013 under which Bimini licensed rights to the Company’s Standalone Fat Transplantation, including the Puregraft Product Line and associated trademarks. Our arbitration demand alleged that Bimini failed to make a \$1.0 million milestone payment due to the Company after Bimini achieved \$10.0 million in gross profits from the sale of the Company’s Puregraft product line, and Bimini deceived the Company about Bimini’s true gross profits figures. Our arbitration demand sought that \$1.0 million milestone payment, as well prejudgment interest and attorneys’ fees. On October 29, 2018 Bimini made the \$1.0 million milestone payment. The parties subsequently entered into a settlement agreement resolving the claims in the Demand for Arbitration.
- On June 22, 2018, Cytori Therapeutics, Inc. received a letter from a law firm on behalf of one purported stockholder demanding a review of the voting results from our 2018 annual meeting of stockholders. The demand letter alleges that the stockholder votes on the proposals to amend our certificate of incorporation to effect a reverse stock split and to increase the number of authorized shares of common stock were tabulated incorrectly because broker non-votes were included in the calculation of votes “for” such proposals when the proxy statement stated that broker non-votes would have the same effect as a vote “against” such proposals. The letter demanded that our board of directors review and recount the votes cast with respect to the proposals and, if necessary, take appropriate remedial actions. After review of these allegations and discussion with the entities responsible for oversight of the voting process, the board has concluded that the tabulation of the votes cast on these proposals was performed correctly and was accurately reported. Under the rules that govern brokers who are voting with respect to shares held in street name, brokers have the discretion to vote those shares on routine matters, but not on non-routine matters. Although the proxy statement for the annual meeting indicated that these two proposals were not routine matters, brokers determined instead that they were routine under applicable rules. As a result, brokers voted shares held in street name with respect to these proposals and,

accordingly, there were no broker non-votes on these proposals. The board responded to the demand letter in a manner consistent with its findings.

**SECTION 3.10
COMPLIANCE WITH LAWS**

(a)

- Each of the litigation matters listed in Section 3.09 herein.

(b)

- The certificates included in Exhibit 3.10(b) to these schedules.
- Not in compliance: Last year, the Company was supposed to perform an audit of the UK facility last year. This has not been done yet. As a result, Inventory assembled in the UK facility cannot be exported to the UK or EU.

(d)

- No disclosure.

(e)

- No disclosure.

SECTION 3.11 INTELLECTUAL PROPERTY

(a)

Business Intellectual Property

- The Intellectual Property listed in Section 2.02(a)(viii) herein.
- The Intellectual Property listed in Section 2.02(b)(viii) herein.

Licensed Intellectual Property

- SolidWorks, solid modeling computer-aided design and engineering software
- ProEngineering, product development software
- Microsoft Office
- The Oxford Agreement

(b)

- SolidWorks, solid modeling computer-aided design and engineering software
- ProEngineering, product development software
- Microsoft Office
- SAGE, traceability software.

(c)

- Certain combination products are subject to a royalty payment pursuant to an agreement with Bimini.

(d)

- No disclosure.

(e)(i)

Business Intellectual Property Licenses

- The Bimini Agreement.
- Amended and Restated License and Supply Agreement dated January 30, 2014 between Seller and Buyer (the “Lorem Agreement”).

(e)(ii)

- No disclosure.

(f)

- No disclosure.

(g)

- Numerous medical clinical and other health providers are potentially infringing on Business Intellectual Property because they are using adipose tissue and injecting in a manner similar to our technology.

(h)

Registered Intellectual Property

- The Intellectual Property listed in Section 2.02(a)(viii) herein.

(n)

- BARDA
- NIH grants funded some of the Business Intellectual Property more than 10 years ago.

**SECTION 3.13
REAL PROPERTY**

(a)

Leased Real Property and Leases

- Each of the leases listed in Section 2.02(a)(i) herein.
- The UK Lease
- An informal warehousing arrangement in Germany for which there is no written agreement.

(c)

- No disclosure.

SECTION 3.14
PURCHASE ASSETS

- Certain assets of the Business are subject to an Encumbrance pursuant to the Oxford Agreement, which Encumbrances on all Purchased Assets will be released at or prior to the Closing

SECTION 3.15 SUFFICIENCY OF ASSETS

- The agreements listed in Section 2.02(a)(vi)(a), and the following agreements, are used by the Seller in operating the Business and may need to be assumed or replaced in order for Buyer operate the Business as presently conducted. Such contracts are collectively immaterial to the Business:
 - Ambrose Cell Therapy, INC.: Supply Agreement (pending)
 - Knobbe Marten - IP support.
 - Parexel- ad hoc FDA consulting for scleroderma
 - Terrie Heidemann – Quality
 - Sharon Spencer – Quality/Reg
 - Le Dich – Regulatory
 - Mike DeEmedio – Tech Support US
 - Lesley Kelley – Tech Support EU/ROW
 - Mark Marino – CMO US – agreement expired.
 - Steven Kesten – CMO US
 - Dinesh Khanna- Scleroderma Consultant; University of Michigan
 - Guy Magalon, Marseille, France- Scleroderma consultant
 - Ryan Hertzog – Software, contract may have expired
 - David Lafraniere – Software
 - Olga Souverneva - Software
 - Dana Lutijens – Drafter/Solidworks
 - Noor Al-Sabah Co.: Sales Representative Agreement
- SolidWorks, solid modeling computer-aided design and engineering software
- ProEngineering, product development software
- Microsoft Office
- SAGE, traceability software.

SECTION 3.17 INVENTORIES

- We are holding inventory for BARDA, under a bill-and-hold arrangement:

Part Number	Part Description	PD Line	Type	Valuation	U of M	Lot/Serial	Transaction ID	Trans Date	Qty	Unit Cost	Ext Cost
1553618	Celase, 35 mg, Clinical, Final	FG E	Finished Good	Lot	EA CH	7106142	W0011358	1/2/2018	28.00	215.370	6,030.36
1553671	Cytori IV Training Kit	FG C	Finished Good	Lot	EA CH	7106248	00005416	11/27/2018	6.00	37.777	226.66
1553676	Pkg Assy, Macro Syringe Filter	FG T	Finished Good	Lot	EA CH	7106127	00005403	3/29/2018	2.00	18.620	37.24
1553676	Pkg Assy, Macro Syringe Filter	FG T	Finished Good	Lot	EA CH	7106219	00005416	11/27/2018	4.00	18.620	74.48
1553678	Intravase, 6mg, Clinical, Final	FG E	Finished Good	Lot	EA CH	7106143	W0011358	1/2/2018	28.00	6,250.000	175,000.00
1553712-04	Celution 800/IV, Clinical, Hea	FG D	Finished Good	Lot	EA CH	2111	00005423	1/30/2019	1.00	43,986.100	43,986.10
1553712-04	Celution 800/IV, Clinical, Hea	FG D	Finished Good	Lot	EA CH	2112	00005423	1/30/2019	1.00	44,228.600	44,228.60
1553713	Celution 805IV Consumable Set,	FG C	Finished Good	Lot	EA CH	7106272	W0011642	12/27/2018	21.00	433.287	9,099.03
1553727	Clinical, (CSA) Collection Syr	FG T	Finished Good	Lot	EA CH	7106126	00005403	3/29/2018	5.00	19.480	97.40
1553727	Clinical, (CSA) Collection Syr	FG T	Finished Good	Lot	EA CH	7106222	00005416	11/27/2018	10.00	19.480	194.80
20012001	Nucleocounter Device Package	CLIN	Finished Good	Serial	EA CH	0315-044-30	00005416	11/27/2018	1.00	9,240.790	9,240.79
20012001	Nucleocounter Device Package	CLIN	Finished Good	Serial	EA CH	0315-044-31	00005416	11/27/2018	1.00	9,240.790	9,240.79
20012001	Nucleocounter Device Package	CLIN	Finished Good	Serial	EA CH	0315-044-32	00005416	11/27/2018	1.00	9,240.790	9,240.79
20012002	Thermal Printer 972-0002	CLIN	Finished Good	Serial	EA CH	5003715090016	00005416	11/27/2018	1.00	547.440	547.44

20012002	Thermal Printer 972-0002	CLIN	Finished Good	Serial	EACH	5003715090020	00005416	11/27/2018	1.00	547.440	547.44
20012002	Thermal Printer 972-0002	CLIN	Finished Good	Serial	EACH	5003715090025	00005416	11/27/2018	1.00	547.440	547.44
20012003	Reagent A (lysis-buffer) 500 m	CLIN	Finished Good	Lot	EACH	0618-18	00005410	10/4/2018	2.00	82.000	164.00
20012003	Reagent A (lysis-buffer) 500 m	CLIN	Finished Good	Lot	EACH	0718-16	00005422	12/11/2018	3.00	82.000	246.00
20012003	Reagent A (lysis-buffer) 500 m	CLIN	Finished Good	Lot	EACH	1017-18	00005403	3/29/2018	2.00	51.000	102.00
20012004	Reagent B (Stabil-buffer) 500	CLIN	Finished Good	Lot	EACH	0617-26	00005403	3/29/2018	2.00	47.000	94.00
20012004	Reagent B (Stabil-buffer) 500	CLIN	Finished Good	Lot	EACH	0618-19	00005410	10/4/2018	1.00	74.000	74.00
20012004	Reagent B (Stabil-buffer) 500	CLIN	Finished Good	Lot	EACH	0718-23	00005422	12/11/2018	2.00	74.000	148.00
20012005	NucleoCas sette 941-0002	CLIN	Finished Good	Lot	EACH	0618-05	00005410	10/4/2018	30.00	2.700	81.00
20012005	NucleoCas sette 941-0002	CLIN	Finished Good	Lot	EACH	0918-04	00005424	2/5/2019	200.00	2.700	540.00
20012005	NucleoCas sette 941-0002	CLIN	Finished Good	Lot	EACH	1017-06	G249761	4/2/2018	110.00	2.700	297.00
20012006	IPA Spray Bottle 16 oz 89097-	CLIN	Finished Good	Lot	EACH	3900034-*-*1	00005416	11/27/2018	3.00	11.934	35.80
20012007	Syringe Luerlock 60 ml BD309	CLIN	Finished Good	Lot	EACH	7255849	00005403	3/29/2018	15.00	0.734	11.01
20012013	1.5-2.0ml Microcentrifuge Tube	CLIN	Finished Good	Lot	EACH	H178366L	00005415	11/27/2018	160.00	0.444	71.04
20012014	Microcentrifuge Tube Holder	CLIN	Finished Good	Lot	EACH	515556	00005418	12/4/2018	4.00	20.450	81.80
20012016	Lactated Ringer 1L Bag 8799	CLIN	Finished Good	Lot	EACH	J6N016	00005403	3/29/2018	12.00	3.250	39.00
20012016	Lactated Ringer 1L Bag 8799	CLIN	Finished Good	Lot	EACH	J8K106	00005415	11/27/2018	96.00	3.738	358.84
20012017	Fluid Dispensing Connector 41	CLIN	Finished Good	Lot	EACH	61633537	00005415	11/27/2018	90.00	1.272	114.48

20012018	5ml Luer Lock Syringe RL5	CLIN	Finished Good	Lot	EACH	15K07C8	00005403	3/29/2018	30.00	0.140	4.20
20012025	Pressure Bandage, Size M 12"	CLIN	Finished Good	Lot	EACH	10571	00005403	3/29/2018	9.00	44.000	396.00
20012026	Pressure Bandage, Size L 12"	CLIN	Finished Good	Lot	EACH	10570	00005403	3/29/2018	9.00	43.708	393.37
20012027	Pressure Bandage, Size XL 12"	CLIN	Finished Good	Lot	EACH	10573	00005403	3/29/2018	9.00	43.728	393.55
20012038	Infrared Thermometer 4475	CLIN	Finished Good	Serial	EACH	181264766	G250276	9/7/2018	1.00	38.890	38.89
20012038	Infrared Thermometer 4475	CLIN	Finished Good	Serial	EACH	191902937	00005425	2/8/2019	1.00	40.660	40.66
20012038	Infrared Thermometer 4475	CLIN	Finished Good	Serial	EACH	191902939	00005425	2/8/2019	1.00	40.660	40.66
20012039	Biohazard ziplock/sealable 6x9	CLIN	Finished Good	Lot	EACH	9266066843	00005416	11/27/2018	30.00	0.127	3.81
20012044	Biohazard Ziplock 12" x 15", 1	CLIN	Finished Good	Lot	EACH	E1230915003	00005403	3/29/2018	15.00	0.118	1.77
20012046	1ml Luer Lock Syringe	CLIN	Finished Good	Lot	EACH	6242511	00005403	3/29/2018	40.00	0.433	17.32
20012046	1ml Luer Lock Syringe	CLIN	Finished Good	Lot	EACH	7207878	G249860	5/14/2018	40.00	0.433	17.32
20012047	Large Kimwipes	CLIN	Finished Good	Lot	BOX	34133	00005403	3/29/2018	3.00	3.314	9.94
20012048	Bench Pads	CLIN	Finished Good	Lot	EACH	73626	00005416	11/27/2018	15.00	0.114	1.71
20012056	TR-51i Thermo Recorder	CLIN	Finished Good	Lot	EACH	150436402	00005403	3/29/2018	1.00	45.910	45.91
20012056	TR-51i Thermo Recorder	CLIN	Finished Good	Lot	EACH	150436404	00005403	3/29/2018	1.00	45.910	45.91
20012056	TR-51i Thermo Recorder	CLIN	Finished Good	Lot	EACH	150436408	00005403	3/29/2018	1.00	45.910	45.91
20012056	TR-51i Thermo Recorder	CLIN	Finished Good	Lot	EACH	150436410	00005403	3/29/2018	1.00	45.910	45.91
20012056	TR-51i Thermo Recorder	CLIN	Finished Good	Lot	EACH	150436411	00005403	3/29/2018	1.00	45.910	45.91
20012056	TR-51i Thermo Recorder	CLIN	Finished Good	Lot	EACH	150436413	00005403	3/29/2018	1.00	45.910	45.91

20012056	TR-51i Thermo Recorder	CLIN	Finished Good	Lot	EACH	170734989	00005403	3/29/2018	1.00	49.900	49.90
20012056	TR-51i Thermo Recorder	CLIN	Finished Good	Lot	EACH	170734991	00005403	3/29/2018	1.00	49.900	49.90
20012058	Dispenser 0.05-0.5 mL for A&B	CLIN	Finished Good	Lot	EACH	08L62730	00005416	11/27/2018	1.00	149.500	149.50
20012058	Dispenser 0.05-0.5 mL for A&B	CLIN	Finished Good	Lot	EACH	10K45619	00005416	11/27/2018	1.00	149.500	149.50
20012058	Dispenser 0.05-0.5 mL for A&B	CLIN	Finished Good	Lot	EACH	10L90312	00005416	11/27/2018	1.00	149.500	149.50
20012058	Dispenser 0.05-0.5 mL for A&B	CLIN	Finished Good	Lot	EACH	10L90313	00005416	11/27/2018	1.00	149.500	149.50
20012058	Dispenser 0.05-0.5 mL for A&B	CLIN	Finished Good	Lot	EACH	10L90315	00005416	11/27/2018	1.00	149.500	149.50
20012058	Dispenser 0.05-0.5 mL for A&B	CLIN	Finished Good	Lot	EACH	12L20283	00005403	3/29/2018	1.00	149.500	149.50
20012058	Dispenser 0.05-0.5 mL for A&B	CLIN	Finished Good	Lot	EACH	12L20284	00005403	3/29/2018	1.00	149.500	149.50
20012059	Alcohol Prep Pads Sterile 156	CLIN	Finished Good	Lot	EACH	11800445	00005415	11/27/2018	3.00	5.370	16.11
20012068	Thermal Printer Paper Roll	CLIN	Finished Good	Lot	EACH	939-0012	00005403	3/29/2018	4.00	0.000	0.00
20012069	Reagent Stand 500ml	CLIN	Finished Good	Lot	EACH	929-0001	00005403	3/29/2018	3.00	0.000	0.00
20012071	Polar Bear Coolers 12 Pack Sof	CLIN	Finished Good	FIFO	EACH		00000000	12/4/2018	3.00	66.990	200.97
20012090	Sterile Fields Drapes	CLIN	Finished Good	FIFO	EACH		00000000	2/19/2019	300.00	0.230	69.00
20012091	Nutating Mixer	CLIN	Finished Good	Serial	EACH	145167361	00005416	11/27/2018	1.00	309.990	309.99
20012091	Nutating Mixer	CLIN	Finished Good	Serial	EACH	145167362	00005416	11/27/2018	1.00	309.990	309.99
20012091	Nutating Mixer	CLIN	Finished Good	Serial	EACH	151069376	00005416	11/27/2018	1.00	309.990	309.99
20012096	50ml Centrifuge	CLIN	Finished Good	Lot	EACH	J257412	00005403	3/29/2018	3.00	34.120	102.36

	Tube PolyGrid										
20012102	Tube Blood Collection (GramSta	CLIN	Finished Good	Lot	EA CH	7305585	00005403	3/29/2018	8.00	0.169	1.35
20012102	Tube Blood Collection (GramSta	CLIN	Finished Good	Lot	EA CH	80899587	00005415	11/27/2018	84.00	0.088	7.40
20012102	Tube Blood Collection (GramSta	CLIN	Finished Good	Lot	EA CH	8187661	00005426	2/13/2019	70.00	0.088	6.16
20012105	Rapid Fluid Warmer, US	CLIN	Finished Good	Lot	EA CH	1686309-000	00005416	11/27/2018	1.00	749.400	749.40
20012105	Rapid Fluid Warmer, US	CLIN	Finished Good	Lot	EA CH	1686310-000	00005416	11/27/2018	1.00	749.400	749.40
20012105	Rapid Fluid Warmer, US	CLIN	Finished Good	Lot	EA CH	1686313-000	00005416	11/27/2018	1.00	749.400	749.40
20012105	Rapid Fluid Warmer, US	CLIN	Finished Good	Lot	EA CH	1686314-000	00005416	11/27/2018	1.00	749.400	749.40
20012105	Rapid Fluid Warmer, US	CLIN	Finished Good	Lot	EA CH	1686315-000	00005416	11/27/2018	1.00	749.400	749.40
20012105	Rapid Fluid Warmer, US	CLIN	Finished Good	Lot	EA CH	1686316-000	00005416	11/27/2018	1.00	749.400	749.40
20012118	Wahl, Temp-Plate Recorder	CLIN	Raw Material	Lot	EA CH	10655408	00005415	11/27/2018	30.00	3.230	96.90
20012119	STOPCOC K 3-WAY	CLIN	Raw Material	Lot	EA CH	181B4126	00005403	3/29/2018	15.00	0.818	12.27
20012121	Drape, Arm, Sterile, 9" x 96"	CLIN	Finished Good	Lot	EA CH	06917100021	00005408	7/6/2018	5.00	0.000	0.00
20012121	Drape, Arm, Sterile, 9" x 96"	CLIN	Finished Good	Lot	EA CH	06918060021	00005415	11/27/2018	20.00	5.700	114.00
20012122	Stainless Steel Ruler	CLIN	Finished Good	Lot	EA CH	21013	00005408	7/6/2018	13.00	0.000	0.00
20012123	BD Vacutainer, Blood Collectio	CLIN	Finished Good	Lot	EA CH	8019897	00005426	2/13/2019	96.00	0.300	28.80

20012123	BD Vacutainer , Blood Collectio	CLIN	Finished Good	Lot	EACH	8025683	00005426	2/13/2019	144.00	0.300	43.20
20012125	SST Serum Separation Tubes	CLIN	Finished Good	Lot	EACH	8261872	00005426	2/13/2019	200.00	0.229	45.80
20012126	Transfer pipette 3.5ml	CLIN	Finished Good	Lot	EACH	18290483	00005428	2/20/2019	500.00	0.156	78.00
20012128	CryoBox	CLIN	Finished Good	Lot	EACH	7295825010	00005426	2/13/2019	20.00	8.220	164.40
5300308	Toomey Syringe Cap (VBQ3740 020	RM T	Raw Material	Lot	EACH	61603043	00005416	11/27/2018	180.00	0.130	23.40
5300311	Spinal Needle	RM T	Raw Material	Lot	EACH	6287578	00005403	3/29/2018	15.00	2.920	43.80
5300331	Soft-Ject Syringe 10 ml	RM T	Raw Material	Lot	EACH	18D16C8	00005416	11/27/2018	30.00	0.200	6.00
5300453	Toomey Syringe, 60ml, Blister	RM T	Raw Material	Lot	EACH	703440X	00005403	3/29/2018	30.00	0.990	29.70
5300472	Fine-Ject Needle, 18G x 1-1/2	RM T	Raw Material	Lot	EACH	14-13519	00005403	3/29/2018	45.00	0.100	4.50
RLF PROCEDURE	RELIEF Procedure Day Kit	CLIN	Finished Good	Lot	EACH	20190206-04	W0011734	2/25/2019	2.00	73.630	147.26
RLF SERUM	RELIEF Patient Serum Collectio	CLIN	Finished Good	Lot	EACH	20180828-01	00005409	8/30/2018	3.00	0.000	0.00
RULER	150mm, Stainless Steel Ruler	CLIN	Finished Good	FIFO	EACH		00000000	5/1/2018	19.00	0.000	0.00
											320,246.04

- There is a reserve in the financial statements for approximately \$500,000 for expired or obsolete Inventory.
- Enzymes have been purchased in larger quantities than needed because our supplier contract expired.

SECTION 3.18
EMPLOYEES AND EMPLOYEE BENEFIT PLANS

(a)

- Keout, Cidean
- Valenciano, Janice
- Savage, Glen
- Dinger, Anthony J.
- Fraser, John
- Girao, Tiago
- Havranek, Russell
- Rice, Cheryl D.
- Hendrick, Marc
- Zhu, Min
- Compensation arrangement in effect as of March 29, 2019 with respect to Transferred Employees
- Compensation amounts payable as of March 29, 2019 with respect to Transferred Employees

(b)

- No disclosure.

(1)

- United HealthCare Medical Plans
 - HMO – California Only
 - PPO with HAS
- United Concordia PPO Dental Plan
- Anthem Vision Plan
- Igoe Flexible Spending Accounts
- CIGNA Life/AD&D/Disability Coverage
- Cytori 401K Retirement Savings Plan
- 2011 Employee Stock Purchase Plan

SECTION 3.19
ENVIRONMENTAL MATTERS

No disclosure.

SECTION 3.20
TAXES

(h)

- Cytori UK has a Tax Return filing obligation in the United Kingdom or has a permanent establishment or other fixed place of business in the United Kingdom.

(m)

- For U.S. federal income Tax purposes, Cytori UK is classified as a controlled foreign corporation.

SECTION 3.21 MATERIAL CONTRACTS

(a)

- Ambrose Cell Therapy, INC.: Supply Agreement (pending)
- The Coastal Agreement
- Henke-Sass, Wolf, GmbH: Exclusive Manufacture and Supply Agreement (FOR CELLBRUSH)
- Centurion
- Cardinal Health (Monoject 60 mL Toomey Syringe)
- Sterigenics
- BSI
- DEKRA
- Best Roads
- Knobbe Marten - eng letter? IP support.
- CPA Global – IP maintenance
- EIP US - IP
- RSQR: Authorized Representative for EU (in process of changing to non-UK source due to Brexit)
- Sephno – Network/Server/IT support
- Accense – Freezer Monitoring
- Anmar – Calibration and Preventative Maintenance
- GL Technologies – Calibration and Preventative Maintenance
- Apple Tree – Customer Service
- OSI – Safety and Permitting
- Waste Management– Chemicals handling
- Intertek – Safety Testing and Certification of device
- Namsa – Biocompatibility and Analytical Testing - consumable
- Nelson – Biocompatibility and Analytical Testing - consumable
- Westpak – Aging Chambers and Testing
- Philip Medisize – CTX2 Tooling (\$0 NBV as of 2/28/19)
- Molecular Devices LLC (Microplate reader, and calibration service)
- Rainin (calibration and repair services for pipettes)

- Parexel- ad hoc FDA consulting for scleroderma
- Clinical Network Services (CNS) Pty Ltd (scleroderma Orphan drug designation to CNS Netherlands)
- The Bimini Agreement
- The Lorem Agreement
- Cogen Korea: Non-Exclusive Distribution Agreement (Celase GMP)
- Worthington Biochemical Corporation: Non-Exclusive Distribution Agreement
- Mira Corporation: Exclusive Distribution Non-Binding Term Sheet
- Terrie Heidemann – Quality
- Sharon Spencer – Quality/Reg
- Le Dich – Regulatory
- Mike DeEmedio – Tech Support US
- Lesley Kelley – Tech Support EU/ROW
- Sharon James – Office support UK
- Mark Marino – CMO US – agreement expired.
- Steven Kesten – CMO US
- Dinesh Khanna- Scleroderma Consultant; University of Michigan
- Guy Magalon, Marseille, France- Scleroderma consultant
- Ryan Hertzog – Software, contract may have expired
- David Lafraniere – Software
- Olga Souverneva - Software
- Dana Lutijens – Drafter/Solidworks
- Noor Al-Sabah Co.: Sales Representative Agreement
- Celution 800 Systems
 - Mayo Clinic, Rochester, MN
 - Winthrop University Hospital, Mineola, NY
 - Okyanos Operating Company Ltd (“Emergency” device provided at no cost under Supply Agreement Amendment 2
 - FacesPlus – we can’t find a record of a Loaner Agreement
 - Hospital de la Conception, Marseille, France
 - Hospital Saint Louis, Paris, France
 - Hospital General La Paz, Madrid, Spain

- Hospital Miguel Dominguez, Pontevedra, Spain
- Fundacion Jimenez Diaz, Madrid, Spain
- Hospital Quiron, Barcelona, Spain
- Glasgow Royal Infirmary, Glasgow, Scotland, UK
- Queen Elizabeth University Hospital, Glasgow, Scotland, UK
- Mira Corporation
- Dr. Joel Aronowitz
- Nucleocounter 100 Devices
 - Hospital de la Conception, Marseille, France
 - CHU Rouen, Rouen, France
 - Hospital Miguel Dominguez, Pontevedra, Spain
 - Hospital Quiron, Barcelona, Spain

The Company is not in compliance with the Oxford Agreement.

SECTION 3.23
RELATIONSHIPS WITH SUPPLIERS, CUSTOMERS AND DISTRIBUTORS

(a)

FY2017

Vendor Name	Sum of Amount
Roche Diagnostics Corporation	\$ 1,145,968.09
Fichtner Medizintechnik	\$ 127,480.53
VWR International, Inc.	\$ 97,295.65
Sartorius Stedim North Am. Inc	\$ 63,780.55
Medtronics	\$ 53,820.06

FY2018

Vendor Name	Sum of Amount
Roche Diagnostics Corporation	368,654.40
VWR International, Inc.	181,225.96
Viant San Antonio, Inc. (Viant Services Inc&Subs)	147,042.00
Fichtner Medizintechnik	105,349.00
Coastal Life Technologies, Inc.	89,754.00
MedPlast Services Inc.	35,229.92
Landsberg Company	20,412.10

YTD2019

Vendor Name	Sum of Amount
Viant San Antonio, Inc. (Viant Services Inc&Subs)	386,600.69
Fichtner Medizintechnik	39,584.07
Kaman Automation Inc.	24,029.23
VWR International, Inc.	23,860.85
Landsberg Company	12,319.60

(b)

2017 Sales

Okyanos Heart Institute	\$ 231,710
Odense Universitets Hospital	\$ 78,362
Amsterdam Plastic Surgery	\$ 33,268
M.D. Anderson Cancer Center	\$ 32,997
Oslo univ. - Radiumhospitalet	\$ 9,693
The Lu-Jean Feng Clinic	\$ 8,376
UniversitätsSpital Zürich	\$ 8,259
Glasgow Royal Infirmary	\$ 7,446
Hospital de la Conception	\$ 6,966
Sarasota Memorial Hospital	\$ 6,825

2018 Sales

Odense Universitets Hospital	\$ 66,282
University of Kansas Medical	\$ 39,486
Oslo univ. - Radiumhospitalet	\$ 33,900
Okyanos Heart Institute	\$ 33,398
UniversitätsSpital Zürich	\$ 10,006
Swiss Stem Cell Foundation	\$ 9,993
Queen Elizabeth Univ. Hospital	\$ 9,699
The Lu-Jean Feng Clinic	\$ 7,376
M.D. Anderson Cancer Center	\$ 5,043
Shewmake Plastic Surgery	\$ 2,769

2019 Sales Year-To-Date

Odense Universitets Hospital	\$ 113,622
Okyanos Heart Institute	\$ 33,481
The Lu-Jean Feng Clinic	\$ 4,524
UniversitätsSpital Zürich	\$ 3,329
Swiss Stem Cell Foundation	\$ 2,232
Amsterdam Plastic Surgery	\$ 1,750

(c)

2017 Sales

Medicina Regenerativa Asclepeia	\$ 43,500
Mira Corporation	\$ 36,250
Lorem Vascular	\$ 33,149
HammerMed Medical Polska Sp	\$ 31,828
Kerastem LLC	\$ 31,670

2018 Sales

Ambrose Cell Therapy	\$ 157,305
Kerastem LLC	\$ 62,191
Medicina Regenerativa Asclepeia	\$ 39,500
Lorem Vascular	\$ 18,000
UpViser Oy	\$ 16,005

2019 Sales Year-To-Date

Lorem Vascular	\$ 67,200
Ambrose Cell Therapy	\$ 25,000
Kerastem LLC	\$ 24,049

STEAMMED	\$ 6,011
Interlux Co., Ltd	\$ 2,781

The foregoing disclosures do not qualify the portions of Section 3.23 with respect to knowledge of a party's intent to stop, materially decrease the rate of, or materially change the terms (whether related to payment, price or otherwise) with respect to, supplying, distributing or purchasing products or materials,

SECTION 3.24
RELATIONSHIPS WITH AFFILIATES

- Cytori UK owes the Seller \$1 million in intercompany payables.
- Transfer Pricing Arrangement.

SECTION 3.25
BROKERS

- TAP Advisors is entitled to a finders' fee in connection with the transactions completed by the APA.

**SECTION 3.26
CAPITALIZATION**

- 100 shares of common stock for Cytori UK.

SECTION 5.09
NO CONFLICT

No disclosure.

SECTION 6.09
TRANSFERRED EMPLOYEES

(a)(i)

- Cidean Koeut
- Janice Valenciano

SECTION 8.01(F)
REQUIRED CONSENTS

- The San Diego Lease
- The San Diego Sublease
- The Storage Lease
- The UK Lease
- The Coastal Agreement
- The Bimini Agreement
- The Oxford Agreement
- Registration and Agent Service Agreement dated December 18, 2017 by and between Seller and Best Roads Meditech (Beijing) Ltd.

SECTION 8.01(H)

REQUIRED APPROVALS, CONSENTS, WAIVERS, AMENDMENTS, AND PERMITS

Seller and Best Roads Meditech (Beijing) Ltd. (“Best Roads”) shall have entered into an amendment of the Registration and Agent Service Agreement dated December 18, 2017 to provide for termination of the Agreement by Seller (or its assignee) for convenience in form satisfactory to Seller

Seller shall deliver to Buyer at Closing all forms, consents, approvals or other documentation necessary or reasonably requested by Buyer or Best Roads for submission to the Chinese National Medical Products Administration (or any other agency) to effect the transfer of Seller’s registration and/or license with respect to the Business.

EXHIBIT 2.02(a)(iii)-1

Part Number	Part Description	PD Line	Type	Valuation	U of M	WHS	WHS Description	Lot/Serial	Transaction ID	Trans Date	Qty	Unit Cost	Ext Cost
10010028	Wire, 22 AWG, Black	RMD	Raw Material	FIFO	FT	205	205-Released Material-SD		PHY CNT	12/19/2014	10.00	0.113	1.13
10010028	Wire, 22 AWG, Black	RMD	Raw Material	FIFO	FT	205	205-Released Material-SD		PHY CNT	12/21/2016	890.00	0.113	100.57
1551529	Stand, Containment Chamber	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104666	W0007797	5/27/2014	116.00	4.800	556.80
1551529	Stand, Containment Chamber	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105496	W0009534	12/4/2015	238.00	4.740	1,128.12
1551640	Wrench, Micro Chamber	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104313	W0007257	12/26/2013	44.00	23.580	1,037.52
1553005	Spindle Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105653	W0009816	2/11/2016	10.00	565.770	5,657.70
1553005	Spindle Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105884	W0010573	11/15/2016	12.00	566.310	6,795.72
1553005	Spindle Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7104827	00004035	4/13/2015	2.00	561.160	1,122.32
1553005	Spindle Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7105399	W0009132	8/18/2015	3.00	563.150	1,689.45
1553005	Spindle Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7105653	W0009816	2/11/2016	2.00	565.770	1,131.54
1553006	Spindle Shaft	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105410	W0009497	11/23/2015	39.00	91.290	3,560.30
1553013	Fat Rocker Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105918	W0010883	4/28/2017	1.00	2,159.360	2,159.36
1553013	Fat Rocker Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105919	W0010883	4/28/2017	1.00	2,159.300	2,159.30
1553013	Fat Rocker Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105920	W0010883	4/28/2017	1.00	2,159.300	2,159.30
1553013	Fat Rocker Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105921	W0010916	5/9/2017	1.00	2,150.030	2,150.03
1553013	Fat Rocker Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105922	W0010883	4/28/2017	1.00	2,150.810	2,150.81
1553013	Fat Rocker Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105923	W0010883	4/28/2017	1.00	2,150.820	2,150.82
1553013	Fat Rocker Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7106039	W0010978	6/2/2017	1.00	2,268.000	2,268.00
1553013	Fat Rocker Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7106040	W0010978	6/2/2017	1.00	2,268.010	2,268.01
1553013	Fat Rocker Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7106041	W0010984	6/7/2017	1.00	2,268.000	2,268.00
1553013	Fat Rocker Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7106042	W0010984	6/7/2017	1.00	2,268.400	2,268.40
1553013	Fat Rocker Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7104978	00004035	4/13/2015	1.00	2,130.700	2,130.70
1553013	Fat Rocker Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7104979	00004035	4/13/2015	1.00	2,100.710	2,100.71
1553013	Fat Rocker Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7105560	W0009787	2/2/2016	1.00	2,152.610	2,152.61
1553013	Fat Rocker Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7105561	W0009787	2/2/2016	1.00	2,151.820	2,151.82
1553013	Fat Rocker Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7105562	W0009787	2/2/2016	1.00	2,152.640	2,152.64
1553016	Accelerometer Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104268	W0007060	11/12/2013	5.00	66.140	330.70
1553016	Accelerometer Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105139	W0008355	1/15/2015	30.00	56.380	1,691.39
1553016	Accelerometer Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105887	W0010510	10/10/2016	14.00	56.260	787.64
1553016	Accelerometer Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7104268	W0007060	11/12/2013	1.00	66.130	66.13
1553027	SMD Strain Gauge Stop	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105413	W0009124	8/13/2015	105.00	7.340	770.75
1553027	SMD Strain Gauge Stop	WPD	Raw Material	Lot	EACH	490	490-At Vendor Location	7102447	00002412	7/22/2011	6.00	0.090	0.54
1553028	Pressure Sensor Base	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7103774	W0006393	4/17/2013	34.00	17.790	604.87
1553028	Pressure Sensor Base	WPD	Raw Material	Lot	EACH	490	490-At Vendor Location	7103774	00003580	2/4/2014	6.00	1.857	11.14
1553029	Sensor Housing Cap	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	071417-01	G249034	7/14/2017	100.00	9.750	975.00
1553029	Sensor Housing Cap	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105299	W0008979	7/16/2015	7.00	7.800	54.60
1553029	Sensor Housing Cap	WPD	Raw Material	Lot	EACH	490	490-At Vendor Location	7105299	W0008979	7/16/2015	6.00	0.563	3.38
1553030	Mounting Enclosure, Optical Se	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	6173-001	TRFR202A	9/30/2010	96.00	12.580	1,207.68
1553045	Dust Shield	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105495	W0009571	12/9/2015	60.00	20.960	1,257.59
1553058	Caster Mount	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105527	W0009552	12/7/2015	170.00	11.370	1,932.97
1553061	Servo Motor Mount	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105047	W0008133	10/10/2014	12.00	35.760	429.12
1553061	Servo Motor Mount	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105506	W0009552	12/7/2015	55.00	34.170	1,879.34
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104592	W0007442	2/21/2014	1.00	1,186.380	1,186.38
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104596	W0007457	3/6/2014	1.00	1,186.380	1,186.38
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104712	W0007656	4/15/2014	1.00	1,184.780	1,184.78
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104713	W0007656	4/15/2014	1.00	1,184.780	1,184.78
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104899	W0007991	8/13/2014	1.00	1,187.690	1,187.69
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104970	W0008013	8/21/2014	1.00	2,323.190	2,323.19
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104971	W0008013	8/21/2014	1.00	2,323.180	2,323.18
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104972	W0008013	8/21/2014	1.00	2,323.160	2,323.16
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104973	W0008013	8/21/2014	1.00	2,323.080	2,323.08
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105036	W0008089	10/2/2014	1.00	2,323.080	2,323.08
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105037	W0008089	10/2/2014	1.00	2,323.080	2,323.08
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105038	W0008089	10/2/2014	1.00	2,323.080	2,323.08
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105039	W0008089	10/2/2014	1.00	2,323.080	2,323.08
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105040	W0008118	10/7/2014	1.00	2,323.080	2,323.08
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105042	W0008127	10/9/2014	1.00	2,324.130	2,324.13
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105043	W0008118	10/7/2014	1.00	2,324.130	2,324.13
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105044	W0008118	10/7/2014	1.00	2,326.460	2,326.46
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105045	W0008118	10/7/2014	1.00	2,326.460	2,326.46
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105046	W0008118	10/7/2014	1.00	2,326.460	2,326.46
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	6215-005	00002521	9/22/2011	1.00	2,348.710	2,348.71
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7104809	M002598	12/1/2015	1.00	2,324.130	2,324.13
1553062	Spindle Motor Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7104818	00004035	4/13/2015	1.00	2,322.420	2,322.42
1553065	Panel EMC Enclosure	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104657	W0007878	6/16/2014	14.00	19.510	273.14
1553066	Latch Base Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105913	W0010855	4/10/2017	6.00	1,829.577	10,977.46
1553066	Latch Base Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	6223-006	00002521	9/22/2011	2.00	1,809.440	3,618.88
1553066	Latch Base Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7102297	00002521	9/22/2011	1.00	1,817.560	1,817.56
1553066	Latch Base Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7104519	0008667	4/22/2015	1.00	1,824.680	1,824.68
1553066	Latch Base Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7105579	W0009669	1/11/2016	2.00	1,827.340	3,654.68
1553067	Solenoid Shaft Support	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105376	W0008979	7/16/2015	22.00	17.550	386.11
1553069	Hook Block	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105508	W0010008	4/1/2016	48.00	10.800	518.38
1553073	Solenoid Mounting Plate	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105377	W0009253	9/18/2015	30.00	48.740	1,462.20
1553074	Latch Base Bushing	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7101983	W0004017	4/11/2011	211.00	1.310	276.43
1553078	Peristaltic Pumphead w/Integra	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105674	W0011034	6/30/2017	1.00	2,742.940	2,742.94
1553078	Peristaltic Pumphead w/Integra	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105675	W0011042	7/6/2017	1.00	2,742.930	2,742.93
1553078	Peristaltic Pumphead w/Integra	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105676	W0011050	7/6/2017	1.00	2,741.440	2,741.44
1553078	Peristaltic Pumphead w/Integra	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105677	W0011059	7/10/2017	1.00	2,742.940	2,742.94
1553078	Peristaltic Pumphead w/Integra	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105678	W0011075	7/17/2017	1.00	2,742.960	2,742.96
1553078	Peristaltic Pumphead w/Integra	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105680	W0011075	7/17/2017	1.00	2,742.920	2,742.92
1553078	Peristaltic Pumphead w/Integra	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	6239-001	00002521	9/22/2011	1.00	2,019.770	2,019.77
1553078	Peristaltic Pumphead w/Integra	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7100614	00002521	9/22/2011	1.00	1,134.180	1,134.18
1553078	Peristaltic Pumphead w/Integra	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7103514	PHYS COU	12/18/2015	1.00	2,216.730	2,216.73
1553078	Peristaltic Pumphead w/Integra	WPD	Raw Material	Lot	EACH								

1553146	Hinge Plate, Fat Rocker	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105384	W0009204	9/4/2015	36.00	40.600	1,461.60
1553147	Motor Crank, Fat Rocker	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7103320	W0005611	5/18/2012	13.00	3.881	50.45
1553148	Shaft Rocker, Fat Rocker	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105441	W0009537	12/4/2015	56.00	11.640	651.84
1553149	Linkage, Fat Rocker	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105385	W0010000	4/1/2016	20.00	8.420	168.40
1553157	Power Entry Module Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7104267	00004035	4/13/2015	1.00	199.400	199.40
1553157-01	4A, Power Entry Module Assy	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104885	00005379	6/15/2017	25.00	198.130	4,953.25
1553157-02	10A, Power Entry Module Assy	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7106067	W0011010	6/16/2017	14.00	196.694	2,753.72
1553165	Frame Assy w/ Rocker and Panel	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD			1/0/1900	0.00	0.000	0.00
1553166	Right Handle Mount	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104654	W0007797	5/27/2014	18.00	34.060	613.08
1553166	Right Handle Mount	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105497	W0010172	5/26/2016	58.00	35.220	2,042.77
1553166	Right Handle Mount	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	6155-001	00002521	9/22/2011	2.00	33.630	67.26
1553167	Hanger Rod Saline	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104667	W0007878	6/16/2014	10.00	10.120	101.20
1553167	Hanger Rod Saline	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7103963	00003477	11/21/2013	1.00	10.300	10.30
1553168	Pole Retainer	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104428	W0007619	4/7/2014	1.00	7.590	7.59
1553168	Pole Retainer	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105412	W0009225	9/11/2015	71.00	7.250	514.75
1553176	Clamp Arm	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105443	W0009470	11/9/2015	8.00	19.140	153.12
1553178	End Support Clamp	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105444	W0009534	12/4/2015	1.00	10.980	10.98
1553179	Canister Clamp Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105755	W0010435	9/8/2016	9.00	329.550	2,965.95
1553179	Canister Clamp Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7103880	PHYS COU	12/13/2013	1.00	49.310	49.31
1553179	Canister Clamp Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7105694	W0010084	4/26/2016	3.00	347.500	1,042.50
1553181	Tube Routing Manifold	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104661	W0007736	5/15/2014	12.00	11.710	140.52
1553181	Tube Routing Manifold	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105499	W0010046	4/14/2016	56.00	12.190	682.64
1553190	Device Assembly	WPD	Raw Material	Serial	EACH	205	205-Released Material-SD	2138	W0010857	4/13/2017	1.00	35,688.990	35,688.99
1553190	Device Assembly	WPD	Raw Material	Serial	EACH	205	205-Released Material-SD	2144	W0009891	3/7/2016	1.00	39,436.190	39,436.19
1553191	Name Plate Blank	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105803	W0010526	10/21/2016	20.00	8.171	163.41
1553196	EMC Enclosure Box	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104656	W0007770	5/27/2014	11.00	179.560	1,975.16
1553197	Gasket, Peristaltic Pump Assem	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104805	W0007656	4/15/2014	49.00	3.500	171.50
1553197	Gasket, Peristaltic Pump Assem	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7104662	00004035	4/13/2015	2.00	0.500	1.00
1553198	Gasket, Optical Sensor Assembl	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105380	W0008957	7/10/2015	124.00	2.980	369.56
1553198	Gasket, Optical Sensor Assembl	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7103847	00004035	4/13/2015	2.00	2.960	5.92
1553199	Gasket, Tube Routing Manifold	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105349	W0008850	6/16/2015	23.00	11.830	272.09
1553199	Gasket, Tube Routing Manifold	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7103703	00004035	4/13/2015	2.00	11.770	23.54
1553200	Gasket, Lid Hinge Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104660	W0007656	4/15/2014	17.00	3.420	58.14
1553200	Gasket, Lid Hinge Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105509	W0009457	11/6/2015	62.00	3.320	205.86
1553200	Gasket, Lid Hinge Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	5917-001	00002521	9/22/2011	2.00	3.190	6.38
1553200	Gasket, Lid Hinge Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7104660	00004035	4/13/2015	2.00	3.420	6.84
1553201	Gasket, Lid Latch Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105378	W0008957	7/10/2015	50.00	3.200	160.00
1553201	Gasket, Lid Latch Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	5862-002	00002521	9/22/2011	5.00	3.180	15.90
1553201	Gasket, Lid Latch Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	6476-004	00002521	9/22/2011	4.00	3.100	12.40
1553201	Gasket, Lid Latch Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7104429	00004035	4/13/2015	2.00	3.210	6.42
1553202	Gasket, Peristaltic Pumphead	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104652	W0007656	4/15/2014	2.00	3.200	6.40
1553202	Gasket, Peristaltic Pumphead	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104806	W0007656	4/15/2014	52.00	3.180	165.38
1553203	Spindle Pulley	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105440	W0009537	12/4/2015	44.00	15.600	686.38
1553204	Servo Motor Pulley	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104651	W0007807	6/2/2014	15.00	20.940	314.10
1553204	Servo Motor Pulley	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105507	W0009771	1/28/2016	54.00	20.240	1,092.98
1553209	Fixed Clamp Arm	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105445	W0009457	11/6/2015	41.00	21.990	901.60
1553225	Left Handle Mount	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104658	W0007878	6/16/2014	22.00	29.720	653.84
1553225	Left Handle Mount	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105500	W0010172	5/26/2016	58.00	30.720	1,781.76
1553225	Left Handle Mount	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	6154-001	00002521	9/22/2011	2.00	29.360	58.72
1553226	Centrifuge Cradle Side	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104655	W0007744	5/19/2014	3.00	38.230	114.69
1553226	Centrifuge Cradle Side	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105409	W0009497	11/23/2015	30.00	44.820	1,344.60
1553241	Gasket, Handle Mount	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104653	W0007656	4/15/2014	26.00	3.400	88.40
1553241	Gasket, Handle Mount	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	5960-001	00002521	9/22/2011	4.00	3.240	12.96
1553242	Lid Hinge Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104930	W0008452	2/9/2015	28.00	116.089	3,250.49
1553242	Lid Hinge Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	6254-001	00002521	9/22/2011	2.00	110.610	221.22
1553242	Lid Hinge Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7104609	00004035	4/13/2015	2.00	107.480	214.96
1553243	Hinge Plate	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104647	W0008387	1/26/2015	2.00	60.350	120.70
1553244	Door Stop	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104646	W0007692	4/28/2014	4.00	18.080	72.32
1553244	Door Stop	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105372	W0009253	9/18/2015	61.00	18.460	1,126.06
1553245	Lid Latch Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105886	W0010549	11/4/2016	6.00	598.970	3,593.82
1553245	Lid Latch Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	71060000	W0010828	3/23/2017	15.00	798.255	11,973.83
1553245	Lid Latch Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7104932	00004035	4/13/2015	1.00	601.700	601.70
1553248	Saline Rod Stop	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104648	W0007982	8/6/2014	26.00	12.690	329.94
1553248	Saline Rod Stop	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105501	W0010461	9/21/2016	64.00	11.630	744.32
1553251	Wrench Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105138	W0008294	12/22/2014	17.00	184.650	3,139.05
1553251	Wrench Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105888	W0010510	10/10/2016	12.00	184.650	2,215.80
1553251	Wrench Assembly	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7104432	W0007354	1/27/2014	4.00	5.408	21.63
1553252	Latch Mounting Base	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105510	W0010004	4/1/2016	24.00	136.070	3,265.67
1553253	Latch Handle	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105512	W0010547	11/1/2016	39.00	31.460	1,226.95
1553253	Latch Handle	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	5805-004	00002521	9/22/2011	4.00	32.170	128.68
1553254	Latch Hook	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105513	W0009760	1/27/2016	22.00	16.080	353.76
1553255	Handle Stop	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105374	W0009204	9/4/2015	26.00	13.880	360.87
1553256	Latch Shaft	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105379	W0009036	7/28/2015	41.00	8.060	330.46
1553265	Molded Tubing Set	WPC	Raw Material	Lot	EACH	205	205-Released Material-SD	7102701	W0004288	5/31/2011	0.00	12.384	0.02-
1553265	Molded Tubing Set	WPC	Raw Material	Lot	EACH	205	205-Released Material-SD	7106075	W0011093	8/7/2017	10.00	37.540	375.40
1553269	Anti Rotation Gasket	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	5920-001	00002521	9/22/2011	1.00	6.420	6.42
1553269	Anti Rotation Gasket	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7102030	00002521	9/22/2011	7.00	7.250	50.75
1553269	Anti Rotation Gasket	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7102813	PHYS COU	12/13/2013	3.00	8.060	24.18
1553272	Modified Pumphead Plate	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	062217-02	G248929	6/22/2017	43.00	32.650	1,403.95
1553278	Shipping Restraint Assembly	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104841	W0007809	6/2/2014	24.00	6.584	158.02
1553279	Shipping Restraint	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7102607	W0004129	4/29/2011	4.00	9.020	36.08
1553279	Shipping Restraint	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105511	W0010000	4/1/2016	120.00	3.490	418.83
1553322	Spindle Housing	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105411	W0009457	11/6/2015	26.00	53.110	1,380.87
1553341	Resistor Assembly, Power Suppl	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	6156-001	00002521	9/22/2011	2.00	42.280	84.56
1553343	Power Supply Module, Regen Res	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	61925	W0010861	4/19/2017	1.00	2,416.970	2,416.97
1553343	Power Supply Module, Regen Res	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	61927	W0010866	4/20/2017	1.00	2,5	

1553406-JJ	Molded Consumable Set Intermed	WPC	Raw Material	Lot	EACH	200	200-QAQC- San Diego	32448136	G250962	2/28/2019	57.00	385.313	21,962.84
1553406-JJ	Molded Consumable Set Intermed	WPC	Raw Material	Lot	EACH	205	205-Released Material-SD	29154871	W0011680	1/23/2019	13.00	389.615	5,064.99
1553419	PureGraft Bag Assembly	WPC	Raw Material	Lot	EACH	440	440-Harmac	7104669	00003653	3/27/2014	0.00	17.558	0.06-
1553434	Slider, Puregraft (540-04)	WPI	Raw Material	Lot	EACH	205	205-Released Material-SD	61997	D0000061	8/29/2018	4.00	5.118	20.47
1553465	Optical Sensor Assy w/ Gasket	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104850	W0007809	6/2/2014	1.00	311.570	311.57
1553465	Optical Sensor Assy w/ Gasket	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105818	W0010378	8/11/2016	12.00	326.370	3,916.44
1553465	Optical Sensor Assy w/ Gasket	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105885	W0010520	10/19/2016	10.00	329.340	3,293.40
1553465	Optical Sensor Assy w/ Gasket	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7104850	00003825	8/1/2014	4.00	311.570	1,246.28
1553550	Pkg Assy, Tissue Collection Au	FGI	Raw Material	Lot	EACH	205	205-Released Material-SD	7104410	W0007105	12/3/2013	3.00	299.720	899.16
1553550	Pkg Assy, Tissue Collection Au	FGI	Raw Material	Lot	EACH	500	500-Fichtner & Ritschel	7101863	00003301	6/21/2013	1.00	299.720	299.72
1553553	Isolated Anti-Rotation Cap	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105285	W0008862	6/17/2015	5.00	26.860	134.30
1553553	Isolated Anti-Rotation Cap	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105502	W0009670	1/8/2016	66.00	25.300	1,669.78
1553553	Isolated Anti-Rotation Cap	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	61546	00002521	9/22/2011	1.00	26.120	26.12
1553553	Isolated Anti-Rotation Cap	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7102028	00002521	9/22/2011	6.00	26.210	157.26
1553553	Isolated Anti-Rotation Cap	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7105285	W0008862	6/17/2015	7.00	26.860	188.02
1553554	Isolated Anti-Rotation Upper R	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7102953	W0004717	8/10/2011	27.00	3.474	93.79
1553555	Isolated Anti-Rotation Lower R	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	61594	W0004685	8/3/2011	20.00	15.250	305.00
1553555	Isolated Anti-Rotation Lower R	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7104436	W0007538	3/21/2014	50.00	16.170	808.49
1553580	Canister Clamp Backbone	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105446	W0009904	3/9/2016	50.00	38.200	1,910.00
1553587	Gasket Retainer, Anti-Rotation	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	61643	W0007602	4/2/2014	0.00	2.722	0.02-
1553587	Gasket Retainer, Anti-Rotation	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105503	W0009571	12/9/2015	84.00	19.780	1,661.48
1553587	Gasket Retainer, Anti-Rotation	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7105286	W0008908	6/26/2015	1.00	19.120	19.12
1553587	Gasket Retainer, Anti-Rotation	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7105503	W0009571	12/9/2015	3.00	19.780	59.34
1553588	Anti-Rotation Gasket	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105287	W0008867	6/23/2015	4.00	10.058	40.23
1553588	Anti-Rotation Gasket	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7104438	00004035	4/13/2015	2.00	4.340	8.68
1553588	Anti-Rotation Gasket	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7105287	W0008867	6/23/2015	10.00	10.060	100.60
1553589	Adjustment Ring, Anti-Rotation	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105504	W0009571	12/9/2015	60.00	24.900	1,493.97
1553589	Adjustment Ring, Anti-Rotation	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7105288	W0008908	6/26/2015	2.00	23.810	47.62
1553589	Adjustment Ring, Anti-Rotation	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7105504	W0009571	12/9/2015	3.00	24.900	74.70
1553590	Anti-Rotation Ring	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7105505	W0010007	4/1/2016	51.00	39.170	1,997.65
1553590	Anti-Rotation Ring	WPD	Raw Material	Lot	EACH	598	F&R Service Parts	7105289	W0008908	6/26/2015	2.00	40.550	81.10
1553719	Transformer Plate, Heater Atta	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	121718-01	G250690	12/19/2018	6.00	58.000	348.00
1553724	Outlet Cover	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7106162	W0011517	8/20/2018	2.00	0.990	1.98
1553725	Directional Outlet Duct	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7106238	W0011674	1/18/2019	2.00	7.935	15.87
1553728	RTD Spacer	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7106164	W0011517	8/20/2018	3.00	2.253	6.76
1553729	Duct, Blower, Lower	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7106239	W0011667	1/8/2019	2.00	14.877	29.75
1553730	Duct, Blower, Upper	WPD	Raw Material	Lot	EACH	205	205-Released Material-SD	7106240	W0011667	1/8/2019	2.00	8.927	17.85
1600006	Micro Chamber Shaft, Lumenless	WPC	Raw Material	Lot	EACH	440	440-Harmac	7106197	W0011465	7/10/2018	46.00	20.369	936.97
2100194	Shipping Insert Box, 8" x 5-7/	RMT	Raw Material	FIFO	EACH	205	205-Released Material-SD		OVERDIST		17.00-	0.590	10.03-
2100194	Shipping Insert Box, 8" x 5-7/	RMT	Raw Material	FIFO	EACH	205	205-Released Material-SD		G250876	2/12/2019	491.00	1.540	756.14
2100220	Insulated Cooler	RMB	Raw Material	FIFO	EACH	206	206-Storage - Sorrento Valley		G240635	11/5/2013	11.00	11.060	121.66
2100220	Insulated Cooler	RMB	Raw Material	FIFO	EACH	206	206-Storage - Sorrento Valley		G245111	9/1/2015	21.00	11.780	247.38
2100220	Insulated Cooler	RMB	Raw Material	FIFO	EACH	206	206-Storage - Sorrento Valley		PHY CNT	12/18/2015	2.00	11.780	23.56
2100222	Inner Carton (Corrugated box)	RMB	Raw Material	FIFO	EACH	205	205-Released Material-SD		G245043	8/25/2015	4.00	5.710	22.84
2100222	Inner Carton (Corrugated box)	RMB	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	10.00	5.710	57.10
2100236	Shipping Carton, 18 1/4" x 15	RMC	Raw Material	FIFO	EACH	205	205-Released Material-SD			1/0/1900	0.00	0.000	0.00
2100242	Shipping Box , 20" x 12" x 6"	RMI	Raw Material	Lot	EACH	206	206-Storage - Sorrento Valley	032514-06	00003695	4/23/2014	99.00	1.700	168.30
2100243	Shipping Box, White, 17-7/8" x	RMT	Raw Material	Lot	EACH	205	205-Released Material-SD	032218-01	G249736	3/22/2018	180.00	3.080	554.40
2100244	Shipping Box, Celbrush	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	033114-11	00003684	4/15/2014	40.00	5.360	214.40
2100251	2 PC Custom Suspension Pack, 1	RMC	Raw Material	Lot	EACH	205	205-Released Material-SD	010819-03	G250759	1/9/2019	467.00	11.080	5,174.36
2100251	2 PC Custom Suspension Pack, 1	RMC	Raw Material	Lot	EACH	500	500-Fichtner & Ritschel	100715-02	G245288	10/7/2015	203.00	8.960	1,818.88
2100252	White Outer Box , 20" x 16" x	RMC	Raw Material	FIFO	EACH	205	205-Released Material-SD		G250758	1/9/2019	529.00	2.910	1,539.39
2100252	White Outer Box , 20" x 16" x	RMC	Raw Material	FIFO	EACH	500	500-Fichtner & Ritschel		G245288	10/7/2015	71.00	2.820	200.22
2100252	White Outer Box , 20" x 16" x	RMC	Raw Material	FIFO	EACH	500	500-Fichtner & Ritschel		G245725	1/19/2016	15.00	2.690	40.35
2100252	White Outer Box , 20" x 16" x	RMC	Raw Material	FIFO	EACH	500	500-Fichtner & Ritschel		PHY CNT	6/30/2016	1.00	2.690	2.69
2100252	White Outer Box , 20" x 16" x	RMC	Raw Material	FIFO	EACH	500	500-Fichtner & Ritschel		PHY CNT	6/28/2018	15.00	2.905	43.58
2100256	Shipping Box, 16" x 8" x 3"	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	090115-01	G245096	9/1/2015	32.00	1.030	32.96
2100263	Poly Bag, 15" x 10", 1.5 MIL,	RMC	Raw Material	FIFO	EACH	205	205-Released Material-SD		OVERDIST		0.00	0.075	0.54
2100263	Poly Bag, 15" x 10", 1.5 MIL,	RMC	Raw Material	FIFO	EACH	205	205-Released Material-SD		G244335	5/6/2015	333.00	0.075	24.97
2100263	Poly Bag, 15" x 10", 1.5 MIL,	RMC	Raw Material	FIFO	EACH	440	440-Harmac		OVERDIST		22,976.00-	0.075	1,723.20-
2100263	Poly Bag, 15" x 10", 1.5 MIL,	RMC	Raw Material	FIFO	EACH	440	440-Harmac		M002202	8/28/2014	21,276.00	0.075	1,595.70
2100263	Poly Bag, 15" x 10", 1.5 MIL,	RMC	Raw Material	FIFO	EACH	440	440-Harmac		G243247	10/10/2014	1,700.00	0.075	127.50
2100272	Biohazard ziplock/sealable 6x9	RMT	Raw Material	Lot	EACH	205	205-Released Material-SD	042817-02	G248710	4/28/2017	434.00	0.123	53.38
2100272	Biohazard ziplock/sealable 6x9	RMT	Raw Material	Lot	EACH	500	500-Fichtner & Ritschel	123013-01	00003538	1/8/2014	40.00	0.240	9.60
2100273	Biohazard Bag, Reclosable 12"	RMT	Raw Material	Lot	EACH	205	205-Released Material-SD	121113-02	00003536	12/30/2013	772.00	0.360	277.92
2100273	Biohazard Bag, Reclosable 12"	RMT	Raw Material	Lot	EACH	500	500-Fichtner & Ritschel	121113-02	00003536	12/30/2013	40.00	0.360	14.40
2100292-01	Dose Delivery Kit	RMC	Raw Material	Lot	EACH	205	205-Released Material-SD	050217-05	G248725	5/2/2017	192.00	1.510	289.92
2100292-01	Dose Delivery Kit	RMC	Raw Material	Lot	EACH	206	206-Storage - Sorrento Valley	072017-03	G249058	7/20/2017	250.00	1.510	377.50
2100292-02	Processing and Preparation kit	RMC	Raw Material	Lot	EACH	205	205-Released Material-SD	050217-09	G248725	5/2/2017	191.00	1.510	288.41
2100292-02	Processing and Preparation kit	RMC	Raw Material	Lot	EACH	206	206-Storage - Sorrento Valley	072017-04	G249058	7/20/2017	250.00	1.510	377.50
2100294	Product Packaging, Accessory K	RMC	Raw Material	Lot	EACH	205	205-Released Material-SD	050217-07	G248725	5/2/2017	8.00	1.830	14.64
2100294	Product Packaging, Accessory K	RMC	Raw Material	Lot	EACH	206	206-Storage - Sorrento Valley	050217-07	G248725	5/2/2017	200.00	1.830	366.00
2100294	Product Packaging, Accessory K	RMC	Raw Material	Lot	EACH	206	206-Storage - Sorrento Valley	072017-06	G249058	7/20/2017	250.00	1.830	457.50
2100295	Shipping Box 17"x13" x 20.5 In	RMC	Raw Material	Lot	EACH	205	205-Released Material-SD	050217-08	G248725	5/2/2017	8.00	3.380	27.04
2100295	Shipping Box 17"x13" x 20.5 In	RMC	Raw Material	Lot	EACH	206	206-Storage - Sorrento Valley	050217-08	G248725	5/2/2017	168.00	3.380	567.84
2100295	Shipping Box 17"x13" x 20.5 In	RMC	Raw Material	Lot	EACH	206	206-Storage - Sorrento Valley	072017-07	G249058	7/20/2017	244.00	3.380	824.72
2100296	Printed Sleeve for Consumable	RMC	Raw Material	Lot	EACH	205	205-Released Material-SD	050317-01	G248726	5/3/2017	8.00	13.630	109.04
2100296	Printed Sleeve for Consumable	RMC	Raw Material	Lot	EACH	206	206-Storage - Sorrento Valley	050317-01	G248726	5/3/2017	137.00	13.630	1,867.31
2100296	Printed Sleeve for Consumable	RMC	Raw Material	Lot	EACH	206	206-Storage - Sorrento Valley	072017-08	G249058	7/20/2017	250.00	13.630	3,407.50
2100320	Shipping Insert box 9 x 9 x 4	RMT	Raw Material	FIFO	EACH	205	205-Released Material-SD		G248489	3/2/2017	100.00	0.870	87.00
2100320	Shipping Insert box 9 x 9 x 4	RMT	Raw Material	FIFO	EACH	205	205-Released Material-SD		0000056	5/23/2017	50.00	0.870	43.50
2100320	Shipping Insert box 9 x 9 x 4	RMT	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/14/2017	1.00	0.870	0.87
2100321	Shipping Box, 12 x 10 x 6	RMT	Raw Material	FIFO	EACH	205	205-Released Material-SD		G248489	3/2/2017	1.00	0.740	0.74
2100321	Shipping Box, 12 x 10 x 6	RMT	Raw Material	FIFO	EACH	205	205-Released Material-SD		0000056	5/23/2017	50.00	0.740	37.00
2100321	Shipping Box, 12 x 10 x 6	RMT	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/14/2017	100.00	0.740	74.00
2300050	Tyvek and Polybag Pouch Sets,	RMB	Raw Material	Lot	E								

3200127	Product Decal, Celution System	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	060816-01	G247394	6/8/2016	2.00	93.000	186.00
3200127	Product Decal, Celution System	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	071818-01	G250095	7/20/2018	4.00	98.000	392.00
3200127	Product Decal, Celution System	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	060816-01	G247394	6/8/2016	1.00	93.000	93.00
3200131	Product Decal, Celution Centri	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	081415-01	G244990	8/14/2015	12.00	75.000	900.00
3200131	Product Decal, Celution Centri	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	111517-01	G249427	11/15/2017	6.00	69.700	418.20
3200131	Product Decal, Celution Centri	RMD	Raw Material	Lot	EACH	500	500-Fichtner & Ritschel	111517-01	G249427	11/15/2017	14.00	69.700	975.80
3200145	Product Decal Stemsources Centr	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	093014-02	00003914	10/22/2014	22.00	105.000	2,310.00
3200149	Product Decal Celution IV Cent	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	010816-01	G245674	1/8/2016	1.00	98.000	98.00
3200149	Product Decal Celution IV Cent	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	010816-01	G245674	1/8/2016	2.00	98.000	196.00
3200176	Product Decal, Celution 800IV	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	052215-01	00004085	5/27/2015	10.00	71.000	710.00
3200181	Product Decal, Celution GP	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	042516-02	G246201	4/25/2016	3.00	89.091	267.27
3200181	Product Decal, Celution GP	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	042516-02	G246201	4/25/2016	4.00	89.093	356.37
3300004	ETO Gas Indicator Circles	RMC	Raw Material	Lot	EA	205	205-Released Material-SD	020117-01	G248361	2/1/2017	3,434.00	0.030	102.96
3300005	Gamma Irradiation Indicator 50	RMC	Raw Material	Lot	EACH	205	205-Released Material-SD			1/0/1900	0.00	0.000	0.00
3500135	Artwork, Cytori Wheel Dosing H	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	092208-05	TRFR204A	9/30/2010	26.00	59.500	1,547.00
4600001	RODAC Contact Plate (7500001)	RMC	Raw Material	Lot	EACH	0	000-MAIN WAREHOUSE	032416-01	G246080	3/24/2016	1.00	22.300	22.30
4600001	RODAC Contact Plate (7500001)	RMC	Raw Material	Lot	EACH	0	000-MAIN WAREHOUSE	033115-01	G244118	3/31/2015	1.00	21.810	21.81
4600009-01	UV Adhesive 1181-M 30ml Dispen	RMC	Raw Material	Lot	EA	205	205-Released Material-SD	040317-01	G248608	4/3/2017	21.00	36.190	759.99
4600027	Dichloromethane Solvent	RMC	Raw Material	Lot	EA	205	205-Released Material-SD	100417-01	G249294	10/6/2017	1.00	75.000	75.00
4600029	Alconox Powdered Cleaner	RMC	Raw Material	Lot	EACH	205	205-Released Material-SD	042817-01	G248710	4/28/2017	3.50	29.620	103.67
4600032	Silicone Grease	RMC	Raw Material	Lot	EA	205	205-Released Material-SD	090616-01	G247805	9/6/2016	2.00	3.332	6.66
4600036	70% Isopropyl Alcohol	RMC	Raw Material	Lot	EA	200	200-QAQC- San Diego	021219-01	G250878	2/12/2019	4.00	60.000	240.00
4600036	70% Isopropyl Alcohol	RMC	Raw Material	Lot	EA	205	205-Released Material-SD	072417-03	G249078	7/24/2017	2.00	40.000	80.00
4600037	Silicone Sealant, Off White	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	051217-01	G248785	5/12/2017	3.00	14.000	42.00
4600037	Silicone Sealant, Off White	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	111313-14	00003477	11/21/2013	1.00	9.000	9.00
4600039	Loctite-222 Threadlocker	RMD	Raw Material	Lot	EA	205	205-Released Material-SD	121218-01	G250668	12/13/2018	2.00	12.700	25.40
4600039	Loctite-222 Threadlocker	RMD	Raw Material	Lot	EA	598	F&R Service Parts	032917-02	G248588	3/29/2017	1.00	16.530	16.53
4600039	Loctite-222 Threadlocker	RMD	Raw Material	Lot	EA	598	F&R Service Parts	072915-02	G244897	7/29/2015	2.00	12.350	24.70
4600050	Reztore	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	081214-01	00003845	8/14/2014	3.00	10.000	30.00
4600051	I.C. Lotion	RMD	Raw Material	FIFO	EACH	0	000-MAIN WAREHOUSE		G244717	7/8/2015	2.00	13.930	27.86
4600051	I.C. Lotion	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G239417	6/3/2013	1.00	13.930	13.93
4600054	High Vacuum Grease, Dow Cornin	RMD	Raw Material	Lot	EA	205	205-Released Material-SD	013017-01	G248342	1/30/2017	5.00	18.270	91.35
4600055	5-Minute Epoxy Gel	RMD	Raw Material	Lot	EA	205	205-Released Material-SD	081516-03	G247710	8/15/2016	7.00	17.000	119.00
4700008	Foam Tipped Swab, Wide Head	RMC	Raw Material	FIFO	EACH	440	440-Harmac		G244416	5/15/2015	1.00	205.420	205.42
4700017-01	Green SS Tip 12.7mm	RMC	Raw Material	FIFO	EACH	440	440-Harmac		G247940	10/12/2016	50.00	0.705	35.27
4700017-03	Green SS Tip 45 Deg, 12.7mm	RMC	Raw Material	FIFO	EACH	205	205-Released Material-SD		M001138	2/3/2011	0.00	0.592	0.01
4700018-01	Pink SS Tip 12.7mm	RMC	Raw Material	FIFO	EACH	440	440-Harmac		G247940	10/12/2016	40.00	0.706	28.22
4700020	Red/White Flexible Tip	RMC	Raw Material	FIFO	EACH	440	440-Harmac		G237618	10/25/2012	10.00	0.858	8.58
4700023-01	Clear Syringe Barrel 10cc	RMC	Raw Material	FIFO	EACH	440	440-Harmac		00005046	2/19/2014	42.00	0.822	34.52
4700023-01	Clear Syringe Barrel 10cc	RMC	Raw Material	FIFO	EACH	440	440-Harmac		PHY CNT	3/31/2016	39.00	24.680	962.52
4700023-01	Clear Syringe Barrel 10cc	RMC	Raw Material	FIFO	EACH	440	440-Harmac		PHY CNT	6/30/2016	26.00	24.680	641.68
4700023-01	Clear Syringe Barrel 10cc	RMC	Raw Material	FIFO	EACH	440	440-Harmac		PHY CNT	12/14/2017	7.00	24.680	172.76
4700026	PP Luer Extension	RMC	Raw Material	FIFO	EACH	205	205-Released Material-SD		G241995	4/9/2014	440.00	0.236	103.84
4700026	PP Luer Extension	RMC	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/19/2014	79.00	0.236	18.64
4700026	PP Luer Extension	RMC	Raw Material	FIFO	EACH	440	440-Harmac		OVERDIST		340.00	0.236	80.24
4700026	PP Luer Extension	RMC	Raw Material	FIFO	EACH	440	440-Harmac		PHY CNT	12/5/2012	100.00	0.189	18.90
4700026	PP Luer Extension	RMC	Raw Material	FIFO	EACH	440	440-Harmac		G241995	4/9/2014	60.00	0.236	14.16
4700027	4" Nylon Cable Tie	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		OVERDIST		30.00-	0.050	1.50-
4700027	4" Nylon Cable Tie	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G245501	11/20/2015	773.00	0.026	20.04
4700027	4" Nylon Cable Tie	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		PHY CNT	12/19/2014	90.00	0.050	4.50
4700027	4" Nylon Cable Tie	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		PHY CNT	12/14/2017	10.00	0.026	0.26
4700028	Amber SS Tip, 1.5" L	RMC	Raw Material	FIFO	EACH	440	440-Harmac		G247839	9/14/2016	50.00	0.839	41.94
4700030-02	30cc Opaque Black Syringe Barr	RMC	Raw Material	FIFO	EACH	440	440-Harmac		PHY CNT	4/17/2015	50.00	2.011	100.55
4700030-02	30cc Opaque Black Syringe Barr	RMC	Raw Material	FIFO	EACH	440	440-Harmac		PHY CNT	9/17/2015	4.00	2.011	8.04
4700030-02	30cc Opaque Black Syringe Barr	RMC	Raw Material	FIFO	EACH	440	440-Harmac		PHY CNT	12/14/2017	1.00	2.011	2.01
4700031-02	30, 55cc End Cap	RMC	Raw Material	FIFO	EACH	205	205-Released Material-SD		G238997	4/12/2013	91.00	0.450	40.95
4700032	Tip Cap	RMC	Raw Material	FIFO	EACH	205	205-Released Material-SD		G238997	4/12/2013	61.00	0.193	11.77
5100043	Servo Motor, "S" Series, Brush	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	901311	00002224	4/6/2011	1.00	1,144.000	1,144.00
5100043	Servo Motor, "S" Series, Brush	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	901312	00002224	4/6/2011	1.00	1,144.000	1,144.00
5100043	Servo Motor, "S" Series, Brush	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	901313	00002224	4/6/2011	1.00	1,144.000	1,144.00
5100043	Servo Motor, "S" Series, Brush	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	901314	00002224	4/6/2011	1.00	1,144.000	1,144.00
5100043	Servo Motor, "S" Series, Brush	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	901315	00002224	4/6/2011	1.00	1,144.000	1,144.00
5100043	Servo Motor, "S" Series, Brush	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	901316	00002224	4/6/2011	1.00	1,144.000	1,144.00
5100043	Servo Motor, "S" Series, Brush	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	901317	00002224	4/6/2011	1.00	1,144.000	1,144.00
5100043	Servo Motor, "S" Series, Brush	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	901318	00002224	4/6/2011	1.00	1,144.000	1,144.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-450	00002236	4/15/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-451	00002070	1/18/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-464	00002070	1/18/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-465	00002236	4/15/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-466	00002236	4/15/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-467	00002236	4/15/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-468	00002070	1/18/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-469	00002236	4/15/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-470	00002070	1/18/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-471	00002070	1/18/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-472	00002070	1/18/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-473	00002070	1/18/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-474	00002145	3/1/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-475	00002145	3/1/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-476	00002145	3/1/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-477	00002145	3/1/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-478	00002145	3/1/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-479	00002145	3/1/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-480	00002145	3/1/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-481	00002145	3/1/2011	1.00	1,004.000	1,004.00
5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	10M-482	00002145	3/1/2011	1.00	1,004.000	

5100046	Servo Drive, PC800 Series, Dig	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	11A-411	00002236	4/15/2011	1.00	1,004.000	1,004.00
5100053	Pressure Sensor Strain Gauge	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	022717-01	G248465	2/27/2017	25.00	135.000	3,375.00
5100053	Pressure Sensor Strain Gauge	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	050714-03	00003763	6/2/2014	10.00	109.000	1,090.00
5100053	Pressure Sensor Strain Gauge	RMD	Raw Material	Lot	EACH	490	490-At Vendor Location	050714-03	00004089	6/1/2015	6.00	109.000	654.00
5100054	Optical Sensor Infrared	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	040914-04	00003764	6/3/2014	26.00	6.160	160.16
5100079	Optical Sensor	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G238683	3/12/2013	37.00	1.350	49.95
5100106	Cable, 10 Conductor, 24 AWG	RMD	Raw Material	FIFO	FT	205	205-Released Material-SD		G241757	3/11/2014	0.00	0.011	5.67-
5100106	Cable, 10 Conductor, 24 AWG	RMD	Raw Material	FIFO	FT	205	205-Released Material-SD		G248035	11/1/2016	5.00	1.208	6.04
5100106	Cable, 10 Conductor, 24 AWG	RMD	Raw Material	FIFO	FT	205	205-Released Material-SD		PHY CNT	12/21/2016	35.00	1.208	42.28
5100113	Crimp Socket, Gold, 20-24 AWG	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G242336	5/20/2014	100.00	0.580	58.00
5100155	Connector, .250" Dia, Female,	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G241757	3/11/2014	338.00	0.347	117.38
5100155	Connector, .250" Dia, Female,	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0010328	7/22/2016	2.00	0.347	0.69
5100155	Connector, .250" Dia, Female,	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	101.00	0.288	29.09
5100155	Connector, .250" Dia, Female,	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		PHY CNT	12/14/2017	2.00	0.347	0.69
5100159	Power Supply, 5 VDC	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	C2008A1039	G245609	12/15/2015	1.00	85.970	85.97
5100159	Power Supply, 5 VDC	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	C2008A1040	G245609	12/15/2015	1.00	85.970	85.97
5100159	Power Supply, 5 VDC	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	C2008A1054	G245609	12/15/2015	1.00	85.970	85.97
5100159	Power Supply, 5 VDC	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	C2008A1112	G245609	12/15/2015	1.00	85.970	85.97
5100159	Power Supply, 5 VDC	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	C2008A1113	G245609	12/15/2015	1.00	85.970	85.97
5100159	Power Supply, 5 VDC	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	C2008A1114	G245609	12/15/2015	1.00	85.970	85.97
5100159	Power Supply, 5 VDC	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	C3919A0006	G245609	12/15/2015	1.00	85.970	85.97
5100159	Power Supply, 5 VDC	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	C3919A0059	G245609	12/15/2015	1.00	85.970	85.97
5100159	Power Supply, 5 VDC	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	C3919A0061	G245609	12/15/2015	1.00	85.970	85.97
5100159	Power Supply, 5 VDC	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	C3919A0069	G245609	12/15/2015	1.00	85.970	85.97
5100159	Power Supply, 5 VDC	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	C3919A0070	G245609	12/15/2015	1.00	85.970	85.97
5100159	Power Supply, 5 VDC	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	C3919A0111	G245609	12/15/2015	1.00	85.970	85.97
5100159	Power Supply, 5 VDC	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	C3919A0113	G245609	12/15/2015	1.00	85.970	85.97
5100159	Power Supply, 5 VDC	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	C3919A0114	G245609	12/15/2015	1.00	85.980	85.98
5100159	Power Supply, 5 VDC	RMD	Raw Material	Serial	EACH	598	F&R Service Parts	C8528T0330	00002521	9/22/2011	1.00	72.970	72.97
5100159	Power Supply, 5 VDC	RMD	Raw Material	Serial	EACH	598	F&R Service Parts	C9122T0139	00002521	9/22/2011	1.00	71.400	71.40
5100163	Power Supply, 24 VDC	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	C4401A0446	G244529	6/2/2015	1.00	476.350	476.35
5100163	Power Supply, 24 VDC	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	C4401A0449	G244529	6/2/2015	1.00	476.350	476.35
5100163	Power Supply, 24 VDC	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	C4401A0450	G244529	6/2/2015	1.00	476.350	476.35
5100163	Power Supply, 24 VDC	RMD	Raw Material	Serial	EACH	598	F&R Service Parts	C8314M0189	00002521	9/22/2011	1.00	300.660	300.66
5100163	Power Supply, 24 VDC	RMD	Raw Material	Serial	EACH	598	F&R Service Parts	C9108M0074	00002521	9/22/2011	1.00	232.000	232.00
5100166-02	Conn Plug CPC 9 Pos STD Serv 1	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G242964	8/20/2014	12.00	4.730	56.76
5100166-02	Conn Plug CPC 9 Pos STD Serv 1	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	1.00	4.730	4.73
5100169-01	Conn Plug CPC 7 Position, STD	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G242964	8/20/2014	16.00	5.910	94.56
5100172-02	I/O Interface Ribbon Cable - 6	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	042915-01	00004059	5/1/2015	33.00	10.130	334.29
5100180	Crimp Socket, Gold, 18-16 AWG	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G242336	5/20/2014	366.00	0.550	201.30
5100181	4A Fuse, 250V, Slow Blow	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G242964	8/20/2014	68.00	0.950	64.60
5100181	4A Fuse, 250V, Slow Blow	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		00002521	9/22/2011	25.00	0.516	12.90
5100193	Cable, Shielded, 22 AWG	RMD	Raw Material	FIFO	FT	205	205-Released Material-SD		PHY CNT	12/3/2009	2.00	0.668	1.34
5100193	Cable, Shielded, 22 AWG	RMD	Raw Material	FIFO	FT	205	205-Released Material-SD		PHY CNT	12/6/2010	26.00	0.328	8.53
5100193	Cable, Shielded, 22 AWG	RMD	Raw Material	FIFO	FT	205	205-Released Material-SD		PHY CNT	12/18/2015	50.00	0.328	16.40
5100193	Cable, Shielded, 22 AWG	RMD	Raw Material	FIFO	FT	205	205-Released Material-SD		0010328	7/22/2016	2.00	0.328	0.66
5100197	Cable, PCB Power Supply	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	072715-01	G244875	7/27/2015	30.00	90.300	2,709.00
5100197	Cable, PCB Power Supply	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	101708-01	00002521	9/22/2011	2.00	143.500	287.00
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	200	200-QAQC- San Diego	52700-40415-018	G242074	4/17/2014	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	200	200-QAQC- San Diego	53928-40902-017	G243105	9/12/2014	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	200	200-QAQC- San Diego	53928-40902-022	G243105	9/12/2014	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66745-70117-004	G248332	1/27/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66745-70117-005	G248332	1/27/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66745-70117-006	G248332	1/27/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66745-70117-007	G248332	1/27/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66745-70117-008	G248332	1/27/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66745-70117-009	G248332	1/27/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66745-70117-010	G248332	1/27/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67055-70310-001	G248531	3/16/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67055-70310-002	G248531	3/16/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67055-70310-003	G248531	3/16/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67055-70310-004	G248531	3/16/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67055-70310-005	G248531	3/16/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67055-70310-006	G248531	3/16/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67511-70526-001	G248844	6/1/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67511-70526-002	G248844	6/1/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67511-70526-003	G248844	6/1/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67511-70526-004	G248844	6/1/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67511-70526-005	G248844	6/1/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68228-70809-001	G249215	8/29/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68228-70809-002	G249215	8/29/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68228-70809-003	G249215	8/29/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68228-70809-004	G249215	8/29/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68228-70809-005	G249215	8/29/2017	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	598	F&R Service Parts	37056-90710-010	00002521	9/22/2011	1.00	344.000	344.00
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	598	F&R Service Parts	53928-40902-011	00004035	4/13/2015	1.00	365.500	365.50
5100198-01	Acro Valve, Modified 1	RMD	Raw Material	Serial	EACH	598	F&R Service Parts	62112-50811-004	G245046	8/27/2015	1.00	365.500	365.50
5100198-02	Acro Valve, Modified 2	RMD	Raw Material	Serial	EACH	200	200-QAQC- San Diego	53929-40903-009	G243105	9/12/2014	1.00	365.500	365.50
5100198-02	Acro Valve, Modified 2	RMD	Raw Material	Serial	EACH	200	200-QAQC- San Diego	53929-40903-014	G243105	9/12/2014	1.00	365.500	365.50
5100198-02	Acro Valve, Modified 2	RMD	Raw Material	Serial	EACH	200	200-QAQC- San Diego	53929-40903-023	G243105	9/12/2014	1.00	365.500	365.50
5100198-02	Acro Valve, Modified 2	RMD	Raw Material	Serial	EACH	200	200-QAQC- San Diego	53929-40903-024	G243105	9/12/2014	1.00	365.500	365.50
5100198-02	Acro Valve, Modified 2	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66746-70117-005	G248332	1/27/2017	1.00	365.500	365.50
5100198-02	Acro Valve, Modified 2	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66746-70117-006	G248332	1/27/2017	1.00	365.500	365.50
5100198-02	Acro Valve, Modified 2	RMD	Raw Material	Serial	E								

5100198-02	Acro Valve, Modified 2	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68229-70809-002	G249215	8/29/2017	1.00	365.500	365.50
5100198-02	Acro Valve, Modified 2	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68229-70809-003	G249215	8/29/2017	1.00	365.500	365.50
5100198-02	Acro Valve, Modified 2	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68229-70809-004	G249215	8/29/2017	1.00	365.500	365.50
5100198-02	Acro Valve, Modified 2	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68229-70809-005	G249215	8/29/2017	1.00	365.500	365.50
5100198-02	Acro Valve, Modified 2	RMD	Raw Material	Serial	EACH	598	F&R Service Parts	3482180811-003	00002521	9/22/2011	1.00	311.720	311.72
5100198-02	Acro Valve, Modified 2	RMD	Raw Material	Serial	EACH	598	F&R Service Parts	37059-90710-011	00002521	9/22/2011	1.00	344.000	344.00
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	200	200-QAQC- San Diego	53930-40903-003	G243105	9/12/2014	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	200	200-QAQC- San Diego	53930-40903-015	G243105	9/12/2014	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66747-70117-003	G248332	1/27/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66747-70117-004	G248332	1/27/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66747-70117-005	G248332	1/27/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66747-70117-006	G248332	1/27/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66747-70117-007	G248332	1/27/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66747-70117-008	G248332	1/27/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66747-70117-009	G248332	1/27/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66747-70117-010	G248332	1/27/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67057-70310-001	G248531	3/16/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67057-70310-002	G248531	3/16/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67057-70310-003	G248531	3/16/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67057-70310-004	G248531	3/16/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67057-70310-005	G248531	3/16/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67512-70526-001	G248844	6/1/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67512-70526-002	G248844	6/1/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67512-70526-003	G248844	6/1/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67512-70526-004	G248844	6/1/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67512-70526-005	G248844	6/1/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68230-70809-001	G249215	8/29/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68230-70809-002	G249215	8/29/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68230-70809-003	G249215	8/29/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68230-70809-004	G249215	8/29/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68230-70809-005	G249215	8/29/2017	1.00	365.500	365.50
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	598	F&R Service Parts	37062-90710-010	00002521	9/22/2011	1.00	344.000	344.00
5100198-03	Acro Valve, Modified 3	RMD	Raw Material	Serial	EACH	598	F&R Service Parts	62114-50813-003	G245046	8/27/2015	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66748-70117-001	G248332	1/27/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66748-70117-002	G248332	1/27/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66748-70117-003	G248332	1/27/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66748-70117-004	G248332	1/27/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66748-70117-005	G248332	1/27/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66748-70117-006	G248332	1/27/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66748-70117-007	G248332	1/27/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66748-70117-008	G248332	1/27/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66748-70117-009	G248332	1/27/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66748-70117-010	G248332	1/27/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67058-70310-001	G248531	3/16/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67058-70310-002	G248531	3/16/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67058-70310-003	G248531	3/16/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67058-70310-004	G248531	3/16/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67058-70310-005	G248531	3/16/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67513-70526-001	G248844	6/1/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67513-70526-002	G248844	6/1/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67513-70526-003	G248844	6/1/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67513-70526-004	G248844	6/1/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67513-70526-005	G248844	6/1/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68231-70809-001	G249215	8/29/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68231-70809-002	G249215	8/29/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68231-70809-003	G249215	8/29/2017	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	598	F&R Service Parts	37065-90713-013	00002521	9/22/2011	1.00	344.000	344.00
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	598	F&R Service Parts	53931-40903-012	00004035	4/13/2015	1.00	365.500	365.50
5100198-04	Acro Valve, Modified 4	RMD	Raw Material	Serial	EACH	598	F&R Service Parts	62115-50813-001	G245046	8/27/2015	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	200	200-QAQC- San Diego	53932-40904-015	G243105	9/12/2014	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	200	200-QAQC- San Diego	53932-40904-018	G243105	9/12/2014	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	200	200-QAQC- San Diego	53932-40904-019	G243105	9/12/2014	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66749-70117-004	G248332	1/27/2017	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66749-70117-005	G248332	1/27/2017	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66749-70117-006	G248332	1/27/2017	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66749-70117-007	G248332	1/27/2017	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66749-70117-008	G248332	1/27/2017	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66749-70117-009	G248332	1/27/2017	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	66749-70117-010	G248332	1/27/2017	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67059-70310-001	G248531	3/16/2017	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67059-70310-002	G248531	3/16/2017	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67059-70310-003	G248531	3/16/2017	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67059-70310-004	G248531	3/16/2017	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67514-70526-001	G248844	6/1/2017	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67514-70526-002	G248844	6/1/2017	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67514-70526-003	G248844	6/1/2017	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67514-70526-004	G248844	6/1/2017	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67514-70526-005	G248844	6/1/2017	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68232-70809-001	G249215	8/29/2017	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68232-70809-002	G249215	8/29/2017	1.00	365.500	365.50
5100198-05	Acro Valve, Modified 5	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68232-7					

5100198-06	Acro Valve, Modified 6	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67060-70310-004	G248531	3/16/2017	1.00	365.500	365.50
5100198-06	Acro Valve, Modified 6	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67060-70310-005	G248531	3/16/2017	1.00	365.500	365.50
5100198-06	Acro Valve, Modified 6	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67515-70526-001	G248844	6/1/2017	1.00	365.500	365.50
5100198-06	Acro Valve, Modified 6	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67515-70526-002	G248844	6/1/2017	1.00	365.500	365.50
5100198-06	Acro Valve, Modified 6	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67515-70526-003	G248844	6/1/2017	1.00	365.500	365.50
5100198-06	Acro Valve, Modified 6	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67515-70526-004	G248844	6/1/2017	1.00	365.500	365.50
5100198-06	Acro Valve, Modified 6	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	67515-70526-005	G248844	6/1/2017	1.00	365.500	365.50
5100198-06	Acro Valve, Modified 6	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68233-70809-001	G249215	8/29/2017	1.00	365.500	365.50
5100198-06	Acro Valve, Modified 6	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68233-70809-002	G249215	8/29/2017	1.00	365.500	365.50
5100198-06	Acro Valve, Modified 6	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68233-70809-003	G249215	8/29/2017	1.00	365.500	365.50
5100198-06	Acro Valve, Modified 6	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68233-70809-004	G249215	8/29/2017	1.00	365.500	365.50
5100198-06	Acro Valve, Modified 6	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68233-70809-005	G249215	8/29/2017	1.00	365.500	365.50
5100198-06	Acro Valve, Modified 6	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68233-70809-006	G249215	8/29/2017	1.00	365.500	365.50
5100198-06	Acro Valve, Modified 6	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	68233-70809-007	G249215	8/29/2017	1.00	365.500	365.50
5100198-06	Acro Valve, Modified 6	RMD	Raw Material	Serial	EACH	598	F&R Service Parts	3482680812-003	PHYS COU	12/19/2014	1.00	365.500	365.50
5100198-06	Acro Valve, Modified 6	RMD	Raw Material	Serial	EACH	598	F&R Service Parts	37071-90710-011	00002521	9/22/2011	1.00	344.000	344.00
5100198-06	Acro Valve, Modified 6	RMD	Raw Material	Serial	EACH	598	F&R Service Parts	53933-40904-011	00004035	4/13/2015	1.00	365.500	365.50
5100199	Cable, Servo Controller Board	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	112415-02	G245511	11/24/2015	14.00	73.000	1,022.00
5100199	Cable, Servo Controller Board	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	062309-01	00002521	9/22/2011	1.00	50.530	50.53
5100199	Cable, Servo Controller Board	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	101408-04	00002521	9/22/2011	2.00	82.500	165.00
5100199	Cable, Servo Controller Board	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	121807-02	00002521	9/22/2011	1.00	82.500	82.50
5100200	Cable, Display	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	072115-01	G244837	7/21/2015	28.00	22.400	627.20
5100200	Cable, Display	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	072115-01	G244837	7/21/2015	1.00	22.400	22.40
5100200	Cable, Display	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	120308-01	00002521	9/22/2011	1.00	18.000	18.00
5100200	Cable, Display	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	121107-03	00002521	9/22/2011	1.00	30.000	30.00
5100201	Cable, Servo Motor Power Suppl	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	011817-01	G248295	1/18/2017	1.00	53.700	53.70
5100201	Cable, Servo Motor Power Suppl	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	072715-04	G244875	7/27/2015	38.00	53.700	2,040.60
5100201	Cable, Servo Motor Power Suppl	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	051608-01	00002521	9/22/2011	1.00	12.000	12.00
5100201	Cable, Servo Motor Power Suppl	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	102209-08	00002521	9/22/2011	1.00	60.650	60.65
5100202	Cable, Descrete Power Supply	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	072715-05	G244875	7/27/2015	38.00	51.600	1,960.80
5100202	Cable, Descrete Power Supply	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	111009-01	00002521	9/22/2011	1.00	56.810	56.81
5100202	Cable, Descrete Power Supply	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	121207-06	00002521	9/22/2011	1.00	56.000	56.00
5100203	Cable, 24V Power Supply	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	020916-02	G245831	2/9/2016	40.00	34.300	1,372.00
5100203	Cable, 24V Power Supply	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	081909-03	00002521	9/22/2011	1.00	28.030	28.03
5100203	Cable, 24V Power Supply	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	120607-03	00002521	9/22/2011	1.00	42.750	42.75
5100204	Cable, Controller Board Power	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	060915-02	00004100	6/12/2015	29.00	23.700	687.30
5100204	Cable, Controller Board Power	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	112608-01	00002521	9/22/2011	1.00	14.000	14.00
5100204	Cable, Controller Board Power	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	120507-03	00002521	9/22/2011	1.00	33.000	33.00
5100205	Cable, Accelerometer	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	072715-02	G244875	7/27/2015	27.00	19.300	521.10
5100205	Cable, Accelerometer	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	120208-02	PHYS COU	12/18/2015	1.00	19.300	19.30
5100206	Cable, Servo Driver Feedback	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	032117-01	G248546	3/21/2017	25.00	55.000	1,375.00
5100206	Cable, Servo Driver Feedback	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	120208-01	00002521	9/22/2011	1.00	35.000	35.00
5100206	Cable, Servo Driver Feedback	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	121007-03	00002521	9/22/2011	1.00	46.500	46.50
5100209	Hall Effect Sensor, Mini Flang	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	031114-03	00003680	4/10/2014	11.00	4.165	45.82
5100210	Single Point Load Cell	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	1F167-012	G245720	1/18/2016	1.00	209.000	209.00
5100210	Single Point Load Cell	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	1F167-013	G245720	1/18/2016	1.00	209.000	209.00
5100210	Single Point Load Cell	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	1F167-014	G245720	1/18/2016	1.00	209.000	209.00
5100210	Single Point Load Cell	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	1F167-015	G245720	1/18/2016	1.00	209.000	209.00
5100210	Single Point Load Cell	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	1F167-016	G245781	1/27/2016	1.00	209.000	209.00
5100210	Single Point Load Cell	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	1F167-017	G245781	1/27/2016	1.00	209.000	209.00
5100210	Single Point Load Cell	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	1F167-018	G245781	1/27/2016	1.00	209.000	209.00
5100210	Single Point Load Cell	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	1F167-019	G245781	1/27/2016	1.00	209.000	209.00
5100210	Single Point Load Cell	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	1F167-020	G245781	1/27/2016	1.00	209.000	209.00
5100210	Single Point Load Cell	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	1F167-021	G245781	1/27/2016	1.00	209.000	209.00
5100210	Single Point Load Cell	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	1F167-022	G245781	1/27/2016	1.00	209.000	209.00
5100210	Single Point Load Cell	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	1F167-023	G245781	1/27/2016	1.00	209.000	209.00
5100210	Single Point Load Cell	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	1F167-024	G245781	1/27/2016	1.00	209.000	209.00
5100210	Single Point Load Cell	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	1F167-025	G245781	1/27/2016	1.00	209.000	209.00
5100210	Single Point Load Cell	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	1F167-026	G245781	1/27/2016	1.00	209.000	209.00
5100210	Single Point Load Cell	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	1F167-027	G245781	1/27/2016	1.00	209.000	209.00
5100210	Single Point Load Cell	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	1F167-028	G245781	1/27/2016	1.00	209.000	209.00
5100210	Single Point Load Cell	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	1F167-029	G245781	1/27/2016	1.00	209.000	209.00
5100210	Single Point Load Cell	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	1F167-030	G245781	1/27/2016	1.00	209.000	209.00
5100212-01	Assy Pressure Sensor 1	RMD	Raw Material	Lot	EACH	200	200-QAQC- San Diego	21201-0508	G244913	7/31/2015	1.00	93.190	93.19
5100212-01	Assy Pressure Sensor 1	RMD	Raw Material	Lot	EACH	200	200-QAQC- San Diego	21201-0511	G244913	7/31/2015	1.00	93.190	93.19
5100212-01	Assy Pressure Sensor 1	RMD	Raw Material	Lot	EACH	200	200-QAQC- San Diego	21201-0517	G244913	7/31/2015	1.00	93.190	93.19
5100212-01	Assy Pressure Sensor 1	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	00703-0119	00002521	9/22/2011	1.00	151.060	151.06
5100212-01	Assy Pressure Sensor 1	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	21201-0214	PHYS COU	12/13/2013	1.00	178.786	178.79
5100212-01	Assy Pressure Sensor 1	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	21201-0462	00004035	4/13/2015	1.00	183.360	183.36
5100212-01	Assy Pressure Sensor 1	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	21201-0463	00004035	4/13/2015	1.00	183.360	183.36
5100212-02	Assy Pressure Sensor 2	RMD	Raw Material	Lot	EACH	200	200-QAQC- San Diego	21202-0532	G244930	8/5/2015	1.00	93.190	93.19
5100212-02	Assy Pressure Sensor 2	RMD	Raw Material	Lot	EACH	200	200-QAQC- San Diego	21202-0542	PHYS COU	9/17/2015	1.00	93.190	93.19
5100212-02	Assy Pressure Sensor 2	RMD	Raw Material	Lot	EACH	200	200-QAQC- San Diego	21202-0545	G244930	8/5/2015	1.00	93.190	93.19
5100212-02	Assy Pressure Sensor 2	RMD	Raw Material	Lot	EACH	200	200-QAQC- San Diego	21202-0549	G244930	8/5/2015	1.00	93.190	93.19
5100212-02	Assy Pressure Sensor 2	RMD	Raw Material	Lot	EACH	200	200-QAQC- San Diego	21202-0556	G244931	8/5/2015	1.00	93.190	93.19
5100212-02	Assy Pressure Sensor 2	RMD	Raw Material	Lot	EACH	200	200-QAQC- San Diego	21202-0560	G244931	8/5/2015	1.00	93.190	93.19
5100212-02	Assy Pressure Sensor 2	RMD	Raw Material	Lot	EACH	200	200-QAQC- San Diego	21202-0562	G244931	8/5/2015	1.00	93.190	93.19
5100212-02	Assy Pressure Sensor 2	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	21202-0534	G244930	8/5/2015	1.00	200.850	200.85
5100212-02	Assy Pressure Sensor 2	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	21202-0537	G244930	8/5/2015	1.00	200.850	200.85
5100212-02	Assy Pressure Sensor 2	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	21202-0539	G244930	8/5/2015	1.00	200.850	200.85
5100212-02	Assy Pressure Sensor 2	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	21202-0540	G244930	8/5/2015	1.00	200.850	200.85
5100212-02	Assy Pressure Sensor 2	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	21202-0541	G244930	8/5/2015	1.00	200.850	200.85
5100212-02	Assy Pressure Sensor 2	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	21202-0543	G244930	8/5/2015	1.00	200.850	200.85
5100212-02	Assy Pressure Sensor 2	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	21202-0544	G244930	8/5/2015	1.00		

5100212-02	Assy Pressure Sensor 2	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	21202-0492	00004035	4/13/2015	1.00	183.360	183.36
5100212-02	Assy Pressure Sensor 2	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	21202-0493	00004035	4/13/2015	1.00	183.360	183.36
5100212-02	Assy Pressure Sensor 2	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	21202-0574	G244931	8/5/2015	1.00	200.850	200.85
5100212-02	Assy Pressure Sensor 2	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	21202-0575	G245155	9/10/2015	1.00	200.850	200.85
5100213	Optical Sensor Assembly	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	072516-01	G247591	7/25/2016	10.00	45.500	455.00
5100215	Cable, 5V Power Supply	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	120415-04	G245570	12/4/2015	2.00	20.600	41.20
5100215	Cable, 5V Power Supply	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	120815-02	G245579	12/8/2015	13.00	20.600	267.80
5100215	Cable, 5V Power Supply	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	070909-12	00002521	9/22/2011	1.00	8.780	8.78
5100215	Cable, 5V Power Supply	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	120507-02	00002521	9/22/2011	1.00	40.250	40.25
5100216-00	Cable, Discrete Power Supply E	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	032514-01	00003723	5/15/2014	54.00	18.000	972.00
5100216-00	Cable, Discrete Power Supply E	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	120508-01	00002521	9/22/2011	1.00	26.000	26.00
5100216-00	Cable, Discrete Power Supply E	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	121407-01	00002521	9/22/2011	1.00	26.000	26.00
5100217	Cable, Power Cord Extension	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	072017-11	G249061	7/20/2017	39.00	38.000	1,482.00
5100217	Cable, Power Cord Extension	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	120308-02	00002521	9/22/2011	1.00	36.750	36.75
5100217	Cable, Power Cord Extension	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	121207-09	00002521	9/22/2011	1.00	36.750	36.75
5100219	Snap Action Switch	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	051314-01	00003750	5/28/2014	25.00	4.450	111.25
5100222	Cable, Rocker Assembly	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	033017-01	G248596	3/30/2017	25.00	38.200	955.00
5100222	Cable, Rocker Assembly	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	022114-01	00003612	2/25/2014	2.00	20.030	40.06
5100222	Cable, Rocker Assembly	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	102909-02	PHYS COU	12/19/2014	1.00	20.030	20.03
5100228	Locknut, 4-40, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		G242371	5/22/2014	945.00	0.130	122.85
5100228	Locknut, 4-40, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		PHY CNT	12/19/2014	143.00	0.130	18.59
5100228	Locknut, 4-40, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		0011096	8/8/2017	2.00	0.130	0.26
5100228	Locknut, 4-40, SS	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts		TRANSFR	9/22/2011	50.00	0.110	5.50
5100229	Graphic VFD Module	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	040314-07	00003673	4/4/2014	1.00	135.770	135.77
5100229	Graphic VFD Module	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	050417-01	G248733	5/4/2017	20.00	153.320	3,066.40
5100232	Fuse Drawer, Power Entry Modul	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	042814-04	00003755	5/29/2014	2.00	3.750	7.50
5100233	Power Entry Module	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	052714-02	00003751	5/29/2014	28.00	13.360	374.08
5100240	Equipotential Stud Receptacle	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	060115-01	00004118	6/24/2015	20.00	10.000	200.00
5100240	Equipotential Stud Receptacle	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	061114-01	00003779	6/12/2014	6.00	9.600	57.60
5100241	Cable, Overlay Switch	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	072715-03	G244875	7/27/2015	37.00	14.250	527.25
5100241	Cable, Overlay Switch	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	121207-07	00002521	9/22/2011	1.00	14.250	14.25
5100242	Fan Assembly	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	072015-03	G244818	7/20/2015	37.00	19.000	703.00
5100243	Maxon Motor with Flying Leads	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	011416-01	G245711	1/14/2016	11.00	266.300	2,929.30
5100247	Cable, 3 Conductor, 24 awg Str	RMD	Raw Material	FIFO	FT	205 205-Released Material-SD		G242964	8/20/2014	35.38	2.748	97.23
5100247	Cable, 3 Conductor, 24 awg Str	RMD	Raw Material	FIFO	FT	205 205-Released Material-SD		PHY CNT	12/19/2014	7.00	2.747	19.23
5100247	Cable, 3 Conductor, 24 awg Str	RMD	Raw Material	FIFO	FT	205 205-Released Material-SD		PHY CNT	12/18/2015	10.00	2.747	27.47
5100247	Cable, 3 Conductor, 24 awg Str	RMD	Raw Material	FIFO	FT	205 205-Released Material-SD		0010328	7/22/2016	4.00	2.747	10.99
5100248	Hall Effect Sensor, Linear	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	090110-07	TRFR202A	9/30/2010	127.00	0.954	121.15
5100249	Receptical Housing, 10 Positio	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		G240691	11/13/2013	27.00	0.460	12.42
5100249	Receptical Housing, 10 Positio	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		PHY CNT	12/13/2013	12.00	0.460	5.52
5100250	Crimp Terminal, Female, 20-24	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		G248035	11/1/2016	400.00	0.102	40.64
5100255	Zener Diode	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		G126269	3/5/2009	726.00	0.290	210.54
5100255	Zener Diode	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		PHY CNT	6/30/2009	5.00	0.290	1.45
5100255	Zener Diode	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		PHY CNT	6/30/2010	10.00	0.290	2.90
5100255	Zener Diode	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		PHY CNT	12/13/2013	10.00	0.290	2.90
5100255	Zener Diode	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		PHY CNT	12/19/2014	30.00	0.290	8.70
5100255	Zener Diode	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts		TRANSFR	9/22/2011	10.00	0.290	2.90
5100256	Latching Solenoid, Bi Directio	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	052814-01	00003757	5/30/2014	22.00	53.700	1,181.40
5100257	Contact Crimp Receptacle, 22-2	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		G123558	7/3/2008	94.00	0.029	2.73
5100257	Contact Crimp Receptacle, 22-2	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		PHY CNT	9/29/2008	1,281.00	0.029	37.15
5100257	Contact Crimp Receptacle, 22-2	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		PHY CNT	12/2/2011	35.00	0.029	1.02
5100258	Transformer, Plitron 600VA	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	070715-01	G244710	7/7/2015	14.00	310.000	4,340.00
5100259	3 POS Crimp Receptacle, 2mm	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		G249210	8/28/2017	200.00	0.103	20.60
5100260	Flange Bearing .375"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		G248034	11/1/2016	61.00	0.900	54.90
5100262-01	Nut Hex 3/4 - 16 SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		G125166	11/10/2008	60.00	1.230	73.80
5100262-01	Nut Hex 3/4 - 16 SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		PHY CNT	6/30/2010	10.00	1.230	12.30
5100262-01	Nut Hex 3/4 - 16 SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		PHY CNT	12/2/2011	1.00	1.230	1.23
5100262-01	Nut Hex 3/4 - 16 SS	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts		TRANSFR	9/22/2011	10.00	1.230	12.30
5100265	Multi-Stud Ring Terminal, #10	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		G1203100	10/4/2007	62.00	0.180	11.16
5100265	Multi-Stud Ring Terminal, #10	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		G120313	10/4/2007	50.00	0.180	9.00
5100265	Multi-Stud Ring Terminal, #10	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		PHY CNT	6/30/2010	50.00	0.180	9.00
5100265	Multi-Stud Ring Terminal, #10	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		PHY CNT	12/2/2011	1.00	0.180	0.18
5100267	Resistor, 25 OHM, 90 Watts RoS	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	060215-05	00004119	6/24/2015	16.00	30.060	480.96
5100268	Cable, Regen Resistor 01 & 02	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	021016-01	G245878	2/10/2016	40.00	10.800	432.00
5100279	Piezo Cable Assembly	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	081815-01	G245005	8/18/2015	18.00	25.000	450.00
5100279	Piezo Cable Assembly	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	022310-01	00003477	11/21/2013	1.00	20.000	20.00
5100279	Piezo Cable Assembly	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	081815-01	G245005	8/18/2015	5.00	25.000	125.00
5100279	Piezo Cable Assembly	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	092408-01	00002521	9/22/2011	2.00	33.000	66.00
5100319	Wire Clip-on Base with Adhesiv	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		00000979	10/14/2008	242.00	0.202	49.00
5100319	Wire Clip-on Base with Adhesiv	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		PHY CNT	12/3/2009	3.00	0.202	0.61
5100319	Wire Clip-on Base with Adhesiv	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		0007760	5/22/2014	2.00	0.202	0.40
5100319	Wire Clip-on Base with Adhesiv	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts		00000979	10/14/2008	50.00	0.202	10.12
5100327	UK 10 AMP Cordset w/C13 Connec	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	011211-02	00002070	1/18/2011	17.00	18.280	310.76
5100333	Peristaltic Pump Brake Motor w	RMD	Raw Material	Serial	EACH	205 205-Released Material-SD	253100/53971-2	G248425	2/16/2017	1.00	1,559.000	1,559.00
5100333	Peristaltic Pump Brake Motor w	RMD	Raw Material	Serial	EACH	205 205-Released Material-SD	424173	G246071	3/21/2016	1.00	1,559.000	1,559.00
5100333	Peristaltic Pump Brake Motor w	RMD	Raw Material	Serial	EACH	205 205-Released Material-SD	424174	G246071	3/21/2016	1.00	1,559.000	1,559.00
5100333	Peristaltic Pump Brake Motor w	RMD	Raw Material	Serial	EACH	205 205-Released Material-SD	424175	G246071	3/21/2016	1.00	1,559.000	1,559.00
5100333	Peristaltic Pump Brake Motor w	RMD	Raw Material	Serial	EACH	205 205-Released Material-SD	504535	G248190	12/12/2016	1.00	1,559.000	1,559.00
5100333	Peristaltic Pump Brake Motor w	RMD	Raw Material	Serial	EACH	205 205-Released Material-SD	504536	G248190	12/12/2016	1.00	1,559.000	1,559.00
5100333	Peristaltic Pump Brake Motor w	RMD	Raw Material	Serial	EACH	205 205-Released Material-SD	504537	G248190	12/12/2016	1.00	1,559.000	1,559.00
5100333	Peristaltic Pump Brake Motor w	RMD	Raw Material	Serial	EACH	205 205-Released Material-SD	504538	G248190	12/12/2016	1.00	1,559.000	1,559.00
5100333	Peristaltic Pump Brake Motor w	RMD	Raw Material	Serial	EACH	205 205-Released Material-SD	504539	G248190	12/12/2016	1.00	1,559.000	1,559.00
5100333	Peristaltic Pump Brake Motor w	RMD	Raw Material	Serial	EACH	205 205-Released Material-SD	504540	G248190	12/12/2016	1.00	1,559.000	1,559.00
5100333	Peristaltic Pump Brake Motor w	RMD	Raw Material	Serial	EACH	205 205-Released Material-SD	504541	G248190	12/12/2016	1.00	1,559.000	1,559.00
5100340	Membrane Switch Control Panel	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	050814-01	00003717	5/13/2014	5.00	43.230	216.15
5100340	Membrane Switch Control Panel	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	050814-01	00004007	3/5/2015	6.00	43.230	259.38
5100340	Membrane Switch Control Panel	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	100410-06	00002534	9/30/2011	2.00	77.200	154.40
5100346	Spacer. 6mm od x 4mm id x 12 m	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		G239328	5/23/2013	2.00	0.600	1.20
5100346	Spacer. 6mm od x 4mm id x 12 m	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		G242419	5/29/2014	500.00	0.600	300.00
5100378	Cordset, 10Amp w/13 Connector,	RMD	Raw Material	Lot	EACH	205 205-Released						

5100389	Terminal Block, Ground, Push-I	RMD	Raw Material	Lot	EACH	200	200-QAQC- San Diego		1/0/1900	0.00	0.000	0.00	
5100389	Terminal Block, Ground, Push-I	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	010517-03	G248267	1/5/2017	1.00	5.704	5.70
5100390	Thermal Cut-Out 75C 10A NC	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	100418-04	G250334	10/5/2018	4.00	6.000	24.00
5100391	Solid State Relay, 10A, 24-240	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	100418-03	G250334	10/5/2018	1.00	26.490	26.49
5100392	Isolation Transformer w/ Volt	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	010719-02	G250755	1/9/2019	4.00	280.000	1,120.00
5100393	Fuse, 5x20mm, 10A 250V Slow Bl	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G248251	12/30/2016	414.00	0.168	69.48
5100394	Partition Plate, Terminal Bloc	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	081616-01	G247712	8/16/2016	1.00	0.740	0.74
5100395	End Clamp, Terminal Block	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	030117-01	G248484	3/1/2017	2.00	1.500	3.00
5100397	Bridge, Terminal Block, 2-Pos,	RMD	Raw Material	Lot	EACH	200	200-QAQC- San Diego			1/0/1900	0.00	0.000	0.00
5100397	Bridge, Terminal Block, 2-Pos,	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	100418-02	G250334	10/5/2018	10.00	0.632	6.32
5100398	LED, Indicator, 125-250 VAC, P	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	100418-05	G250334	10/5/2018	4.00	7.520	30.08
5100400	Ring Terminal, #8 Stud, 16-22	RMD	Raw Material	Lot	EACH	200	200-QAQC- San Diego			1/0/1900	0.00	0.000	0.00
5100400	Ring Terminal, #8 Stud, 16-22	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	010517-05	G248267	1/5/2017	2.00	0.140	0.28
5100400	Ring Terminal, #8 Stud, 16-22	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	112718-01	G250600	11/28/2018	100.00	0.113	11.26
5100401	Quick Connect, Female, 0.187in	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G248251	12/30/2016	67.00	0.208	13.96
5100402	Quick Connect, Female, 0.250in	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G247712	8/16/2016	40.00	0.180	7.20
5100403	Ferrule, 16 AWG, Black	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	010517-06	G248267	1/5/2017	43.00	0.191	8.21
5100403	Ferrule, 16 AWG, Black	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	082117-01	G249170	8/21/2017	300.00	0.191	57.24
5100404	Ferrule, 18 AWG, Red	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	081018-01	G250171	8/10/2018	236.00	0.180	42.54
5100405	Ferrule, 24 AWG, Turquoise	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	010517-08	G248267	1/5/2017	7.00	0.178	1.25
5100405	Ferrule, 24 AWG, Turquoise	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	112718-02	G250600	11/28/2018	100.00	0.257	25.72
5100407	Quick Connect, Female, 0.187in	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	123016-05	G248251	12/30/2016	36.00	0.176	6.35
5100409	Micro-Fit Plug Housing 1x3, Pa	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	123016-07	G248251	12/30/2016	11.00	0.345	3.80
5100410	Micro-Fit Crimp Terminal, 20-2	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	123016-08	G248251	12/30/2016	458.00	0.069	31.76
5100416	Din Rail, 4" Long	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	082317-01	G249189	8/23/2017	13.00	3.200	41.60
5101015	Cordset, North American, 13Amp	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	111318-01	G250537	11/19/2018	14.00	30.360	425.04
5101015	Cordset, North American, 13Amp	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	031908-02	00002521	9/22/2011	2.00	21.520	43.04
5101015	Cordset, North American, 13Amp	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	102209-10	00002525	9/23/2011	3.00	29.500	88.50
5101015	Cordset, North American, 13Amp	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	111313-02	0008502	3/25/2015	2.00	29.500	59.00
5101017	Cordset, European, 10 Amp	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	111313-03	00003463	11/15/2013	3.00	16.140	48.42
5101017	Cordset, European, 10 Amp	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	092410-01	00002525	9/23/2011	9.00	14.150	127.35
5101017	Cordset, European, 10 Amp	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	111313-03	0008502	3/25/2015	5.00	16.140	80.70
5101018	Cordset, Japanese, 7 Amp	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	080318-01	G250144	8/3/2018	25.00	18.190	454.75
5101018	Cordset, Japanese, 7 Amp	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	090616-02	G247806	9/6/2016	3.00	24.000	72.00
5101018	Cordset, Japanese, 7 Amp	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	110917-01	G249399	11/10/2017	10.00	18.190	181.90
5101018	Cordset, Japanese, 7 Amp	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	071615-03	G244784	7/16/2015	2.00	18.710	37.42
5101020	Wire, 22 AWG, Green/Yellow	RMD	Raw Material	FIFO	FT	205	205-Released Material-SD		G238645	3/5/2013	168.00	0.113	18.90
5101020	Wire, 22 AWG, Green/Yellow	RMD	Raw Material	FIFO	FT	205	205-Released Material-SD		0010328	7/22/2016	2.00	0.113	0.23
5101033	Wire, 16 AWG, Green/Yellow	RMD	Raw Material	FIFO	FT	205	205-Released Material-SD		G249212	8/28/2017	87.00	1.010	87.91
5101038	Wire, 18 AWG, Brown	RMD	Raw Material	FIFO	FT	205	205-Released Material-SD		G249212	8/28/2017	4.00	0.787	3.15
5101038	Wire, 18 AWG, Brown	RMD	Raw Material	FIFO	FT	205	205-Released Material-SD		G250208	8/22/2018	200.00	0.787	157.46
5101039	Wire, 18 AWG, Blue	RMD	Raw Material	FIFO	FT	205	205-Released Material-SD		G249212	8/28/2017	62.38	0.788	49.13
5101040	Wire, 18 AWG, Black	RMD	Raw Material	FIFO	FT	205	205-Released Material-SD		G247631	8/2/2016	27.62	0.769	21.23
5101040	Wire, 18 AWG, Black	RMD	Raw Material	FIFO	FT	205	205-Released Material-SD		G249212	8/28/2017	100.00	0.787	78.73
5101045	Housing, High Pressure Termina	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G122450	4/11/2008	161.00	0.065	10.46
5101045	Housing, High Pressure Termina	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/6/2010	6.00	0.066	0.40
5101045	Housing, High Pressure Termina	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/5/2012	2.00	0.065	0.13
5101045	Housing, High Pressure Termina	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/13/2013	1.00	0.070	0.07
5101045	Housing, High Pressure Termina	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0007861	6/10/2014	1.00	0.066	0.06
5101046	Housing, High Pressure Termina	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G241757	3/11/2014	106.00	0.090	9.54
5101046	Housing, High Pressure Termina	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0007861	6/10/2014	1.00	0.090	0.09
5101046	Housing, High Pressure Termina	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	23.00	0.090	2.07
5101046	Housing, High Pressure Termina	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0010328	7/22/2016	1.00	0.090	0.09
5101047	Housing, High Pressure Termina	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G130731	8/16/2010	1,861.00	0.116	215.34
5101047	Housing, High Pressure Termina	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0007861	6/10/2014	1.00	0.116	0.11
5101048	Housing, High Pressure Termina	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		TRANSFR	12/23/2010	373.00	0.175	65.27
5101048	Housing, High Pressure Termina	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/13/2013	3.00	0.173	0.52
5101048	Housing, High Pressure Termina	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0010328	7/22/2016	1.00	0.174	0.17
5101048	Housing, High Pressure Termina	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/21/2016	8.00	0.174	1.39
5101048	Housing, High Pressure Termina	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0011047	7/6/2017	8.00	0.174	1.39
5101050	Crimp, High Pressure, 22-30 AW	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		OVERDIST		26.00-	0.290	7.54-
5101050	Crimp, High Pressure, 22-30 AW	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G248138	11/29/2016	920.00	0.104	95.65
5101050	Crimp, High Pressure, 22-30 AW	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/21/2016	30.00	0.104	3.12
5110001-03	PCA, Relay AP	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	QS15200034	00004106	6/17/2015	1.00	655.500	655.50
5110001-03	PCA, Relay AP	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	QS15200035	00004106	6/17/2015	1.00	655.500	655.50
5110001-03	PCA, Relay AP	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	QS15200037	00004106	6/17/2015	1.00	655.500	655.50
5110001-03	PCA, Relay AP	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	QS15200038	00004106	6/17/2015	1.00	655.500	655.50
5110001-03	PCA, Relay AP	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	QS15200039	00004106	6/17/2015	1.00	655.500	655.50
5110001-03	PCA, Relay AP	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	QS15200040	00004106	6/17/2015	1.00	655.500	655.50
5110001-03	PCA, Relay AP	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	QS15200041	00004106	6/17/2015	1.00	655.500	655.50
5110001-03	PCA, Relay AP	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	QS15200042	00004106	6/17/2015	1.00	655.500	655.50
5110001-03	PCA, Relay AP	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	QS15200044	00004115	6/18/2015	1.00	655.500	655.50
5110001-03	PCA, Relay AP	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	QS15200045	00004115	6/18/2015	1.00	655.500	655.50
5110001-03	PCA, Relay AP	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	QS15200046	00004115	6/18/2015	1.00	655.500	655.50
5110001-03	PCA, Relay AP	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	QS15200047	00004115	6/18/2015	1.00	655.500	655.50
5110001-03	PCA, Relay AP	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	QS15200048	00004115	6/18/2015	1.00	655.500	655.50
5110001-03	PCA, Relay AP	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	QS15200049	00004115	6/18/2015	1.00	655.500	655.50
5110001-03	PCA, Relay AP	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	QS15200050	00004115	6/18/2015	1.00	655.500	655.50
5110001-03	PCA, Relay AP	RMD	Raw Material	Serial	EACH	598	F&R Service Parts	9641-0051	00002521	9/22/2011	1.00	795.000	795.00
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	200	200-QAQC- San Diego	QS1313043	G238942	4/8/2013	1.00	408.600	408.60
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	200	200-QAQC- San Diego	QS15130021	G244197	4/9/2015	1.00	411.000	411.00
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	200	200-QAQC- San Diego	QS15130046	G244207	4/10/2015	0.00	411.000	411.00
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0011	G247537	7/13/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0013	G247537	7/13/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0014	G247537	7/13/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0015	G247537	7/13/2016	1.00	325.700	325.

5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0028	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0029	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0030	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0031	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0032	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0033	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0034	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0035	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0036	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0037	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0038	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0039	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0040	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0041	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0042	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0043	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0044	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0045	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0046	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0047	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0048	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0049	G248136	11/29/2016	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	205	205-Released Material-SD	21036-0050	00005369	1/23/2017	1.00	325.700	325.70
5110002-03	PCB, Controller Celution	RMD	Raw Material	Serial	EACH	598	F&R Service Parts	21036-0009	G247537	7/13/2016	1.00	325.700	325.70
5110003-03	PCA Accelerometer Board	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	032414-01	00003650	3/25/2014	43.00	31.000	1,333.00
5110004-03	Board Servo Assembly, PCA	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	0206-0059	00003801	7/8/2014	1.00	49.000	49.00
5110004-03	Board Servo Assembly, PCA	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	0206-0060	00003801	7/8/2014	1.00	49.000	49.00
5110004-03	Board Servo Assembly, PCA	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	0206-0053	00003801	7/8/2014	1.00	49.000	49.00
5110004-03	Board Servo Assembly, PCA	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	0206-0054	00003801	7/8/2014	1.00	49.000	49.00
5110004-03	Board Servo Assembly, PCA	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	10526-0045	00004737	6/27/2012	1.00	25.000	25.00
5110005-03	PCA Board Power Distribution	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	031414-01	00003651	3/27/2014	4.00	58.000	232.00
5110008-03	Board Inst. Amp. Load Cell Ass	RMD	Raw Material	Lot	EACH	200	200-QAQC- San Diego	00085	G243667	1/15/2015	3.00-	80.590	241.77-
5110008-03	Board Inst. Amp. Load Cell Ass	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	0210622-020	G248570	3/27/2017	1.00	88.500	88.50
5110008-03	Board Inst. Amp. Load Cell Ass	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	0210622-021	G248570	3/27/2017	1.00	88.500	88.50
5110008-03	Board Inst. Amp. Load Cell Ass	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	0210622-022	G248570	3/27/2017	1.00	88.500	88.50
5110008-03	Board Inst. Amp. Load Cell Ass	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	0210622-023	G248570	3/27/2017	1.00	88.500	88.50
5110008-03	Board Inst. Amp. Load Cell Ass	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	0210622-024	G248570	3/27/2017	1.00	88.500	88.50
5110008-03	Board Inst. Amp. Load Cell Ass	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	0210622-025	G248570	3/27/2017	1.00	88.500	88.50
5110013	Filter, Power Inlet	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	051514-01	00003750	5/28/2014	65.00	4.320	280.80
5110013	Filter, Power Inlet	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	061307-02	00002521	9/22/2011	1.00	3.530	3.53
5110014	Resistor, 1 Meg OHM	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	090314-01	00003867	9/3/2014	24.00	0.056	1.34
5110015	Resistor, 51 kOHM	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	082014-06	00003849	8/21/2014	31.00	0.100	3.10
5110025	Power Supply Module OCS-CYT-PN	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	010719-01	G250754	1/9/2019	3.00	3,320.000	9,960.00
5110026	Servo Motor AKM SDE-CYT-PNLMT	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	184400303	G250730	12/26/2018	1.00	920.000	920.00
5110026	Servo Motor AKM SDE-CYT-PNLMT	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	184400304	G250730	12/26/2018	1.00	920.000	920.00
5110026	Servo Motor AKM SDE-CYT-PNLMT	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	184400305	G250730	12/26/2018	1.00	920.000	920.00
5110027	Motor Feedback Cable, 24 SDE	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	122118-02	G250730	12/26/2018	2.00	130.000	260.00
5110028	Motor Power Cable, 24" SDE-CY	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	122118-03	G250730	12/26/2018	2.00	130.000	260.00
5200018-01	18-8 SS Pin Dowl 3/16 Dia x .5	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	G242371		5/22/2014	571.00	0.150	85.65
5200018-01	18-8 SS Pin Dowl 3/16 Dia x .5	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	PHY CNT		12/19/2014	2.00	0.150	0.30
5200018-03	18-8 SS Pin Dowl 3/16 Dia x 1"	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	G243753		1/29/2015	310.00	0.320	99.20
5200018-03	18-8 SS Pin Dowl 3/16 Dia x 1"	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	G245526		11/25/2015	1.00	0.320	0.32
5200018-05	18-8 SS Pin Dowl 3/16 Dia x 1	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	G242406		5/28/2014	382.00	0.430	164.26
5200034	Set Screw, 1/4-20 x 5/16"	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	G124683		9/30/2008	181.00	0.660	119.46
5200034	Set Screw, 1/4-20 x 5/16"	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	PHY CNT		6/30/2010	50.00	0.660	33.00
5200034	Set Screw, 1/4-20 x 5/16"	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts	TRANSFR		9/22/2011	50.00	0.660	33.00
5200048-01	10-32 Threaded Set Screw 1/4"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	G1224800		4/11/2008	214.00	0.350	74.90
5200048-01	10-32 Threaded Set Screw 1/4"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	G122483		4/11/2008	32.00	0.350	11.20
5200048-01	10-32 Threaded Set Screw 1/4"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	G1229400		5/14/2008	668.00	0.390	260.52
5200048-01	10-32 Threaded Set Screw 1/4"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	G122946		5/14/2008	32.00	0.390	12.48
5200048-01	10-32 Threaded Set Screw 1/4"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	PHY CNT		6/27/2008	28.00	0.350	9.80
5200048-01	10-32 Threaded Set Screw 1/4"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	PHY CNT		12/17/2008	4.00	0.350	1.40
5200048-01	10-32 Threaded Set Screw 1/4"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	PHY CNT		12/19/2014	34.00	0.390	13.26
5200048-02	10-32 Thread Screw Set - 1/2"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	G122483		4/11/2008	423.00	0.480	203.04
5200048-02	10-32 Thread Screw Set - 1/2"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	PHY CNT		12/5/2012	100.00	0.480	48.00
5200050-01	8-32SS Sckt Head Screw,5/8" L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	G1257501		1/14/2009	629.00	0.120	75.48
5200050-01	8-32SS Sckt Head Screw,5/8" L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	G125751		1/14/2009	32.00	0.120	3.84
5200050-01	8-32SS Sckt Head Screw,5/8" L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	PHY CNT		6/30/2010	50.00	0.120	6.00
5200050-01	8-32SS Sckt Head Screw,5/8" L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	0007861		6/10/2014	1.00	0.120	0.12
5200050-01	8-32SS Sckt Head Screw,5/8" L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	PHY CNT		12/21/2016	2.00	0.120	0.24
5200050-01	8-32SS Sckt Head Screw,5/8" L	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts	TRANSFR		9/22/2011	78.00	0.120	9.36
5200050-01	8-32SS Sckt Head Screw,5/8" L	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts	PHY CNT		12/14/2017	78.00	0.120	9.36
5200050-03	Screw, BSHCS SS, 8-32 x 1/2"	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	G241858		3/24/2014	169.00	0.070	11.83
5200050-03	Screw, BSHCS SS, 8-32 x 1/2"	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	PHY CNT		12/21/2016	5.00	0.070	0.35
5200050-03	Screw, BSHCS SS, 8-32 x 1/2"	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts	TRANSFR		9/22/2011	50.00	0.100	5.00
5200050-04	Screw, BSHCS SS, 8-32 x 3/8"	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	G239787		7/22/2013	582.00	0.120	69.84
5200050-04	Screw, BSHCS SS, 8-32 x 3/8"	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	PHY CNT		12/13/2013	6.00	0.120	0.72
5200050-04	Screw, BSHCS SS, 8-32 x 3/8"	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	0009007		7/20/2015	6.00	0.120	0.72
5200050-04	Screw, BSHCS SS, 8-32 x 3/8"	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	PHY CNT		12/21/2016	19.00	0.120	2.28
5200050-04	Screw, BSHCS SS, 8-32 x 3/8"	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts	TRANSFR		9/22/2011	50.00	0.050	2.50
5200050-04	Screw, BSHCS SS, 8-32 x 3/8"	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts	PHY CNT		12/14/2017	39.00	0.120	4.68
5200050-05	Screw, BSHCS SS, 8-32 x 5/16	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	G1243700		9/5/2008	343.00	0.110	37.73
5200050-05	Screw, BSHCS SS, 8-32 x 5/16	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	G124373		9/5/2008	48.00	0.110	5.28
5200050-05	Screw, BSHCS SS, 8-32 x 5/16	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD	PHY CNT		12/3/2009	48.00	0.110	5.28
5200050-05	Screw, BSHCS SS, 8-32 x 5/16	RMD	Raw Material	FIFO									

5200064-02	1/4" Flat Washer	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	PHY CNT	12/14/2017	55.00	0.100	5.50
5200064-03	#4 Flat Washer, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	TRANSFR	4/1/2011	972.00	0.030	29.16
5200064-03	#4 Flat Washer, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0009007	7/20/2015	8.00	0.030	0.24
5200064-03	#4 Flat Washer, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/21/2016	9.00	0.030	0.27
5200064-03	#4 Flat Washer, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0011096	8/8/2017	2.00	0.030	0.06
5200064-03	#4 Flat Washer, SS	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	70.00	0.030	2.10
5200064-04	#6 Flat Washer, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G243742	1/26/2015	793.00	0.070	55.51
5200064-04	#6 Flat Washer, SS	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	50.00	0.030	1.50
5200064-06	#8 Flat Washer, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G243742	1/26/2015	419.00	0.060	25.14
5200064-06	#8 Flat Washer, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0009007	7/20/2015	14.00	0.060	0.84
5200064-06	#8 Flat Washer, SS	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	50.00	0.030	1.50
5200065-01	#10 SS Lock Washer	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G242371	5/22/2014	2,260.00	0.070	158.20
5200065-01	#10 SS Lock Washer	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0009007	7/20/2015	2.00	0.070	0.14
5200065-01	#10 SS Lock Washer	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	62.00	0.030	1.86
5200065-01	#10 SS Lock Washer	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	PHY CNT	12/14/2017	26.00	0.070	1.82
5200065-02	18-8 SS Lock Washer x 1/4"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G242371	5/22/2014	2,705.00	0.080	216.40
5200065-02	18-8 SS Lock Washer x 1/4"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/18/2015	146.00	0.080	11.68
5200065-02	18-8 SS Lock Washer x 1/4"	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	50.00	0.040	2.00
5200065-02	18-8 SS Lock Washer x 1/4"	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	PHY CNT	12/14/2017	29.00	0.080	2.32
5200065-04	#6 SS Lock Washer	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G131393	10/21/2010	23.00	0.020	0.46
5200065-04	#6 SS Lock Washer	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0006362	4/8/2013	4.00	0.020	0.08
5200065-04	#6 SS Lock Washer	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0007760	5/22/2014	4.00	0.020	0.08
5200065-04	#6 SS Lock Washer	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/21/2016	1.00	0.020	0.02
5200065-04	#6 SS Lock Washer	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR1	9/22/2011	50.00	0.020	1.00
5200065-05	Washer, Lock, SS, #8	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G241842	3/21/2014	435.00	0.090	39.15
5200065-05	Washer, Lock, SS, #8	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/18/2015	3.00	0.090	0.27
5200065-05	Washer, Lock, SS, #8	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	38.00	0.020	0.76
5200065-05	Washer, Lock, SS, #8	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	PHY CNT	12/13/2013	12.00	0.070	0.84
5200065-06	Washer, Lock, SS, #4	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G242371	5/22/2014	2,759.00	0.080	220.72
5200065-06	Washer, Lock, SS, #4	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0009007	7/20/2015	12.00	0.080	0.96
5200065-06	Washer, Lock, SS, #4	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/18/2015	36.00	0.080	2.88
5200065-06	Washer, Lock, SS, #4	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	20.00	0.020	0.40
5200065-06	Washer, Lock, SS, #4	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	PHY CNT	12/18/2015	30.00	0.080	2.40
5200066-01	Screw, BSHCS SS, 10-32 x 3/8"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	6/30/2010	45.00	0.050	2.25
5200066-01	Screw, BSHCS SS, 10-32 x 3/8"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0009007	7/20/2015	2.00	0.050	0.10
5200066-01	Screw, BSHCS SS, 10-32 x 3/8"	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	50.00	0.050	2.50
5200066-01	Screw, BSHCS SS, 10-32 x 3/8"	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	PHY CNT	12/14/2017	78.00	0.050	3.90
5200066-02	Screw, BSHCS SS, #10-32x1/2"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G028562	12/28/2009	136.00	0.080	10.88
5200066-02	Screw, BSHCS SS, #10-32x1/2"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	6/30/2010	50.00	0.080	4.00
5200066-02	Screw, BSHCS SS, #10-32x1/2"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/13/2013	92.00	0.080	7.36
5200066-02	Screw, BSHCS SS, #10-32x1/2"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/19/2014	5.00	0.080	0.40
5200066-02	Screw, BSHCS SS, #10-32x1/2"	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	68.00	0.080	5.44
5200066-03	10-32 Threaded SS Button Socke	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G0285600	12/28/2009	660.00	0.110	72.60
5200066-03	10-32 Threaded SS Button Socke	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G028562	12/28/2009	2.00	0.110	0.22
5200066-03	10-32 Threaded SS Button Socke	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CN00	6/30/2010	48.00	0.110	5.28
5200066-03	10-32 Threaded SS Button Socke	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	6/30/2010	2.00	0.110	0.22
5200066-03	10-32 Threaded SS Button Socke	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	W0002640	8/31/2010	2.00	0.110	0.22
5200066-03	10-32 Threaded SS Button Socke	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0004700	8/4/2011	10.00	0.110	1.10
5200066-03	10-32 Threaded SS Button Socke	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0006362	4/8/2013	2.00	0.110	0.22
5200066-03	10-32 Threaded SS Button Socke	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/18/2015	2.00	0.110	0.22
5200066-03	10-32 Threaded SS Button Socke	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	50.00	0.110	5.50
5200066-04	Screw, BSHCS SS, 10-32 x 1"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/5/2012	407.00	0.150	61.05
5200066-04	Screw, BSHCS SS, 10-32 x 1"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0006654	7/11/2013	24.00	0.150	3.60
5200066-04	Screw, BSHCS SS, 10-32 x 1"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/13/2013	198.00	0.150	29.70
5200066-04	Screw, BSHCS SS, 10-32 x 1"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/21/2016	1.00	0.150	0.15
5200066-04	Screw, BSHCS SS, 10-32 x 1"	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	50.00	0.131	6.56
5200066-04	Screw, BSHCS SS, 10-32 x 1"	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	PHY CNT	12/21/2016	4.00	0.150	0.60
5200070-01	Screw, BSHCS SS, 1/4-20 x 1/2"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G1247401	10/6/2008	259.00	0.130	33.67
5200070-01	Screw, BSHCS SS, 1/4-20 x 1/2"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G124745	10/6/2008	50.00	0.130	6.50
5200070-01	Screw, BSHCS SS, 1/4-20 x 1/2"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	3/27/2009	71.00	0.130	9.23
5200070-01	Screw, BSHCS SS, 1/4-20 x 1/2"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	6/30/2010	50.00	0.130	6.50
5200070-01	Screw, BSHCS SS, 1/4-20 x 1/2"	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	50.00	0.130	6.50
5200070-01	Screw, BSHCS SS, 1/4-20 x 1/2"	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	PHY CNT	12/14/2017	24.00	0.130	3.12
5200070-02	Screw, BSHCS SS, 1/4-20 x 5/8"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G241858	3/24/2014	200.00	0.150	30.00
5200070-02	Screw, BSHCS SS, 1/4-20 x 5/8"	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	50.00	0.140	7.00
5200070-02	Screw, BSHCS SS, 1/4-20 x 5/8"	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	PHY CNT	12/14/2017	22.00	0.150	3.30
5200070-03	Screw, BSHCS SS, 1/4-20 x 3/4"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/5/2012	160.00	0.150	24.00
5200070-03	Screw, BSHCS SS, 1/4-20 x 3/4"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0006654	7/11/2013	24.00	0.150	3.60
5200070-03	Screw, BSHCS SS, 1/4-20 x 3/4"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/13/2013	160.00	0.150	24.00
5200070-03	Screw, BSHCS SS, 1/4-20 x 3/4"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0007760	5/22/2014	8.00	0.150	1.20
5200070-03	Screw, BSHCS SS, 1/4-20 x 3/4"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/19/2014	79.00	0.150	11.85
5200070-03	Screw, BSHCS SS, 1/4-20 x 3/4"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/18/2015	172.00	0.150	25.80
5200070-03	Screw, BSHCS SS, 1/4-20 x 3/4"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/21/2016	42.00	0.150	6.30
5200070-03	Screw, BSHCS SS, 1/4-20 x 3/4"	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	50.00	0.130	6.50
5200070-03	Screw, BSHCS SS, 1/4-20 x 3/4"	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	PHY CNT	12/14/2017	50.00	0.150	7.50
5200071	Screw, 3/8"-16 x 1-3/4" BHCS,	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G241858	3/24/2014	45.00	0.850	38.25
5200071	Screw, 3/8"-16 x 1-3/4" BHCS,	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0007760	5/22/2014	4.00	0.850	3.40
5200071	Screw, 3/8"-16 x 1-3/4" BHCS,	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G245526	11/25/2015	200.00	0.850	170.00
5200071	Screw, 3/8"-16 x 1-3/4" BHCS,	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/21/2016	4.00	0.850	3.40
5200071	Screw, 3/8"-16 x 1-3/4" BHCS,	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	20.00	0.850	17.00
5200073	3/4"-16 18-8 SS Hex Lock Nut	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G242406	5/28/2014	33.00	2.250	74.25
5200073	3/4"-16 18-8 SS Hex Lock Nut	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/18/2015	7.00	2.250	15.75
5200074	Machine Key, 3/16" x 1/2"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G241925	4/1/2014	53.00	2.000	106.00
5200075	Locknut, #8-32, Nylon Insert	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G241842	3/21/2014	346.00	0.200	69.20
5200075	Locknut, #8-32, Nylon Insert	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0009007	7/20/2015	12.00	0.200	2.40
5200075	Locknut, #8-32, Nylon Insert	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/18/2015	140.00	0.200	28.00
5200075	Locknut, #8-32, Nylon Insert	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	48.00	0.170	8.16
5200088	Screw, #4-40 x 3/8" FHCS, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G241861	3/25/2014	228.00	0.080	18.24
5200088	Screw, #4-40 x 3/8" FHCS, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/19/2014	18.00	0.080	1.44
5200088	Screw, #4-40 x 3/8" FHCS, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/18/2015	9.00	0.080	0.72
5200088	Screw, #4-40 x 3/8" FHCS, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/21/2016	5.00	0.080	0.40
5200088	Screw, #4-40 x 3/8" FHCS, SS	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	50.00	0.060	3.00
5200102	Locknut, 1/4-20, Nylon Insert	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G242371	5/22/2014	1,218.00	0.250	304.50
5200102	Locknut, 1/4-20, Nylon Insert	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	50.00	0.130	6.50
5200105	Locknut, #10-32, Nylon Insert	RMD	Raw Material	FIFO	EACH						

5200105	Locknut, #10-32, Nylon Insert	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	PHY CNT	12/19/2014	15.00	1.400	21.00
5200105	Locknut, #10-32, Nylon Insert	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	PHY CNT	12/14/2017	170.00	1.400	238.00
5200108	1/8" Rivet	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G245042	8/25/2015	126.00	0.235	29.61
5200108	1/8" Rivet	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G250825	1/28/2019	500.00	0.300	150.00
5200108	1/8" Rivet	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	G245042	8/25/2015	100.00	0.235	23.50
5200111-01	Screw, BHCS SS, #4-40 X 1/4"	RMD	Raw Material	FIFO	EA	205 205-Released Material-SD	OVERDIST		41.00-	0.060	2.46-
5200111-01	Screw, BHCS SS, #4-40 X 1/4"	RMD	Raw Material	FIFO	EA	205 205-Released Material-SD	G245501	11/20/2015	188.00	0.060	11.28
5200111-01	Screw, BHCS SS, #4-40 X 1/4"	RMD	Raw Material	FIFO	EA	205 205-Released Material-SD	PHY CNT	12/21/2016	2.00	0.060	0.12
5200111-01	Screw, BHCS SS, #4-40 X 1/4"	RMD	Raw Material	FIFO	EA	598 F&R Service Parts	TRANSFR	9/22/2011	48.00	0.045	2.16
5200111-01	Screw, BHCS SS, #4-40 X 1/4"	RMD	Raw Material	FIFO	EA	598 F&R Service Parts	PHY CNT	12/14/2017	2.00	0.060	0.12
5200111-02	Screw, BHCS SS, 4-40 x 3/8"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G001961	2/6/2015	233.00	0.660	153.78
5200111-02	Screw, BHCS SS, 4-40 x 3/8"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0009007	7/20/2015	12.00	0.660	7.92
5200111-02	Screw, BHCS SS, 4-40 x 3/8"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/18/2015	39.00	0.660	25.74
5200111-02	Screw, BHCS SS, 4-40 x 3/8"	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	48.00	0.900	43.20
5200111-04	Screw, BSHCS SS 4-40 x 1/2"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G245501	11/20/2015	149.00	0.110	16.39
5200111-04	Screw, BSHCS SS 4-40 x 1/2"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/21/2016	19.00	0.110	2.09
5200111-04	Screw, BSHCS SS 4-40 x 1/2"	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	50.00	0.110	5.50
5200112-01	6-32 Thread SS Button Head Soc	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G241842	3/21/2014	746.00	0.130	96.98
5200112-01	6-32 Thread SS Button Head Soc	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/19/2014	32.00	0.130	4.16
5200112-01	6-32 Thread SS Button Head Soc	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/18/2015	84.00	0.130	10.92
5200112-01	6-32 Thread SS Button Head Soc	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	45.00	0.110	4.95
5200112-01	6-32 Thread SS Button Head Soc	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	PHY CNT	12/14/2017	5.00	0.130	0.65
5200112-02	Screw, BHCS SS, 6-32 x 1/2"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	OVERDIST		61.00-	0.150	9.15-
5200112-02	Screw, BHCS SS, 6-32 x 1/2"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G243753	1/29/2015	217.00	0.130	28.21
5200112-02	Screw, BHCS SS, 6-32 x 1/2"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0009006	7/20/2015	12.00	0.130	1.56
5200112-02	Screw, BHCS SS, 6-32 x 1/2"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0009008	7/20/2015	12.00	0.130	1.56
5200112-02	Screw, BHCS SS, 6-32 x 1/2"	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	50.00	0.060	3.00
5200112-02	Screw, BHCS SS, 6-32 x 1/2"	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	PHY CNT	12/14/2017	50.00	0.130	6.50
5200112-03	Screw, BHCS, 18-8 SS, #6-32 x	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G128034	10/26/2009	420.00	0.056	23.36
5200112-03	Screw, BHCS, 18-8 SS, #6-32 x	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/3/2009	4.00	0.056	0.22
5200112-03	Screw, BHCS, 18-8 SS, #6-32 x	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	6/30/2010	50.00	0.056	2.80
5200112-03	Screw, BHCS, 18-8 SS, #6-32 x	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	W0002640	8/31/2010	8.00	0.056	0.45
5200112-03	Screw, BHCS, 18-8 SS, #6-32 x	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/2/2011	32.00	0.056	1.79
5200112-03	Screw, BHCS, 18-8 SS, #6-32 x	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0006362	4/8/2013	8.00	0.056	0.44
5200112-03	Screw, BHCS, 18-8 SS, #6-32 x	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/13/2013	56.00	0.056	3.14
5200112-03	Screw, BHCS, 18-8 SS, #6-32 x	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	30.00	0.056	1.68
5200112-03	Screw, BHCS, 18-8 SS, #6-32 x	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	PHY CNT	12/19/2014	20.00	0.056	1.12
5200112-03	Screw, BHCS, 18-8 SS, #6-32 x	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	PHY CNT	12/14/2017	91.00	0.056	5.10
5200112-04	6-32 Thread SS Button Head Soc	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G241858	3/24/2014	361.00	0.140	50.54
5200112-04	6-32 Thread SS Button Head Soc	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/19/2014	3.00	0.140	0.42
5200112-04	6-32 Thread SS Button Head Soc	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/18/2015	2.00	0.140	0.28
5200112-04	6-32 Thread SS Button Head Soc	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	50.00	0.090	4.50
5200112-05	6-32 Thread SS Button Head Soc	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G1255600	12/18/2008	58.00	0.110	6.38
5200112-05	6-32 Thread SS Button Head Soc	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G125566	12/18/2008	19.00	0.110	2.09
5200112-05	6-32 Thread SS Button Head Soc	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G1257500	1/14/2009	50.00	0.110	5.50
5200112-05	6-32 Thread SS Button Head Soc	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G1257501	1/14/2009	31.00	0.110	3.41
5200112-05	6-32 Thread SS Button Head Soc	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G125751	1/14/2009	819.00	0.110	90.09
5200112-05	6-32 Thread SS Button Head Soc	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/3/2009	50.00	0.130	6.50
5200112-05	6-32 Thread SS Button Head Soc	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CN00	6/30/2010	6.00	0.130	0.78
5200112-05	6-32 Thread SS Button Head Soc	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CN01	6/30/2010	25.00	0.130	3.25
5200112-05	6-32 Thread SS Button Head Soc	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	6/30/2010	19.00	0.130	2.47
5200112-05	6-32 Thread SS Button Head Soc	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	50.00	0.110	5.50
5200115-01	Screw, SHCS SS, #10-32x3/4"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G241842	3/21/2014	261.00	0.160	41.76
5200115-01	Screw, SHCS SS, #10-32x3/4"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0007760	5/22/2014	10.00	0.160	1.60
5200115-01	Screw, SHCS SS, #10-32x3/4"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/19/2014	466.00	0.160	74.56
5200115-01	Screw, SHCS SS, #10-32x3/4"	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	50.00	0.140	7.00
5200115-02	10-32x 1 1/4" SS Socket Head C	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G241842	3/21/2014	626.00	0.160	100.16
5200115-02	10-32x 1 1/4" SS Socket Head C	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0007760	5/22/2014	6.00	0.160	0.96
5200115-02	10-32x 1 1/4" SS Socket Head C	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/19/2014	4.00	0.160	0.64
5200115-02	10-32x 1 1/4" SS Socket Head C	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/21/2016	2.00	0.160	0.32
5200115-02	10-32x 1 1/4" SS Socket Head C	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	50.00	0.160	8.00
5200115-02	10-32x 1 1/4" SS Socket Head C	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	PHY CNT	12/19/2014	6.00	0.160	0.96
5200115-02	10-32x 1 1/4" SS Socket Head C	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	PHY CNT	12/14/2017	68.00	0.160	10.88
5200130	Locknut, #6-32, Nylon Insert	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G242371	5/22/2014	1,840.00	0.110	202.40
5200130	Locknut, #6-32, Nylon Insert	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/18/2015	115.00	0.110	12.65
5200130	Locknut, #6-32, Nylon Insert	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	50.00	0.093	4.65
5200136	Shim, .062" Thick, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	6/30/2010	8.00	1.200	9.60
5200136	Shim, .062" Thick, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0004016	4/11/2011	5.00	1.200	6.00
5200136	Shim, .062" Thick, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/2/2011	1.00	1.200	1.20
5200136	Shim, .062" Thick, SS	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	10.00	1.200	12.00
5200146	Screw, 1/2-13 x 4", SHCS, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G241194	1/16/2014	65.00	3.800	247.00
5200146	Screw, 1/2-13 x 4", SHCS, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/19/2014	3.00	3.800	11.40
5200146	Screw, 1/2-13 x 4", SHCS, SS	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts	TRANSFR	9/22/2011	2.00	3.770	7.54
5200153	Screw, #10-32 x 3/4", FHCS, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G028562	12/28/2009	266.00	0.100	26.60
5200153	Screw, #10-32 x 3/4", FHCS, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/2/2011	78.00	0.100	7.80
5200153	Screw, #10-32 x 3/4", FHCS, SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0007861	6/10/2014	4.00	0.100	0.40
5200161	Fan Guard & Mesh Filter	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G241757	3/11/2014	30.00	1.320	39.60
5200162	Standoff, Hex #8-32 x 1/2	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G249077	7/24/2017	172.00	0.300	51.60
5200173	Dowel Pin, 1/4" Dia x 2.5", SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G240692	11/13/2013	11.00	0.900	9.90
5200173	Dowel Pin, 1/4" Dia x 2.5", SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0007861	6/10/2014	1.00	0.900	0.90
5200173	Dowel Pin, 1/4" Dia x 2.5", SS	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/19/2014	18.00	0.900	16.20
5200176-02	18-8 SS FHSCS M3 x 0.5" x 8mm	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G028562	12/28/2009	244.00	0.060	14.64
5200176-02	18-8 SS FHSCS M3 x 0.5" x 8mm	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/2/2011	10.00	0.060	0.60
5200176-02	18-8 SS FHSCS M3 x 0.5" x 8mm	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/13/2013	15.00	0.060	0.90
5200176-02	18-8 SS FHSCS M3 x 0.5" x 8mm	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	0007861	6/10/2014	4.00	0.060	0.24
5200176-02	18-8 SS FHSCS M3 x 0.5" x 8mm	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	12/19/2014	7.00	0.060	0.42
5200178	Spring Pin, 5/64" Dia. x 9/16"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G1197900	8/16/2007	31.00	0.100	3.10
5200178	Spring Pin, 5/64" Dia. x 9/16"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G1197901	8/16/2007	21.00	0.100	2.10
5200178	Spring Pin, 5/64" Dia. x 9/16"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G1197902	8/16/2007	19.00	0.100	1.90
5200178	Spring Pin, 5/64" Dia. x 9/16"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	G119795	8/16/2007	8.00	0.100	0.80
5200178	Spring Pin, 5/64" Dia. x 9/16"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CN00	11/18/2007	18.00	0.100	1.80
5200178	Spring Pin, 5/64" Dia. x 9/16"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	11/18/2007	21.00	0.100	2.10
5200178	Spring Pin, 5/64" Dia. x 9/16"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT	3/31/2008	40.00	0.100	4.00
5200178	Spring Pin, 5/64" Dia. x 9/16"	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD	PHY CNT				

5200179	External Retaining Ring, 1/2"	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0007861	6/10/2014	2.00	0.170	0.34
5200188	Shoulder Screw, #10-32, 1/4" O	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G245569	12/4/2015	48.00	1.600	76.80
5200188	Shoulder Screw, #10-32, 1/4" O	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	1.00	1.600	1.60
5200188	Shoulder Screw, #10-32, 1/4" O	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/21/2016	2.00	1.600	3.20
5200190	Screw, M3 x 14mm, SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G243742	1/26/2015	76.00	0.150	11.40
5200196	Screw, M4 x 8mm SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G125474	12/9/2008	8.00	0.120	0.96
5200196	Screw, M4 x 8mm SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	6/30/2010	50.00	0.120	6.00
5200196	Screw, M4 x 8mm SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		W0002640	8/31/2010	2.00	0.120	0.24
5200196	Screw, M4 x 8mm SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0006362	4/8/2013	2.00	0.120	0.24
5200196	Screw, M4 x 8mm SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	2.00	0.120	0.24
5200196	Screw, M4 x 8mm SHCS, SS	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	50.00	0.120	6.00
5200198	Bottom Plate	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	040717-03	G248625	4/7/2017	20.00	82.490	1,649.80
5200200	Caster	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	051616-01	G246294	5/16/2016	92.00	16.080	1,479.36
5200200	Caster	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	051616-01	G246294	5/16/2016	4.00	16.080	64.32
5200205	Compression Spring	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	052114-01	00003757	5/30/2014	84.00	1.500	126.00
5200207	Wire Guard	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G243751	1/28/2015	10.00	0.948	9.48
5200207	Wire Guard	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	4.00	0.949	3.80
5200207	Wire Guard	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/14/2017	1.00	0.949	0.95
5200216-01	Screw, FHSCS 1/4-20 SS 1 5/8	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/3/2009	43.00	1.880	80.84
5200216-01	Screw, FHSCS 1/4-20 SS 1 5/8	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	6/30/2010	20.00	1.880	37.60
5200216-01	Screw, FHSCS 1/4-20 SS 1 5/8	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G1311200	9/24/2010	64.00	1.880	120.32
5200216-01	Screw, FHSCS 1/4-20 SS 1 5/8	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G1311201	9/24/2010	20.00	1.880	37.60
5200216-01	Screw, FHSCS 1/4-20 SS 1 5/8	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G131129	9/24/2010	116.00	1.880	218.08
5200216-01	Screw, FHSCS 1/4-20 SS 1 5/8	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/6/2010	43.00	1.880	80.84
5200216-01	Screw, FHSCS 1/4-20 SS 1 5/8	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/2/2011	72.00	1.880	135.36
5200216-01	Screw, FHSCS 1/4-20 SS 1 5/8	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	20.00	1.880	37.60
5200216-02	Screw, FHSCS 1/4-20 SS 1 3/4	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		00001467	1/4/2010	171.00	0.520	88.92
5200216-02	Screw, FHSCS 1/4-20 SS 1 3/4	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	20.00	0.520	10.40
5200218	Handle	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	060514-01	00003771	6/6/2014	12.00	105.000	1,260.00
5200231	Waste Bag Mount	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G239502	6/12/2013	12.00	8.000	96.00
5200231	Waste Bag Mount	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	1.00	8.000	8.00
5200231	Waste Bag Mount	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G248030	10/28/2016	39.00	12.800	499.20
5200231	Waste Bag Mount	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G248083	11/11/2016	11.00	12.800	140.80
5200231	Waste Bag Mount	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0011096	8/8/2017	2.00	12.800	25.60
5200231	Waste Bag Mount	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	20.00	6.950	139.00
5200231	Waste Bag Mount	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		PHY CNT	12/14/2017	7.00	12.800	89.60
5200232	Washer, #8 Split Lock, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G1252402	11/17/2008	433.00	0.040	17.32
5200232	Washer, #8 Split Lock, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G125243	11/17/2008	101.00	0.040	4.04
5200232	Washer, #8 Split Lock, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/17/2008	1.00	0.040	0.04
5200232	Washer, #8 Split Lock, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CN00	3/27/2009	657.00	0.040	26.28
5200232	Washer, #8 Split Lock, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	3/27/2009	303.00	0.040	12.12
5200232	Washer, #8 Split Lock, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		W0001286	11/12/2009	4.00	0.040	0.16
5200232	Washer, #8 Split Lock, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/3/2009	101.00	0.040	4.04
5200232	Washer, #8 Split Lock, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CN00	6/30/2010	1.00	0.040	0.04
5200232	Washer, #8 Split Lock, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	6/30/2010	49.00	0.040	1.96
5200232	Washer, #8 Split Lock, SS	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	50.00	0.040	2.00
5200236	Nut, Square, #8-32 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G1252400	11/17/2008	471.00	0.120	56.52
5200236	Nut, Square, #8-32 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G125243	11/17/2008	3.00	0.120	0.36
5200236	Nut, Square, #8-32 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	3/27/2009	3.00	0.120	0.36
5200236	Nut, Square, #8-32 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	6/30/2010	50.00	0.120	6.00
5200236	Nut, Square, #8-32 SS	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	50.00	0.120	6.00
5200237-01	Screw #8-32 Socket Head SS 5/1	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G240692	11/13/2013	54.00	0.160	8.64
5200237-01	Screw #8-32 Socket Head SS 5/1	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	1.00	0.160	0.16
5200237-02	Screw #8-32 Socket Head SS 3/8	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	022817-02	G248474	2/28/2017	27.00	0.220	5.94
5200237-04	Screw #8-32 Socket Head SS 1/2	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G241842	3/21/2014	287.00	0.150	43.05
5200237-04	Screw #8-32 Socket Head SS 1/2	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/19/2014	509.00	0.150	76.35
5200238	Compression Spring, .125"OD x	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/19/2014	7.00	1.000	7.00
5200238	Compression Spring, .125"OD x	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	36.00	1.000	36.00
5200239	Shoulder Screw, 1/4-20, 5/16"	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G242406	5/28/2014	102.00	2.750	280.50
5200239	Shoulder Screw, 1/4-20, 5/16"	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	5.00	2.750	13.75
5200240-01	Screw, #4-40 x .25", SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G123349	6/13/2008	544.00	0.050	27.20
5200240-01	Screw, #4-40 x .25", SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	6/30/2010	50.00	0.050	2.50
5200240-01	Screw, #4-40 x .25", SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/2/2011	55.00	0.050	2.75
5200240-01	Screw, #4-40 x .25", SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/5/2012	3.00	0.050	0.15
5200240-01	Screw, #4-40 x .25", SHCS, SS	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	12.00	0.050	0.60
5200240-01	Screw, #4-40 x .25", SHCS, SS	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		PHY CNT	12/14/2017	138.00	0.050	6.90
5200240-05	Screw, #4-40 x .5", SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G237692	11/6/2012	291.00	0.040	11.64
5200240-05	Screw, #4-40 x .5", SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/13/2013	67.00	0.040	2.68
5200240-05	Screw, #4-40 x .5", SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0011096	8/8/2017	3.00	0.040	0.12
5200240-05	Screw, #4-40 x .5", SHCS, SS	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		G237692	11/6/2012	9.00	0.040	0.36
5200240-08	Screw, #4-40 x .75", SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G237692	11/6/2012	443.00	0.050	22.15
5200240-08	Screw, #4-40 x .75", SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0011096	8/8/2017	3.00	0.050	0.15
5200240-08	Screw, #4-40 x .75", SHCS, SS	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		G237692	11/6/2012	9.00	0.050	0.45
5200240-09	Screw, #4-40 x .875", SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G237692	11/6/2012	397.00	0.050	19.85
5200240-09	Screw, #4-40 x .875", SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/13/2013	3.00	0.050	0.15
5200240-10	Screw, #4-40 x 1", SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G237692	11/6/2012	474.00	0.050	23.70
5200240-10	Screw, #4-40 x 1", SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/13/2013	9.00	0.050	0.45
5200241	Screw, SHCS 2-56 x 3/8	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G129743	5/3/2010	647.00	0.120	77.64
5200241	Screw, SHCS 2-56 x 3/8	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CN00	6/30/2010	43.00	0.080	3.44
5200241	Screw, SHCS 2-56 x 3/8	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	6/30/2010	7.00	0.080	0.56
5200241	Screw, SHCS 2-56 x 3/8	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/2/2011	31.00	0.120	3.72
5200241	Screw, SHCS 2-56 x 3/8	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	50.00	0.080	4.00
5200243	Door Latch Sensor Bracket	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	092914-01	00003893	10/1/2014	22.00	7.220	158.84
5200244	Solenoid Sensor Bracket	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	092914-02	00003893	10/1/2014	43.00	8.320	357.76
5200245	Snap Switch Bracket	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	102416-02	G247985	10/24/2016	38.00	10.450	397.10
5200246	Latch Base Cover	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	102416-03	G247985	10/24/2016	29.00	18.150	526.35
5200246	Latch Base Cover	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	111513-02	00003515	12/16/2013	3.00	16.500	49.50
5200247	Standoff 6-32 x 7/8	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	9/30/2009	280.00	0.440	123.20
5200250	Screw, 10-24 x 5/8" Long SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD</						

5200251	Pre Assembled Cart and Crate	RMD	Raw Material	Lot	EACH	206	206-Storage - Sorrento Valley	060216-01	G247379	6/2/2016	5.00	2,696.940	13,484.70
5200253	Containment Chamber	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	040717-01	G248625	4/7/2017	26.00	199.720	5,192.72
5200254-01	Screw SHCS 6-32 x 1/4 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G245501	11/20/2015	117.00	0.080	9.36
5200254-01	Screw SHCS 6-32 x 1/4 SS	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	50.00	0.080	4.00
5200254-01	Screw SHCS 6-32 x 1/4 SS	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		PHY CNT	12/14/2017	17.00	0.080	1.36
5200254-03	Screw, SHCS #6-32 x 7/16 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G1247400	10/6/2008	290.00	0.080	23.20
5200254-03	Screw, SHCS #6-32 x 7/16 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G124745	10/6/2008	20.00	0.080	1.60
5200254-03	Screw, SHCS #6-32 x 7/16 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/17/2008	2.00	0.080	0.16
5200254-03	Screw, SHCS #6-32 x 7/16 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CN00	6/30/2010	2.00	0.080	0.16
5200254-03	Screw, SHCS #6-32 x 7/16 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	6/30/2010	18.00	0.080	1.44
5200254-03	Screw, SHCS #6-32 x 7/16 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	20.00	0.080	1.60
5200254-03	Screw, SHCS #6-32 x 7/16 SS	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	12.00	0.080	0.96
5200254-04	Screw, SHCS #6-32 x 5/8 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		TRANSFR	4/1/2011	286.00	0.114	32.53
5200254-04	Screw, SHCS #6-32 x 5/8 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/2/2011	23.00	0.114	2.62
5200254-04	Screw, SHCS #6-32 x 5/8 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/5/2012	4.00	0.115	0.46
5200254-04	Screw, SHCS #6-32 x 5/8 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/13/2013	27.00	0.114	3.08
5200254-04	Screw, SHCS #6-32 x 5/8 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0007761	5/22/2014	8.00	0.114	0.91
5200255-01	Pin 1/8 x 3/4, SS Spring	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G241902	3/28/2014	334.00	0.120	40.08
5200255-01	Pin 1/8 x 3/4, SS Spring	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		PHY CNT	12/1/2011	20.00	0.100	2.00
5200256-01	Screw #8-32 x 3/8 L PFHS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G242371	5/22/2014	47.00	0.070	3.29
5200256-01	Screw #8-32 x 3/8 L PFHS, SS	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	20.00	0.050	1.00
5200257	Nut Hex 6-32 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	6/30/2010	35.00	0.040	1.40
5200257	Nut Hex 6-32 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/2/2011	16.00	0.040	0.64
5200257	Nut Hex 6-32 SS	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	50.00	0.040	2.00
5200258	Torsion Spring	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	050710-02	TRFR202A	9/30/2010	27.00	1.100	29.70
5200259	Collar Shaft 3/8 Bore	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G245569	12/4/2015	46.00	2.800	128.80
5200259	Collar Shaft 3/8 Bore	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	10.00	2.800	28.00
5200266-01	Screw SHCS 1/4 - 20	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G245501	11/20/2015	94.00	0.210	19.74
5200266-01	Screw SHCS 1/4 - 20	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	28.00	0.210	5.88
5200267-01	18-8SS SHCS 1/4-20, 1/2"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G243742	1/26/2015	845.00	0.160	135.20
5200267-02	18-8SS SHCS 1/4-20, 5/8"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G128536	12/21/2009	182.00	0.200	36.40
5200267-02	18-8SS SHCS 1/4-20, 5/8"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/13/2013	3.00	0.200	0.60
5200267-02	18-8SS SHCS 1/4-20, 5/8"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0007760	5/22/2014	2.00	0.200	0.40
5200267-02	18-8SS SHCS 1/4-20, 5/8"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	4.00	0.200	0.80
5200267-03	18-8SS SHCS 1/4-20, 3/4"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	9/30/2010	262.00	0.250	65.50
5200267-04	18-8SS SHCS 1/4-20, 1"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/2/2011	486.00	0.260	126.36
5200267-04	18-8SS SHCS 1/4-20, 1"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/5/2012	42.00	0.260	10.92
5200267-04	18-8SS SHCS 1/4-20, 1"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/13/2013	25.00	0.260	6.50
5200267-04	18-8SS SHCS 1/4-20, 1"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/21/2016	22.00	0.260	5.72
5200267-04	18-8SS SHCS 1/4-20, 1"L	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0011096	8/8/2017	4.00	0.260	1.04
5200267-04	18-8SS SHCS 1/4-20, 1"L	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	2.00	0.260	0.52
5200268	Screw, M4 x 35mm, SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G242406	5/28/2014	73.00	0.150	10.95
5200268	Screw, M4 x 35mm, SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	8.00	0.150	1.20
5200268	Screw, M4 x 35mm, SHCS, SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0011096	8/8/2017	2.00	0.150	0.30
5200268	Screw, M4 x 35mm, SHCS, SS	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	50.00	0.150	7.50
5200269	Washer, #8, Flat, Zinc-Plated	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G1231300	5/29/2008	406.00	0.120	48.72
5200269	Washer, #8, Flat, Zinc-Plated	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G123133	5/29/2008	50.00	0.120	6.00
5200269	Washer, #8, Flat, Zinc-Plated	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	6/30/2010	50.00	0.120	6.00
5200269	Washer, #8, Flat, Zinc-Plated	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/5/2012	4.00	0.120	0.48
5200269	Washer, #8, Flat, Zinc-Plated	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0011096	8/8/2017	2.00	0.120	0.24
5200269	Washer, #8, Flat, Zinc-Plated	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	50.00	0.120	6.00
5200269	Washer, #8, Flat, Zinc-Plated	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		PHY CNT	12/14/2017	15.00	0.120	1.80
5200273	Stud 1/4 Turn Fastener	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	103112-02	00002984	11/9/2012	54.00	2.840	153.36
5200273	Stud 1/4 Turn Fastener	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	031109-04	00002521	9/22/2011	3.00	3.000	9.00
5200273	Stud 1/4 Turn Fastener	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	061908-02	00002521	9/22/2011	45.00	2.840	127.80
5200274	Stud Retaining Ring	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	061908-03	TRFR202A	9/30/2010	72.00	0.200	14.40
5200274	Stud Retaining Ring	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	061908-03	00002521	9/22/2011	10.00	0.200	2.00
5200275	1/4 Turn Receptacle	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	061908-04	TRFR202A	9/30/2010	12.00	3.100	37.20
5200275	1/4 Turn Receptacle	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	121808-07	TRFR202A	9/30/2010	100.00	3.100	310.00
5200275	1/4 Turn Receptacle	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	061908-04	00002521	9/22/2011	10.00	3.100	31.00
5200277	Tumescent LAMIS Cannula, 14gau	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	131218-02	00003635	3/17/2014	37.00	111.570	4,128.09
5200278	Tumescent LAMIS Cannula, 14 ga	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	130910-01	00003638	3/17/2014	23.00	111.570	2,566.11
5200279	Tumescent LAMIS Cannula, 14 ga	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	140107-03	00003809	7/14/2014	20.00	111.570	2,231.40
5200280	Harvest Cannula, 3 mm x 32 cm	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	110929-01	00003536	12/30/2013	2.00	174.970	349.94
5200280	Harvest Cannula, 3 mm x 32 cm	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	140523-01	00003813	7/21/2014	9.00	176.570	1,589.13
5200281	Harvest Cannula, 3 mm x 26 cm	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	130221-03	00003536	12/30/2013	10.00	175.570	1,755.70
5200281	Harvest Cannula, 3 mm x 26 cm	RMI	Raw Material	Lot	EACH	500	500-Fichtner & Ritschel	010711-01	00002667	1/18/2012	4.00	101.570	406.28
5200281	Harvest Cannula, 3 mm x 26 cm	RMI	Raw Material	Lot	EACH	500	500-Fichtner & Ritschel	111006-03	00003011	11/30/2012	10.00	159.070	1,590.70
5200282	Harvest Cannula, 3 mm x 15 cm	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	15112005	G246108	4/5/2016	10.00	215.980	2,159.80
5200282	Harvest Cannula, 3 mm x 15 cm	RMI	Raw Material	Lot	EACH	500	500-Fichtner & Ritschel	111006-02	00003011	11/30/2012	8.00	159.070	1,272.56
5200283	Infiltration Cannula, 16 gauge	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	130708-02	00003678	4/9/2014	9.00	165.630	1,490.67
5200283	Infiltration Cannula, 16 gauge	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	61991	D0000061	8/29/2018	8.00	95.630	765.04
5200283	Infiltration Cannula, 16 gauge	RMI	Raw Material	Lot	EACH	500	500-Fichtner & Ritschel	091112-02	00003011	11/30/2012	12.00	144.630	1,735.56
5200284	Convex Infiltration Cannula, 1	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	071708-16	TRFR204A	9/30/2010	7.00	95.000	665.00
5200284	Convex Infiltration Cannula, 1	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	113009-11	TRFR204A	9/30/2010	2.00	95.000	190.00
5200285	Concave Infiltration Cannula,	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	130801-02	00003813	7/21/2014	20.00	161.570	3,231.40
5200285	Concave Infiltration Cannula,	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	61992	D0000061	8/29/2018	8.00	161.570	1,292.56
5200286	Luer Lock Connector, Female to	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	15042202	G245207	9/23/2015	14.00	51.570	721.98
5200286	Luer Lock Connector, Female to	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	61993	D0000061	8/29/2018	8.00	51.570	412.56
5200287	Snapper for 60cc Syringe	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	050610-01	TRFR204A	9/30/2010	3.00	50.000	150.00
5200287	Snapper for 60cc Syringe	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	050710-01	TRFR204A	9/30/2010	16.00	50.000	800.00
5200287	Snapper for 60cc Syringe	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	060809-09	00004438	11/4/2010	2.00	50.000	100.00
5200287	Snapper for 60cc Syringe	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	071708-19	TRFR204A	9/30/2010	3.00	50.000	150.00
5200289	Toomey to Luer Lock (Needle)	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	072208-04	TRFR204A	9/30/2010	4.00	45.000	180.00
5200289	Toomey to Luer Lock (Needle)	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	113009-03	TRFR204A	9/30/2010			

5200301-04	Shim .251ID x .375OD x .060 Th	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		M001542	4/5/2012	53.00	0.440	23.32
5200301-04	Shim .251ID x .375OD x .060 Th	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	50.00	0.440	22.00
5200309	Adapter, Celbrush	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	121415-03	G245599	12/14/2015	14.00	105.000	1,470.00
5200309	Adapter, Celbrush	RMI	Raw Material	Lot	EACH	500	500-Fichtner & Ritschel	121415-03	G245599	12/14/2015	2.00	105.000	210.00
5200310	Handle Assembly, Celbrush	RMI	Raw Material	Lot	EACH	200	200-QAQC- San Diego	091015-02	G245154	9/10/2015	2.00	305.000	610.00
5200310	Handle Assembly, Celbrush	RMI	Raw Material	Lot	EACH	200	200-QAQC- San Diego	121415-01	G245599	12/14/2015	10.00	305.000	3,050.00
5200325	10 mL Rack Assembly, Celbrush	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	121415-02	G245599	12/14/2015	7.00	115.000	805.00
5200333	Set Screw, SS 1/4"-20 Dog Poin	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/2/2011	31.00	0.550	17.05
5200333	Set Screw, SS 1/4"-20 Dog Poin	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/5/2012	42.00	0.550	23.10
5200333	Set Screw, SS 1/4"-20 Dog Poin	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/13/2013	17.00	0.550	9.35
5200333	Set Screw, SS 1/4"-20 Dog Poin	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	10.00	0.550	5.50
5200336-01	Screw 18-8 SSBH 4-40 1/2	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G242371	5/22/2014	1,346.00	0.160	215.36
5200336-01	Screw 18-8 SSBH 4-40 1/2	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	6.00	0.160	0.96
5200336-01	Screw 18-8 SSBH 4-40 1/2	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		PHY CNT	12/21/2016	74.00	0.160	11.84
5200337-01	Washer, Flat Stainless Steel 9	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		TRANSFR	4/25/2011	4.00	0.130	0.52
5200337-01	Washer, Flat Stainless Steel 9	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/2/2011	12.00	0.130	1.56
5200337-01	Washer, Flat Stainless Steel 9	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/5/2012	18.00	0.130	2.34
5200337-01	Washer, Flat Stainless Steel 9	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0006362	4/8/2013	2.00	0.130	0.26
5200337-01	Washer, Flat Stainless Steel 9	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0007760	5/22/2014	4.00	0.130	0.52
5200337-01	Washer, Flat Stainless Steel 9	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G245526	11/25/2015	200.00	0.130	26.00
5200337-01	Washer, Flat Stainless Steel 9	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	2.00	0.130	0.26
5200338-01	Locknut, Nylon Insert 303 Stai	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G239987	8/5/2013	307.00	0.480	147.36
5200338-01	Locknut, Nylon Insert 303 Stai	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0007099	11/25/2013	4.00	0.480	1.92
5200338-01	Locknut, Nylon Insert 303 Stai	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	101.00	0.480	48.48
5200339-01	Standoff, 6-32 SS 7/8	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/3/2009	19.00	1.160	22.04
5200339-01	Standoff, 6-32 SS 7/8	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/21/2016	1.00	1.160	1.16
5200340-01	Screw Machine Metric Ph M2 x 8	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G242384	5/27/2014	36.00	0.100	3.60
5200341-01	Nut Hex Metric M2 Zinc	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G243094	9/11/2014	677.00	0.020	13.54
5200341-01	Nut Hex Metric M2 Zinc	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	60.00	0.020	1.20
5200342-01	Washer Lock Metric M2 Zinc	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G241963	4/3/2014	304.00	0.030	9.12
5200342-01	Washer Lock Metric M2 Zinc	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0007760	5/22/2014	2.00	0.030	0.06
5200342-01	Washer Lock Metric M2 Zinc	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	26.00	0.030	0.78
5200345	Spring Pin 5/64" x 3/8"	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G245526	11/25/2015	467.00	0.060	28.02
5200345	Spring Pin 5/64" x 3/8"	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	1.00	0.060	0.06
5200349	3mL Rack Assembly, Celbrush	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	010312-05	00002661	1/5/2012	8.00	99.000	792.00
5200349	3mL Rack Assembly, Celbrush	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	030612-04	00002719	3/7/2012	75.00	99.000	7,425.00
5200349	3mL Rack Assembly, Celbrush	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	091015-05	G245154	9/10/2015	50.00	100.000	5,000.00
5200351	Wave Springs, 1.00 id x 1.25 o	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G241902	3/28/2014	43.00	2.500	107.50
5200352	Snap Ring Internal, 1.850 Bore	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/19/2014	85.00	0.600	51.00
5200352	Snap Ring Internal, 1.850 Bore	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/21/2016	1.00	0.600	0.60
5200354	Autoclave Case, Tissue Collect	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	022814-01	00003619	3/6/2014	4.00	284.000	1,136.00
5200355	Autoclave Case, Graft Delivery	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	61990	D0000061	8/29/2018	4.00	332.000	1,328.00
5200357	V-dissector cannula, 3mm x 2	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	130703-04	00003335	7/30/2013	19.00	189.570	3,601.83
5200357	V-dissector cannula, 3mm x 2	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	61996	D0000061	8/29/2018	4.00	189.570	758.28
5200360	Document Holder	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	040717-04	G248625	4/7/2017	9.00	16.950	152.55
5200365	Insert Nut, 10-32	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G246289	5/13/2016	212.00	2.500	530.00
5200365	Insert Nut, 10-32	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0011096	8/8/2017	8.00	2.500	20.00
5200365	Insert Nut, 10-32	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		G245215	9/23/2015	24.00	2.400	57.60
5200365	Insert Nut, 10-32	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		G246289	5/13/2016	12.00	2.500	30.00
5200365	Insert Nut, 10-32	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		PHY CNT	12/14/2017	8.00	2.500	20.00
5200366	Nut, Hex, #10 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G131664	11/30/2010	753.00	0.055	41.41
5200366	Nut, Hex, #10 SS	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/2/2011	1.00	0.060	0.06
5200369	Easel Set, Puregraft	RMI	Raw Material	Lot	EACH	205	205-Released Material-SD	61998	D0000061	8/29/2018	4.00	42.000	168.00
5200374	Rivet, Tubular, Oval HD, 1/8"	RMI	Raw Material	FIFO	EACH	205	205-Released Material-SD		00002744	3/28/2012	223.00	0.250	55.75
5200374	Rivet, Tubular, Oval HD, 1/8"	RMI	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	3/21/2013	15.00	0.250	3.75
5200396	Housing Front Assembly, 10ff	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	081717-02	G249164	8/17/2017	1.00	42.120	42.12
5200397	Housing Top, 10ff	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	081717-03	G249164	8/17/2017	1.00	55.320	55.32
5200398	Housing Bottom Assembly, 10ff	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	082917-01	G249213	8/29/2017	1.00	38.120	38.12
5200399	Housing Mount Assembly, 10ff	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	081717-04	G249164	8/17/2017	5.00	19.370	96.85
5200402	Duct Support Bracket	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	081717-05	G249164	8/17/2017	5.00	17.340	86.70
5200403	Controller Mounting Bracket	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	081717-06	G249164	8/17/2017	5.00	16.510	82.55
5200405	Washer, Flat, .44 ID x 1.25OD	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G247613	7/28/2016	80.00	0.240	19.20
5200406	Nut, Lock, 5/16-18, Nylon Inse	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G247613	7/28/2016	80.00	0.220	17.60
5200407	Screw, Flat Head Sock Cap 5/16	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G247666	8/5/2016	5.00	1.490	7.45
5200411	Screw,Flange Head Socket Cap,	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G247666	8/5/2016	200.00	0.350	70.00
5200413	Screw,Pan Head Sheet Metal #8-	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G248474	2/28/2017	24.00	0.110	2.64
5200419	Washer, External Tooth, No. 8	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G249077	7/24/2017	958.00	0.040	38.32
5300113-01	3/16" Dia. Heat Shrink Tubing,	RMD	Raw Material	FIFO	INCH	205	205-Released Material-SD		PHY CNT	12/6/2010	45.00	0.000	0.00
5300113-01	3/16" Dia. Heat Shrink Tubing,	RMD	Raw Material	FIFO	INCH	205	205-Released Material-SD		PHY CNT	12/5/2012	895.00	0.000	0.00
5300113-01	3/16" Dia. Heat Shrink Tubing,	RMD	Raw Material	FIFO	INCH	205	205-Released Material-SD		PHY CNT	12/21/2016	30.00	0.000	0.00
5300113-02	1/16" Dia. Heat Shrink Tubing,	RMD	Raw Material	FIFO	INCH	205	205-Released Material-SD		G127158	7/8/2009	487.50	0.028	13.81
5300113-02	1/16" Dia. Heat Shrink Tubing,	RMD	Raw Material	FIFO	INCH	205	205-Released Material-SD		PHY CNT	12/5/2012	45.00	0.028	1.26
5300113-02	1/16" Dia. Heat Shrink Tubing,	RMD	Raw Material	FIFO	INCH	205	205-Released Material-SD		PHY CNT	12/13/2013	19.50	0.028	0.55
5300113-02	1/16" Dia. Heat Shrink Tubing,	RMD	Raw Material	FIFO	INCH	205	205-Released Material-SD		0010328	7/22/2016	2.00	0.028	0.06
5300113-02	1/16" Dia. Heat Shrink Tubing,	RMD	Raw Material	FIFO	INCH	205	205-Released Material-SD		PHY CNT	12/21/2016	250.00	0.028	7.00
5300113-03	1/4" Dia. Heat Shrink Tubing,	RMD	Raw Material	FIFO	INCH	205	205-Released Material-SD		G241827	3/18/2014	216.00	0.198	42.70
5300113-04	3/8" Dia. Heat Shrink Tubing,	RMD	Raw Material	FIFO	INCH	205	205-Released Material-SD		G242964	8/21/2014	108.00	0.048	5.18
5300113-04	3/8" Dia. Heat Shrink Tubing,	RMD	Raw Material	FIFO	INCH	205	205-Released Material-SD		PHY CNT	12/21/2016	162.00	0.048	7.78
5300113-05	1/2" Dia. Heat Shrink Tubing,	RMD	Raw Material	FIFO	INCH	205	205-Released Material-SD		G244492	5/28/2015	245.50	0.249	61.18
5300113-05	1/2" Dia. Heat Shrink Tubing,	RMD	Raw Material	FIFO	INCH	205	205-Released Material-SD		0009007	7/20/2015	0.50	0.249	0.12
5300113-05	1/2" Dia. Heat Shrink Tubing,	RMD	Raw Material	FIFO	INCH	205	205-Released Material-SD		PHY CNT	12/21/2016	254.00	0.249	63.25
5300123	Press-In Plug	RMC	Raw Material	FIFO	EACH	205	205-Released Material-SD		G246070	3/21/2016	2,400.00	0.384	921.60
5300129	E Gasket Lid Seal Material	RMD	Raw Material	Lot	FT	205	205-Released Material-SD	060115-02	00004119	6/24/2015	45.00	4.800	216.00
5300129	E Gasket Lid Seal Material	RMD	Raw Material	Lot	FT	598	F&R Service Parts	031014-02	00004035	4/13/2015	5.00	4.800	24.00
5300129	E Gasket Lid Seal Material	RMD	Raw Material	Lot	FT	598	F&R Service Parts	041008-12	00002521	9/22/2011	5.00	2.950	14.75
5300129	E Gasket Lid Seal Material	RMD	Raw Material	Lot	FT	598	F&R Service Parts	060115-02	00004119	6/24/2015	10.00	4.800	48.00
5300130	Sealing Washer, Neoprene Rubbe	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G241858	3/24/2014	196.00	0.750	147.00
5300130	Sealing Washer, Neoprene Rubbe	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0007760	5/22/2014	4.00	0.750	3.00
5300130	Sealing Washer, Neoprene Rubbe	RMD	Raw Material	FIFO									

5300186	Grommet, Rubber, 3/16"	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0010328	7/22/2016	1.00	0.329	0.33
5300195	Containment Chamber Gasket	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	102615-01	G245363	10/26/2015	37.00	3.650	135.05
5300195	Containment Chamber Gasket	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	021710-04	00004035	4/13/2015	2.00	3.640	7.28
5300195	Containment Chamber Gasket	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	102615-01	G245363	10/26/2015	3.00	3.650	10.95
5300208-02	Straight Cable Clamp, Size 13	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G241757	3/11/2014	56.00	5.170	289.52
5300208-02	Straight Cable Clamp, Size 13	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/19/2014	7.00	5.170	36.19
5300210	Macro Syringe Filter, 25mm Syr	RMT	Raw Material	Lot	EACH	205	205-Released Material-SD	12832117	G246004	3/8/2016	8,899.00	2.600	23,137.40
5300220	O-Ring, 1 1/2 x 1 5/8 x 1/16",	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	081010-04	TRFR202A	9/30/2010	420.00	0.340	142.80
5300220	O-Ring, 1 1/2 x 1 5/8 x 1/16",	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	042808-01	00002521	9/22/2011	10.00	0.340	3.40
5300233	Standoff, 6-32 x 1", Nylon Hex	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G244544	6/5/2015	77.00	0.960	73.92
5300233	Standoff, 6-32 x 1", Nylon Hex	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	4.00	0.960	3.84
5300233	Standoff, 6-32 x 1", Nylon Hex	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/21/2016	13.00	0.960	12.48
5300233	Standoff, 6-32 x 1", Nylon Hex	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	50.00	0.220	11.00
5300234	Grommet, 1/8" ID x 3/4" OD x 3	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G240788	11/26/2013	64.00	0.250	16.00
5300234	Grommet, 1/8" ID x 3/4" OD x 3	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0007861	6/10/2014	2.00	0.250	0.50
5300234	Grommet, 1/8" ID x 3/4" OD x 3	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/19/2014	13.00	0.250	3.25
5300234	Grommet, 1/8" ID x 3/4" OD x 3	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	50.00	0.220	11.00
5300235	Grommet, 1" ID x 1 3/4" OD x 1	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G130938	9/7/2010	22.00	1.200	26.40
5300235	Grommet, 1" ID x 1 3/4" OD x 1	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/2/2011	1.00	1.200	1.20
5300235	Grommet, 1" ID x 1 3/4" OD x 1	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0007861	6/10/2014	1.00	1.200	1.20
5300235	Grommet, 1" ID x 1 3/4" OD x 1	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		PHY CNT	12/18/2015	10.00	1.200	12.00
5300239	Lid- CT800	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	032414-02	00003673	4/4/2014	1.00	150.000	150.00
5300239	Lid- CT800	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	032414-02	00004007	3/5/2015	6.00	150.000	900.00
5300242	Grommet, 1 1/2" ID x 2 1/8" OD	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G242470	6/3/2014	99.00	2.600	257.40
5300242	Grommet, 1 1/2" ID x 2 1/8" OD	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	20.00	1.480	29.60
5300248-01	Klip, Adhesive Kwik, Dia 0.312	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G247458	6/24/2016	970.00	0.320	310.40
5300248-01	Klip, Adhesive Kwik, Dia 0.312	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0011096	8/8/2017	3.00	0.320	0.96
5300248-01	Klip, Adhesive Kwik, Dia 0.312	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	97.00	0.667	64.69
5300248-01	Klip, Adhesive Kwik, Dia 0.312	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		PHY CNT	12/14/2017	5.00	0.320	1.60
5300248-03	Klip, Adhesive Kwik, Dia 0.578	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G130816	8/26/2010	97.00	0.575	55.77
5300248-03	Klip, Adhesive Kwik, Dia 0.578	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	4.00	0.575	2.30
5300248-03	Klip, Adhesive Kwik, Dia 0.578	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0011096	8/8/2017	5.00	0.575	2.88
5300248-03	Klip, Adhesive Kwik, Dia 0.578	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	95.00	0.850	80.75
5300248-04	Klip, Adhesive Kwik, Dia 0..87	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G242419	5/29/2014	1.00	1.300	1.30
5300248-04	Klip, Adhesive Kwik, Dia 0..87	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	161.00	1.300	209.30
5300248-04	Klip, Adhesive Kwik, Dia 0..87	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0011096	8/8/2017	2.00	1.300	2.60
5300248-04	Klip, Adhesive Kwik, Dia 0..87	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	96.00	1.300	124.80
5300249	Rectangle Plug Plastic 1" x 1	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	021908-02	TRFR202A	9/30/2010	169.00	0.397	67.12
5300250-01	Top Plate Overlay 1 - Green	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	052715-02	00004087	5/29/2015	65.00	6.900	448.50
5300250-01	Top Plate Overlay 1 - Green	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	052715-02	00004087	5/29/2015	3.00	6.900	20.70
5300250-01	Top Plate Overlay 1 - Green	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	061013-01	00004035	4/13/2015	1.00	9.920	9.92
5300250-02	Top Plate Overlay 2 - Blue	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	052715-03	00004087	5/29/2015	65.00	6.900	448.50
5300250-02	Top Plate Overlay 2 - Blue	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	052715-03	00004087	5/29/2015	3.00	6.900	20.70
5300250-02	Top Plate Overlay 2 - Blue	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	061013-02	00004035	4/13/2015	1.00	9.920	9.92
5300256-02	18-8 SS Flange Head Socket Cap	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/13/2013	56.00	0.360	20.16
5300256-02	18-8 SS Flange Head Socket Cap	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0007760	5/22/2014	5.00	0.360	1.80
5300256-02	18-8 SS Flange Head Socket Cap	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0011096	8/8/2017	4.00	0.360	1.44
5300256-02	18-8 SS Flange Head Socket Cap	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	44.00	0.360	15.84
5300256-02	18-8 SS Flange Head Socket Cap	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		PHY CNT	12/14/2017	47.00	0.360	16.92
5300265	Bumper, Rubber	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G248362	2/1/2017	180.00	0.600	108.00
5300265	Bumper, Rubber	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	6.00	0.400	2.40
5300265	Bumper, Rubber	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		PHY CNT	12/21/2016	1.00	0.500	0.50
5300265	Bumper, Rubber	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		PHY CNT	12/14/2017	7.00	0.600	4.20
5300266	Hinge, Adjustable Friction, Bl	RMD	Raw Material	Lot	EACH	598	F&R Service Parts	031108-02	00002521	9/22/2011	1.00	9.560	9.56
5300267	Bearing, Sleeve	RMD	Raw Material	Lot	EACH	205	205-Released Material-SD	091208-06	TRFR202A	9/30/2010	400.00	0.437	174.80
5300268	Grommet, 1/2" ID x 1 1/16" OD	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/6/2010	191.00	0.660	126.06
5300268	Grommet, 1/2" ID x 1 1/16" OD	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/13/2013	201.00	0.660	132.66
5300268	Grommet, 1/2" ID x 1 1/16" OD	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0007760	5/22/2014	1.00	0.660	0.66
5300268	Grommet, 1/2" ID x 1 1/16" OD	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/18/2015	1.00	0.660	0.66
5300268	Grommet, 1/2" ID x 1 1/16" OD	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/21/2016	1.00	0.660	0.66
5300268	Grommet, 1/2" ID x 1 1/16" OD	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	50.00	0.570	28.50
5300269	Santoprene 1/32" Thick Black,	RMD	Raw Material	Lot	EA	205	205-Released Material-SD	032114-09	00003680	4/10/2014	20.00	7.490	149.80
5300269	Santoprene 1/32" Thick Black,	RMD	Raw Material	Lot	EA	205	205-Released Material-SD	032414-04	00003680	4/10/2014	2.00	8.000	16.00
5300273	Coiled Lanyard Plastics	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G248135	11/29/2016	100.00	3.690	369.00
5300278	1/16" Foam Sheet, Adhesive Bac	RMD	Raw Material	Lot	EA	205	205-Released Material-SD	032114-10	00003684	4/15/2014	14.00	8.000	112.00
5300285	.120" Silicone Rubber Sheet, 6	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G249082	7/25/2017	5.00	90.000	450.00
5300292	Washer, #12, Rubber Sealing	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		G239797	7/23/2013	54.00	0.500	27.00
5300292	Washer, #12, Rubber Sealing	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/19/2014	26.00	0.500	13.00
5300292	Washer, #12, Rubber Sealing	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		PHY CNT	12/21/2016	1.00	0.500	0.50
5300292	Washer, #12, Rubber Sealing	RMD	Raw Material	FIFO	EACH	205	205-Released Material-SD		0011096	8/8/2017	2.00	0.500	1.00
5300292	Washer, #12, Rubber Sealing	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		TRANSFR	9/22/2011	50.00	0.490	24.50
5300292	Washer, #12, Rubber Sealing	RMD	Raw Material	FIFO	EACH	598	F&R Service Parts		PHY CNT	12/14/2017	21.00	0.500	10.50
5300308	Toomey Syringe Cap (VBQ3740020	RMT	Raw Material	Lot	EACH	205	205-Released Material-SD	61507532	00000157	2/15/2017	10.00	0.136	1.36
5300308	Toomey Syringe Cap (VBQ3740020	RMT	Raw Material	Lot	EACH	205	205-Released Material-SD	61603043	G249880	5/17/2018	2,830.00	0.130	367.90
5300308	Toomey Syringe Cap (VBQ3740020	RMT	Raw Material	Lot	EACH	470	470 -Cell Bank Offsite Storage	011811-11	00002464	8/25/2011	0.00	0.084	0.02-
5300308	Toomey Syringe Cap (VBQ3740020	RMT	Raw Material	Lot	EACH	500	500-Fichtner & Ritschel	61363955	00003842	8/14/2014	5,970.00	0.130	776.10
5300308	Toomey Syringe Cap (VBQ3740020	RMT	Raw Material	Lot	EACH	500	500-Fichtner & Ritschel	61446355	G245713	1/14/2016	1,600.00	0.130	208.00
5300308	Toomey Syringe Cap (VBQ3740020	RMT	Raw Material	Lot	EACH	500	500-Fichtner & Ritschel	61450538	G245714	1/14/2016	3,900.00	0.130	507.00
5300311	Spinal Needle	RMT	Raw Material	Lot	EACH	200	200-QAQC- San Diego	8061606	G250827	1/30/2019	100.00	2.966	296.58
5300311	Spinal Needle	RMT	Raw Material	Lot	EACH	200	200-QAQC- San Diego	8274884	G250827	1/30/2019	100.00	2.966	296.58
5300311	Spinal Needle	RMT	Raw Material	Lot	EACH	205	205-Released Material-SD	6287578	G248468	2/27/2017	89.00	2.920	259.88
5300311	Spinal Needle	RMT	Raw Material	Lot	EACH	500	500-Fichtner & Ritschel	5280867	G245982	3/2/2016	40.00	2.920	116.80
5300313	Hook and Loop Fastener	RMD	Raw Material	FIFO	INCH	205	205-Released Material-SD		G241858	3/24/2014	152.50	0.208	31.68
5300313	Hook and Loop Fastener	RMD	Raw Material	FIFO	INCH	205	205-Released Material-SD		0007677	4/23/2014	2.00	0.208	0.41
5300313	Hook and Loop Fastener	RMD	Raw Material	FIFO	INCH	205	205-Released Material-SD		0007849	6/9/2014	2.00	0.208	0.41
5300313	Hook and Loop Fastener	RMD	Raw Material	FIFO	INCH	205	205-Released Material-SD		00078491	6/9/2014	2.00	0.208	0.41
5300313	Hook and Loop Fastener	RMD	Raw Material	FIFO	INCH	205	205-Released Material-SD		00078492	6/9/2014	2.00	0.208	0.4

5300322	V-Belt 4-Rib	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	072611-06	PHYS COU	12/13/2013	1.00	6.000	6.00
5300331	Soft-Ject Syringe 10 ml	RMT	Raw Material	Lot	EACH	200 200-QAQC- San Diego	18D16C8	G250097	7/26/2018	1,200.00	0.180	215.40
5300331	Soft-Ject Syringe 10 ml	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	17G17C8	G249400	11/10/2017	30.00	0.144	4.32
5300331	Soft-Ject Syringe 10 ml	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	18D16C8	G250097	7/26/2018	1.00	0.199	0.20
5300331	Soft-Ject Syringe 10 ml	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	18F25C8	G250669	12/13/2018	282.00	0.200	56.26
5300331	Soft-Ject Syringe 10 ml	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	15L26C8	G245705	1/12/2016	240.00	0.160	38.40
5300331	Soft-Ject Syringe 10 ml	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	17M13C8	G249567	1/19/2018	1,000.00	0.120	120.00
5300342	Spacer, Nylon .147 x .25 x 7/1	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		VAL CHAN	11/30/2011	177.00	0.034	6.06
5300342	Spacer, Nylon .147 x .25 x 7/1	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		PHY CNT	12/2/2011	1,994.00	0.024	47.86
5300342	Spacer, Nylon .147 x .25 x 7/1	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		PHY CNT	12/19/2014	100.00	0.024	2.40
5300342	Spacer, Nylon .147 x .25 x 7/1	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts		VAL CHAN	11/30/2011	50.00	0.024	1.20
5300364	6-Position Silicone Cradle	RMI	Raw Material	Lot	EACH	205 205-Released Material-SD	092208-02	TRFR204A	9/30/2010	2.00	122.679	245.36
5300364	6-Position Silicone Cradle	RMI	Raw Material	Lot	EACH	205 205-Released Material-SD	121009-01	TRFR204A	9/30/2010	4.00	86.100	344.40
5300367	O-RING, 7/16 X 9/16 X 1/16 (SI	RMI	Raw Material	Lot	EACH	205 205-Released Material-SD	111412-06	00003017	11/30/2012	36.00	3.400	122.40
5300367	O-RING, 7/16 X 9/16 X 1/16 (SI	RMI	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	111412-06	00003414	10/17/2013	18.00	3.400	61.20
5300400	Plastic Plugs Push-In 3/8" Hol	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		G12624	3/4/2009	581.00	0.085	49.38
5300400	Plastic Plugs Push-In 3/8" Hol	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		PHY CNT	12/19/2014	122.00	0.085	10.37
5300430	Soft-Ject Syringe 3ml	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	16A11C8	G248131	11/28/2016	300.00	0.150	45.00
5300430	Soft-Ject Syringe 3ml	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	16E30C8	G248131	11/28/2016	2,600.00	0.150	390.00
5300430	Soft-Ject Syringe 3ml	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	17L16C8	G249568	1/19/2018	600.00	0.120	72.00
5300430	Soft-Ject Syringe 3ml	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	3G01048	00003478	11/21/2013	1,300.00	0.090	117.00
5300453	Toomey Syringe, 60ml, Blister	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	703440X	G248416	2/14/2017	2,206.00	1.214	2,679.12
5300453	Toomey Syringe, 60ml, Blister	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	329100028X	00004121	6/25/2015	600.00	0.990	593.99
5300463	Polysulfone Collection Syringe	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	011012-02	00002672	1/18/2012	0.00	3.319	0.01-
5300463	Polysulfone Collection Syringe	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	2014032401	00003706	5/7/2014	38.00	3.710	140.98
5300463	Polysulfone Collection Syringe	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	2016112801	G248243	12/27/2016	81.00	3.760	304.56
5300463	Polysulfone Collection Syringe	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	2018070201	G250172	8/10/2018	800.00	4.040	3,232.00
5300467	Vibration Mount 10-32 Thread S	RMD	Raw Material	Lot	EACH	205 205-Released Material-SD	100616-04	G247929	10/6/2016	25.00	35.770	894.25
5300467	Vibration Mount 10-32 Thread S	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	020211-01	00002521	9/22/2011	1.00	26.000	26.00
5300467	Vibration Mount 10-32 Thread S	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	100616-04	G247929	10/6/2016	12.00	35.770	429.24
5300467	Vibration Mount 10-32 Thread S	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	122115-01	G245646	12/21/2015	9.00	34.000	306.00
5300467	Vibration Mount 10-32 Thread S	RMD	Raw Material	Lot	EACH	598 F&R Service Parts	122215-01	G245647	12/22/2015	6.00	34.000	204.00
5300469	O-Ring, Size 014, Silicone 70	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		TRANSFR	2/1/2011	158.00	0.500	79.00
5300469	O-Ring, Size 014, Silicone 70	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		PHY CNT	12/21/2016	2.00	0.500	1.00
5300469	O-Ring, Size 014, Silicone 70	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts		TRANSFR	9/22/2011	28.00	0.500	14.00
5300472	Fine-Ject Needle, 18G x 1-1/2	RMT	Raw Material	Lot	EACH	200 200-QAQC- San Diego	14-14225	G250826	1/30/2019	600.00	0.036	21.60
5300472	Fine-Ject Needle, 18G x 1-1/2	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	14-13519	G248948	6/26/2017	862.00	0.100	86.20
5300472	Fine-Ject Needle, 18G x 1-1/2	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	14-12946	G246210	4/28/2016	272.00	0.060	16.32
5300475	Finishing Plug, 1/2 Threaded H	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		G246171	4/18/2016	902.00	0.079	70.83
5300475	Finishing Plug, 1/2 Threaded H	RMD	Raw Material	FIFO	EACH	205 205-Released Material-SD		0011096	8/8/2017	4.00	0.079	0.32
5300475	Finishing Plug, 1/2 Threaded H	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts		PHY CNT	12/18/2015	9.00	0.043	0.39
5300475	Finishing Plug, 1/2 Threaded H	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts		G246171	4/18/2016	50.00	0.079	3.93
5300475	Finishing Plug, 1/2 Threaded H	RMD	Raw Material	FIFO	EACH	598 F&R Service Parts		PHY CNT	12/14/2017	58.00	0.079	4.58
5300476	Drain Bag Assy, Puregraft 850	RMC	Raw Material	Lot	EACH	205 205-Released Material-SD			1/0/1900	0.00	0.000	0.00
5300497	Bench Pads	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	040816-02	G246133	4/8/2016	220.00	0.114	24.99
5300497	Bench Pads	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	040816-02	G246133	4/8/2016	80.00	0.114	9.09
5300498	Sterile Gauze 4" x 4"	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	041416-02	G246162	4/14/2016	1,120.00	0.188	211.01
5300498	Sterile Gauze 4" x 4"	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	041416-02	G246162	4/14/2016	80.00	0.188	15.07
5300499	Needles 25g x 5/8	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	091416-03	G247843	9/14/2016	100.00	0.032	3.20
5300500	GEMS 25 Gauge Cannula	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	50804BC	D0000054	10/6/2016	120.00	15.000	1,800.00
5300500	GEMS 25 Gauge Cannula	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	60401DE	PHYS COU	12/21/2016	145.00	15.000	2,175.00
5300500	GEMS 25 Gauge Cannula	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	60404CE	D0000054	10/6/2016	15.00	15.000	225.00
5300500	GEMS 25 Gauge Cannula	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	042516-01	G001984	4/26/2016	60.00	15.000	900.00
5300501	Pressure Bandages, Size M, 12	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	042816-01	G246215	4/28/2016	40.00	44.000	1,760.00
5300502	Pressure Bandages, Size L, 12	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	042816-02	G246215	4/28/2016	40.00	44.000	1,760.00
5300503	Pressure Bandages, Size XL, 12	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	042816-03	G246215	4/28/2016	40.00	44.000	1,760.00
5300504	Centrifuge Tube PoxGrid® 50mL	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	040816-03	G246133	4/8/2016	4.00	44.350	177.40
5300505	Micro-Centrifuge Tube Holder	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	042016-01	G246179	4/20/2016	20.00	16.808	336.16
5300505	Micro-Centrifuge Tube Holder	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	042016-01	G246179	4/20/2016	5.00	16.808	84.04
5300507	Reagent Micro-Dispenser	RMT	Raw Material	Serial	EACH	500 500-Fichtner & Ritschel	03L01567	G246146	4/12/2016	1.00	361.000	361.00
5300507	Reagent Micro-Dispenser	RMT	Raw Material	Serial	EACH	500 500-Fichtner & Ritschel	04N68024	G246146	4/12/2016	1.00	361.000	361.00
5300507	Reagent Micro-Dispenser	RMT	Raw Material	Serial	EACH	500 500-Fichtner & Ritschel	04N68025	G246146	4/12/2016	1.00	361.000	361.00
5300507	Reagent Micro-Dispenser	RMT	Raw Material	Serial	EACH	500 500-Fichtner & Ritschel	04N68039	G246146	4/12/2016	1.00	361.000	361.00
5300507	Reagent Micro-Dispenser	RMT	Raw Material	Serial	EACH	500 500-Fichtner & Ritschel	04N68040	G246146	4/12/2016	1.00	361.000	361.00
5300507	Reagent Micro-Dispenser	RMT	Raw Material	Serial	EACH	500 500-Fichtner & Ritschel	07L52039	G246146	4/12/2016	1.00	361.000	361.00
5300507	Reagent Micro-Dispenser	RMT	Raw Material	Serial	EACH	500 500-Fichtner & Ritschel	10L90307	00005316	4/28/2016	1.00	149.500	149.50
5300507	Reagent Micro-Dispenser	RMT	Raw Material	Serial	EACH	500 500-Fichtner & Ritschel	10L90310	00005316	4/28/2016	1.00	149.500	149.50
5300512	Disposable Toomey Cannula	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	091415-05	G247843	9/14/2016	10.00	36.000	360.00
5300512	Disposable Toomey Cannula	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	091416-04	G247843	9/14/2016	10.00	36.000	360.00
5300539-02	5ml Soft-Ject Syringe w/ Luer	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	18D23C8	G250097	7/26/2018	125.00	0.175	21.87
5300539-02	5ml Soft-Ject Syringe w/ Luer	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	16C21C8	G247864	9/21/2016	264.00	0.100	26.40
5300541	Sterile Syringe Cap, Luer Lock	RMT	Raw Material	Lot	PK10	205 205-Released Material-SD	2089237	00002975	11/6/2012	198.00	0.800	158.40
5300542	Microcentrifuge Tube, 1.5mL, S	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	E163471P	00005320	5/4/2016	250.00	0.421	105.25
5300542	Microcentrifuge Tube, 1.5mL, S	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	EE163471P	G246196	4/22/2016	0.00	0.421	0.30-
5300543	Needle Blunt 18 GA. x 1.5" Lon	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	3220317	00003491	12/4/2013	209.00	0.210	43.89
5300543	Needle Blunt 18 GA. x 1.5" Lon	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	5119670	G248321	1/23/2017	482.00	0.214	103.15
5300544-01	1 mL BD Syringe w/ Luer Lock	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	5295695	G246196	4/22/2016	1,576.00	0.406	639.86
5300544-01	1 mL BD Syringe w/ Luer Lock	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	5112928	G244774	7/15/2015	720.00	0.390	280.80
5300544-06	60 mL BD Syringe w/ Luer Lock	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	8054822	G250821	1/24/2019	550.00	0.735	404.52
5300545	Fluid Dispensing Connector	RMT	Raw Material	Lot	EACH	205 205-Released Material-SD	61481265	G246195	4/22/2016	517.00	1.370	708.29
5300545	Fluid Dispensing Connector	RMT	Raw Material	Lot	EACH	500 500-Fichtner & Ritschel	61328995	00003456	11/12/2013	160.00	1.230	196.80
5300546	Tubing Positioner	RMC	Raw Material	FIFO	EACH	205 205-Released Material-SD		G238099	12/26/2012	192.00	0.603	115.77
5300546	Tubing Positioner	RMC	Raw Material	FIFO	EACH	205 205-Released Material-SD		PHY CNT	12/19/2014	2.00	0.605	1.21
5300580	Sterile Syringe Tip Cap	RMT	Raw Material	Lot	PK10	205 205-Released Material-SD	122013-03	00003558	1/22/2014	350.00	0.450	157.50
5300581	Sleeve Handle, 7.34" x 0.79"	RMC	Raw Material	Lot	EACH	205 205-Released Material-SD	122013-01	00003530	12/23/2013	1,400.00	0.110	154.00
5300599	Duct Gasket	WPD	Raw Material	Lot	EACH	205 205-Released Material-SD						

EXHIBIT 2.02(a)(iii)-2

Estimated Consumable Inventory as of 3/25/19

SD	Germany	Japan	Total	
207		225	432	Fully finished, unpackaged
64			64	pending steril, centurium
336			336	pending steril, Centurium (NOT PAID FOR BY CYTORI)
14	16		30	Fully finished packaged
621	16	225	862	

Estimated Celase Inventory

SD	Germany	Japan	Total	
8,800	250	240	9,290	Multiple lots, split to be made by lots
8,800	250	240	9,290	

Estimated Intravase Inventory

SD	Germany	Japan	Total	
5,800	88	-	5,888	Multiple lots, split to be made by lots
5,800	88	-	5,888	

Estimated Devices - 3/25/19

	SD	Germany	Japan	Total	
New	2	13	10	25	2 sitting in final stage of WIP, new power supply work (in stock)
Used, on-site	20	7	1	28	Most of these need refurb, the one in JP is ready.
Used, offsite/loaner	5		2	7	Estimate
	27	20	13	60	

Estimated NucleoCounter - 3/25/19

	SD	Germany	Japan	Total	
New	-	4	2	6	
Used, on-site	19	2		21	
Used, offsite/loaner	2			2	Estimate
	21	6	2	29	

Proposed Split

Japan	ROW	
185	247	
27	37	
-	336	Lorem gets 100%, if it assumes the full payable.
13	17	
225	637	

Proposed Split

Japan	ROW	
450	8,840	Negotiated in exchange of escrow.
-	-	
-	-	
-	-	
450	8,840	

Proposed Split

Japan	ROW	
100	5,788	Negotiated in exchange of escrow.
-	-	
-	-	
-	-	
100	5,788	

Proposed Split

Japan	ROW	
11	14	
7	21	Negotiated in exchange of escrow.
3	4	
-	-	
21	39	

Proposed Split

Japan	ROW	
3	3	
7	14	Negotiated in exchange of escrow.
-	2	
-	-	
10	19	

EXHIBIT 2.02(a)(vi)(a)

Open Purchase Order Report

Sorted by Purchase Order Number

For Order Types: Standard Orders, Repeating Orders, Master

Currency: Base, As Posted, Entry Curr: TO ZZZZ
Cytori Therapeutics (MP2)

P.O. Number	Item Code/Description Vendor Number	U T	T C	Wh se	Required Date	U/ M	Ordered	Received	Backordered	Unit Cost	Original Unit Cost	Extension	
0204539	00-MAR: Marshall's Indust. Hardware			Ty	Standard	St Ho	Backorder No CA SDI	P.O. Last Receipt:	3/21/2018 6/22/2017		Required Date: Last Invoice:	3/21/2018 6/22/2017	Overall Development
	Comme				Tax								
	/BLANKET Misc Hardware Supplies Vendor BLANKET PO	Nc	NT		4/26/2018	EACH	7,000.00	2,093.72	4,906.28	1.000	1.000	4,906.28	
											Taxes	120.02-	
								Order 0204539 Total:				4,786.26	No risk
0211249	00-MOLI Molecular Devices LLC			Ty	Standard	St Ho	Backorder No CA SDI	P.O. Last Receipt:	2/1/2018 3/15/2018		Required Date: Last Invoice:	2/7/2018 3/9/2018	Development
	Comme				Tax								
	/ITEM Plate Reader IQOQ Service	Nc	NT		1/29/2018	EACH	1.00	0.00	1.00	4,279.000	4,279.000	4,279.00	
								Order 0211249 Total:				4,279.00	John - do we need to do?
0211269	00-PRU Prudential Overall Supply			Ty	Standard	St Ho	Backorder No CA SDI	P.O. Last Receipt:	3/1/2018 10/30/2018		Required Date: Last Invoice:	3/1/2018 4/2/2018	Being cancelled, final invoice pending of approx \$1000 Lab coats
	Comme				Tax								
	/BLANKET ESD Coats/Warehouse Mat	Nc	NT		3/4/2018	EACH	2,500.00	2,424.07	75.93	1.000	1.000	75.93	
								Order 0211269 Total:				75.93	No risk
0211284	00-FLIC Flintshire County Council			Ty	Standard	St Ho	Backorder No CA SDI	P.O. Last Receipt:	3/20/2018 12/28/2018		Required Date: Last Invoice:	3/23/2018	UK taxes/bills
	Comme				Tax								
	/MISC2 UK Property and Premise Tax	Nc	NT		3/20/2018	EACH	10.00	10.00	0.00	1,830.680	1,830.680	0.00	
								Order 0211284 Total:				0.00	
0211336	00-NAM: NAMSA			Ty	Standard	St Ho	Open No CA SDI	P.O. Last Receipt:	5/21/2018		Required Date: Last Invoice:	5/21/2018	Development needed for ongoing device changes.
	Comme				Tax								
	/MISC2 ISO-10993-18 Chem Char Testin Estimated total cost based on current testing protocol. Attached proposal illustrates the per sample	Nc	NT		5/13/2018	EACH	16.00	0.00	0.00	3,085.000	3,085.000	49,360.00	
								Order 0211336 Total:				49,360.00	
0211373	00-SHA: Sharon James			Ty	Standard	St Ho	Backorder No CA SDI	P.O. Last Receipt:	6/25/2018 12/11/2018		Required Date: Last Invoice:	6/25/2018	UK consultant
	Comme				Tax								
	/BLANKET UK Consultant WHSE	Nc	NT		6/30/2018	EACH	2,500.00	2,500.00	0.00	1.000	1.000	0.00	
								Order 0211373 Total:				0.00	
0211377	00-OCSI Occupational Services, Inc.			Ty	Standard	St Ho	Backorder No	P.O. Last Receipt:	6/27/2018 10/10/2018		Required Date: Last Invoice:	6/27/2018 10/1/2018	Facility Safety

Comme			Tax	CA SDI						
/BLANKET training, audits, permitting training, audits, permitting, etc.	Nc NT	6/30/2018	EACH	1,000.00	481.25	518.75	1.000	1.000	518.75	
Order 0211377 Total:									518.75	
0211390 00-IDSI Integrated Digital Service	Ty	Standard	St Ho	Backorder No	P.O. Last Receipt:	7/19/2018 11/27/2018	Required Date: Last Invoice:	7/23/2018		UK - Phone/Internet Service
Comme			Tax	CA SDI						
/BLANKET BLANKET	Nc NT	7/22/2018	EACH	2,500.00	1,762.94	737.06	1.000	1.000	737.06	
Order 0211390 Total:									737.06	
0211406 00-ANM/ Anmar Metrology, Inc. (Trans	Ty	Standard	St Ho	Backorder No	P.O. Last Receipt:	8/3/2018 12/20/2018	Required Date: Last Invoice:	8/3/2018 12/12/2018		Calibration of Manuf Equipment
Comme			Tax	CA SDI						
/BLANKET Calibration Services	Nc NT	8/6/2018	EACH	1,500.00	886.10	613.90	1.000	1.000	613.90	
Order 0211406 Total:									613.90	
0211428 00-IRON Iron Mountain	Ty	Standard	St Ho	Backorder No	P.O. Last Receipt:	8/22/2018 3/14/2019	Required Date: Last Invoice:	8/22/2018 2/28/2019		SECURY CODE- Data/Record management
Comme			Tax	CA SDI						
/BLANKET BLANKET	Nc NT	8/19/2018	EACH	5,000.00	3,895.47	1,104.53	1.000	1.000	1,104.53	
Order 0211428 Total:									1,104.53	
0211438 00-OPUI Opus Energy Ltd	Ty	Standard	St Ho	Backorder No	P.O. Last Receipt:	9/4/2018 3/14/2019	Required Date: Last Invoice:	9/7/2018		UK Electricity
Comme			Tax	CA SDI						
/BLANKET UK Electric	Nc NT	8/28/2018	EACH	500.00	238.88	261.12	1.000	1.000	261.12	
Order 0211438 Total:									261.12	
0211439 00-INTU Intertek Testing Service N.A.	Ty	Standard	St Ho	New No	P.O. Last Receipt:	9/4/2018	Required Date: Last Invoice:	9/7/2018		Device testing compliance
Comme			Tax	CA SDI						
/BLANKET Testing 4th Edition	Nc NT	8/29/2018	EACH	23,800.00	0.00	0.00	1.000	1.000	23,800.00	
Order 0211439 Total:									23,800.00	
0211440 00-DE Michael DeEmedio	Ty	Standard	St Ho	Backorder No	P.O. Last Receipt:	9/4/2018 10/26/2018	Required Date: Last Invoice:	9/7/2018 10/24/2018		Consultant/Tech support
Comme			Tax	CA SDI						
/BLANKET	Nc NT	9/1/2018	EACH	10,000.00	8,080.00	1,920.00	1.000	1.000	1,920.00	
Order 0211440 Total:									1,920.00	
0211445 00-ACOI Acorn Industries, Inc.	Ty	Standard	St Ho	Backorder No	P.O. Last Receipt:	9/13/2018 10/25/2018	Required Date: Last Invoice:	9/13/2018 10/23/2018		Product WIP
Comme			Tax	CA SDI						
CLEANING 1600006 Micro Chamber Shaft	Nc NT	209/16/2018	EACH	500.00	499.00	1.00	7.450	7.450	7.45	
CLEANING NVR Lot Testing	Nc NT	209/16/2018	EACH	1.00	1.00	0.00	Invoice 120.000	499.00 120.000	0.00	
Invoice								1.00		

CLEANING Particle Lot Count	Nc NT 209/16/2018	EACH	1.00	1.00	0.00	80.000	80.000	0.00		
Order 0211445 Total:									7.45	
0211489 00-LABC LabConnect, LLC	Ty Standard	St Backorder Ho No CA SDI		P.O. 10/19/2018 Last Receipt: 10/19/2018		Required Date: 10/19/2018 Last Invoice: 10/16/2018				Barda Related
Comme	Tax									
/BLANKET BLANKET	Nc NT 10/21/2018	EACH	92,160.00	17,675.00	74,485.00	1.000	1.000	74,485.00		
Order 0211489 Total:									74,485.00	
0211500 00-COA Viant San Antonio, Inc. (Vian	Ty Standard	St Backorder Ho No CA SDI		P.O. 10/30/2018 Last Receipt: 3/26/2019		Required Date: 10/30/2018 Last Invoice: 3/15/2019				
Comme	Tax									
1553406-JJ Molded Consumable Set Intermex 1st Deliv. 350 sets 03/15/19, 2nd Deliv 350 sets 04/15/2019, 3rd Deliv. 05/16/2019	Nc NT 202/15/2019	EACH	1,000.00	564.00	436.00	385.313	385.310	167,996.47		
Order 0211500 Total:									167,996.47	
0211515 00-PRU Prudential Overall Supply	Ty Standard	St Backorder Ho No CA SDI		P.O. 11/2/2018 Last Receipt: 3/14/2019		Required Date: 11/2/2018 Last Invoice: 3/11/2019				ESD coats
Comme	Tax									
/BLANKET ESD Coats/Warehouse Mat	Nc NT 11/3/2018	EACH	2,500.00	1,493.99	1,006.01	1.000	1.000	1,006.01		
Order 0211515 Total:									1,006.01	
0211516 00-AMA Amazon.com, Inc.	Ty Standard	St New Ho No CA SDI		P.O. 11/2/2018 Last Receipt:		Required Date: 11/2/2018 Last Invoice:				Barda Related
Comme	Tax									
/ITEM Polar Bear Coolers 12 Pack Sof	Nc NT 11/7/2018	EACH	4.00	0.00	0.00	66.990	66.990	267.96		
Order 0211516 Total:									267.96	
0211548 00-INTU Intertek Testing Service N.A.	Ty Standard	St Backorder Ho No CA SDI		P.O. 11/29/2018 Last Receipt: 1/15/2019		Required Date: 12/4/2018 Last Invoice: 1/4/2019				Device testing/compliance
Comme	Tax									
/ITEM Quaterly Certification	Nc NT 11/24/2018	EACH	4.00	1.00	3.00	800.000	800.000	2,400.00		
/ITEM Direct Imprint	Nc NT 11/24/2018	EACH	4.00	1.00	3.00	200.000	200.000	600.00		
Order 0211548 Total:									3,000.00	
0211557 00-WES Westpak, Inc.	Ty Standard	St New Ho No CA SDI		P.O. 12/5/2018 Last Receipt:		Required Date: 12/5/2018 Last Invoice:				Development - MSF Label Testing
Comme	Tax									
/ITEM Accelerated Aging	Nc NT 12/9/2018	EACH	1.00	0.00	0.00	560.000	560.000	560.00		
/ITEM Visual Inspection	Nc NT 12/9/2018	EACH	1.00	0.00	0.00	175.000	175.000	175.00		
/ITEM Test Report	Nc NT 12/9/2018	EACH	1.00	0.00	0.00	0.000	0.000	0.00		
Order 0211557 Total:									735.00	
0211568 00-SHA Sharon James	Ty Standard	St Backorder Ho No		P.O. 12/11/2018 Last Receipt: 3/14/2019		Required Date: 12/11/2018 Last Invoice:				UK Consultant

Comme			Tax	CA SDI						
/BLANKET	Nc NT	12/15/2018	EACH	2,500.00	1,458.78	1,041.22	1.000	1.000	1,041.22	
UK Consultant WHSE										
Order 0211568 Total:									1,041.22	
0211570	00-HENI	Ty	Standard	St New	P.O.	12/13/2018	Required Date:	12/19/2018		
	Henke - Sass - Wolf			Ho No	Last Receipt:		Last Invoice:			Celbrush - Ancillary
Comme			Tax	CA SDI						
5200310	Nc NT	203/20/2018	EACH	100.00	0.00	0.00	245.000	245.000	24,500.00	
Handle Assembly, Celbrush										
5200309	Nc NT	203/20/2018	EACH	100.00	0.00	0.00	89.700	89.700	8,970.00	
Adapter, Celbrush										
5200325	Nc NT	203/20/2018	EACH	100.00	0.00	0.00	98.300	98.300	9,830.00	
10 mL Rack Assembly, Celbrush										
Order 0211570 Total:									43,300.00	
0211571	00-COA	Ty	Standard	St Backorder	P.O.	12/13/2018	Required Date:	12/19/2018		
	Viant San Antonio, Inc. (Vian			Ho No	Last Receipt:	1/22/2019	Last Invoice:	1/17/2019		
Comme			Tax	CA SDI						
/BLANKET	Nc NT	12/15/2018	EACH	5,000.00	1,236.00	3,764.00	1.000	1.000	3,764.00	
Service Items for Cytori Equip										
Order 0211571 Total:									3,764.00	
0211578	00-CAR	Ty	Standard	St New	P.O.	12/21/2018	Required Date:	12/21/2018		
	Cardinal Health 200, LLC			Ho No	Last Receipt:		Last Invoice:			Product related, FULLY PREPAID, not received
Comme			Tax	CA SDI						
5300453	Nc NT	202/15/2019	EACH	50,040.00	0.00	0.00	1.350	1.350	67,554.00	
Toomey Syringe, 60ml, Blister										
Order 0211578 Total:									67,554.00	
0211579	00-APP	Ty	Standard	St Backorder	P.O.	12/21/2018	Required Date:	12/21/2018		
	Stericycle, Inc. (Stericycle C			Ho No	Last Receipt:	3/7/2019	Last Invoice:	3/6/2019		Corporate - Answering service
Comme			Tax	CA SDI						
/BLANKET	Nc NT	12/23/2018	EACH	1,800.00	415.58	1,384.42	1.000	1.000	1,384.42	
							Order 0211579 Total:		1,384.42	
0211588	00-CALC	Ty	Standard	St New	P.O.	1/4/2019	Required Date:	1/8/2019		
	GL Technologies, LLC			Ho No	Last Receipt:		Last Invoice:			Equipment Calibration
Comme			Tax	CA SDI						
/BLANKET	Nc NT	1/8/2019	EACH	3,500.00	0.00	0.00	1.000	1.000	3,500.00	
BLANKET										
Order 0211588 Total:									3,500.00	
0211602	00-DE	Ty	Standard	St Backorder	P.O.	1/22/2019	Required Date:	1/24/2019		
	Michael DeEmedio			Ho No	Last Receipt:	2/28/2019	Last Invoice:	2/26/2019		
Comme			Tax	CA SDI						
/BLANKET	Nc NT	1/22/2019	EACH	20,000.00	6,390.00	13,610.00	1.000	1.000	13,610.00	
BLANKET										
Order 0211602 Total:									13,610.00	
0211624	00-VWR	Ty	Standard	St Backorder	P.O.	2/8/2019	Required Date:	2/8/2019		
	VWR International, Inc.			Ho No	Last Receipt:	2/22/2019	Last Invoice:	2/14/2019		Barda Related
Comme	statements@vwr.com FAX484-881-		Tax Schedule:	CA SDI						

/ITEM 20012123 - Collection Needle VT-368607	Nc NT	2/11/2019	EACH	5.00	5.00	0.00	14.400	14.400	0.00	
/ITEM 20012125 - Serum Tube BD367986	Nc NT	2/11/2019	EACH	2.00	2.00	0.00	22.960	22.960	0.00	
/ITEM 20012126 - Pipette 103575-124	Nc NT	2/11/2019	EACH	1.00	1.00	0.00	78.200	78.200	0.00	
/ITEM 20012127 - Cryo Vial 66008-708	Nc NT	2/11/2019	EACH	2.00	0.00	2.00	210.420	210.420	420.84	
/ITEM 20012128 - Cyro Box 66008-714	Nc NT	2/11/2019	EACH	2.00	2.00	0.00	82.200	82.200	0.00	
Order 0211624 Total:									420.84	
0211630 00-ABSC Absorption Systems Californ	Ty	Standard	St Ho	New No		P.O. Last Receipt:	2/8/2019	Required Date: Last Invoice:	2/12/2019	Barda Related
Comme		Tax	CA	SDI						
/MISC2 (Fill in : P/N, Description) Fixed Fee \$750	Nc NT	2/11/2019	EACH	1.00	0.00	0.00	750.000	750.000	750.00	
Order 0211630 Total:									750.00	
0211641 00-ACOI Acorn Industries, Inc.	Ty	Standard	St Ho	New No		P.O. Last Receipt:	2/20/2019	Required Date: Last Invoice:	3/1/2019	Product Cleaning
Comme		Tax	CA	SDI						
CLEANING 1600006 Micro Chamber Shaft	Nc NT	202/18/2019	EACH	1,000.00	0.00	0.00	8.000	8.000	8,000.00	
CLEANING Lot Testing	Nc NT	202/18/2019	EACH	1.00	0.00	0.00	250.000	250.000	250.00	
Order 0211641 Total:									8,250.00	
0211646 00-COA Viant San Antonio, Inc. (Vian	Ty	Standard	St Ho	New No		P.O. Last Receipt:	2/21/2019	Required Date: Last Invoice:	3/1/2019	
Comme		Tax	CA	SDI						
/ITEM Service, Replace Spru bushing Replace sprue bushing on Canister Bottom Mold at Balda	Nc NT	2/26/2019	EACH	1.00	0.00	0.00	3,250.000	3,250.000	3,250.00	
Order 0211646 Total:									3,250.00	
0211665 00-ANAE ANAEROBE SYSTEM	Ty	Standard	St Ho	Backorder No		P.O. Last Receipt:	3/8/2019 3/26/2019	Required Date: Last Invoice:	3/11/2019 3/11/2019	Barda Related
Comme		Tax	CA	SDI						
/BLANKET	Nc NT	3/6/2019	EACH	150.00	36.81	113.19	1.000	1.000	113.19	
Order 0211665 Total:									113.19	
0211674 00-IOG S&G Global Holdings, Inc.	Ty	Standard	St Ho	New No		P.O. Last Receipt:	3/26/2019	Required Date: Last Invoice:	3/26/2019	Label for product
Comme		Tax	CA	SDI						

3100033	Nc NT 203/20/2019	EACH	1,100.00	0.00	0.00	0.591	0.591	650.10
Label Template, Celase Vial								
3100033 Rev C								
Vendor	LABEL #8					Invoice	0.00	
3100034	Nc NT 203/20/2019	EACH	1,100.00	0.00	0.00	0.724	0.724	796.40
Label Template, Celase Caniste								
3100034 Rev C								
Vendor	LABEL #8					Invoice	0.00	
3100035	Nc NT 203/20/2019	EACH	1,100.00	0.00	0.00	0.591	0.591	650.10
Label Template, Intravase Vial								
Vendor	LABEL #8					Invoice	0.00	
Order 0211674 Total:								2,096.60
0211689	00-CENT	Ty Standard	St New		P.O.	3/26/2019	Required Date:	3/26/2019
Comme	Centurion Sterilization Serv		Ho No		Last Receipt:		Last Invoice:	
		Tax	CA SDI					
STERILIZATION	Nc NT 203/25/2019	EACH	1.00	0.00	0.00	1,531.200	1,531.200	1,531.20
Sterilization - Production Ser								
Order 0211689 Total:								1,531.20
0211691	00-FLIC	Ty Standard	St Backorder		P.O.	3/26/2019	Required Date:	3/26/2019
Comme	Flintshire County Council		Ho No		Last Receipt:	3/26/2019	Last Invoice:	
		Tax	CA SDI					
/MISC2	Nc NT 3/19/2019	EACH	10.00	1.00	9.00	1,766.750	1,766.750	15,900.75
UK Property and Premise Tax								
Order 0211691 Total:								15,900.75
Total								501,420.658

EXHIBIT 2.02(a)(viii)

CYTORI THERAPEUTICS INC.**Patent Status Report
as of March 7, 2019**

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9673PR	CYTH.001PR	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	US	Closed	60/462911	4/15/2003			
MA9673AU	CYTH.001VAU	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	AU	Issued	2004213858	2/20/2004	2004213858	5/7/2009	2/20/2024
MA9673EP	CYTH.001VBE	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	AU	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024
MA9673BR	CYTH.001VBR	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	BR	Published	PI0407694-0	2/20/2004			
MA9673CA	CYTH.001VCA	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	CA	Issued	2516510	2/20/2004	2516510	7/10/2012	2/20/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9673EP	CYTH.001VCH	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	CH	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024
MA9673CN	CYTH.001VCN	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	CN	Issued	2.0048E+11	2/20/2004	ZL 200480010610.4	12/29/2010	2/20/2024
MA9673EP	CYTH.001VCZ	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	CZ	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024
MA9673EP	CYTH.001VDE	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	DE	Issued	4713403.6	2/20/2004	6.02004E+11	9/14/2011	2/20/2024
MA9673EPDIV1	CYTH.001VDED1	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	DE	Issued	11180767.3	2/20/2004	60 2004 050 659.1	1/11/2017	2/20/2024
MA9673EP	CYTH.001VDK	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	DK	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9673EP	CYTH.001VEP	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	EP	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024
MA9673EPDIV1	CYTH.001VEPD1	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	EP	Issued	11180767.3	2/20/2004	2422622	1/11/2017	2/20/2024
MA9673EP	CYTH.001VES	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	ES	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024
MA9673EP	CYTH.001VFR	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	FR	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024
MA9673EPDIV1	CYTH.001VFRD1	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	FR	Issued	11180767.3	2/20/2004	2422622	1/11/2017	2/20/2024
MA9673EP	CYTH.001VGB	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	GB	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9673EPDIV1	CYTH.001VGBD1	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	GB	Issued	11180767.3	2/20/2004	2422622	1/11/2017	2/20/2024
MA9673HK	CYTH.001VHK	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	HK	Issued	7106854.5	2/20/2004	HK1102085	11/4/2011	2/20/2024
MA9673EP	CYTH.001VIE	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	IE	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024
MA9673IL	CYTH.001VIL	USE OF ADIPOSE TISSUE-DERIVED CELLS IN THE PREPARATION OF A COMPOSITION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	IL	Issued	170354	2/20/2004	170354	11/1/2011	2/20/2024
MA9673ILDIV1	CYTH.001VILD1	USE OF ADIPOSE TISSUE-DERIVED CELLS IN THE PREPARATION OF A COMPOSITION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES	IL	Issued	214373	2/20/2004	214373	12/31/2014	2/20/2024
MA9673IN	CYTH.001VIN	AN AUTOMATED CELL PROCESSING DEVICE FOR ISOLATING ADIPOSE-DERIVED REGENERATIVE CELLS FROM ADIPOSE TISSUE	IN	ABA Intent	2332/CHENP/2005	2/20/2004	230706	2/27/2009	2/20/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9673EP	CYTH.001VIT	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	IT	Issued	4713403.6	2/20/2004	5.02012E+14	9/14/2011	2/20/2024
MA9673KR	CYTH.001VKR	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	KR	Issued	10-2005-7015336	2/20/2004	10-1310578	9/12/2013	2/20/2024
MA9673KRDIV1	CYTH.001VKRD1	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	KR	Abandoned	10-2012-7005073	2/20/2004			
MA9673EP	CYTH.001VMC	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	MC	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024
MA9673MX	CYTH.001VMX	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	MX	Issued	PA/a/2005/009044	2/20/2004	279775	10/6/2010	2/20/2024
MA9673EP	CYTH.001VNL	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	NL	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9673PCT	CYTH.001VPC	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	WO	Closed	PCT/US2004/005117	2/20/2004			
MA9673RU	CYTH.001VRU	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	RU	Issued	2005128964	2/20/2004	2372924	11/20/2009	2/20/2024
MA9673EP	CYTH.001VSE	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	SE	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024
MA9673SG	CYTH.001VSG	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	SG	Issued	200505359-0	2/20/2004	114309	4/30/2008	2/20/2024
MA9673EP	CYTH.001VSK	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	SK	Issued	4713403.6	2/20/2004	1599575	9/14/2011	2/20/2024
MA9673ZA	CYTH.001VZA	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	ZA	Issued	2005/07446	2/20/2004	2005/07446	4/25/2007	2/20/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9673EPOPP	CYTH.001ZPEP	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	EP	Unfiled					
MA9658P	CYTH.002A	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	US	Abandoned	10/316127	12/9/2002			
MA9658C1	CYTH.002C1	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	US	Issued	11/584202	10/20/2006	7687059	3/30/2010	1/13/2024
MA9658DIV4CON4	CYTH.002C5	ADIPOSE-DERIVED REGENERATIVE CELLS FOR TREATING LIVER INJURY	US	Issued	13/725814	12/21/2012	9198937	12/1/2015	4/20/2023
MA9658DIV4CON5	CYTH.002C6	ADIPOSE-DERIVED REGENERATIVE CELLS FOR TREATING LIVER INJURY	US	Abandoned	14/954584	11/30/2015			
MA9658DIV4CON5	CYTH.002C7	ADIPOSE-DERIVED REGENERATIVE CELLS FOR TREATING LIVER INJURY	US	Abandoned	15/844091	12/15/2017			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9673P	CYTH.002CP1	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	US	Abandoned	10/783957	2/20/2004			
MA9795P	CYTH.002CP10	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF STROKE AND RELATED DISEASES AND DISORDERS	US	Abandoned	10/884861	7/1/2004			
MA9796P	CYTH.002CP11	SYSTEMS AND METHODS FOR ISOLATING AND USING CLINICALLY SAFE ADIPOSE DERIVED REGENERATIVE CELLS	US	Issued	10/884638	7/2/2004	7585670	9/8/2009	1/13/2024
MA9796DIV1	CYTH.002CP11DV1	SYSTEMS AND METHODS FOR ISOLATING AND USING CLINICALLY SAFE ADIPOSE DERIVED REGENERATIVE CELLS	US	Issued	12/554755	9/4/2009	8163276	4/24/2012	12/9/2022
MA9673C1	CYTH.002CP1C1	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	US	Abandoned	12/414582	3/30/2009			
MA9684P	CYTH.002CP2	SYSTEMS AND METHODS FOR SEPARATING AND CONCENTRATING REGENERATIVE CELLS FROM TISSUE	US	Issued	10/877822	6/25/2004	7514075	4/7/2009	1/13/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9685P	CYTH.002CP3	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	US	Issued	10/871503	6/18/2004	7651684	1/26/2010	1/13/2024
MA9685DIV1	CYTH.002CP3DV1	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	US	Issued	12/694103	1/26/2010	8246947	8/21/2012	12/9/2022
MA9778P	CYTH.002CP4	METHOD FOR PROCESSING AND USING ADIPOSE-DERIVED STEM CELLS	US	Issued	10/885293	7/1/2004	7595043	9/29/2009	1/13/2024
MA9778DIV1	CYTH.002CP4DV1	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	US	Abandoned	12/568533	9/28/2009			
MA9790P	CYTH.002CP5	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	US	Issued	10/884637	7/1/2004	7771716	8/10/2010	1/13/2024
MA9790DIV1	CYTH.002CP5DV1	METHODS OF USING ADIPOSE DERIVED REGENERATIVE CELLS TO PROMOTE RESTORATION OF INTEVERTEBRAL DISC	US	Issued	12/853110	8/9/2010	9504716	11/29/2016	12/9/2022

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9791P	CYTH.002CP6	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF RENAL DISEASES AND DISORDERS	US	Issued	10/884639	7/1/2004	8404229	3/26/2013	6/6/2026
MA9792P	CYTH.002CP7	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF INHERITED AND ACQUIRED DISORDERS OF THE BONE, BONE MARROW, LIVER AND	US	Abandoned	10/885294	7/1/2004			
MA9793P	CYTH.002CP8	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	US	Issued	10/884860	7/1/2004	8105580	1/31/2012	12/9/2022
MA9794P	CYTH.002CP9	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	US	Abandoned	10/884871	7/1/2004			
MA9794C1	CYTH.002CP9C1	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	US	Abandoned	12/494211	6/29/2009			
MA9658DIV4CON3	CYTH.002D4C3	METHODS OF MAKING ENHANCED, AUTOLOGOUS FAT GRAFTS	US	Issued	13/042334	3/7/2011	8337834	12/25/2012	12/9/2022

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9658DIV1	CYTH.002DV1	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	US	Issued	10/614431	7/7/2003	7473420	1/6/2009	1/13/2024
MA9658DIV2	CYTH.002DV2	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	US	Issued	10/614392	7/7/2003	7501115	3/10/2009	1/13/2024
MA9658DIV3	CYTH.002DV3	SELF-CONTAINED ADIPOSE DERIVED STEM CELL PROCESSING UNIT	US	Issued	10/614644	7/7/2003	7390484	6/24/2008	5/22/2024
MA9658DIV4	CYTH.002DV4	AUTOLOGOUS ADIPOSE TISSUE IMPLANT WITH CONCENTRATED STEM CELLS	US	Issued	10/614648	7/7/2003	8119121	2/21/2012	12/9/2022
MA9658DIV4C1	CYTH.002DV4C1	METHODS OF MAKING ENHANCED, AUTOLOGOUS FAT GRAFTS	US	Issued	12/886353	9/20/2010	7901672	3/8/2011	12/9/2022
MA9658DIV4C2	CYTH.002DV4C2	METHODS OF MAKING ENHANCED, AUTOLOGOUS FAT GRAFTS	US	Issued	12/886341	9/20/2010	7887795	2/15/2011	12/9/2022

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9658DIV5	CYTH.002DV5	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	US	Issued	10/614643	7/7/2003	7429488	9/30/2008	1/13/2024
MA9795CON1	CYTH.002P10C1	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF STROKE AND RELATED DISEASES AND DISORDERS	US	Issued	13/586735	8/15/2012	9511094	12/6/2016	7/2/2023
MA9796CON2	CYTH.002P11C2	SYSTEMS AND METHODS FOR ISOLATING AND USING CLINICALLY SAFE ADIPOSE DERIVED REGENERATIVE CELLS	US	Issued	13/452349	4/20/2012	8883499	11/11/2014	12/9/2022
MA9796CON2	CYTH.002P11C3	SYSTEMS AND METHODS FOR ISOLATING AND USING CLINICALLY SAFE ADIPOSE DERIVED REGENERATIVE CELLS	US	Abandoned	14/537724	11/10/2014			
MA9796CON4	CYTH.002P11C4	SYSTEMS FOR ISOLATING AND USING CLINICALLY SAFE ADIPOSE DERIVED REGENERATIVE CELLS	US	Issued	14/880891	10/12/2015	10119113	11/6/2018	12/9/2022
MA9685CON1	CYTH.002P3C1	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	US	Issued	13/588989	8/17/2012	8771678	7/8/2014	12/9/2022

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9889P	CYTH.002P3C2	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	US	Abandoned	15/462643	3/17/2017			
MA9778CON1	CYTH.002P4C1	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	US	Abandoned	13/598203	8/29/2012			
MA9778CON2	CYTH.002P4C2	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	US	Abandoned	15/366924	12/1/2016			
MA9778CON3	CYTH.002P4C3	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	US	Abandoned	15/833813	12/6/2017			
MA9790DIV1	CYTH.002P5C1	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	US	Abandoned	15/362713	11/28/2016			
MA9790DIV1	CYTH.002P5C2	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	US	Abandoned	15/846950	12/19/2017			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9790DIV2	CYTH.002P5D2	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	US	Issued	14/462392	8/18/2014	9463203	10/11/2016	12/9/2022
MA9791CON1	CYTH.002P6C1	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF RENAL DISEASES AND DISORDERS	US	Issued	13/849900	3/25/2013	9504718	11/29/2016	12/9/2022
MA9791CON2	CYTH.002P6C2	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF RENAL DISEASES AND DISORDERS	US	Abandoned	15/362249	11/28/2016			
MA9793CON1	CYTH.002P8C1	METHODS OF USING REGENERATIVE CELLS TO PROMOTE EPITHELIALIZATION OR NEODERMIS FORMATION	US	Issued	15/203684	7/6/2016	9872877	1/23/2018	12/9/2022
MA9793DIV1	CYTH.002P8D1	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	US	Issued	13/360022	1/27/2012	8691216	4/8/2014	12/9/2022
MA9793DIV2	CYTH.002P8D2	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	US	Issued	14/180589	2/14/2014	9492483	11/15/2016	12/9/2022

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9793DIV3	CYTH.002P8D3	METHODS OF USING REGENERATIVE CELLS TO TREAT AN ISCHEMIC WOUND	US	Issued	14/180553	2/14/2014	9511096	12/6/2016	12/9/2022
MA9793CON1	CYTH.002P8D4	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	US	Abandoned	15/877324	1/22/2018			
MA9794CON2	CYTH.002P9C2	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	US	Abandoned	13/296075	11/14/2011			
MA9794CON3	CYTH.002P9C3	METHODS OF USING ADIPOSE-DERIVED REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	US	Issued	13/587700	8/16/2012	9480718	11/1/2016	3/16/2023
MA9794CON4	CYTH.002P9C4	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF ERECTILE DYSFUNCTION	US	Issued	14/567937	12/11/2014	9849149	12/26/2017	6/17/2023
MA9794CON4	CYTH.002P9C5	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	US	Abandoned	15/847709	12/19/2017			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9843CON2	CYTH.002Q12C3	DEVICES AND METHODS FOR MONITORING, MANAGING, AND SERVICING MEDICAL DEVICES	US	Abandoned	14/629305	2/23/2015			
MA9889AU	CYTH.002Q3AU	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	AU	Issued	2005332046	5/25/2005	2005332046	8/29/2013	5/25/2025
MA9889AUDIV1	CYTH.002Q3AUD1	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	AU	Issued	2013216683	8/16/2013	2013216683	10/6/2016	5/25/2025
MA9889EP	CYTH.002Q3BE	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	BE	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
MA9889CA	CYTH.002Q3CA	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	CA	Issued	2609361	5/25/2005	2609361	11/14/2017	5/25/2025
MA9889EP	CYTH.002Q3CH	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	CH	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9889CN	CYTH.002Q3CN	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	CN	Abandoned	2.0058E+11	5/25/2005			
MA9889CNDIV1	CYTH.002Q3CND1	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	CN	Abandoned	2.0121E+11	7/27/2012			
	CYTH.002Q3CND2	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	CN	Closed					
MA9889EP	CYTH.002Q3CZ	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	CZ	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
MA9889EP	CYTH.002Q3DE	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	DE	Issued	5754073.4	5/25/2005	60 2005 026 724.7	3/2/2011	5/25/2025
MA9889EP	CYTH.002Q3DK	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	DK	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9889EP	CYTH.002Q3EP	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	EP	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
MA9889EPDIV1	CYTH.002Q3EPD1	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	EP	ABA Intent	11152868.3	5/25/2005	2465923	4/11/2018	5/25/2025
MA9889EP	CYTH.002Q3ES	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	ES	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
MA9889EP	CYTH.002Q3FR	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	FR	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
MA9889EP	CYTH.002Q3GB	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	GB	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
MA9889HK	CYTH.002Q3HK	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	HK	Abandoned	9111059.6	5/25/2005			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
	CYTH.002Q3HKD1	METHOD OF CURING CARDIOVASCULAR DISEASES BY USING CELLS FROM ADIPOSE TISSUE	HK	Abandoned	13107964.2	7/8/2013			
MA9889EP	CYTH.002Q3IT	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	IT	Issued	5754073.4	5/25/2005	5.02012E+14	3/2/2011	5/25/2025
MA9889KR	CYTH.002Q3KR	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	KR	Issued	10-2007-7030170	5/25/2005	10-1278437	6/18/2013	5/25/2025
MA9889KRDIV1	CYTH.002Q3KRD1	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	KR	Issued	10-2013-7005581	3/4/2013	10-1400544	5/21/2014	5/25/2025
MA9889EP	CYTH.002Q3LU	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	LU	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
MA9889EP	CYTH.002Q3MC	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	MC	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9889EP	CYTH.002Q3NL	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	NL	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
MA9889PCT	CYTH.002Q3PC	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	WO	Closed	PCT/US2005/018605	5/25/2005			
MA9889EP	CYTH.002Q3PL	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	PL	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
MA9889EP	CYTH.002Q3SE	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	SE	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
MA9889EP	CYTH.002Q3SK	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	SK	Issued	5754073.4	5/25/2005	1885382	3/2/2011	5/25/2025
MA9889EPOPP	CYTH.002Q3ZEP	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	EP	Closed	5754073.4	5/25/2004	1885382	3/2/2011	

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9778EPDIV1	CYTH.002Q5ATD1	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	AT	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024
MA9778AU	CYTH.002Q5AU	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	AU	Abandoned	2004318008	7/1/2004			
MA9778EPDIV1	CYTH.002Q5BED1	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	BE	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024
MA9778BR	CYTH.002Q5BR	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	BR	Abandoned	PI0418662-1	7/1/2004			
MA9778CA	CYTH.002Q5CA	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	CA	Abandoned	2560052	7/1/2004			
MA9778EPDIV1	CYTH.002Q5CHD1	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	CH	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9778EP	CYTH.002Q5DE	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	DE	Issued	4756624.5	7/1/2004	60 2004 044 686.6	3/26/2014	7/1/2024
MA9778EPDIV1	CYTH.002Q5DED1	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	DE	Issued	12193602.5	11/21/2012	60 2004 049 813.0	8/17/2016	7/1/2024
MA9778EPDIV1	CYTH.002Q5DKD1	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	DK	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024
MA9778EP	CYTH.002Q5EP	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	EP	Issued	4756624.5	7/1/2004	1743021	3/26/2014	7/1/2024
MA9778EPDIV1	CYTH.002Q5EPD1	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	EP	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024
MA9778EPDIV1	CYTH.002Q5ESD1	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	ES	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9778EPDIV1	CYTH.002Q5FID1	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	FI	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024
MA9778EP	CYTH.002Q5FR	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	FR	Issued	4756624.5	7/1/2004	1743021	3/26/2014	7/1/2024
MA9778EPDIV1	CYTH.002Q5FRD1	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	FR	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024
MA9778EP	CYTH.002Q5GB	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	GB	Issued	4756624.5	7/1/2004	1743021	3/26/2014	7/1/2024
MA9778EPDIV1	CYTH.002Q5GBD1	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	GB	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024
MA9778HKDIV1	CYTH.002Q5HKD1	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	HK	Issued	1410074.7	1/23/2014	HK1187551	11/17/2017	7/1/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9778EP	CYTH.002Q5IE	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	IE	Issued	4756624.5	7/1/2004	1743021	3/26/2014	7/1/2024
MA9778EPDIV1	CYTH.002Q5IED1	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	IE	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024
MA9778KR	CYTH.002Q5KR	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	KR	Abandoned	10-2006-7021635	7/1/2004			
MA9778EPDIV1	CYTH.002Q5LUD1	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	LU	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024
MA9778EP	CYTH.002Q5NL	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	NL	Issued	4756624.5	7/1/2004	1743021	3/26/2014	7/1/2024
MA9778EPDIV1	CYTH.002Q5NLD1	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	NL	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9778PCT	CYTH.002Q5PC	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	WO	Closed	PCT/US2004/021417	7/1/2004			
MA9778EPDIV1	CYTH.002Q5SED1	CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS	SE	Issued	12193602.5	11/21/2012	2617427	8/17/2016	7/1/2024
	CYTH.002QBE6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	BE	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
MA9793CA	CYTH.002QCA6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	CA	Issued	2572113	7/1/2004	2572113	4/18/2017	7/1/2024
MA9795EP	CYTH.002QCH3	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF STROKE AND RELATED DISEASES AND DISORDERS	CH	Issued	4777546.5	7/1/2004	1776126	5/13/2015	7/1/2024
MA9790EP	CYTH.002QCH4	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	CH	Issued	4756626	7/1/2004	1778293	4/22/2015	7/1/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9791EP	CYTH.002QCH5	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF RENAL DISEASES AND DISORDERS	CH	Issued	4777586.1	7/2/2004	1778834	8/25/2010	7/1/2024
	CYTH.002QCH6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	CH	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
MA9793CN	CYTH.002QCN6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	CN	Abandoned	2.0048E+11	7/1/2004			
MA9793CNDIV1	CYTH.002QCN6D1	USE OF REGENERATIVE CELLS FOR PROMOTING WOUND HEALING	CN	Issued	201110116176.X	7/1/2004	ZL 201110116176.X	9/17/2014	7/1/2024
	CYTH.002QCZ6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	CZ	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
MA9795EP	CYTH.002QDE3	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF STROKE AND RELATED DISEASES AND DISORDERS	DE	Issued	4777546.5	7/1/2004	60 2004 047 183.6	5/13/2015	7/1/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9790EP	CYTH.002QDE4	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	DE	Issued	4756626	7/1/2004	60 2004 047 061.9	4/22/2015	7/1/2024
MA9791EP	CYTH.002QDE5	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF RENAL DISEASES AND DISORDERS	DE	Issued	4777586.1	7/2/2004	60 2004 028 876.4	8/25/2010	7/1/2024
	CYTH.002QDE6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	DE	Issued	4756623.7	7/1/2004	60 2004 031 782.9	3/9/2011	7/1/2024
MA9791EP	CYTH.002QDK5	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF RENAL DISEASES AND DISORDERS	DK	Issued	4777586.1	7/2/2004	1778834	8/25/2010	7/1/2024
	CYTH.002QDK6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	DK	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
MA9796EP	CYTH.002QEP	SYSTEMS AND METHODS FOR ISOLATING AND USING CLINICALLY SAFE ADIPOSE DERIVED REGENERATIVE CELLS	EP	Abandoned	4756607	7/2/2004			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9795EP	CYTH.002QEP3	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF STROKE AND RELATED DISEASES AND DISORDERS	EP	Issued	4777546.5	7/1/2004	1776126	5/13/2015	7/1/2024
MA9790EP	CYTH.002QEP4	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	EP	Issued	4756626	7/1/2004	1778293	4/22/2015	7/1/2024
MA9790EPDIV1	CYTH.002QEP4D1	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	EP	Published	15164538.9	4/21/2015			
MA9791EP	CYTH.002QEP5	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF RENAL DISEASES AND DISORDERS	EP	Issued	4777586.1	7/2/2004	1778834	8/25/2010	7/2/2024
MA9793EP	CYTH.002QEP6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	EP	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
MA9793EPDIV1	CYTH.002QEP6D1	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	EP	Abandoned	10184623.6	7/1/2004			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9791EP	CYTH.002QES5	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF RENAL DISEASES AND DISORDERS	ES	Issued	4777586.1	7/2/2004	1778834	8/25/2010	7/1/2024
	CYTH.002QES6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	ES	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
MA9795EP	CYTH.002QFR3	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF STROKE AND RELATED DISEASES AND DISORDERS	FR	Issued	4777546.5	7/1/2004	1776126	5/13/2015	7/1/2024
MA9790EP	CYTH.002QFR4	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	FR	Issued	4756626	7/1/2004	1778293	4/22/2015	7/1/2024
MA9791EP	CYTH.002QFR5	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF RENAL DISEASES AND DISORDERS	FR	Issued	4777586.1	7/2/2004	1778834	8/25/2010	7/1/2024
	CYTH.002QFR6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	FR	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9795EP	CYTH.002QGB3	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF STROKE AND RELATED DISEASES AND DISORDERS	GB	Issued	4777546.5	7/1/2004	1776126	5/13/2015	7/1/2024
MA9790EP	CYTH.002QGB4	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	GB	Issued	4756626	7/1/2004	1778293	4/22/2015	7/1/2024
MA9791EP	CYTH.002QGB5	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF RENAL DISEASES AND DISORDERS	GB	Issued	4777586.1	7/2/2004	1778834	8/25/2010	7/1/2024
	CYTH.002QGB6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	GB	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
MA9796HK	CYTH.002QHK	SYSTEMS AND METHODS FOR ISOLATING AND USING CLINICALLY SAFE ADIPOSE DERIVED REGENERATIVE CELLS	HK	Confirm ABA	7110355.1	7/2/2004			
MA9793HKDIV1	CYTH.002QHK6D1	USE OF REGENERATIVE CELLS FOR PROMOTING WOUND HEALING	HK	Issued	12101967.3	7/1/2004	1165261	8/14/2015	7/1/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
	CYTH.002QIE6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	IE	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
MA9793IN	CYTH.002QIN6	MEDICAMENT COMPRISING CONCENTRATED POPULATION OF ADIPOSE-DERIVED REGENERATIVE STEM CELLS FOR	IN	ABA Intent	442/CHENP/2007	7/1/2004	247580	4/25/2011	7/1/2024
MA9793INDIV1	CYTH.002QIN6D1	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	IN	Abandoned	2231/CHENP/2011	7/1/2004			
	CYTH.002QIT6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	IT	Issued	4756623.7	7/1/2004	5.02012E+14	3/9/2011	7/1/2024
MA9793KR	CYTH.002QKR6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	KR	Issued	10-2007-7002519	7/1/2004	10-1197909	10/30/2012	7/1/2024
	CYTH.002QLU6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	LU	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
	CYTH.002QMC6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	MC	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
MA9795EP	CYTH.002QNL3	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF STROKE AND RELATED DISEASES AND DISORDERS	NL	Issued	4777546.5	7/1/2004	1776126	5/13/2015	7/1/2024
MA9790EP	CYTH.002QNL4	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	NL	Issued	4756626	7/1/2004	1778293	4/22/2015	7/1/2024
MA9791EP	CYTH.002QNL5	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF RENAL DISEASES AND DISORDERS	NL	Issued	4777586.1	7/2/2004	1778834	8/25/2010	7/1/2024
	CYTH.002QNL6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	NL	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
MA9796PCT	CYTH.002QPC	SYSTEMS AND METHODS FOR ISOLATING AND USING CLINICALLY SAFE ADIPOSE DERIVED REGENERATIVE CELLS	WO	Closed	PCT/US2004/021391	7/2/2004			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9792PCT	CYTH.002QPC2	TREATING DISORDERS BY ADMINISTERING REGENERATIVE CELLS	WO	Closed	PCT/US2004/021418	7/1/2004			
MA9795PCT	CYTH.002QPC3	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF STROKE AND RELATED DISEASES AND DISORDERS	WO	Closed	PCT/US2004/021483	7/1/2004			
MA9790PCT	CYTH.002QPC4	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	WO	Closed	PCT/US2004/021419	7/1/2004			
MA9791PCT	CYTH.002QPC5	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF RENAL DISEASES AND DISORDERS	WO	Closed	PCT/US2004/021549	7/1/2004			
MA9793PCT	CYTH.002QPC6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	WO	Closed	PCT/US2004/021415	7/1/2004			
	CYTH.002QPL6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	PL	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9795EP	CYTH.002QSE3	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF STROKE AND RELATED DISEASES AND DISORDERS	SE	Issued	4777546.5	7/1/2004	1776126	5/13/2015	7/1/2024
MA9790EP	CYTH.002QSE4	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS	SE	Issued	4756626	7/1/2004	1778293	4/22/2015	7/1/2024
	CYTH.002QSE6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	SE	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
	CYTH.002QSK6	METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING	SK	Issued	4756623.7	7/1/2004	1778833	3/9/2011	7/1/2024
MA9658AU	CYTH.002VAU	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	AU	Issued	2002357135	12/9/2002	2002357135	1/8/2009	12/9/2022
MA9658BR	CYTH.002VBR	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	BR	Abandoned	PI0214772-6	12/9/2002			11/1/2017

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9658BRDIV1	CYTH.002VBRD1	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	BR	Abandoned	BR 12 2017 017694 3	8/17/2017			
MA9658CA	CYTH.002VCA	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	CA	Issued	2469370	12/9/2002	2469370	7/8/2014	12/9/2022
MA9658CADIV1	CYTH.002VCAD1	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	CA	Abandoned	2849201	4/17/2014			
MA9658EP	CYTH.002VCH	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	CH	Issued	2805565.5	12/9/2002	1572071	10/3/2018	12/9/2022
MA9658CN	CYTH.002VCN	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	CN	Issued	2827968.9	12/9/2002	ZL02827968.9	5/5/2010	12/9/2022
MA9658EP	CYTH.002VDE	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	DE	Issued	2805565.5	12/9/2002	602 49 631.4	10/3/2018	12/9/2022

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9658EP	CYTH.002VEP	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	EP	Issued	2805565.5	12/9/2002	1572071	10/3/2018	12/9/2022
MA9658EPDIV2	CYTH.002VEPD2	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	EP	Abandoned	10183690.6	12/9/2002			
MA9658EPDIV3	CYTH.002VEPD3	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	EP	ABA Intent	10183737.5	12/9/2002			
MA9658EP	CYTH.002VFR	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	FR	Issued	2805565.5	12/9/2002	1572071	10/3/2018	12/9/2022
MA9658EP	CYTH.002VGB	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	GB	Issued	2805565.5	12/9/2002	1572071	10/3/2018	12/9/2022
MA9658HK	CYTH.002VHK	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	HK	Issued	5110006.6	12/9/2002	HK1078009	6/30/2011	12/9/2022

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9658KR	CYTH.002VKR	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	KR	Issued	10-2004-7008785	12/9/2002	10-0811995	3/3/2008	12/9/2022
MA9658PCT	CYTH.002VPC	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	WO	Closed	PCT/US2002/039465	12/9/2002			
MA9658EPDIV1	CYTH.002VRAT	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	AT	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
MA9658EPDIV1	CYTH.002VRBE	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	BE	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
MA9658EPDIV1	CYTH.002VRCH	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	CH	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
MA9658CNDIV1	CYTH.002VRCN	A METHOD OF MAKING A SOFT TISSUE FILTER AND A METHOD OF MAKING AN ADIPOSE TISSUE IMPLANT	CN	Issued	2.0101E+11	12/9/2002	2461773	4/19/2017	12/9/2022

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9658EPDIV1	CYTH.002VRDE	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	DE	Issued	7124088.1	12/9/2002	602 47 199.0	5/20/2015	12/9/2022
MA9658EPDIV1	CYTH.002VRDK	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	DK	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
MA9658EPDIV1	CYTH.002VREP	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	EP	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
MA9658EPDIV1	CYTH.002VRES	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	ES	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
MA9658EPDIV1	CYTH.002VRFI	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	FI	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
MA9658EPDIV1	CYTH.002VRFR	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	FR	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9658EPDIV1	CYTH.002VRGB	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	GB	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
MA9658HKC1	CYTH.002VRHK	A METHOD OF MAKING A SOFT TISSUE FILTER AND A METHOD OF MAKING AN ADIPOSE TISSUE IMPLANT	HK	Issued	11105504.5	12/9/2002	HK1153382	3/16/2018	12/9/2022
MA9658EPDIV1	CYTH.002VRIE	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	IE	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
MA9658KRDIV1	CYTH.002VRKR	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	KR	Issued	10-2007-7018245	12/9/2002	10-0930139	11/27/2009	12/9/2022
MA9658KRDIV2	CYTH.002VRKRD1	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	KR	Issued	10-2008-7027860	12/9/2002	10-1083454	11/8/2011	12/9/2022
MA9658KRDIV3	CYTH.002VRKRD2	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	KR	Issued	10-2010-7002719	12/9/2002	10-1150666	5/21/2012	12/9/2022

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9658KRDIV4	CYTH.002VRKRD3	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	KR	Abandoned	10-2011-7028207	12/9/2002			
MA9658EPDIV1	CYTH.002VRLU	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	LU	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
MA9658EPDIV1	CYTH.002VRNL	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	NL	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
MA9658EPDIV1	CYTH.002VRSE	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS	SE	Issued	7124088.1	12/9/2002	1921133	5/20/2015	12/9/2022
	CYTH.003PR	SYSTEMS AND METHODS FOR SEPARATING CELLS FROM ADIPOSE TISSUE	US	Closed	60/496467	8/20/2003			
MA9684AU	CYTH.003QAU	SYSTEMS AND METHODS FOR SEPARATING AND CONCENTRATING REGENERATIVE CELLS FROM TISSUE	AU	Issued	2004260937	6/25/2004	2004260937	8/26/2010	6/25/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9684BR	CYTH.003QBR	SYSTEMS AND METHODS FOR SEPARATING AND CONCENTRATING REGENERATIVE CELLS FROM TISSUE	BR	Pending	PI0411798-0	6/25/2004			
MA9684CA	CYTH.003QCA	SYSTEMS AND METHODS FOR SEPARATING AND CONCENTRATING REGENERATIVE CELLS FROM TISSUE	CA	Abandoned	2530630	6/25/2004			
MA9684CN	CYTH.003QCN	SYSTEMS AND METHODS FOR SEPARATING AND CONCENTRATING REGENERATIVE CELLS FROM TISSUE	CN	Issued	2.0048E+11	6/25/2004	ZL20048002462 41	4/25/2012	6/25/2024
MA9684EP	CYTH.003QEP	SYSTEMS AND METHODS FOR SEPARATING AND CONCENTRATING REGENERATIVE CELLS FROM TISSUE	EP	Abandoned	4777155.5	6/25/2004			
MA9684EPDIV1	CYTH.003QEPD1	SYSTEMS AND METHODS FOR SEPARATING AND CONCENTRATING REGENERATIVE CELLS FROM TISSUE	EP	Abandoned	11156001.7	6/25/2004	2380970	12/20/2017	6/25/2024
MA9684HK	CYTH.003QHK	SYSTEMS AND METHODS FOR SEPARATING AND CONCENTRATING REGENERATIVE CELLS FROM TISSUE	HK	Issued	7103532.2	6/25/2004	HK1096424	2/1/2013	6/25/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9684IL	CYTH.003QIL	SYSTEMS AND METHODS FOR SEPARATING AND CONCENTRATING REGENERATIVE CELLS FROM TISSUE	IL	Issued	172800	6/25/2004	172800	2/1/2011	6/25/2024
MA9684IN	CYTH.003QIN	SYSTEMS AND METHODS FOR SEPARATING AND CONCENTRATING REGENERATIVE CELLS FROM TISSUE	IN	ABA Intent	302/CHENP/2006	6/25/2004	229529	2/18/2009	6/25/2024
MA9684KR	CYTH.003QKR	SYSTEMS AND METHODS FOR SEPARATING AND CONCENTRATING REGENERATIVE CELLS FROM TISSUE	KR	Issued	10-2005-7024986	6/25/2004	10-1127305	3/8/2012	6/25/2024
MA9684MX	CYTH.003QMX	SYSTEMS AND METHODS FOR SEPARATING AND CONCENTRATING REGENERATIVE CELLS FROM TISSUE	MX	Issued	PA/a/2006/000062	6/25/2004	270348	9/23/2009	6/25/2024
MA9684PCT	CYTH.003QPC	SYSTEMS AND METHODS FOR SEPARATING AND CONCENTRATING REGENERATIVE CELLS FROM TISSUE	WO	Closed	PCT/US2004/020594	6/25/2004			
MA9684SG	CYTH.003QSG	SYSTEMS AND METHODS FOR SEPARATING AND CONCENTRATING REGENERATIVE CELLS FROM TISSUE	SG	Issued	200508560-0	6/25/2004	118683	12/31/2007	6/25/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
	CYTH.004PR	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED CONDITIONS	US	Closed	60/503589	9/17/2003			
MA9794EP	CYTH.004QAT	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	AT	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
MA9794AU	CYTH.004QAU	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	AU	Abandoned	2004280149	7/1/2004			
MA9794EP	CYTH.004QBE	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	BE	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
MA9794BR	CYTH.004QBR	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	BR	Abandoned	PI04144554	7/1/2004			
MA9794CA	CYTH.004QCA	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	CA	Abandoned	2539346	7/1/2004			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9794EP	CYTH.004QCH	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	CH	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
MA9794CN	CYTH.004QCN	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	CN	Abandoned	200480033368.2	7/1/2004			
MA9794EP	CYTH.004QDE	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	DE	Issued	4756641.9	7/1/2004	6.02004E+12	4/19/2017	7/1/2024
MA9794EP	CYTH.004QDK	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	DK	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
MA9794EP	CYTH.004QEP	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	EP	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
MA9794EPDIV1	CYTH.004QEPD1	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	EP	Published	10183850.6	7/1/2004	2348103		

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9794EP	CYTH.004QES	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	ES	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
MA9794EP	CYTH.004QFI	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	FI	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
MA9794EP	CYTH.004QFR	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	FR	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
MA9794EP	CYTH.004QGB	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	GB	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
MA9794EP	CYTH.004QIE	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	IE	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
MA9794EP	CYTH.004QIT	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	IT	Issued	4756641.9	7/1/2004	5.02017E+14	4/19/2017	7/1/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9794KR	CYTH.004QKR	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	KR	Abandoned	10-2006-7007257	7/1/2004			
MA9794EP	CYTH.004QLU	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	LU	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
MA9794MX	CYTH.004QMX	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	MX	Abandoned	PA/a/2006/003088	7/1/2004			
MA9794EP	CYTH.004QNL	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	NL	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
MA9794EP	CYTH.004QNO	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	NO	Issued	4756641.9	7/1/2004	1670315	4/19/2017	
MA9794PCT	CYTH.004QPC	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	WO	Closed	PCT/US2004/021480	7/1/2004			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9794SGDIV1	CYTH.004QRSG	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	SG	Abandoned	200806960-1	7/1/2004			
MA9794EP	CYTH.004QSE	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	SE	Issued	4756641.9	7/1/2004	1670315	4/19/2017	7/1/2024
MA9794SG	CYTH.004QSG	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS	SG	Abandoned	200601759-4	7/1/2004			
	CYTH.005PR	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	US	Closed	60/479418	6/18/2003			
MA9685AU	CYTH.005QAU	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	AU	Abandoned	2004260638	6/18/2004			
MA9685BR	CYTH.005QBR	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	BR	Abandoned	PI0411621-6	6/18/2004			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9685CA	CYTH.005QCA	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	CA	Abandoned	2529954	6/18/2004			
MA9685EP	CYTH.005QCH	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	CH	Issued	4776784.3	6/18/2004	1638507	3/22/2017	6/18/2024
MA9685CN	CYTH.005QCN	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	CN	Abandoned	2.0048E+11	6/18/2004			
MA9685EP	CYTH.005QDE	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	DE	Issued	4776784.3	6/18/2004	6.02004E+11	3/22/2017	6/18/2024
MA9685EP	CYTH.005QDK	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	DK	Issued	4776784.3	6/18/2004	1638507	3/22/2017	6/18/2024
MA9685EP	CYTH.005QEP	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	EP	Issued	4776784.3	6/18/2004	1638507	3/22/2017	6/18/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9685EP	CYTH.005QFR	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	FR	Issued	4776784.3	6/18/2004	1638507	3/22/2017	6/18/2024
MA9685EP	CYTH.005QGB	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	GB	Issued	4776784.3	6/18/2004	1638507	3/22/2017	6/18/2024
MA9685HK	CYTH.005QHK	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	HK	Abandoned	6110836.1	6/18/2004			
MA9685KR	CYTH.005QKR	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	KR	Issued	10-2005-7024356	6/18/2004	10-1145508	5/4/2012	6/18/2024
MA9685MX	CYTH.005QMX	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	MX	Abandoned	PA/a/2005/013967	6/18/2004			
MA9685EP	CYTH.005QNL	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	NL	Issued	4776784.3	6/18/2004	1638507	3/22/2017	6/18/2024

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9685PCT	CYTH.005QPC	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	WO	Closed	PCT/US2004/019611	6/18/2004			
MA9685EP	CYTH.005QSE	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER	SE	Issued	4776784.3	6/18/2004	1638507	3/22/2017	6/18/2024
MA9890CON1	CYTH.006C1	SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS FROM ADIPOSE TISSUE	US	Abandoned	13/926854	6/25/2013			
MA9890CON2	CYTH.006C2	SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS FROM ADIPOSE TISSUE	US	Abandoned	14/860416	9/21/2015			
MA9890NP	CYTH.006NP	SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS SEPARATED AND CONCENTRATED FROM ADIPOSE TISSUE	US	Abandoned	12/302787	8/12/2009			
	CYTH.006PR	SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS SEPARATED AND CONCENTRATED FROM ADIPOSE TISSUE	US	Closed	60/685206	5/27/2005			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9890PCT	CYTH.006VPC	SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS SEPARATED AND CONCENTRATED FROM ADIPOSE TISSUE	WO	Closed	PCT/US2006/021017	5/30/2006			
	CYTH.007PR	SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS SEPARATED AND CONCENTRATED FROM ADIPOSE TISSUE	US	Closed	60/693323	6/22/2005			
MA9928NP	CYTH.008NP	CELL DELIVERY CATHETERS WITH DISTAL TIP HIGH FIDELITY SENSORS	US	Abandoned	12/090241	9/10/2008			
MA9928PR	CYTH.008PR	CELL DELIVERY CATHETERS WITH DISTAL TIP HIGH FIDELITY SENSORS	US	Closed	60/727174	10/14/2005			
MA9928EP	CYTH.008VEP	CELL DELIVERY CATHETERS WITH DISTAL TIP HIGH FIDELITY SENSORS	EP	Abandoned	6825964.7	10/16/2006			
MA9928PCT	CYTH.008VPC	CELL DELIVERY CATHETERS WITH DISTAL TIP HIGH FIDELITY SENSORS	WO	Closed	PCT/US2006/040221	10/16/2006			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
	CYTH.009PR	ADIPOSE-DERIVED CELLS FOR ARTERIOLE AND ARTERY FORMATION	US	Closed	60/730153	10/24/2005			
	CYTH.010PR	ADIPOSE-DERIVED CELL-DERIVED NEOTISSUE FOR SOFT TISSUE FILLING	US	Closed	60/730127	10/24/2005			
MA9945PR	CYTH.011PR	ADIPOSE-DERIVED CELL-DERIVED NEOTISSUE FOR SOFT TISSUE FILLING	US	Closed	60/793422	4/19/2006			
MA9947PR	CYTH.012PR	ADIPOSE-DERIVED CELLS FOR ARTERIOLE AND ARTERY FORMATION	US	Closed	60/793421	4/19/2006			
MA9948C1	CYTH.013C1	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF THE LYMPHATIC SYSTEM AND MALIGNANT DISEASE	US	Issued	13/031031	2/18/2011	8784801	7/22/2014	2/18/2030
MA9948CON2	CYTH.013C2	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF THE LYMPHATIC SYSTEM AND MALIGNANT DISEASE	US	Issued	14/336755	7/21/2014	9486484	11/8/2016	2/6/2030

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9948CON2	CYTH.013C3	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF THE LYMPHATIC SYSTEM AND MALIGNANT DISEASE	US	Abandoned	15/345294	11/7/2016			
MA9948PR	CYTH.013PR	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF THE LYMPHATIC SYSTEM AND MALIGNANT DISEASE	US	Closed	60/795334	4/26/2006			
MA9948PR2	CYTH.013PR2	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF THE LYMPHATIC SYSTEM AND MALIGNANT DISEASE	US	Closed	60/945320	6/20/2007			
MA9948PR3	CYTH.013PR3	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF THE LYMPHATIC SYSTEM AND MALIGNANT DISEASE	US	Abandoned	61/074299	6/20/2008			
MA9948PR4	CYTH.013PR4	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF THE LYMPHATIC SYSTEM AND MALIGNANT DISEASE	US	Closed	61/090186	8/19/2008			
MA9948PCT	CYTH.013VPC	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF THE LYMPHATIC SYSTEM AND MALIGNANT DISEASE	WO	Expired	PCT/US2009/054055	8/17/2009			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9964	CYTH.014A	GENERATION OF ADIPOSE TISSUE AND ADIPOCYTES	US	Closed					
MA9964NP	CYTH.014NP	GENERATION OF ADIPOSE TISSUE AND ADIPOCYTES	US	Abandoned	12/375005	9/25/2009			
MA9964PR	CYTH.014PR	GENERATION OF ADIPOSE TISSUE AND ADIPOCYTES	US	Closed	60/833561	7/26/2006			
MA9964PCT	CYTH.014VPC	GENERATION OF ADIPOSE TISSUE AND ADIPOCYTES	WO	Closed	PCT/US2007/016750	7/25/2007			
MA9970P	CYTH.015A	INDIVIDUALIZED DOSAGE DETERMINATION FOR SAFE INTRAVASCULAR ADMINISTRATION OF PARTICLES	US	Abandoned	12/188950	8/8/2008			
MA9970PR	CYTH.015PR	INDIVIDUALIZED DOSAGE DETERMINATION FOR SAFE INTRAVASCULAR ADMINISTRATION OF PARTICLES	US	Closed	60/838288	8/16/2006			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9970PR2	CYTH.015PR2	INDIVIDUALIZED DOSAGE DETERMINATION FOR SAFE INTRAVASCULAR ADMINISTRATION OF PARTICLES	US	Closed	60/955252	8/10/2007			
MA9661	CYTH.017A	PRESERVATION OF NON EMBRYONIC CELLS FROM NON HEMATOPOIETIC TISSUES	US	Abandoned	10/242094	9/12/2002			
MA9661PR	CYTH.017PR	DEVICES, METHODS AND COMPOSITION FOR THE PRESERVATION AND USE OF MAMMALIAN NONEMBRYONIC STEM/PROGENITOR	US	Closed	60/322070	9/14/2001			
MA9661AU	CYTH.017VAU	PRESERVATION OF NON EMBRYONIC CELLS FROM NON HEMATOPOIETIC TISSUES	AU	Issued	2002326901	9/13/2002	2002326901	2/14/2008	9/13/2022
MA9661CA	CYTH.017VCA	PRESERVATION OF NON EMBRYONIC CELLS FROM NON HEMATOPOIETIC TISSUES	CA	Abandoned	2460402	9/13/2002			
MA9661CN	CYTH.017VCN	PRESERVATION OF NON EMBRYONIC CELLS FROM NON HEMATOPOIETIC TISSUES	CN	Abandoned	2822628.3	9/13/2002			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9661EP	CYTH.017VEP	PRESERVATION OF NON EMBRYONIC CELLS FROM NON HEMATOPOIETIC TISSUES	EP	Published	2761654.9	9/13/2002			
MA9661HK	CYTH.017VHK	PRESERVATION OF NON EMBRYONIC CELLS FROM NON HEMATOPOIETIC TISSUES	HK	Abandoned	4108806.3	9/13/2002			
MA9661KR	CYTH.017VKR	PRESERVATION OF NON EMBRYONIC CELLS FROM NON HEMATOPOIETIC TISSUES	KR	Issued	10-2004-7003710	9/13/2002	10-0779812	11/20/2007	9/13/2022
MA9661PCT	CYTH.017VPC	PRESERVATION OF NON EMBRYONIC CELLS FROM NON HEMATOPOIETIC TISSUES	WO	Closed	PCT/US02/29207	9/13/2002			
	CYTH.018PR	SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS USING ELECTRICAL FIELDS	US	Closed	60/720060	9/23/2005			
MA9659P	CYTH.019A	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH COLLAGEN-RICH MATERIAL EXTRACTED FROM ADIPOSE TISSUE	US	Abandoned	10/325728	12/20/2002			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9659CA	CYTH.019VCA	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH COLLAGEN-RICH MATERIAL EXTRACTED FROM ADIPOSE TISSUE	CA	Abandoned	2470031	12/20/2002			
MA9659CN	CYTH.019VCN	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH COLLAGEN-RICH MATERIAL EXTRACTED FROM ADIPOSE TISSUE	CN	Abandoned	02828237.X	12/20/2002			
MA9659EP	CYTH.019VEP	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH COLLAGEN-RICH MATERIAL EXTRACTED FROM ADIPOSE TISSUE	EP	Abandoned	2805648.9	12/20/2002			
MA9659HK	CYTH.019VHK	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH COLLAGEN-RICH MATERIAL EXTRACTED FROM ADIPOSE TISSUE	HK	Abandoned	5110647.1	12/20/2002			
MA9659PCT	CYTH.019VPC	SYSTEMS AND METHODS FOR TREATING PATIENTS WITH COLLAGEN-RICH MATERIAL EXTRACTED FROM ADIPOSE TISSUE	WO	Closed	PCT/US02/40921	12/20/2002			
	CYTH.020PR	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS RESORBABLE	US	Closed	60/449279	2/20/2003			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
	CYTH.021PR	DEVICES AND METHODS FOR INDUCING TISSUE FORMATION AND BILLING A USER OF THE DEVICES AND METHODS	US	Closed	60/642954	1/10/2005			
	CYTH.022PR	SYSTEMS AND METHODS FOR SEPARATING CELLS FROM ADIPOSE TISSUE	US	Closed	60/482820	6/25/2003			
MA9837PR	CYTH.023PR	CELL-LOADED PROSTHESES FOR REGENERATIVE INTRALUMINAL APPLICATIONS	US	Closed	60/639013	12/22/2004			
MA9837EP	CYTH.023VEP	CELL-LOADED PROSTHESES FOR REGENERATIVE INTRALUMINAL APPLICATIONS	EP	Abandoned					
MA9837PCT	CYTH.023VPC	CELL-LOADED PROSTHESES FOR REGENERATIVE INTRALUMINAL APPLICATIONS	WO	Abandoned	PCT/US2005/046926	12/22/2005			
MA9971PR	CYTH.025PR	INDIVIDUALIZED DOSAGE DETERMINATION FOR LOCAL ADMINISTRATION OF THERAPEUTICS PARTICLES	US	Closed	60/858161	11/10/2006			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9971PCT	CYTH.025VPC	INDIVIDUALIZED DOSAGE DETERMINATION FOR LOCAL ADMINISTRATION OF THERAPEUTIC PARTICLES	WO	Closed	PCT/US2007/023646	11/9/2007			
MA9972PR	CYTH.028PR	ALTERNATING CONNECTION ROTATION SEAL APPARATUS	US	Closed	60/903485	2/26/2007			
MA9972PCT	CYTH.028VPC	ALTERNATING CONNECTION ROTATION SEAL APPARATUS	WO	Abandoned	PCT/US2008/054921	2/25/2008			
MA9824P	CYTH.029A	METHODS FOR MAKING AND USING COMPOSITES, POLYMER SCAFFOLDS, AND COMPOSITE SCAFFOLDS	US	Abandoned	11/229028	9/15/2005			
MA9824PR	CYTH.029PR	METHODS FOR MAKING AND USING COMPOSITES, POLYMER SCAFFOLDS, AND COMPOSITE SCAFFOLDS	US	Closed	60/615140	9/30/2004			
MA9824EP	CYTH.029VEP	METHODS FOR MAKING AND USING COMPOSITES, POLYMER SCAFFOLDS, AND COMPOSITE SCAFFOLDS	EP	Abandoned	5814850.3	9/15/2005			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9824PCT	CYTH.029VPC	METHODS FOR MAKING AND USING COMPOSITES, POLYMER SCAFFOLDS, AND COMPOSITE SCAFFOLDS	WO	Closed	PCT/US2005/033329	9/15/2005			
MA9973CON	CYTH.050C1	SYRINGE SYSTEM FOR CONTROLLED DELIVERY OR REMOVAL OF MATERIAL	US	Abandoned	12/766768	4/23/2010			
MA9973CON2	CYTH.050C2	SYRINGE SYSTEM FOR CONTROLLED DELIVERY OR REMOVAL OF MATERIAL	US	Abandoned	13/450262	4/18/2012			
MA9973PR	CYTH.050PR	SYRINGE SYSTEM FOR CONTROLLED DELIVERY OR REMOVAL OF MATERIAL	US	Closed	60/983054	10/26/2007			
MA9973PR2	CYTH.050PR2	SYRINGE SYSTEM FOR CONTROLLED DELIVERY OR REMOVAL OF MATERIAL	US	Closed	60/987738	11/13/2007			
MA9973IN	CYTH.050VIN	SYRINGE SYSTEM FOR CONTROLLED DELIVERY OR REMOVAL OF MATERIAL	IN	Abandoned	3177/DELNP/2010	10/23/2008			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9973PCT	CYTH.050VPC	SYRINGE SYSTEM FOR CONTROLLED DELIVERY OR REMOVAL OF MATERIAL	WO	Closed	PCT/US2008/081012	10/23/2008			
MA9974PR	CYTH.059PR	METHODS OF INHIBITING TUMOR DEVELOPMENT USING ADIPOSE-DERIVED REGENERATIVE CELLS	US	Closed	61/013442	12/13/2007			
MA9974PCT	CYTH.059VPC	METHODS OF INHIBITING TUMOR DEVELOPMENT USING ADIPOSE-DERIVED REGENERATIVE CELLS	WO	Closed	PCT/US2008/086470	12/11/2008			
	CYTH.068PR	METHODS OF TREATING PANCREATITIS USING ADIPOSE-DERIVED REGENERATIVE CELLS	US	Closed					
	CYTH.072PR	USE OF HUMAN TISSUE FOR THE PURPOSE AS A CELL TRAP AS A METHOD OF CONCENTRATING THE CELL DURING PROCESSING	US	Closed					
MA9975C1	CYTH.074C1	USE ADIPOSE TISSUE-DERIVED REGENERATIVE CELLS IN THE MODULATION OF INFLAMMATION IN THE PANCREAS AND IN THE KIDNEY	US	Abandoned	13/279090	10/21/2011			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9975C2	CYTH.074C2	USE ADIPOSE TISSUE-DERIVED REGENERATIVE CELLS IN THE MODULATION OF INFLAMMATION IN THE PANCREAS AND IN THE KIDNEY	US	Abandoned	13/720829	12/19/2012			
MA9975EP	CYTH.074EP	USE ADIPOSE TISSUE-DERIVED REGENERATIVE CELLS IN THE MODULATION OF INFLAMMATION IN THE PANCREAS AND IN THE KIDNEY	EP	Abandoned	10715641.6	4/23/2010			
MA9975PR	CYTH.074PR	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF INFLAMMATION	US	Expired	61/172152	4/23/2009			4/23/2010
MA9975PCT	CYTH.074VPC	USE ADIPOSE TISSUE-DERIVED REGENERATIVE CELLS IN THE MODULATION OF INFLAMMATION IN THE PANCREAS AND IN THE KIDNEY	WO	Expired	PCT/US2010/032275	4/23/2010			
MA9976P	CYTH.075A	SYSTEMS, METHODS AND COMPOSITIONS FOR OPTIMIZING TISSUE AND CELL ENRICHED GRAFTS	US	Transferred	12/771985	4/30/2010			
MA9976AU	CYTH.075AU	SYSTEMS, METHODS AND COMPOSITIONS FOR OPTIMIZING TISSUE AND CELL ENRICHED GRAFTS	AU	Transferred	2010242780	4/30/2010			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9976BR	CYTH.075BR	SYSTEMS, METHODS AND COMPOSITIONS FOR OPTIMIZING TISSUE AND CELL ENRICHED GRAFTS	BR	Transferred	PI1009981-6	4/30/2010			
MA9976C1	CYTH.075C1	SYSTEMS, METHODS AND COMPOSITIONS FOR OPTIMIZING TISSUE AND CELL ENRICHED GRAFTS	US	Transferred					
MA9976CA	CYTH.075CA	SYSTEMS, METHODS AND COMPOSITIONS FOR OPTIMIZING TISSUE AND CELL ENRICHED GRAFTS	CA	Transferred	2760574	4/30/2010			
MA9976CN	CYTH.075CN	SYSTEMS, METHODS AND COMPOSITIONS FOR OPTIMIZING TISSUE AND CELL ENRICHED GRAFTS	CN	Transferred	2.0108E+11	4/30/2010			
MA9976EP	CYTH.075EP	SYSTEMS, METHODS AND COMPOSITIONS FOR OPTIMIZING TISSUE AND CELL ENRICHED GRAFTS	EP	Transferred	10770460.3	4/30/2010			
MA9976HK	CYTH.075HK	SYSTEMS, METHODS AND COMPOSITIONS FOR OPTIMIZING TISSUE AND CELL ENRICHED GRAFTS	HK	Transferred	12109852.4	10/8/2012			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9976IN	CYTH.075IN	SYSTEMS, METHODS AND COMPOSITIONS FOR OPTIMIZING TISSUE AND CELL ENRICHED GRAFTS	IN	Transferred	8801/DELNP/2011	4/30/2010			
MA9976KR	CYTH.075KR	SYSTEMS, METHODS AND COMPOSITIONS FOR OPTIMIZING TISSUE AND CELL ENRICHED GRAFTS	KR	Transferred	10-2011-7028621	4/30/2010			
MA9976MX	CYTH.075MX	SYSTEMS, METHODS AND COMPOSITIONS FOR OPTIMIZING TISSUE AND CELL ENRICHED GRAFTS	MX	Transferred	MX/a/2011/011402	4/30/2010			
MA9976PR	CYTH.075PR	SYSTEMS, METHODS AND COMPOSITIONS FOR OPTIMIZING TISSUE AND CELL GRAFTS	US	Transferred	61/174860	5/1/2009			5/1/2010
MA9976PCT	CYTH.075VPC	SYSTEMS, METHODS AND COMPOSITIONS FOR OPTIMIZING TISSUE AND CELL ENRICHED GRAFTS	WO	Transferred	PCT/US2010/033283	4/30/2010			
MA9976ZA	CYTH.075ZA	SYSTEMS, METHODS AND COMPOSITIONS FOR OPTIMIZING TISSUE AND CELL ENRICHED GRAFTS	ZA	Transferred	2011/8756	4/30/2010	2011/8756	2/26/2014	4/30/2030

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
	CYTH.078RX	ADIPOSE DERIVED STEM CELL ISOLATION DEVICE	US	Closed					
	CYTH.080PR	AN APPARATUS FOR ISOLATING STEM CELLS FROM ADIPOSE DERIVED TISSUE WHEREIN THE ADIPOSE DERIVED TISSUE IS TREATED WITH DNASE	US	Closed					
	CYTH.095PR	USE OF CYSTEINE AND CYSTEINE DERIVATIVES	US	Unfiled					
OLY-058PCT	CYTH.097WO	METHOD FOR WASHING CELLS	WO	Expired	PCT/JP2009/068237	10/23/2009			
OLY-049EP	CYTH.098EP	CENTRIFUGAL SEPARATION CONTAINER	EP	Abandoned		9/18/2009			
OLY-049NP	CYTH.098NP	CENTRIFUGAL SEPARATION CONTAINER	US	Abandoned	13/120636	3/23/2011			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
OLY-049PCT	CYTH.098WO	CENTRIFUGAL SEPARATION CONTAINER	WO	Expired	PCT/JP2009/066371	9/18/2009			
	CYTH.104ZEP	USE OF ADIPOSE TISSUE CELLS FOR INITIATING THE FORMATION OF A FUNCTIONAL VASCULAR NETWORK	EP	Closed					
	CYTH.106ZPEP	USE OF CELLS DERIVED FROM ADIPOSE TISSUE FOR THE PREPARATION OF AN ANTI-TUMOR MEDICAMENT	EP	Closed					
MA112PCT	CYTH.112AT	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	AT	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
MA112AU	CYTH.112AU	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	AU	Abandoned	2014323629	4/19/2016			
MA112PCT	CYTH.112BE	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	BE	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA112PCT	CYTH.112CA	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	CA	Pending	2924883	3/18/2016			
MA112PCT	CYTH.112CH	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	CH	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
MA112PCT	CYTH.112CN	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	CN	Abandoned	2.0148E+11	5/18/2016			
MA112PCT	CYTH.112DE	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	DE	Issued	14845486.1	4/18/2016	60 2014 011 601.9	7/5/2017	9/17/2034
MA112PCT	CYTH.112DK	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	DK	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
MA112PCT	CYTH.112EP	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	EP	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA112EPD1	CYTH.112EPD1	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	EP	Published	17172872.8	5/24/2017			
MA112PCT	CYTH.112ES	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	ES	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
MA112PCT	CYTH.112FI	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	FI	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
MA112PCT	CYTH.112FR	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	FR	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
MA112PCT	CYTH.112GB	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	GB	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
MA112PCT	CYTH.112HK	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	HK	Issued	17100171.2	1/6/2017	HK1226601	6/1/2018	9/17/2034

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA112PCT	CYTH.112IE	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	IE	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
MA112PCT	CYTH.112IT	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	IT	Issued	14845486.1	4/18/2016	5.02017E+14	7/5/2017	9/17/2034
MA112KR	CYTH.112KR	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	KR	Pending	10-2016-7008154	3/28/2016			
MA112PCT	CYTH.112LU	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	LU	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
MA112MX	CYTH.112MX	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	MX	ABA Intent	MX/a/2016/003127	3/10/2016			
MA112PCT	CYTH.112NL	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	NL	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA112PCT	CYTH.112NO	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	NO	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034
MA112PCT	CYTH.112NP	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	US	Published	14/917441	3/8/2016			
MA112PR	CYTH.112PR	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	US	Expired	61/880086	9/19/2013			9/19/2014
MA112PR2	CYTH.112PR2	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	US	Expired	61/977466	4/9/2014			4/9/2015
MA112RU	CYTH.112RU	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	RU	Abandoned	2016109646	3/17/2016			
MA112PCT	CYTH.112SE	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	SE	Issued	14845486.1	4/18/2016	3046417	7/5/2017	9/17/2034

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA112PCT	CYTH.112WO	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	WO	Expired	PCT/US2014/056145	9/17/2014			5/19/2016
MA112ZA	CYTH.112ZA	METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS	ZA	Abandoned	2016/02209	4/4/2016			
MA115PCT	CYTH.114EP	REGENERATIVE CELL THERAPY FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS AND PTSD	EP	Abandoned	15747076.6	9/9/2016			
MA115PCT	CYTH.114NP	REGENERATIVE CELL THERAPY FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS AND PTSD	US	Abandoned	15/117665	8/9/2016			
MA114PR	CYTH.114PR	ADIPOSE-DERIVED REGENERATIVE CELL THERAPY FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS	US	Expired	61/938040	2/10/2014			2/10/2015
MA115PCT	CYTH.114WO	REGENERATIVE CELL THERAPY FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS AND PTSD	WO	Expired	PCT/US2015/015028	2/9/2015			10/10/2016

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA115PR	CYTH.115PR	ADIPOSE-DERIVED REGENERATIVE CELL THERAPY FOR POST- TRAUMATIC STRESS DISORDER	US	Expired	61/938052	2/10/2014			2/10/2015
MA116P	CYTH.116A	TISSUE TRANSFER SYSTEM	US	Abandoned	14/750932	6/25/2015			
MA122NP	CYTH.117NP	CENTRIFUGE CHAMBER	US	Abandoned	15/324596	1/6/2017			
	CYTH.117PR	CENTRIFUGE CHAMBER	US	Expired	62/022131	7/8/2014			7/8/2015
MA122PCT	CYTH.117WO	CENTRIFUGE CHAMBER	WO	Expired	PCT/US2015/039250	7/6/2015			4/4/2018
CIT-7380-CA	CYTH.118CA	USE OF REGENERATIVE CELLS IN MITIGATING BURN PROGRESSION AND IMPROVING SKIN GRAFT INCORPORATION AND HEALING	CA	Abandoned	2963468	3/31/2017			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
	CYTH.118EP	USE OF REGENERATIVE CELLS IN MITIGATING BURN PROGRESSION AND IMPROVING SKIN GRAFT INCORPORATION AND HEALING	EP	Published	15847625.9	5/3/2017			
MA118NP	CYTH.118NP	USE OF REGENERATIVE CELLS IN MITIGATING BURN PROGRESSION AND IMPROVING SKIN GRAFT INCORPORATION AND HEALING	US	Published	15/515870	3/30/2017			
	CYTH.118PR	USE OF REGENERATIVE CELLS IN MITIGATING BURN PROGRESSION AND IMPROVING SKIN GRAFT INCORPORATION AND HEALING	US	Expired	62/059773	10/3/2014			10/3/2015
MA118PCT	CYTH.118WO	USE OF REGENERATIVE CELLS IN MITIGATING BURN PROGRESSION AND IMPROVING SKIN GRAFT INCORPORATION AND HEALING	WO	Expired	PCT/US2015/053856	10/2/2015			6/3/2017
MA123A3	CYTH.123A3	ENDOTHELIAL CELL FUNCTION	US	Unfiled					
MA124PR	CYTH.123PR	ENDOTHELIAL CELL FUNCTION	US	Expired	62/298389	2/22/2016			2/22/2017

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA123PR2	CYTH.123PR2	IMPROVEMENT OF ENDOTHELIAL CELL FUNCTION	US	Expired	62/463508	2/24/2017			2/24/2018
MA123PR3	CYTH.123PR3	ENDOTHELIAL CELL FUNCTION	US	Expired	62/635685	2/27/2018			2/27/2019
MA123WO	CYTH.123WO3	IMPROVEMENT OF ENDOTHELIAL CELL FUNCTION	WO	Pending	PCT/US2019/018176	2/15/2019			10/27/2020
MA124WO	CYTH.124WO	REGENERATIVE CELL THERAPY FOR MUSCULOSKELETAL DISORDERS	WO	Published	PCT/US2016/056043	10/7/2016			6/7/2019
MA124EP	CYTH.124EP	REGENERATIVE CELL THERAPY FOR MUSCULOSKELETAL DISORDERS	EP	To be filed					
MA124NP	CYTH.124NP	REGENERATIVE CELL THERAPY FOR MUSCULOSKELETAL DISORDERS	US	Pending	16/331427	3/7/2019			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA126PR	CYTH.126PR	REGENERATIVE CELLS FOR TREATING OCULAR DAMAGE	US	Expired	62/430290	12/5/2016			12/5/2017
MA127PR	CYTH.127PR	LIPOSOMAL REGENERATIVE CELL SECRETIONS	US	Expired	62/436260	12/19/2016			12/19/2017
MA127PR2	CYTH.127PR2	LIPOSOMAL REGENERATIVE CELL SECRETIONS	US	Abandoned	62/608243	12/20/2017			12/20/2018
MA9837P	CYTH.2CP4CP	CELL-LOADED PROSTHESES FOR REGENERATIVE INTRALUMINAL APPLICATIONS	US	Abandoned	11/317422	12/22/2005			
MA9889P	CYTH.2CPCPCP	METHODS OF USING ADIPOSE TISSUE- DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS	US	Issued	11/138083	5/25/2005	9597395	3/21/2017	9/4/2024
	CYTH.2Q12C2	DEVICES AND METHODS FOR MONITORING, MANAGING, AND SERVICING MEDICAL DEVICES	US	Abandoned	13/467828	5/9/2012			

Cytori Reference:	Knobbe Reference:	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	Expiration Date:
MA9843EP	CYTH.2Q12EP	DEVICES AND METHODS FOR MONITORING, MANAGING, AND SERVICING MEDICAL DEVICES	EP	Abandoned	5711479.5	1/12/2005			
MA9843NP	CYTH.2Q12NP	DEVICES AND METHODS FOR MONITORING, MANAGING, AND SERVICING MEDICAL DEVICES	US	Abandoned	11/813579	12/13/2007			
MA9843PCT	CYTH.2Q12PC	DEVICES AND METHODS FOR MONITORING, MANAGING, AND SERVICING MEDICAL DEVICES	WO	Closed	PCT/US2005/001267	1/12/2005			

Case No.	Title:	Country:	Status:	Application No.	Filing Date:	Reg Date:	Reg No:	Next Renewal:
CYTH.031T	STEMSOURCE	US	Renewed	76/321292	10/3/2001	4/11/2006	3080039	4/11/2026
CYTH.031TD1	STEMSOURCE	US	Renewed	76/975922	10/3/2001	2/3/2004	2811603	2/3/2024
CYTH.032WAU	STEMSOURCE	AU	Renewed	1210865	11/19/2007	10/13/2008	1210865	11/19/2027
CYTH.032WCA	STEMSOURCE	CA	Registered	1136060	4/3/2002	8/28/2006	TMA671319	8/28/2021
CYTH.032WCN	STEMSOURCE	CN	Registered	6390077	11/20/2007	3/28/2010	6390077	3/27/2020
CYTH.032WEU	STEMSOURCE	EM	Renewed	2640597	4/3/2002	4/14/2004	2640597	4/3/2022
CYTH.032WKR	STEMSOURCE	KR	Renewed	45-2007-0005218	11/20/2007	1/5/2009	45-25988	1/5/2029
CYTH.036T	CELUTION	US	Renewed	78/423221	5/21/2004	2/12/2008	3382732	2/12/2028
CYTH.036WCA	CELUTION	CA	Registered	1238400	11/19/2004	2/9/2016	TMA928520	2/9/2031
CYTH.036WEU	CELUTION	EM	Renewed	4130332	11/18/2004	11/21/2005	4130332	11/18/2024
CYTH.037WBR	CELUTION	BR	Renewed	827090188	11/22/2004	4/8/2008	827090188	4/8/2028
CYTH.037WCN	CELUTION	CN	Renewed	4375048	11/22/2004	2/7/2008	4375048	2/6/2028
CYTH.038WBR	CELUTION	BR	Renewed	827090170	11/22/2004	4/8/2008	827090170	4/8/2028
CYTH.038WCN	CELUTION	CN	Renewed	4375051	11/22/2004	2/7/2008	4375051	2/6/2028
CYTH.039WBR	CELUTION	BR	Registered	827090161	11/22/2004	6/29/2010	827090161	6/29/2020
CYTH.039WCN	CELUTION	CN	Renewed	4375050	11/22/2004	6/28/2007	4375050	6/28/2027
CYTH.040WCN	CELUTION	CN	Renewed	4375049	11/22/2004	6/21/2008	4375049	6/20/2028
CYTH.041WKR	CELUTION	KR	Renewed	45-2004-3968	11/19/2004	6/7/2006	45-0016301	6/7/2026
CYTH.043IAU	CYTORI THERAPEUTICS	AU	Renewed	899295	12/14/2005	12/14/2005	899295	12/14/2025
CYTH.043ICN	CYTORI THERAPEUTICS	CN	Renewed	899295	12/14/2005	12/14/2005	899295	12/14/2025
CYTH.043IEM	CYTORI THERAPEUTICS	EM	Renewed	899295	12/14/2005	12/14/2005	899295	12/14/2025
CYTH.043IKR	CYTORI THERAPEUTICS	KR	Renewed	899295	12/14/2005	12/14/2005	899295	12/14/2025
CYTH.043WWO	CYTORI THERAPEUTICS	WO	Renewed	899295	12/14/2005	12/14/2005	899295	12/14/2025
CYTH.045WMX	CYTORI THERAPEUTICS	MX	Renewed	800922	8/17/2006	9/15/2006	952608	8/17/2026
CYTH.046WMX	CYTORI THERAPEUTICS	MX	Renewed	800923	8/17/2006	9/15/2006	952609	8/17/2026
CYTH.048WMX	CYTORI THERAPEUTICS	MX	Renewed	800925	8/17/2006	9/15/2006	952611	8/17/2026
CYTH.049WMX	CYTORI THERAPEUTICS	MX	Renewed	800924	8/17/2006	9/15/2006	952610	8/17/2026

Case No.	Title:	Country:	Status:	Application No.	Filing Date:	Reg Date:	Reg No:	Next Renewal:
CYTH.051ICN	CELASE	CN	Renewed	968466	5/28/2008	5/28/2008	968466	5/28/2028
CYTH.051IEU	CELASE	EM	Renewed	968466	5/28/2008	5/28/2008	968466	5/28/2028
CYTH.051IKR	CELASE	KR	Renewed	968466	5/28/2008	5/28/2008	968466	5/28/2028
CYTH.051T	CELASE	US	Renewed	77/343271	12/4/2007	2/17/2009	3577574	2/17/2029
CYTH.051WBR	CELASE	BR	Registered	829752587	6/4/2008	5/21/2013	829752587	5/21/2023
CYTH.051WCA	CELASE	CA	Registered	1398731	5/30/2008	6/10/2015	TMA905824	6/10/2030
CYTH.051WWO	CELASE	WO	Renewed	968466	5/28/2008	5/28/2008	968466	5/28/2028
CYTH.056WCN	STEMSOURCE	CN	Registered	6390079	11/20/2007	3/28/2010	6390079	3/27/2020
CYTH.057WCN	STEMSOURCE	CN	Registered	6390078	11/20/2007	2/28/2010	6390078	2/27/2020
CYTH.058WCN	STEMSOURCE	CN	Registered	6390080	11/20/2007	8/21/2010	6390080	8/20/2020
CYTH.060WCN	CYTORI & Device	CN	Registered	6930844	9/1/2008	5/14/2010	6930844	5/13/2020
CYTH.060WEU	CYTORI and Design	EM	Renewed	7210041	9/3/2008	4/27/2009	7210041	9/3/2028
CYTH.061WCN	CELUTION and Design	CN	Registered	6930843	9/1/2008	2/14/2012	6930843	2/13/2022
CYTH.061WEU	CELUTION and Design	EM	Renewed	7209976	9/3/2008	5/11/2011	7209976	9/3/2028
CYTH.070T	INTRAVASE	US	Registered	77/566913	9/10/2008	12/7/2010	3886844	12/7/2020
CYTH.070WBR	INTRAVASE	BR	Registered	901496529	3/4/2009	12/4/2012	901496529	12/4/2022
CYTH.070WCA	INTRAVASE	CA	Registered	1430567	3/2/2009	2/9/2016	TMA928516	2/9/2031
CYTH.070WCN	INTRAVASE	CN	Registered	7223034	2/27/2009	11/7/2013	7223034	11/6/2023
CYTH.070WEU	INTRAVASE	EM	Renewed	8131583	3/2/2009	3/1/2010	8131583	3/2/2029
CYTH.070WKR	INTRAVASE	KR	Registered	40-2009-9106	2/27/2009	4/30/2010	40-0821733	4/30/2020
CYTH.076WTW	CYTORI	TW	Registered	98027045	6/24/2009	6/1/2010	1412069	5/31/2020
CYTH.082ICN	CELBRUSH	CN	Registered	1040124	5/19/2010	5/19/2010	1040124	5/19/2020
CYTH.082IEU	CELBRUSH	EM	Registered	1040124	5/19/2010	5/19/2010	1040124	5/19/2020
CYTH.082IKR	CELBRUSH	KR	Registered	1040124	5/19/2010	5/19/2010	1040124	5/19/2020
CYTH.082T	CELBRUSH	US	Registered	77/886129	12/4/2009	8/31/2010	3840473	8/31/2020
CYTH.082WBR	CELBRUSH	BR	Registered	830626778	5/21/2010	8/9/2016	830626778	8/9/2026
CYTH.082WIN	CELBRUSH	IN	Registered	1969451	5/21/2010	5/21/2010	1969451	5/21/2020
CYTH.082WWO	CELBRUSH	WO	Registered	1040124	5/19/2010	5/19/2010	1040124	5/19/2020
CYTH.084WAR	CYTORI	AR	Registered	2988375	3/22/2010	2/28/2011	2425937	2/28/2021

Case No.	Title:	Country:	Status:	Application No.	Filing Date:	Reg Date:	Reg No:	Next Renewal:
CYTH.084WCA	CYTORI	CA	Registered	1534156	7/4/2011	1/4/2016	TMA924742	1/4/2031
CYTH.084WIN	CYTORI	IN	Registered	1937603	3/17/2010	6/25/2015	1937603	3/17/2020
CYTH.085WAU	CELUTION	AU	Registered	1603865	2/3/2014	9/3/2014	1603865	2/3/2024
CYTH.085WIN	CELUTION	IN	Registered	1937602	3/17/2010	3/6/2012	1937602	3/17/2020
CYTH.091WHK	CELUTION	HK	Registered	301699318	8/26/2010	3/8/2011	301699318	8/25/2020
CYTH.122T	HABEO	US	Allowed	87/258999	12/6/2016			
CYTH.122WEM	HABEO	EM	Registered	16662942	5/2/2017	9/1/2017	16662942	5/2/2027
CYTH.129T	CYTORI CELL THERAPY	US	Registered	87/428735	4/27/2017	6/19/2018	5495256	6/19/2028
CYTH.134T	CELUTION	US	Registered	87/164962	9/8/2016	4/18/2017	5185855	4/18/2027
CYTH.135T	CELUTION and Design	US	Registered	87/171408	9/14/2016	6/20/2017	5226684	6/20/2027
CYTH.136T	CYTORI and Design	US	Registered	87/171348	9/14/2016	1/9/2018	5372681	1/9/2028
CYTH.137T	CYTORI	US	Registered	87/165268	9/8/2016	1/23/2018	5383395	1/23/2028

EXHIBIT 2.02(b)(iii)

Cyt Inv Date	Quarter	Cyt Inv Num	Cat Num	New Cat	Cat Desc	FX Rate	Item Num	Lot/Serial Num	Item Description	Class	Units Remaining	Balance Sheet Value USD
02/26/19	Q1-2019	17613	CK001(CD501)		Celution Disposable Set	110.7634	CK001(CD501)	7106296		Consumables	200	102,447.09
09/23/13	Q3 2013	0015335	SC1	SC1	Stemsource Centrifuge	99.4280	1553623	2074		Device	1	32,652.25
11/07/14	Q4-2014	15964	SC1	SC1	Stemsource Centrifuge	114.7100	1553623	2109		Device	1	46,121.87
11/07/14	Q4-2014	15964	SC1	SC1	Stemsource Centrifuge	114.7100	1553623	2114		Device	1	46,121.87
11/07/14	Q4-2014	15964	SC1	SC1	Stemsource Centrifuge	114.7100	1553623	2115		Device	1	46,121.87
12/18/18	Q4-2018	17586	CK001(CD501)		Celution Disposable Set	112.5178	CK001(CD501)	7106262		Consumables	83	43,188.94
01/18/19	Q1-2019	17598	CK001(CR101)		Celase Reagent	109.5201	CK001(CR101)	7106279		Consumables	200	42,480.77
03/09/17	Q1-2017	17200	CV1	CV1	Celution Centrifuge IV	114.6263	CV1	2141		Device	1	40,430.13
09/21/17	Q3-2017	17321	CC1	CC1	Celution Centrifuge	112.4524	CC1	1919		Device	1	39,663.38
09/21/17	Q3-2017	17320	CC1	CC1	Celution Centrifuge	112.4524	CC1	2120		Device	1	39,663.38
08/01/16	Q3-2016	17006	CV1	CV1	Celution Centrifuge IV	102.0200	1553638	2140		Device	1	36,346.53
11/30/17	Q4-2017	17372	CIS201	CIS201	Delivery Instrument Set	111.6900	CIS201			Ancillaries	8	22,943.45
06/07/16	Q2-2016	16873	CC1	CC1	Celution Centrifuge	107.0500	1553624	1983-R		Device	1	22,850.31
01/04/19	Q1-2019	17592	CK001(CR101)		Celase Reagent	108.1984	CK001(CR101)	7106270		Consumables	100	20,984.05
11/30/17	Q4-2017	17372	CIS101	CIS101	Collection Instrument Set	111.6900	CIS101			Ancillaries	7	13,673.36
04/21/17	Q2-2017	17236	1553343	1553343	Power Supply Module	109.1811	1553343			PartsV	1	5,868.15
01/26/17	Q1-2017	17167	1553078	1553078	Peristaltic Pumphead w/Integra	113.6300	1553078			PartsV	2	5,578.41
01/26/17	Q1-2017	17167	1553590	1553590	Anti-Rotation Ring	113.6300	1553590			PartsV	2	5,046.51
01/26/17	Q1-2017	17167	1553013	1553013	Fat Rocker Assembly	113.6300	1553013			PartsV	2	4,399.89
01/26/17	Q1-2017	17167	1553553	1553553	Isolated Anti-Rotation Cap	113.6300	1553553			PartsV	2	3,788.73
01/26/17	Q1-2017	17167	1553587	1553587	Gasket Retainer, Anti Rotation	113.6300	1553587			PartsV	2	3,775.84
01/26/17	Q1-2017	17167	1553066	1553066	Latch Base Assembly	113.6300	1553066			PartsV	2	3,739.60
01/26/17	Q1-2017	17167	1553589	1553589	Adjustment Ring, Anti-Rotation	113.6300	1553589			PartsV	2	3,604.68
12/26/18	Q4-2018	Xfter CR101 to CK001 (CR101)	CK001(CR101)		Celase Reagent	110.6740	CK001(CR101)	7106198		Consumables	14	3,004.98
01/26/17	Q1-2017	17167	1553062	1553062	Spindle Motor Assembly	113.6300	1553062			PartsV	1	2,377.17
09/21/17	Q3-2017	17322	1553066	1553066	Latch Base Assembly	112.4524	1553066			PartsV	1	1,934.49
01/26/17	Q1-2017	17167	1553180	1553180	Lid Assembly	113.6300	1553180			PartsV	2	1,238.64
01/26/17	Q1-2017	17167	1553245	1553245	Lid Latch Assembly	113.6300	1553245			PartsV	2	1,225.78
09/24/18	Q3-2018	17545	CC201		Celution Convenience Kit	112.6400	CC201			Consumables	27	1,149.49
09/28/17	Q3-2017	Shindo	CSS001	CSS001	Syringe Stand	112.7396	CSS001			Ancillaries	9	972.72
11/11/16	Q4-2016	17082	5300467	5300467	Vibration Mount 10-32 Thread S	106.0800	5300467			PartsV	26	844.44
01/26/17	Q1-2017	17167	1553179	1553179	Canister Clamp Assembly	113.6300	1553179			PartsV	2	711.16
01/26/17	Q1-2017	17167	5110002-03	5110002-03	PCB, Controller Celution	113.6300	5110002-03			PartsV	2	666.54
01/26/17	Q1-2017	17167	1553465	1553465	Optical Sensor Assy w/ Gasket	113.6300	1553465			PartsV	2	637.62
01/26/17	Q1-2017	17167	1553005	1553005	Spindle Assembly	113.6300	1553005			PartsV	1	576.23
04/22/15	Q2-2015	16215	CC1	CC1	Pkg Assy, Celution Centrifuge	119.4700	CC1	2117		Device	1	42,110.73
05/13/15	Q2-2015	16263	CC1	CC1	Pkg Assy, Celution Centrifuge	120.0300	CC1	2122		Device	1	42,308.12
05/18/15	Q2-2015	16276	900-0004	900-0004	Nucleocounter	119.2700	900-0004			Ancillaries	2	19,762.08
05/18/15	Q2-2015	16276	950-003	950-003	USB Stock-NucleoView software	119.2700	950-003			Ancillaries	3	-
12/03/15	Q4-2015	16597	CIS201	CIS201	Instrument Set 540/IS	123.2000	941-0002			Ancillaries	2	6,725.51
03/17/16	Q1-2016	16749	CB003	CB003	Celbrush, 3ml	113.3800	CB003	7105192		Ancillaries	1	572.85
12/14/18	Q4-2018	17585	CB010		Celbrush, 10ml	113.4727	CB010	7106229		Ancillaries	1	558.00
07/14/17	Q3-2017	17280	CB003	CB003	Celbrush, 3ml	112.9391	CB003	7105937		Ancillaries	1	539.10
01/26/17	Q1-2017	17167	1553157	1553157	Power Entry Module Assembly	113.6300	1553157			PartsV	2	405.46
06/02/17	Q2-2017	17257	5100212-01	5100212-01	Assy Pressure Sensor 1	111.1729	5100212-01			PartsV	2	402.15
08/23/16	Q3-2016	17031	5100336	5100336	Rapid Fluid Warmer, JPN	100.5400	5100336			Ancillaries	10	379.08
01/26/17	Q1-2017	17167	5100198-04	5100198-04	Acro Valve, Modified 4	113.6300	5100198-04			PartsV	1	373.99
04/21/17	Q2-2017	17236	5100198-01	5100198-01	Acro Valve, Modified 1	109.1811	5100198-01			PartsV	1	359.35
04/21/17	Q2-2017	17236	5100198-02	5100198-02	Acro Valve, Modified 2	109.1811	5100198-02			PartsV	1	359.35
04/21/17	Q2-2017	17236	5100198-03	5100198-03	Acro Valve, Modified 3	109.1811	5100198-03			PartsV	1	359.35
04/21/17	Q2-2017	17236	5100198-05	5100198-05	Acro Valve, Modified 5	109.1811	5100198-05			PartsV	1	359.35
04/21/17	Q2-2017	17236	5100198-06	5100198-06	Acro Valve, Modified 6	109.1811	5100198-06			PartsV	1	359.35

Cyt Inv Date	Quarter	Cyt Inv Num	Cat Num	New Cat	Cat Desc	FX Rate	Item Num	Lot/Serial Num	Item Description	Class	Units Remaining	Balance Sheet Value USD
09/24/18	Q3-2018	17545	CC202		Celution Convenience Kit SB	112.6400	CC202			Consumables	35	306.00
05/12/16	Q2-2016	16842	PG201	PG201	PG Instrument Set	108.7500	1553579			Ancillaries	4	283.52
01/26/17	Q1-2017	17167	1553242	1553242	Lid Hinge Assembly	113.6300	1553242			PartsV	2	237.59
01/26/17	Q1-2017	17167	1553167	1553167	Hanger Rod Saline	113.6300	1553167			PartsV	2	228.14
01/26/17	Q1-2017	17167	1553100	1553100	Centrifuge Cradle Assembly	113.6300	1553100			PartsV	1	190.73
01/26/17	Q1-2017	17167	1553016	1553016	Accelerometer Assembly	113.6300	1553016			PartsV	2	135.35
01/26/17	Q1-2017	17167	5200218	5200218	Handle	113.6300	5200218			PartsV	1	107.44
01/26/17	Q1-2017	17167	5110004-03	5110004-03	Board Servo Assembly, PCA	113.6300	5110004-03			PartsV	2	100.28
01/26/17	Q1-2017	17167	5101018	5101018	Cordset, Japanese, 7 AMP	113.6300	5101018			PartsV	4	98.23
04/21/17	Q2-2017	17236	5200360	5200360	Document Holder	109.1811	5200360			PartsV	1	83.57
	Q3-2016		02-002	02-002	Nipro Catelin Needle	101.2620	02-002		Nipro Catelin Needle	Ancillaries	5	71.00
01/26/17	Q1-2017	17167	5200200	5200200	Caster	113.6300	5200200			PartsV	4	65.81
11/11/16	Q4-2016	17082	1553588	1553588	Anti-Rotation Gasket	106.0800	1553588			PartsV	8	43.69
01/24/17	Q1-2017	17165	900-0004	20012001	Nucleocounter Device Package	113.5500	900-0004	20012001		Ancillaries	1	41.71
07/12/18	Q3-2018	17489	CS003		3ml Compatible Syringe	112.3982	CS003	15M16C8		Ancillaries	2	31.16
01/26/17	Q1-2017	17167	5100279	5100279	Piezo Cable Assembly	113.6300	5100279			PartsV	1	25.58
01/26/17	Q1-2017	17167	5300322	5300322	V-Belt 4-Rib	113.6300	5300322			PartsV	4	24.56
01/26/17	Q1-2017	17167	5200365	5200365	Insert Nut, 10-32	113.6300	5200365			PartsV	8	20.46
	Q3-2016		01-001	01-001	Nipro Disposable Needle	101.2620	01-001		Nipro Disposable Needle	Ancillaries	5	19.45
04/21/17	Q2-2017	17236	5300265	5300265	Bumper, Rubber	109.1811	5300265			PartsV	20	9.83
05/19/15	Q2-2015	16277	1235-01	1235-01	Celase GMP	119.6900	1235-01		Celase GMP	Consumables	5	30.81
	Q3-2016		01-001	01-001	Nipro Disposable Needle	101.2620	01-001		Nipro Disposable Needle	Ancillaries	1	3.89
01/26/17	Q1-2017	17167	5300475	5300475	Finishing Plug, 1/2 Threaded H	113.6300	5300475			PartsV	20	1.60
01/26/17	Q1-2017	17167	5200240-08	5200240-08	Screw, #4-40 x .75", SHCS, SS	113.6300	5200240-08			PartsV	8	0.41
01/26/17	Q1-2017	17167	5200240-05	5200240-05	Screw, #4-40 x .5", SHCS, SS	113.6300	5200240-05			PartsV	7	0.29

LIVE DATA:

BS Consolidated Value (USD)

764,925.27

EXHIBIT 2.02(b)(vi)

Government Funded Equipment														
Contract Number:	HHSO100201200008C													
Contractor:	Cytori Therapeutics, Inc													
Contractor Address	3020 Callan Road, San Diego, CA 92121													
Contract Property POC	Anthony J. Dinger													
POC Phone #	(858) 458-0900 x5435													
POC email	adinger@cytori.com													
Contract Type:	Cost Reimbursable													
AMCG CO:	Wendell Conyers													
AMCG CS:														
BARDA COR:	Oxana Selivanova													
Award Date:	9/28/2012													
Expiration Date:	11/30/2020													
Contract Value:	\$34,621,774.00													
Update	8/10/2018													
HHS Barcode #	Serial Number	Manufacturer	Model	Brief Description	Operator (provide name)	Site	Location/address	Purchase Price	Current Value	CLIN#	COA#	Additional information	Image Names	
Five to six digit number on HHS barcode	N/A (custom)	Manufacturer name	N/A (custom equipment)	ex. Functional Test equipment	Primary Contractor or subcontractor, where equipment is stored	Facility name where equipment is stored	1038 East 15th St. Jasper, IN 47549	\$122,594	\$122,594	Specify which CLIN funds were utilized	Contracting Officer Authorization for	Place additional information about the equipment which is not captured in the previous columns		
431141	2139/H107	Cytori Therapeutics, Inc	Celution 800/IV	Cell Processing Device	Cytori Therapeutics, Inc	Site 2 UTMB	815 Market Street Galveston, TX 77550	\$45,000	\$45,000	004	42.0	Site 2 UTMB Shriners Hospital for Children: Herndon	CTX1_431141_2139/H107	
	2107/H118	Cytori Therapeutics, Inc	Celution 800/IV	Cell Processing Device	Cytori Therapeutics, Inc	Site 10 USF	1 Tampa General Circle G208	\$45,000	\$45,000	004	51.0	Site 10 USF Smith		
431139	2148/H109	Cytori Therapeutics, Inc	Celution 800/IV	Cell Processing Device	Cytori Therapeutics, Inc	Site 3 Medstar DC	110 Irving Street NW: GHRB Room 304 Washington DC, 20010	\$45,000	\$45,000	004	42.0	Site 3 Medstar Hospital Washington DC: Shupp	CTX1_431139_2148/H109	
431138	2149/H110	Cytori Therapeutics, Inc	Celution 800/IV	Cell Processing Device	Cytori Therapeutics, Inc	Site 5 Maricopa	2601 East Roosevelt St Phoenix, AZ 85008	\$45,000	\$45,000	004	42.0	Site 5 Arizona Burn Center at Maicopa Med Center: Foster	CTX1_431138_2149/H110	
431137	2150/H111	Cytori Therapeutics, Inc	Celution 800/IV	Cell Processing Device	Cytori Therapeutics, Inc	Site 7 U of Florida	1600 SW Archer Rd M602 Gainesville, FL 32610	\$45,000	\$45,000	004	42.0	Site 7 Shads Burn Center at University of Florida: Mozingo	CTX1_431137_2150/H111	
431136	2151/H112	Cytori Therapeutics, Inc	Celution 800/IV	Cell Processing Device	Cytori Therapeutics, Inc	Site 6 Ohio State	395 W 12th Ave Columbus, OH 43210	\$45,000	\$45,000	004	42.0	Site 6 Ohio State University: Cochran	CTX1_431136_2151/H112	
461026	2112/H120	Cytori Therapeutics, Inc	Celution 800/IV	Cell Processing Device	Cytori Therapeutics, Inc	San Diego	3020 Callan Road, San Diego 92121	\$45,000	\$45,000	004	51.0	Stored until deployed to clinical sites	CTX1_461026_2112/H120	
461180	2111/H119	Cytori Therapeutics, Inc	Celution 800/IV	Cell Processing Device	Cytori Therapeutics, Inc	San Diego	3020 Callan Road, San Diego 92121	\$45,000	\$45,000	004	51.0	Stored until deployed to clinical sites	CTX1_461180_2111/H119	
431140	2145/H108	Cytori Therapeutics, Inc	Celution 800/IV	Cell Processing Device	Cytori Therapeutics, Inc	San Diego	3020 Callan Road, San Diego 92121	\$45,000	\$45,000	004	42.0	Stored until deployed to clinical sites	CTX1_431140_2145/H108	
451179	2103/H117	Cytori Therapeutics, Inc	Celution 800/IV	Cell Processing Device	Cytori Therapeutics, Inc	Site 1 USC	2051 Marengost. IPT-Burn Unit 5D& 5M Los Angeles, CA 90033	\$45,000	\$45,000	004	51.0	Site 01 USC Warner Garner	CTX1_451179_2103/H117	
431182	A18A00002	Aranz Medical	SilhouetteStar 2000.01	Wound Imaging Camera	Cytori Therapeutics, Inc	Site 5 Maricopa	2601 East Roosevelt St Phoenix, AZ 85008	\$2,500	\$2,500	004	44-18	Site 5 Arizona Burn Center at Maicopa Med Center: Foster	Aranz_431182_A18A00002	
431183	A18A00004	Aranz Medical	SilhouetteStar 2000.01	Wound Imaging Camera	Cytori Therapeutics, Inc	Site 3 Medstar DC	110 Irving Street NW: GHRB Room 304 Washington DC, 20010	\$2,500	\$2,500	004	44-18	Site 3 Medstar Hospital Washington DC: Shupp	Aranz_431183_A18A00004	
431184	A18A00006	Aranz Medical	SilhouetteStar 2000.01	Wound Imaging Camera	Cytori Therapeutics, Inc	Site 7 U of Florida	1600 SW Archer Rd M602 Gainesville, FL 32610	\$2,500	\$2,500	004	44-18	Site 7 Shads Burn Center at University of Florida: Mozingo	Aranz_431184_A18A00006	
431185	A18A00007	Aranz Medical	SilhouetteStar 2000.01	Wound Imaging Camera	Cytori Therapeutics, Inc	San Diego	3020 Callan Road, San Diego 92121	\$2,500	\$2,500	004	44-18	Stored until deployed to clinical sites	Aranz_431185_A18A00007	
431186	A18A00008	Aranz Medical	SilhouetteStar 2000.01	Wound Imaging Camera	Cytori Therapeutics, Inc	San Diego	3020 Callan Road, San Diego 92121	\$2,500	\$2,500	004	44-18	Stored until deployed to clinical sites	Aranz_431186_A18A00008	
431187	A18A00009	Aranz Medical	SilhouetteStar 2000.01	Wound Imaging Camera	Cytori Therapeutics, Inc	Site 1 USC	2051 Marengost. IPT-Burn Unit 5D& 5M Los Angeles, CA 90033	\$2,500	\$2,500	004	44-18	Site 01 USC Warner Garner	Aranz_431187_A18A00009	
431188	A18A00010	Aranz Medical	SilhouetteStar 2000.01	Wound Imaging Camera	Cytori Therapeutics, Inc	Site 2 UTMB	815 Market Street Galveston, TX 77550	\$2,500	\$2,500	004	44-18	Site 2 UTMB Shriners Hospital for Children: Herndon	Aranz_431188_A18A00010	
431189	A18A00011	Aranz Medical	SilhouetteStar 2000.01	Wound Imaging Camera	Cytori Therapeutics, Inc	San Diego	3020 Callan Road, San Diego 92121	\$2,500	\$2,500	004	44-18	Stored until deployed to clinical sites	Aranz_431189_A18A00011	
431190	A18A00012	Aranz Medical	SilhouetteStar 2000.01	Wound Imaging Camera	Cytori Therapeutics, Inc	Site 10 USF	1 Tampa General Circle G208	\$2,500	\$2,500	004	44-18	Site 10 USF Smith	Aranz_431190_A18A00012	
431191	A18A00016	Aranz Medical	SilhouetteStar 2000.01	Wound Imaging Camera	Cytori Therapeutics, Inc	Site 6 Ohio State	395 W 12th Ave Columbus, OH 43210	\$2,500	\$2,500	004	44-18	Site 6 Ohio State University: Cochran	Aranz_431191_A18A00016	
460845	SWL5288	Defin Technologies	VapoMeter	TEWL Measurement	Cytori Therapeutics, Inc	Site 1 USC	2051 Marengost. IPT-Burn Unit 5D& 5M Los Angeles, CA 90033	\$6,340	\$6,340	004	46-18	Site 01 USC Warner Garner	Delfin_460845_SWL5288	
460846	SWL5289	Defin Technologies	VapoMeter	TEWL Measurement	Cytori Therapeutics, Inc	San Diego	3020 Callan Road, San Diego 92121	\$6,340	\$6,340	004	46-18	Stored until deployed to clinical sites	Delfin_460846_SWL5289	
460847	SWL5290	Defin Technologies	VapoMeter	TEWL Measurement	Cytori Therapeutics, Inc	San Diego	3020 Callan Road, San Diego 92121	\$6,340	\$6,340	004	46-18	Stored until deployed to clinical sites	Delfin_460847_SWL5290	
460848	SWL5294	Defin Technologies	VapoMeter	TEWL Measurement	Cytori Therapeutics, Inc	Site 2 UTMB	815 Market Street Galveston, TX 77550	\$6,340	\$6,340	004	46-18	Site 2 UTMB Shriners Hospital for Children: Herndon	Delfin_460848_SWL5294	
460849	SWL5291	Defin Technologies	VapoMeter	TEWL Measurement	Cytori Therapeutics, Inc	Site 7 U of Florida	1600 SW Archer Rd M602 Gainesville, FL 32610	\$6,340	\$6,340	004	46-18	Site 7 Shads Burn Center at University of Florida: Mozingo	Delfin_460849_SWL5291	
460851	SWL5293	Defin Technologies	VapoMeter	TEWL Measurement	Cytori Therapeutics, Inc	Site 10 USF	1 Tampa General Circle G208	\$6,340	\$6,340	004	46-18	Site 10 USF Smith	Delfin_460851_SWL5293	
460852	SWL5297	Defin Technologies	VapoMeter	TEWL Measurement	Cytori Therapeutics, Inc	San Diego	3020 Callan Road, San Diego 92121	\$6,340	\$6,340	004	46-18	Stored until deployed to clinical sites	Delfin_460852_SWL5297	
460850	SWL5292	Defin Technologies	VapoMeter	TEWL Measurement	Cytori Therapeutics, Inc	Site 5 Maricopa	2601 East Roosevelt St Phoenix, AZ 85008	\$6,340	\$6,340	004	46-18	Site 5 Arizona Burn Center at Maicopa Med Center: Foster	Delfin_460850_SWL5292	
460853	SWL5296	Defin Technologies	VapoMeter	TEWL Measurement	Cytori Therapeutics, Inc	Site 6 Ohio State	395 W 12th Ave Columbus, OH 43210	\$6,340	\$6,340	004	46-18	Site 6 Ohio State University: Cochran	Delfin_460853_SWL5296	
460854	SWL5295	Defin Technologies	VapoMeter	TEWL Measurement	Cytori Therapeutics, Inc	Site 3 Medstar DC	110 Irving Street NW: GHRB Room 304 Washington DC, 20010	\$6,340	\$6,340	004	46-18	Site 3 Medstar Hospital Washington DC: Shupp	Delfin_460854_SWL5295	
460855	SFM1072	Defin Technologies	Skin FibroMeter	Skin Hardness Measurement	Cytori Therapeutics, Inc	San Diego	3020 Callan Road, San Diego 92121	\$3,960	\$3,960	004	46-18	Stored until deployed to clinical sites	Delfin_460855_SFM1072	
460856	SFM1075	Defin Technologies	Skin FibroMeter	Skin Hardness Measurement	Cytori Therapeutics, Inc	San Diego	3020 Callan Road, San Diego 92121	\$3,960	\$3,960	004	46-18	Stored until deployed to clinical sites	Delfin_460856_SFM1075	
460857	SFM1076	Defin Technologies	Skin FibroMeter	Skin Hardness Measurement	Cytori Therapeutics, Inc	Site 1 USC	2051 Marengost. IPT-Burn Unit 5D& 5M Los Angeles, CA 90033	\$3,960	\$3,960	004	46-18	Site 01 USC Warner Garner	Delfin_460857_SFM1076	
460858	SFM1079	Defin Technologies	Skin FibroMeter	Skin Hardness Measurement	Cytori Therapeutics, Inc	Site 2 UTMB	815 Market Street Galveston, TX 77550	\$3,960	\$3,960	004	46-18	Site 2 UTMB Shriners Hospital for Children: Herndon	Delfin_460858_SFM1079	
460859	SFM1074	Defin Technologies	Skin FibroMeter	Skin Hardness Measurement	Cytori Therapeutics, Inc	Site 7 U of Florida	1600 SW Archer Rd M602 Gainesville, FL 32610	\$3,960	\$3,960	004	46-18	Site 7 Shads Burn Center at University of Florida: Mozingo	Delfin_460859_SFM1074	
460860	SFM1077	Defin Technologies	Skin FibroMeter	Skin Hardness Measurement	Cytori Therapeutics, Inc	Site 5 Maricopa	2601 East Roosevelt St Phoenix, AZ 85008	\$3,960	\$3,960	004	46-18	Site 5 Arizona Burn Center at Maicopa Med Center: Foster	Delfin_460860_SFM1077	
460861	SFM1078	Defin Technologies	Skin FibroMeter	Skin Hardness Measurement	Cytori Therapeutics, Inc	Site 10 USF	1 Tampa General Circle G208	\$3,960	\$3,960	004	46-18	Site 10 USF Smith	Delfin_460861_SFM1078	
460862	SFM1080	Defin Technologies	Skin FibroMeter	Skin Hardness Measurement	Cytori Therapeutics, Inc	Site 3 Medstar DC	110 Irving Street NW: GHRB Room 304 Washington DC, 20010	\$3,960	\$3,960	004	46-18	Site 3 Medstar Hospital Washington DC: Shupp	Delfin_460862_SFM1080	
461143	SFM1082	Defin Technologies	Skin FibroMeter	Skin Hardness Measurement	Cytori Therapeutics, Inc	San Diego	3020 Callan Road, San Diego 92121	\$3,960	\$3,960	004	46-18	Stored until deployed to clinical sites This Item was found to be defective Original DHHS U.S. Govt Property tag # 460863 *replacement unit recived *	Delfin_461143_SFM1082	
460864	SFM1081	Defin Technologies	Skin FibroMeter	Skin Hardness Measurement	Cytori Therapeutics, Inc	Site 6 Ohio State	395 W 12th Ave Columbus, OH 43210	\$3,960	\$3,960	004	46-18	Site 6 Ohio State University: Cochran	Delfin_460864_SFM1081	
460865	ELM1106	Defin Technologies	ElastiMeter	Skin Elasticity Measurement	Cytori Therapeutics, Inc	San Diego	3020 Callan Road, San Diego 92121	\$3,960	\$3,960	004	46-18	Stored until deployed to clinical sites	Delfin_460865_ELM1106	
460866	ELM1107	Defin Technologies	ElastiMeter	Skin Elasticity Measurement	Cytori Therapeutics, Inc	Site 1 USC	2051 Marengost. IPT-Burn Unit 5D& 5M Los Angeles, CA 90033	\$3,960	\$3,960	004	46-18	Site 01 USC Warner Garner	Delfin_460866_ELM1107	
460867	ELM1109	Defin Technologies	ElastiMeter	Skin Elasticity Measurement	Cytori Therapeutics, Inc	San Diego	3020 Callan Road, San Diego 92121	\$3,960	\$3,960	004	46-18	Stored until deployed to clinical sites	Delfin_460867_ELM1109	
460868	ELM1112	Defin Technologies	ElastiMeter	Skin Elasticity Measurement	Cytori Therapeutics, Inc	Site 2 UTMB	815 Market Street Galveston, TX 77550	\$3,960	\$3,960	004	46-18	Site 2 UTMB Shriners Hospital for Children: Herndon	Delfin_460868_ELM1112	
46086														

HHS Barcode #	Serial Number	Manufacturer	Model	Brief Description	Operator (provide name)	Site	Location/address	Purchase Price	Current Value	CLIN#	COA#	Additional information	Image Names
Five to six digit number on HHS barcode	N/A (custom)	Manufacturer name	N/A (custom equipment)	ex. Functional Test equipment	Primary Contractor or subcontractor, where equipment is stored	Facility name where equipment is stored	1038 East 15th St. Jasper, IN 47549	\$122,594	\$122,594	Specify which CLIN funds were utilized	Contractin g Officer Authorizati on for	Place additional information about the equipment which is not captured in the previous columns	
460991	CND8056VYB	HP	1NW57UT#ATA	Assessment Laptop	Cytori Therapeutics, Inc	Site 1 USC	2051 Marengost. IPT-Burn Unit 5D& 5M Los Angeles, CA 90033	\$680	\$680	004	47-18	Site 01 USC Warner Garner	HP_460991_CND8056VYB
460992	CND8056VWG	HP	1NW57UT#ATA	Assessment Laptop	Cytori Therapeutics, Inc	Site 5 Maricopa	2601 East Roosevelt St Phoenix, AZ 85008	\$680	\$680	004	47-18	Site 5 Arizona Burn Center at Maicopa Med Center: Foster	HP_460992_CND8056VWG
460993	CND8056W2T	HP	1NW57UT#ATA	Assessment Laptop	Cytori Therapeutics, Inc	San Diego	3020 Callan Road, San Diego 92121	\$680	\$680	004	47-18	Stored until deployed to clinical sites	HP_460993_CND8056W2T
460994	CND8056VYN	HP	1NW57UT#ATA	Assessment Laptop	Cytori Therapeutics, Inc	Site 6 Ohio State	395 W 12th Ave Columbus, OH 43210	\$680	\$680	004	47-18	Site 6 Ohio State University: Cochran	HP_460994_CND8056VYN
460995	CND8056VXT	HP	1NW57UT#ATA	Assessment Laptop	Cytori Therapeutics, Inc	Site 2 UTMB	815 Market Street Galveston, TX 77550	\$680	\$680	004	47-18	Site 2 UTMB Shriners Hospital for Children: Herndon	HP_460995_CND8056VXT
460996	CND8056W13	HP	1NW57UT#ATA	Assessment Laptop	Cytori Therapeutics, Inc	San Diego	3020 Callan Road, San Diego 92121	\$680	\$680	004	47-18	Stored until deployed to clinical sites	HP_460996_CND8056W13
460997	CND8056W32	HP	1NW57UT#ATA	Assessment Laptop	Cytori Therapeutics, Inc	Site 3 Medstar DC	110 Irving Street NW: GHRB Room 304 Washington DC, 20010	\$680	\$680	004	47-18	Site 3 Medstar Hospital Washington DC: Shupp	HP_460997_CND8056W32
460998	CND8056VXB	HP	1NW57UT#ATA	Assessment Laptop	Cytori Therapeutics, Inc	San Diego	3020 Callan Road, San Diego 92121	\$680	\$680	004	47-18	Stored until deployed to clinical sites	HP_460998_CND8056VXB

EXHIBIT 3.10(b)

EC CERTIFICATE

for the Quality Assurance System



**according the Directive 93/42/EEC,
Annex II excluding section (4)**

As a Notified Body of the European Union, DEKRA Certification GmbH certifies, that the company
Cytori Therapeutics Inc.

3020 Callan Road, San Diego, California, 92121, USA

Certified locations:

3020 Callan Road, San Diego, California, 92121, USA

applies a quality assurance system according to the Directive 93/42/EEC Annex II for the medical devices listed in the annex. The approval is based on the result of the re-certification audit report no. 51034-Z4-00, the decision dated 2018-07-27 and is only valid in connection with the successful performance of the annual surveillance audits.

This certificate is valid from 2018-10-22 to 2023-10-21

Registration No.: 51034-16-03



Ruth Delbeck-Bayer
DEKRA Certification GmbH Stuttgart; 2018-07-27
Notified Body ID-number: 0124

DEKRA Certification GmbH * Handwerkstraße 15 * D-70565 Stuttgart * www.dekra-certification.de



Benannt durch/Designated by
Zentralstelle der Länder
für Gesundheitsschutz
bei Arzneimitteln und
Medizinprodukten
www.zlg.de
ZLG-BS-295.10.02

CERTIFICATE



EN ISO 13485:2016

DEKRA Certification GmbH hereby certifies that the company

Cytori Therapeutics Inc.

Scope of certification:

Design, development, production, distribution and service of devices, disposables and reagents for collecting, storing, processing and delivery of adult adipose tissue and/or stromal stem cells and progenitor cells

Certified location:

3020 Callan Road, San Diego, California, 92121, USA

(further locations see annex)

has established and maintains a quality management system according to the above mentioned standard. The conformity was adduced with audit report no. 51034-Z4-00.

This certificate is valid from 2018-10-22 to 2021-10-21

Registration No.: 51034-14-00


Ruth Delbeck-Bayer



DEKRA Certification GmbH Stuttgart; 2018-07-27





By Royal Charter

EC Certificate - Full Quality Assurance System

Directive 93/42/EEC on Medical Devices, Annex II excluding Section 4

No.

CE 544833

Issued To:

Cytori Therapeutics, Inc.
3020 Callan Road
San Diego
California
92121
USA

In respect of:

The design, development, manufacture and final inspection of the Celution 800 Cell Processing Device, Celution 805 Consumable Set, Celase reagent and Intravase reagent.

on the basis of our examination of the quality assurance system under the requirements of Council Directive 93/42/EEC, Annex II excluding section 4. The quality assurance system meets the requirements of the directive. For the placing on the market of class III products an Annex II section 4 certificate is required.

For and on behalf of BSI, a Notified Body for the above Directive (Notified Body Number 0086):

Stewart Brain, Head of Compliance & Risk -
Medical Devices

First Issued: **2009-01-16**

Date: **2019-01-29**

Expiry Date: **2024-01-15**

...making excellence a habit.™

Page 1 of 1

Validity of this certificate is conditional on the quality system being maintained to the requirements of the Directive as demonstrated through the required surveillance activities of the Notified Body. This approval excludes all products designed and/or manufactured by a third party on behalf of the company named on this certificate, unless specifically agreed with BSI.

This certificate was issued electronically and is bound by the conditions of the contract.



By Royal Charter

EC Certificate - Full Quality Assurance System

Directive 93/42/EEC on Medical Devices, Annex II excluding Section 4

List of Significant Subcontractors

Recognised as being involved in services relating to the product covered by:

Certificate No: **CE 544833**
 Date: **2019-01-29**
 Issued To: **Cytori Therapeutics, Inc.**
3020 Callan Road
San Diego
California
92121
USA

Subcontractor:

Service(s) supplied

Centurion Sterilization Services
 A Division of Centurion Medical Products Corporation
 3173 East 43rd Street
 Yuma
 Arizona
 85365
 USA

ETO Sterilization

Cytori Ltd
 Deeside Industrial Park East
 Unit 68, Third Avenue
 Deeside
 CH5 2LA
 United Kingdom

Manufacture

Roche Diagnostics GmbH
 Business Area Roche Applied Science
 Nonnenwald 2
 82377 Penzberg
 Germany

Crucial Supplier

...making excellence a habit.™



By Royal Charter

EC Certificate - Full Quality Assurance System

Directive 93/42/EEC on Medical Devices, Annex II excluding Section 4

List of Significant Subcontractors

Recognised as being involved in services relating to the product covered by:

Certificate No: **CE 544833**
Date: **2019-01-29**
Issued To: **Cytori Therapeutics, Inc.**
3020 Callan Road
San Diego
California
92121
USA

Subcontractor:

Service(s) supplied

RSQR Ltd.
Ludgate House
107 Fleet Street
London EC4A 2AB
United Kingdom

EU Representative

Sterigenics UK Limited
Cotes Park Estate
Somercotes
Alfreton
DE55 4NJ
United Kingdom

ETO Sterilization

...making excellence a habit.™



By Royal Charter

EC Certificate - Full Quality Assurance System Certificate History

Certificate No: **CE 544833**
 Date: **2019-01-29**
 Issued To: **Cytori Therapeutics, Inc.**
3020 Callan Road
San Diego
California
92121
USA

Date	Reference Number	Action
16 January 2009	7295372	First issue -transfer from another Notified Body
23 July 2010	7558305	Change to Action wording on History Page for 16 January 2009 from "DEKRA" to "another Notified Body". Extension to scope to include details of specific clinical indications of Plastic & Reconstruction Procedures and General Surgery Procedures to facilitate healing. Addition of RSQR Ltd as EU Representative
23 July 2010	7505991	Extension to scope to include PureGraft 250 I PURE System. Addition of significant subcontractors Dravon Medical Inc. and Sterigenics International Inc.
20 January 2011	7611648	Transfer of Celase reagent from another Notified Body.
16 February 2012	7781768	Removal of 250 ml size restriction by change of scope expression from 'PureGraft 250/PURE System' to 'Puregraft System'. Addition of significant subcontractors Harmac Medical Products Ltd (Manufacture) and Synergy Health Westport Ltd (Gamma Sterilization).
22 February 2013	7945994	Addition of Intravase reagent 6mg to certificate scope.

...making excellence a habit.™

Page 1 of 2

Validity of this certificate is conditional on the quality system being maintained to the requirements of the Directive as demonstrated through the required surveillance activities of the Notified Body. This approval excludes all products designed and/or manufactured by a third party on behalf of the company named on this certificate, unless specifically agreed with BSI.

This certificate was issued electronically and is bound by the conditions of the contract.



By Royal Charter

EC Certificate - Full Quality Assurance System

Certificate History

Certificate No: **CE 544833**
 Date: **2019-01-29**
 Issued To: **Cytori Therapeutics, Inc.**
3020 Callan Road
San Diego
California
92121
USA

Date	Reference Number	Action
23 December 2013	8081404	Certificate Renewal; Administrative update to the EU Rep Address; Removal of Centurion Sterilization Services, Howell and Sterigenics, Oak Brook as significant sub-contractors; Addition of Centurion Sterilization Services, Yuma and Sterigenics US LLC, Corona as significant sub-contractors. Company name updated to include 'Inc.'
29 October 2014	8244219	Extension to scope to include Celution 800/IV System; Addition of Roche Diagnostics, Cytori Ltd, and Sterigenics Alfreton to the list of significant sub-contractors.
24 November 2014	7604378	Classification update for Celase
21 October 2015	8416634	Removal of Puregraft System from scope of certification and supplementary page due to sale of product. Removal of Dravon Medical Inc. Harmac Medical Prodcuts, Ltd., Sterigenics US, LLC and Synergy Health Westport Ltd. as significant sub-contractors.
Current	9703288	Renewal; Removal of supplementary page with indication of the output cells.

...making excellence a habit.™

Page 2 of 2

Validity of this certificate is conditional on the quality system being maintained to the requirements of the Directive as demonstrated through the required surveillance activities of the Notified Body. This approval excludes all products designed and/or manufactured by a third party on behalf of the company named on this certificate, unless specifically agreed with BSI.

This certificate was issued electronically and is bound by the conditions of the contract.

Information and Contact: BSI, Kitemark Court, Davy Avenue, Knowlhill, Milton Keynes MK5 8PP. Tel: + 44 345 080 9000
 BSI Assurance UK Limited, registered in England under number 7805321 at 389 Chiswick High Road, London W4 4AL, UK.
 A member of BSI Group of Companies.

[6.7.4.6.2][CE 544833.pdf][Page 5 of 5]

Safeguarding public health

Our Ref: **CA012371**

Mr Arthur Ellis
Russell Square Quality Representatives Ltd
Ludgate House
107-111 Fleet Street
London
EC4A 2AB
United Kingdom

17 June 2011

Dear Mr Arthur Ellis,

MEDICAL DEVICES REGULATIONS 2002: REGULATION 19
Registration of Persons Placing General Medical Devices on the Market

Thank you for informing the Competent Authority of the details of **Manufacturers Name:- Cytori Therapeutics Inc located at Manufacturers Address:- 3020 Callan Road San Diego California CA 92121 United States** for whom you are acting as the authorised representative and for supplying the medical device information.

Your registration has been recorded based on your declaration that you have determined that the device(s) fall within the definition of "medical device", and that you have classified it/them as falling within Regulation 19 taking into account the intended purpose(s) and mode(s) of action. In accepting your registration, I should make clear that the Competent Authority does not examine each individual notification and therefore cannot and does not necessarily endorse these determinations. Neither does this letter represent any form of accreditation or approval by the UK Competent Authority.

Your registration is based upon your declaration on the RG2 form and means that:

For Manufacturers of Class I medical devices, Assemblers, and Sterilisers

You should now be operating under the Medical Devices Directive and the above Regulations for the products you asked us to register, by fully complying with the essential requirements, CE marking those products or labelling them as such.

For Manufacturers of Custom-made devices

You should be ready to claim compliance with the Directive and Regulations and should be manufacturing custom-made devices in accordance with their requirements.

If you stop placing devices on the market or if you are not complying with the Regulations you should inform us so that we can amend our records. You should be aware that it is an offence to place on the market CE marked devices that do not comply with the regulations.

The information you provided has been recorded against the reference number shown at the top of this letter, which we ask you to quote in all future correspondence and communications.

Please inform us of any changes to:

- the company information
- additional generic groups of devices (not individual products within an existing generic group)
- discontinuation of a generic group of devices.

Safeguarding public health

MHRA

Please use RG2, the Registration form, to tell us about any of these changes.

Thank you for registering the following generic groups of devices:

Class I Devices:

Surgical Instrument Accessories

Custom Made Devices:

None

Products Covered By Article 12:

Surgical Procedure Packs (Includes Instruments Supplied Singulary)

Confidentiality

Please note that in accordance with Directive 2007/47/EC as of 21st March 2010 information on the registration of persons responsible for placing devices on the market will no longer be treated as confidential and the Competent Authority will provide third parties with information on the name and address of manufacturers and authorised representatives and their devices that have been registered. However the names of individuals, their telephone numbers and email addresses will remain confidential unless you have chosen to trade using personal details. This change only applies to medical devices and does not affect In Vitro Diagnostic devices registration, which remain confidentiality under Article 19 of the In Vitro Diagnostic Directive 98/79EC.

If your company name or that of a manufacturer that you represent is based on an individual's personal name it will be published unless you inform the MHRA that you would like the company name to remain confidential.

Likewise, if your company address or that of a manufacturer that you represent is the personal home address of an individual it will be published unless you inform the MHRA that you would like the company address to remain confidential.

Should you have any queries regarding your registration please do not hesitate in contacting us.

Yours sincerely



Sean Williams
Regulatory Affairs Administrator

Direct Tel: 0203 080 7325
Email: sean.williams@mhra.gsi.gov.uk

EXHIBIT 2

AMENDED AND RESTATED LICENSE / SUPPLY AGREEMENT

THIS AMENDED AND RESTATED LICENSE/SUPPLY AGREEMENT (the “Agreement”), effective as of the last signature date affixed below (the “**Effective Date**”), is made and entered into by and between **LOREM VASCULAR, PTY. LTD.**, located at Level 12, 2 Queen Street, Melbourne 3000, Australia (“**Lorem**”) and **CYTORI THERAPEUTICS, INC.**, a Delaware corporation, located at 3020 Callan Road, San Diego, CA 92121 (“**Cytori**”). This Agreement replaces and supersedes in its entirety the original **LICENSE/SUPPLY AGREEMENT** entered into between the Parties hereto on the 29th day of October, 2013 (the “Original Agreement”).

(Lorem and Cytori may each be individually referred to herein as a “**Party**” and collectively as the “**Parties**”).

RECITALS

A. WHEREAS, Cytori has acquired, developed and possesses, through the expenditure of considerable time, effort and money, certain proprietary products and intellectual property rights (including medical devices, techniques and therapies, know-how, patents, patent applications and technical trade secrets) in connection with regenerative cell technology and cell/tissue banking technology, used to carry out regenerative cell therapies and treatments (“Cytori Technology”), and

B. WHEREAS, Lorem desires to obtain from Cytori, the exclusive license rights to market, to sell and distribute the “Cytori Products” in the “Fields of Use” within the “Territory” (as each of these terms are defined below); and

C. WHEREAS, Lorem has agreed to purchase Eight Million (8,000,000) shares common stock in Cytori at a price of Three Dollars (\$3.00) per share for a total of Twenty Four Million (\$24,000,000) pursuant to the terms of the Stock Purchase Agreement executed between the Parties; and

D. WHEREAS, Cytori desires to grant to Lorem exclusive license rights to market, to sell and distribute the “Cytori Products” in the Fields of Use within the Territory, and to manufacture and supply to Lorem, the Cytori Products on the terms and conditions set forth herein; and

NOW, THEREFORE, in consideration of the foregoing, the mutual promises herein contained, and for other good and valuable consideration, the receipt and adequacy of which are acknowledged, the Parties agree as follows:

1. DEFINITIONS

1.1 Defined Terms. As used in this Agreement, the capitalized terms set forth in this Section 1 shall have the following meanings:

“**Affiliate**” means, as to any Party, any Person that, directly or indirectly, controls, or is controlled by, or is under common control with, such Party, where “control” (including, with its correlative meanings, “controlled by” and “under common control with”) means (a) the beneficial ownership of fifty percent (50%) or more of the outstanding voting securities of a Party, or (b) the possession, directly or indirectly, of the power to direct or cause the direction of management or policies of a Party, whether through the ownership of securities or partnership or other ownership interests, by contract or otherwise.

“**Agreement**” shall have the meaning set forth in the Preamble.

“**Business Day**” shall mean any day on which banking institutions are open in the United States.

“**Cardiovascular Field**” shall mean applications of the Cytori Products for use in the treatment of cardiovascular disease, including but not limited to:

- Coronary heart disease (also ischemic heart disease or coronary artery disease)
- Cardiomyopathy - diseases of cardiac muscle
- Acute myocardial infarction
- Hypertensive heart disease - diseases of the heart secondary to high blood pressure
- Heart failure
- Inflammatory heart disease
 - Endocarditis – inflammation of the endocardium.
 - Myocarditis – inflammation of the myocardium
- Cerebrovascular disease- disease of blood vessels that supplies to the brain such as stroke (including the brain)
- PVD/PAD (Peripheral arterial/vascular disease) - disease of blood vessels that supplies to the arms and legs
- Valvular disease
- Cardiac conduction system disorders
- Pulmonary hypertension
- Chronic obstructive pulmonary disease (COPD)
- Acute Kidney Injury
- Renal Failure
- Other Kidney organ conditions

The Cardiovascular Field also includes Cytori’s proprietary, state-of-the-art system for adipose tissue and adipose-derived stem and regenerative cell (“**ADRC**”) harvesting, processing, cryopreservation, storage, and retrieval in connection with the treatment of Cardiovascular Field related injuries and conditions.

“**Cytori**” shall have the meaning set forth in the Preamble.

“**Cytori Products**” shall mean all Cytori products identified in the attached Schedule 1, including all future generations of such related Cytori products applicable to the Fields of Use during the License Term.

“**Delivery Date**” shall mean the date of delivery of Cytori Product(s) by Cytori to Lorem.

“**Diabetes Field of Use**” shall mean the treatment of Diabetes and related conditions that are directly caused by Diabetes.

“**Documentation**” shall mean the user and technical manuals and other documentation necessary in connection with commercialization of the Cytori Products.

“**Effective Date**” shall have the meaning set forth in the Preamble.

“**Equine Field of Use**” shall mean the treatment of Horses for any and all medical conditions where the Celution System may be applicable.

“**Fields of Use**” shall mean all applications and uses of the Cytori Products in humans including but not limited to, the Cardiovascular Field, the Diabetes Field of Use, the Orthopedic Field of use. The only excluded human medical applications are the Hair Field of use, which has been previously licensed to Bimini Technologies, Inc. This definition also includes the Equine Field of Use for the treatment of horses.

“**Force Majeure Event**” shall have the meaning set forth in Section 3.10.1

“**Hair Field**” shall mean sale and use of the Celution Product derived ADRC’s applied "Locally" to the affected skin to reverse, stop or slow hair loss and/or re-grow lost or removed hair and/or improve existing hair follicle thickness, hair color, texture or form, whether alone or in combination with Puregraft processed fat and/or scaffolds or matrices and/or any other additive or combination of additives and alone or in combination with other procedures and treatments. "Locally" is defined as the delivery of cells into the skin and/or epicutaneous and /or subcutaneous space at or adjacent to an affected area. This Field of use may not be used or marketed to treat the underlying systemic conditions that may be the causes of hair loss, such as thyroid or hormone regulation, or immune disorders, though in such cases it may be used as a localized treatment into the skin or subcutaneous space at or adjacent to an affected area. This Hair Field specifically excludes any and all marketing and use of the Celution Products for the treatment of thermal and radiation burns to the skin, as well as any systemic (such as intravascular, blood vessel) delivery of cells.

“Intellectual Property Rights” shall mean (a) all inventions (whether patentable or not and whether or not actually reduced to practice), all improvements thereto, and all patents, provisional and non-provisional patent applications and patent disclosures, together with all reissuance’s, divisions, continuations, continuations-in-part, renewals, extensions and reexaminations thereof, (b) all copyrightable works, all works of authorship, all copyrights, and all applications, registrations and renewals in connection therewith, (c) all mask works and all applications, registrations and renewals in connection therewith, (d) all trademarks, service marks, trade names, service names, brand names, trade dress rights, logos, Internet domain names and corporate names, together with the goodwill associated with any of the foregoing, (e) all trade secrets and confidential business information (including, but not limited to, ideas, research and development information, know-how, formulas, compositions, biochemical and biological materials, reagents, assays, manufacturing and production processes and techniques, technical data, data base rights, designs, drawings, specifications, customer and supplier lists, pricing and cost information and business and marketing plans and proposals, and (f) any and all applications and registrations of the foregoing (in any jurisdiction).

“Liens” shall mean all liens, pledges, charges, mortgages, deeds of trust, hypothecations, title defects, restrictions, conditions, easements, claims, options, leases, rights of possession or use, encumbrances, adverse rights or claims and security interests of any kind or nature whatsoever (including any restriction on the right to vote or transfer), whether voluntarily incurred or arising by operation of law or otherwise, including, without limitation, any written or oral agreement to give or grant any of the foregoing.

“NDA” shall mean the Mutual Non-Disclosure Agreement, dated August __, 2013, entered into by and among Cytori, and Lorem.

“Lorem IP” shall mean all Intellectual Property Rights owned by or acquired by Lorem in connection with and during the term of this Agreement.

“Orthopedic Field” shall mean applications of the Cytori Products for use in connection with the tissues of the musculoskeletal system including: bones, muscles, cartilage, and associated joints of the spinal and skeletal system, and associated tendons, ligaments, spinal discs and synovium.

“Party” and **“Parties”** shall have the meaning set forth in the Preamble.

“Person” shall mean an association, corporation, individual, partnership, trust or any other entity or organization, including a governmental entity, other than a Party.

“Term” shall have the meaning set forth in Section 2.3.

“Territory” or “Territories” shall mean the Country of Peoples Republic of China, including Hong Kong, and the Countries of Australia, Malaysia and Singapore. Taiwan is not included within the Territory.

“**Trademark**” shall mean all trademarks, service marks, trademark and service mark applications, trade dress, trade names, logos, insignia, symbols, designs or other marks identifying a party or its products.

“**Warranty Period**” shall have the meaning set forth in Section 3.6.1.

1.2 References. In this Agreement, a reference to:

(a) A Section, Sub-section, Preamble, Recital, Attachment, Schedule or Exhibit is, unless the context otherwise requires, a reference to a section or sub-section of, or a preamble, recital, attachment, schedule or exhibit to, this Agreement;

(b) “This Agreement” (or any specific provision hereof) shall be construed as references to this Agreement or that provision as amended, varied or modified from time to time;

(c) “\$” or “USD” refers to United States Dollars, the lawful currency for the time being of the United States of America; and

(d) All references in this Agreement to “days” will, unless otherwise specified herein, mean calendar days.

1.3 Headings. Headings in this Agreement are for ease of reference only and shall not affect the interpretation or construction of this Agreement.

1.4 Attachments, Schedules and Exhibits. The Attachments, Schedules and Exhibits attached hereto are incorporated herein and form a part of this Agreement.

2. THE LICENSE GRANTED BY CYTORI

2.1 License Grant and Sublicenses.

2.1.1 Cytori License Grant. Subject to the terms, conditions and limitations set forth in this Agreement, Cytori hereby grants to Lorem an exclusive, sublicenseable, fully paid-up, license to sell and use (including but not limited to: import, market, offer to sell, use, distribute, service & maintain) the Cytori Products within “Fields of Use” in the Territory during the Term, excluding only the human fields of use as excluded in that definition. The right of Lorem to grant sublicenses to any third party shall be subject to the reasonable and prompt consent of Cytori, and full compliance with the terms of this Agreement, and any breach thereof by any sublicensee shall be the responsibility of Lorem.

2.1.2 Sales and Distribution Restrictions. Lorem acknowledges and agrees that its right of License granted above does not include any rights outside of the Territory and therefore, Lorem may not: (a) seek customers through marketing or any other means in outside of the Territory, (b) establish any branch or maintain any distribution depot for the Cytori Products outside of the Territory; (c) market or sell the Cytori Products to any customer outside of the Territory. Lorem also agrees that it shall not during the Term of this Agreement, offer, promote, market, distribute or sell any form of cell therapy, or other therapy that is or reasonably could be competitive to the Cytori Products in the Fields of Use in the Territory. Lorem and Cytori each agree to comply with the additional obligations and restrictions provided in Section 3.4 of this Agreement.

2.2 License Fees, Royalty Payments & Opening Purchase Commitments.

2.2.1 License Fees. In consideration of the license granted by Cytori to Lorem pursuant to Section 2.1, and for Cytori's other obligations set forth in this Agreement, Lorem shall pay Cytori a license fee in the amount of Five Hundred Million Dollars (\$500,000,000) (the "License Fee") as follows:

- (a) Within thirty (30) calendar days of each date Lorem sequentially achieves cumulative Gross Profits of Fifty Million Dollars (US\$50,000,000) from the sale of Cytori Products and related services, Lorem shall pay Cytori Ten Million Dollars (US\$10,000,000) in license fees (the "License Fee Payments") by wire transfer of immediately available funds to the bank account designated by Cytori in writing. The License Fee Payments (for each subsequent increment of US\$50,000,000 in gross revenues) shall continue until Lorem has paid a total of fifty (50) License Fee Payments for a total of Five Hundred Million Dollars (US\$500,000,000) . The above License Fee Payment rate was based upon a substantially discounted Fields of Use consumable transfer price.

For purposes of illustration, when Lorem's aggregate cumulative gross profits equals Fifty Million Dollars (US\$50,000,000), Lorem will immediately notify and pay Cytori Ten Million Dollars (US\$10,000,000). When aggregate cumulative gross profits equals One Hundred Million Dollars (US\$100,000,000), Lorem will immediately notify and pay Cytori Ten Million Dollars (US\$10,000,000). The License Fee Payments will continue until Lorem aggregate cumulative gross profits exceeds Two Billion, Five Hundred Million Dollars (US\$2,500,000,000).

2.2.2 Royalty Payments. In consideration of the license and rights granted by Cytori to Lorem pursuant to Section 2.1, and for Cytori's supply obligations set forth in this Agreement (specifically Product transfer pricing), Lorem shall pay Cytori a Royalty (in addition to the License Fee Payments) of thirty percent (30%) of Lorem's Gross Profits for its operations in China, Malaysia and Hong Kong each quarter, provided that royalty payments are to be made two quarters (six months) in arrears. This Royalty Payment shall be payable for the full Term of this Agreement.

2.2.3 Opening Commercial Purchases.

- (a) Initial Order. On or before December 24, 2013, Lorem shall place an Initial Order for the purchase of a minimum of: twelve (12) Celution 800/IV Devices; and one hundred and thirty (130) Celution 805/IV Consumable Sets for immediate delivery in December. The Initial Order price for each of the Celution 800/IV Devices is***, and the Initial Order price for each of the Celution 805/IV Consumable Sets is ***.
- (b) Effective upon receipt of regulatory approval in China (including class 1 approval), Lorem shall be required to place an opening order to purchase a minimum of: twenty-three (23) Celution 800/IV Devices; and one thousand one hundred (1,100) Celution 805/IV Consumable Sets. The Cytori Product Pricing for this order shall be as specified in Section 3.2.1.

2.3 Term and Termination.

2.3.1 Term of this Agreement. The term of this Agreement shall commence on the Effective Date and shall continue in full force and effect until the expiration or termination of the “Term” for the License granted herein as provided in Section 2.3.2 below.

2.3.2 Term of Licenses. The term of the Licenses granted herein shall extend from the Effective Date for a period of Thirty (30) years thereafter (the “**Term**”).

2.3.3 License Term Extension. An extension of the Term for the License shall be granted provided the parties, acting in good faith (each using their best efforts) are able to agree upon commercially reasonable extension terms within six months prior to the end of the then current Term.

2.3.4 Termination. This Agreement shall terminate in its entirety:

- (a) Upon the expiration or earlier termination of the License granted under this Agreement.

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

- (b) Upon the material breach of this Agreement by a Party, their successors or assigns or sublicensees (as applicable), provided such breach has not been cured within sixty (60) days of receipt of notice of breach from the other Party. The parties also agree that: (i) where the termination of a sublicensee may be fully sufficient to prevent the breach from recurring (except in the case of Corrupt activities in Section 3.13.1), that such lesser remedies may be pursued in preference to terminating the entire Agreement, and (ii) If the Default is due to a Failure of Supply event by Cytori (as defined in Section 3.3.8), such Default shall be handled exclusively as prescribed in Section 3.3.8, which shall be the sole remedy therefore

2.3.5 Bankruptcy.

- (a) In the event of the filing or institution of bankruptcy, liquidation or receivership proceedings by or against Lorem; which proceedings are not dismissed within 90 days after the filing thereof, Cytori shall then have the full, unrestricted right to market, distribute and sell the Cytori Products into the Territory within the Fields of Use for its own account. Nonetheless, if any reorganized Lorem, or any lawful successor of Lorem's undivided herein licensed interests is fully capable and willing to abide by the terms of this Agreement and meet market demand for the Cytori Products in the Territory within one (1) calendar year from the initial filing of bankruptcy, liquidation or receivership proceedings, Cytori shall cease all such activities within the Fields of Use in the Territory, and honor the terms of this Agreement with such party, provided such party assumes all reasonable liabilities or commitments entered into by Cytori in the Territory during such interim period. If no reorganized Lorem, or any lawful successor of Lorem's undivided interests licensed herein is capable and willing to meet market demand for the Cytori Products within the (1) year period, this Agreement shall terminate in its entirety.
- (b) In the event of the filing or institution of bankruptcy, liquidation or receivership proceedings by or against Cytori; which proceedings are not dismissed within 90 days after the filing thereof, Lorem shall be entitled to exercise all rights pursuant to a Failure of Supply (Section 3.3.8), including access to all Technology and Source Codes in Escrow, unless Cytori is able to provide commercially reasonable assurances that it can and will continue to supply the Celution Products to Lorem as contemplated by the Agreement.

2.4 Representations and Warranties.

2.4.1 Representations and Warranties of Cytori. Cytori represents and warrants to Lorem that:

(a) Cytori is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, and that Cytori has full power and authority, and has taken all action necessary, to execute and deliver this Agreement and to fulfill its obligations under, and to consummate the transactions contemplated by, this Agreement.

(b) The execution, delivery and performance of this Agreement by Cytori will not result in any breach or violation of, or conflict with, any contract, agreement, undertaking, judgment, decree, order, law, regulation or rule to which Cytori is a party or by which Cytori or any of its assets are bound.

(c) This Agreement has been duly and validly executed and delivered by Cytori and is binding upon and enforceable against Cytori and its successors and assigns in accordance with its terms.

(e) Cytori has the full right and authority to grant the licenses provided under Section 2.1 herein.

2.4.2 Representations and Warranties of Lorem. Lorem represents and warrants to Cytori that:

(a) Lorem is a corporation duly organized, validly existing and in good standing under the laws of the Australia, and that Lorem has full power and authority, and has taken all action necessary, to execute and deliver this Agreement and to fulfill its obligations under, and to consummate the transactions contemplated by, this Agreement.

(b) The execution, delivery and performance of this Agreement by Lorem will not result in any breach or violation of, or conflict with, any contract, agreement, undertaking, judgment, decree, order, law, regulation or rule to which Lorem is a party or by which Lorem or any of its assets are bound.

(c) This Agreement has been duly and validly executed and delivered by Lorem and is binding upon and enforceable against Lorem in accordance with its terms.

3. COMMERCIAL AGREEMENT

3.2 Supply Arrangement. Cytori agrees to manufacture and sell the Cytori Products to Lorem during the Term of this Agreement for Lorem's exercise of the Licenses granted by Cytori in accordance with the commercial terms contained herein, and subject to Lorem's material compliance with all applicable laws and the restrictions and obligations contained herein.

3.2 Prices and Payment Terms.

3.2.1 Product Price- China/Malaysia. The transfer price for the Cytori Product(s) for China, Hong Kong and Malaysia (excluding- shipping costs, duties, taxes, import or export fees, installation, service or maintenance) shall be determined as follows:

- (a) Celution Cell Processing Devices (Celution 800 IV Devices)- initial transfer price shall be***. One year standard warranty included.
- (b) Celution Consumable Kits (Celution 805 IV Consumable Sets)- transfer price for consumables shall*** with initial pricing established in Schedule 2. For clarity, *** are anticipated to go down over time through efficiencies, economies of scale and next generation products.
- (c) Standard Cardiovascular Cell/Tissue Bank- the initial transfer price for all standard bank equipment, installation, training, software and SOP's from Cytori is *** (subject to inflation adjustments, demonstrated equipment cost increases). The StemSource Web-based Software Database- shall be available for use by Lorem customers free of charge for the first two years of operation of the bank, and thereafter subject to flat annual access fee. The fee shall be established annually based on a 30% discount from our standard annual fee per Bank. Our current standard Database fee is ***.
- (d) Loaner Devices- Cytori shall provide Lorem One (1) Loaner Celution Device (Loaner Devices) for every ten (10) new Celution Devices initially ordered pursuant to Section 2.2.3 by Lorem. The Loaner Devices shall be provided to Lorem free of charge (excluding- shipping costs, duties, taxes, import or export fees, installation, service or maintenance) and may consist of used and/or refurbished devices (in good operating condition) or new devices in Cytori's sole discretion. Lorem may only use the Loaner Devices for temporary short term use (not to exceed 3 months) as required in the event of malfunctions or necessary repairs of a purchased system. These "Loaner Devices" may not be sold or leased or otherwise lent to any customer except as expressly indicated above. Subsequent to the first full year of commercial sales by Lorem, additional Loaner Devices shall be made available to Lorem free of charge from time to time as needed, based on mutual consultation concerning failure rates and required loaner system availability, subject to the limitation that the total number of Loaner Devices available shall at no time exceed ten percent (10%) of the total purchased Celution Devices then operational in the field within three (3) years of their original purchase date. Lorem is fully responsible to maintain and repair all Loaner Devices keeping them in good working order during the reasonable life expectancy thereof.

3.2.2 Intravascular/Cardiac Product Prices- Australia/Singapore. After completion of the Initial Order in Section 2.2.3 (a) the transfer price for the Intravascular/Cardiac Cytori Product(s) for Singapore and Australia (excluding- shipping costs, duties, taxes, import or export fees, installation, service or maintenance) shall be determined as follows:

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

- (a) Celution Cell Processing Devices (Celution 800 IV Devices)- initial transfer price shall be***. Standard warranty included.
- (b) Celution Consumable Kits (Celution 805 IV Consumable Sets)- initial transfer price shall be***for the consumables.
- (c) Standard Cardiovascular Cell/Tissue Bank- the initial transfer price for all standard bank equipment, installation, training, software and SOP's from Cytori is *** (subject to inflation adjustments, demonstrated equipment cost increases). The StemSource Web-based Software Database- shall be available for use by Lorem customers free of charge for the first two years of operation of the bank, and thereafter subject to flat annual access fee. The fee shall be established annually based on a 30% discount from our standard annual fee per Bank. Our current standard Database fee is ***.

3.2.3 Product Price- Australia/Singapore. The transfer price for the non-vascular Consumables Product(s) and Celution Cell Processing Devices for Singapore and Australia (excluding- shipping costs, duties, taxes, import or export fees, installation, service or maintenance) shall be ***for Consumable Kits, and ***Celution Cell Processing Devices.

3.2.4 Market Conditions and Inflation Adjustments- All fixed transfer prices shall be subject to annual review to take into account market conditions and necessary inflation adjustments based on the relevant Bureau of Labor and Statistics Consumer Price Index. Price adjustments must not exceed 5% in any year (either up or down), provided that such adjustments may exceed this 5% limitation in the event that Cytori reasonably demonstrates that it has experienced substantial cost increases, or in the event market price data reasonably demonstrate the need for price reductions. Cytori shall provide written notice in the event of any such price adjustment no less than 30 days prior to the effectiveness of the increase.

3.2.5 Invoicing and Payment Procedure. Cytori shall invoice Lorem concurrently with its delivery of the Cytori Product(s) ordered by Lorem. Lorem shall pay for the Cytori Product(s) delivered in accordance with each Order within a maximum of forty-five (45) calendar days from the date that Lorem receives the corresponding invoice issued by Cytori. Invoices issued by Cytori shall reference the relevant Order number, and indicate (a) applicable tax (if any), (b) quantities of Cytori Product(s) shipped, and (c) date of shipment of the Cytori Product(s) to Lorem or its designee.

3.2.6 Late Payment. If any payment amount under any invoice issued by Cytori as specified herein becomes overdue, Lorem shall pay to Cytori, upon written demand from Cytori, interest on the unpaid, overdue, balance at the lesser of (a) the maximum rate permitted by law, and (b) ten percent (10%) per annum on the outstanding, balance. To the extent that any payment of Lorem is overdue, payments received by Cytori from Lorem shall first be applied to any such accrued but unpaid overdue amount. In the even any overdue amounts exceed ninety (90) days from the date of invoice, Cytori shall not be required to accept or ship any additional orders by Lorem until all outstanding invoices are paid in full.

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

3.3 Order and Forecast.

3.3.1 Orders. The purchase and sale of the Cytori Product(s) hereunder shall be made by written or electronic purchase order issued by Lorem to Cytori, for purchase of Cytori Product(s) by Lorem ("**Order(s)**"). Lorem shall, on or before the first Business Day of each month, place an Order for Cytori Product(s) in amounts for such month that are in accordance with the applicable Forecast(s) previously submitted by Lorem in accordance with this Section 3.3. For all orders in each Territory that are purchased pursuant to Binding Forecasts under Section 3.3.5, the "**Delivery Date**" specified in an Order shall be no earlier than forty-five (45) days from the date the relevant Order is placed by Lorem, provided that Cytori shall use commercially reasonable efforts to deliver the Cytori Products sooner if early delivery is requested. For all Orders purchased prior to the implementation of Binding forecasts, the Delivery Date specified in such Orders shall be no earlier than ninety (90) days from the date the relevant Order is placed, unless an earlier date is mutually agreed by the parties. Each Order will include: (a) a reference to this Agreement and Section, (b) Order quantities, (c) specifications and/or type/model number of the Cytori Product(s) ordered; (d) each Cytori Product unit price and the total price for all Cytori Product(s) in the Order, (e) shipping instructions, (f) requested Delivery Date in accordance with this Section 3.3.1 (including Delivery Dates for partial shipments of ordered Cytori Product(s) on different dates); and (g) shipping and billing address. In the event of any conflict between or among the terms and conditions of this Agreement and the terms and conditions specified in a Order (including Order acknowledgement by Cytori), such provisions shall be construed in a mutually consistent manner or, if such construction is not reasonably possible, the provisions of this Agreement shall govern and prevail.

3.3.2 Order Acknowledgment. Cytori shall confirm its receipt of an Order electronically or by facsimile to Lorem within five (5) Business Days of Cytori's receipt of each such Order, stating the applicable Product purchase price and expected Delivery Date. For any Orders that exceed one hundred twenty-five percent (125%) of the applicable Forecast in quantity, Cytori may reject such Orders to the extent such Order exceeds 125% of the applicable Forecast. Cytori shall specifically acknowledge or reject any Order that exceeds 125% of the Forecast within five (5) Business Days from the date on which Cytori receives such Order, or the order will be deemed accepted and binding on the Parties.

3.3.3 Order Address. All Orders shall be sent to the following address:

Cytori Therapeutics, Inc.
 3020 Callan Road
 San Diego, CA 92121, U.S.A.
 Fax: 858-200-0951
 E-mail: orders@cytori.com

Attn: Customer Service

3.3.4 Order Changes. Once submitted, Orders may not be withdrawn, revoked or altered in any way by Lorem without Cytori's prior written consent. Furthermore, except as specifically provided herein or otherwise agreed by Lorem and Cytori, Orders accepted by Cytori may not be withdrawn, revoked, altered or cancelled.

3.3.5 Partially Binding Forecast. Beginning on the later of: (i) twelve (12) months from the Effective Date, or (ii) twelve (12) months after the receipt of regulatory approval for any specific country in the Territory, then, on the [15th] day of every second calendar month thereafter during the Term (or, if such day is not a Business Day, then on the immediately following Business Day), Lorem shall submit to Cytori a six (6) month rolling, partially binding forecast (each a "**Forecast**") of the quantities of each Cytori Product anticipated to be purchased during the upcoming six (6) calendar month period (the "**Forecast Period**"). Each Forecast, and the quantities forecasted for purchase during the Forecast Period covered thereby, shall be partially binding upon CYTORI and Lorem as follows:

Month after delivery of Forecast by Lorem	Flexibility
Month 1:	Binding (100%) (Shall be reflected without change in Orders sent in the month immediately following the month on which the Forecast is delivered by CYTORI).
Month 2:	Binding (100%) (Shall be reflected without change in the Forecast of the immediately following month as Month 1).
Month 3: (Partially Binding Month)	Partially binding (Upward adjustment by no more than thirty percent (30%), or downward adjustment by more than twenty percent (20%) of the amounts indicated for Month 3 may be made by Lorem, as any such adjustments shall be reflected in the Forecast of the immediately following month as Month 2).
Month 4: (Partially Binding Month)	Partially binding (Upward adjustment by no more than thirty percent (30%), or downward adjustment by more than twenty percent (20%) of the amounts indicated for Month 4 may be made by Lorem, as any such adjustments shall be reflected in the Forecast of the immediately following month as Month 3).

Month 5:	Non-binding (0%) (May be completely changed in the Forecast, as any such adjustments shall be reflected in the Forecast of the immediately following month as Month 4).
Month 6:	Non-binding (0%) (May be completely changed in the Forecast, as any such adjustments shall be reflected in the Forecast of the immediately following month as Month 5).

3.3.6 Manufacturing Capacity. The Parties agree and acknowledge that Cytori has a finite capacity to manufacture, or procure the manufacture of, Cytori Product(s) during any given calendar quarter. In the event Cytori production limits result in material (25% or more) delivery shortfalls for any two consecutive quarters, Cytori shall use its best efforts to increase production capacity provided the then current Forecasts of Lorem (taken together with other anticipated Product sales by Cytori) reasonably warrant such increased capacity.

3.3.7 [Reserved].

3.3.8 Failure of Supply. In the event Cytori is unable to, or fails to supply at least fifty percent (50%) of Lorem's reasonable requirements for the Celution Products for a period longer than four (4) months after the specified delivery date, or one hundred percent (100%) of Lorem's reasonable requirements for the Celution Products for a period longer than eight (8) months after the specified delivery date, and Cytori cannot provide Lorem with reasonably satisfactory assurances that such failures or delays have been or will be fully and completely eliminated (promptly), then Lorem shall be entitled to declare a "Failure of Supply" by written notice to Cytori of its intent to exercise its right to access the "Technology & Source Codes in Escrow". Then, ten (10) business days after delivery of the notice, Lorem shall be entitled to full use and access to the escrowed information for the purpose of self manufacture of the Celution Products for use in the Fields of Use in the Territory. Cytori shall use its best efforts to supply the Celution Products to Lorem from the date of the notice until Lorem is able to self manufacture the Celution Products. In the event Lorem begins self manufacture of the Celution Products, Lorem shall continue to be required to pay Cytori the License Fees and Royalty payments required by Sections 2.2.1 and 2.2.2, provided that Lorem shall be entitled to offset one hundred and fifty percent (150%) of the reasonable and documented expenses for developing the manufacturing capacity against such License Fees and Royalty Payments owed under Sections 2.2.1 and 2.2.2. These rights shall be Lorem's sole remedy for Cytori's failure of supply. Lorem's right to self manufacture Celution Products due to a Failure of Supply is expressly and strictly subject to absolute compliance with the Field of Use and Territorial restrictions of this Agreement.

3.3.9 Technology & Source Codes in Escrow. Within sixty days of the Effective Date of this Agreement, The parties shall enter into a mutually negotiated Escrow Agreement, comparable to Iron Mountain's standard "Three-Party Master Depositor Escrow Service Agreement", and any necessary supplemental agreements, with an agreed commercially reliable technology storage company (such as Iron Mountain) for the Celution Products manufacturing technology and software codes. The information stored shall be necessary and sufficient for a third party manufacturer to make the Celution Products independently of the original manufacturer and shall include all suppliers, vendors and third party manufacturer contacts & contracts. This information shall continue to be confidential between the Parties, and shall not be accessed by the non-manufacturing party except as expressly permitted in Section Section 3.3.8. Cytori shall be responsible for acknowledging the rights of the Lorem exercising its rights granted herein with respect to any third party, and shall fully cooperate with the exercise of these rights. Cytori shall be responsible for the start up fees payable to the Escrow provider (approximately \$4,000), and the parties shall share the annual maintenance fees (approximately \$1,800) equally thereafter.

3.4 Marketing & Supply Obligations and Restrictions.

3.4.1 Marketing Obligations of Lorem / Supply Obligations of Cytori. Lorem shall at all times use its best efforts to market Cytori Products within the Fields of Use in the Licensed Territories, and Cytori shall at all times use its best efforts to supply Cytori Products as ordered by Lorem hereunder in keeping with the requirements of Section 3.3. Notwithstanding the foregoing, Lorem's due diligence requirements for China for the first five (5) years from the Effective Date or three (3) years after receipt of regulatory approval in China (whichever is shorter) are as follows:

- (a) Lorem shall use its best efforts to gain regulatory approval in China to market and sell the Cytori Products in China for both non-vascular and Intravascular/Cardiac indications. In support of this effort Cytori shall establish partial manufacturing for the Celution Device and Consumable Cytori Products in the United Kingdom to establish regulatory country of origin designation in the U.K. Cytori shall also cooperate with Lorem's efforts to obtain approval in China with validated translations of Cytori documentation and advice on the regulatory framework in the EU.
- (b) In each of the first three (3) years after regulatory approval is obtained for intravascular use of the Celution Device in China, Lorem shall purchase a minimum of fifty (50) Celution Devices each year for the China market, and at least fifty (50) Consumable kits each year for each of the Celution Devices purchased that year and fifty (50) Consumable kits for each Device previously purchased for China.

3.4.2 Distributors, Sub-Distributors, Sublicensees of Lorem. Lorem shall at all times seek, and use its best efforts to maximize the profit margins of Lorem Vascular unless expressly agreed with Cytori in writing, excepting only the initial stocking order for China which may be offered in China at a price below Lorem's cost of goods from Cytori. Without limitation on the foregoing, Lorem agrees that it shall not enter into any sublicense, sales or distribution relationships with any company, person or other entity that is either directly or indirectly related to (via either family relationship, business relationship or other financial relationship) any officer, manager, director or shareholder in Lorem, or any of their Affiliates, or Lorem Affiliates, unless the relationship (including all proposed terms) are fully disclosed to and approved by Cytori in writing prior to finalizing such agreements.

3.5 Inventory Management and Shipment of Products.

3.5.1 Shipment. Unless otherwise specifically agreed between the Parties in writing, Cytori shall, at its own expense, procure from contract manufacturer(s), if any, shipment and delivery of Cytori Product(s) EXW – Ex Works (San Diego, to manufacturing subcontractor facilities, as interpreted in accordance with INCOTERMS 2010).

3.5.2 Title and Risk of Loss. Risk of loss and title to any Cytori Product(s) purchased by Lorem pursuant to this Agreement shall pass from Cytori to Lorem EXW shipping point.

3.5.3 Notice of Inability to Deliver Cytori Product(s). Cytori shall provide Lorem with immediate written notice if Cytori becomes aware that it will not be able to deliver the relevant Cytori Product(s) on or within three (3) days prior to the relevant Delivery Date specified in an accepted Order, or if Cytori becomes aware that only a portion of the relevant Cytori Product(s) can be delivered on or within three (3) days prior to the relevant Delivery Date specified in an accepted Order. Upon receipt by Lorem of such notice from Cytori, Lorem shall instruct Cytori to either (a) deliver such deliverable portion of the Cytori Product(s) in accordance with this Agreement and relevant Order, or (b) reschedule shipment of all or a portion of such Cytori Product(s). If Cytori delivers a portion of the Cytori Product(s) ordered under a certain Order pursuant to Lorem's instructions pursuant to item (a) of this Section 3.5.3, Cytori shall, at Cytori's sole cost and expense (including air transportation) and upon becoming able to complete such Order, promptly deliver all remaining undelivered Cytori Product(s) specified in such partially performed Order by air transportation, or such other means of transportation directed by and/or reasonably acceptable to Lorem.

3.6 Product Warranties.

3.6.1. Product Warranties. Cytori warrants to Lorem for a period that is the lesser of: (a) twenty-four (24) months from the Delivery Date of the relevant Cytori Product(s) by Cytori to Lorem; or (b) twelve (12) months from the date of delivery of such Cytori Product(s) by Lorem or its designee to the end-user or customer, (the applicable period referred to herein as the "**Warranty Period**"), that any such Cytori Product(s) sold by Cytori to Lorem hereunder shall:

- (i) operate in a manner that meets the relevant Cytori Product(s) specifications; and
- (ii) be free from defects, for reason(s) attributable to Cytori, in material, design and workmanship.

3.6.2 Warranty Obligations. During the Warranty Period, The Cytori Devices and Consumables shall each carry the limited warranty as specified in Schedule 3 hereto. Cytori Products manufactured by third parties (including various Cell/Tissue Bank products, shall have only the warranty as provided by the manufacturer of such products.

3.6.3 Disclaimer of Warranty. EXCEPT AS SPECIFICALLY SET FORTH IN THIS SECTION 3.6, CYTORI DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND THOSE ARISING FROM A COURSE OF DEALING. Lorem DOES NOT WARRANT THAT ALL DEFICIENCIES, ERRORS, DEFECTS OR NON-CONFORMITIES OF THE CYTORI PRODUCT(S) OR PARTS OR COMPONENTS THEREOF (WHETHER DIRECTLY OR INDIRECTLY) SUPPLIED BY Lorem CAN BE CORRECTED.

3.7 Obsolescence.

3.7.1 Discontinuance by Cytori. Cytori agrees and acknowledges that it has an obligation to manufacture, supply and support the Cytori Product(s) without interruption during the Term. If Cytori wishes to discontinue the manufacture and supply of any particular Cytori Product(s) during the Term, Cytori shall provide written notice of such to Lorem not less than four (4) months in advance of the last date such Cytori Product(s) can be ordered. Upon Lorem's receipt of any such discontinuance notice by Cytori, Cytori shall provide Lorem with the appropriate designation for a suitable replacement Cytori Product(s) as reasonably necessary to the use of the Cytori Products in the Fields of Use as herein contemplated by the parties. Cytori shall continue to provide support for Cytori manufactured discontinued products as required for a period of at least three years from the date of discontinuance.

3.7.2 Final Order. Prior to the effective date of the (a) the expiration or sooner termination of this Agreement, or (b) discontinuance of any Cytori Product(s) by Lorem under Section 3.7.1, Lorem may make, and Cytori agrees to accept, a final Order for the relevant Cytori Product(s) to be paid for and shipped during a period commencing on the date of any such expiration, sooner termination or discontinuance, and ending on the date that is six (6) months after such date of any such expiration, sooner termination or discontinuance.

3.8 Marketing, Licensing and Insurance.

3.8.1 Marketing Authority. Cytori retains the sole and exclusive right and authority to market, distribute and sell the Cytori Product(s) in all non-licensed Territories and/or Fields. Lorem retains the sole and exclusive right and authority to market, distribute and sell the Cytori Product(s) in the Fields of Use in the licensed Territories, provided that upon either parties reasonable request, the other Party shall, when reasonably practicable, allow the requesting party access to the general marketing research & activities in relation to the Cytori Product(s) to further the mutual expansion and development of Fields of Use.

3.8.2 Product Use Restrictions/Representations. Lorem understands and agrees that the Cytori Products which are labeled and intended for specific indications may cause injury or death if used for applications outside such specified labeling and instructions for use. Lorem agrees that only qualified trained and licensed healthcare professionals in the Territory will be provided authorization to use the Products in a manner consistent with all applicable laws and regulations.

3.8.3. False or Misleading Representations. Lorem shall make no false or misleading representations to customers or other persons with regard to the Cytori Products or Cytori. Cytori shall permit Lorem to externally link the Lorem website to the Cytori website, provided Cytori has the opportunity to review and approve the content of the Lorem website that refers to Cytori or its products (or utilizes Cytori Trademarks), which review and approval shall not be unreasonably delayed or withheld.

3.8.4. Rights In Marks. Except as expressly agreed by the Parties herein or elsewhere in writing, nothing in this Agreement shall be construed to grant either Party any rights in any Trademarks of the other Party. Notwithstanding the immediately preceding sentence, Cytori hereby authorizes Lorem, only for the purposes of labeling, marketing and selling the Cytori Product(s), to use the Cytori Product(s)-related Trademark(s) of Cytori in the conduct of the operation of the Fields of Use license. Use of specified Cytori Trademarks by Lorem, shall be expressly limited by the following terms of use:

(a) Use of Cytori Marks by Lorem. Cytori hereby grants to Lorem the exclusive right and license within the Fields of Use to use the specified Cytori Marks solely in connection with the promotion, sale and distribution of the Products in the Territory during the Term of this Agreement. Lorem may grant sublicenses to any third party, subject to the reasonable & prompt consent of Cytori, provided Cytori may not object to any sublicense grant reasonably related to Lorem's operations contemplated in the letter and spirit of this Agreement. Sublicensees must remain in full compliance with the terms of this Agreement, and any breach thereof in relation to the Cytori Marks shall be the responsibility of Lorem. All rights with respect to Cytori Marks and all other trademarks, service marks and trade names used by Cytori not specifically granted to Lorem in this Agreement shall be and hereby are reserved to Cytori.

(a) Acknowledgment of Ownership. Lorem acknowledges that (i) Cytori owns the Cytori Marks and all goodwill associated with or symbolized by Cytori Marks, (ii) Lorem has no ownership right in or to any Cytori Marks, and (iii) Lorem shall acquire no ownership interest in or to any of Cytori Marks by virtue of this Agreement. Lorem shall do nothing inconsistent with Cytori's ownership of the Cytori Marks and related goodwill and agrees that all use the Cytori Marks by Lorem shall inure to the benefit of Cytori. Nothing in this Agreement shall be deemed to constitute or result in an assignment of any Cytori Marks to Lorem or the creation of any equitable or other interests therein. Lorem shall not use any Cytori Marks in any manner as a part of its business, corporate or trade name or otherwise.

(b) Form of Use. Lorem shall use Cytori Marks only in the form and manner as reasonably agreed from time to time by Cytori. Lorem shall mark each Product and/or all advertising, promotional or other materials bearing any of Cytori Marks with such notices as Cytori may require, including, but not limited to, notices that Cytori's Marks are trademarks of Cytori and are being used with the permission of Cytori.

(c) Submissions. Lorem shall submit to Cytori for its written approval before any use is made thereof, representative samples of all Products, stationery, invoices, catalogs, brochures, packages, containers, and advertising or promotional materials bearing any of Cytori Marks which Lorem or its Agents prepare. Lorem shall not make any use of Cytori Marks unless and until it receives Cytori's prior written approval. Cytori shall have the absolute right to approve or reject any proposed use(s) of any of Cytori Marks, in its sole discretion.

(d) Registration. Cytori shall have the sole and exclusive right (but not the obligation) to obtain trademark registration in the Territory for any Cytori Marks (or any confusingly similar Marks) or to take such other action with respect to the Cytori Marks as it deems appropriate.

(e) Infringement Information. Lorem shall notify Cytori promptly of any unauthorized use of Cytori Marks or of any mark confusingly similar thereto which comes to its attention. Cytori shall have the sole right to determine whether or not any action shall be taken against any such infringement.

3.8.5. Software Rights. With respect to any software products incorporated in or forming a part of the Products hereunder, Cytori and Lorem intend and agree that such software products are being licensed and not sold, and that the words "purchase", "sell" or similar or derivative words are understood and agreed to mean "license", and that the word "Lorem" or similar or derivative words are understood and agreed to mean "licensee" with respect to the software component. Notwithstanding anything to the contrary contained herein, Cytori or its licensor, as the case may be, retains all rights and interest in software products provided hereunder.

3.8.6. Grant of Rights. Cytori hereby grants to Lorem a royalty-free, non-exclusive license, to use software provided hereunder solely for end-users business purposes on the hardware products provided hereunder and to use the related documentation solely for the purpose of the use of Products as authorized under this Agreement. This license terminates when Lorem lawful possession of the hardware products provided hereunder ceases, unless earlier terminated as provided herein. Lorem agrees to hold in confidence and not to sell, transfer, license, loan or otherwise make available in any form to third parties the software products and related documentation provided hereunder. Neither may Lorem disassemble, decompile or reverse engineer, copy, modify, enhance or otherwise change or supplement the software products provided hereunder without Cytori's prior written consent. Cytori will be entitled to terminate this license if Lorem fails to comply with any term or condition herein. Lorem agrees, upon termination of this license, immediately to return to Cytori all software products and related documentation provided hereunder and all copies and portions thereof.

3.8.7. Third Party Software. Certain of the software products provided by Cytori may be owned by one or more third parties and licensed to Cytori. Accordingly, Cytori and Lorem agree that such third parties retain ownership of and title to such software products.

3.8.8 Insurance. Each Party will, maintain adequate commercial general liability insurance and product liability insurance, in amounts which are reasonable and customary within the industry. Subject to reasonable insurance policy limitations and exclusions, such product liability insurance of each Party shall insure against all liability arising out of the use, manufacture (including packaging and delivery), sale, offer for sale, importation, distribution, marketing and promotion of the Cytori Product(s) throughout the world.

3.9 Country of Manufacture.

3.9.1 Country of Origin Certification. Upon Lorem request, Cytori shall provide Lorem with an appropriate certification stating the country of origin for Cytori Product(s), sufficient to satisfy the requirements of the customs authorities of the country of receipt and any applicable export licensing regulations, including those of the United States, United Kingdom, Germany, Europe, and Japan.

3.9.2 Customs Authorities; Export Regulations. Lorem shall notify Cytori of any requirement from applicable customs authorities, and Lorem will comply in a timely manner with such requirements. Upon Lorem's reasonable request, Cytori shall assist Lorem with certification stating the country of origin to satisfy the requirements of the customs authorities of the country of receipt and the countries of Lorem's distribution operations.

3.10 Force Majeure Events.

3.10.1 Force Majeure. To the extent that either Party to this Agreement is temporarily unable to perform its obligations hereunder, in whole or in part, due to causes beyond such Party's reasonable control, including, but not limited to, acts of God, acts of war, acts of terrorism, civil disturbance, governmental action, strikes, fire, flood, typhoon, peril or accident at sea, inability to secure materials and transportation or facilities, walkouts or lock-outs or other labor disputes beyond the reasonable control of such Party (each, a "**Force Majeure Event**"), the time for performing such Party's obligations will be extended until such time (a) as the Force Majeure Event has been resolved or otherwise mitigated or eliminated, or (b) as mutually agreed by the Parties, and in case of either (a) or (b), so as not to materially impede or prevent performance of such Party's obligations; provided, however, that the Party claiming the benefit of this provision shall provide to the other Party prompt written notice and reasonable evidence of the occurrence of such Force Majeure Event, and shall cooperate with the other Party in taking all such commercially reasonable actions as may be necessary or appropriate to mitigate, avoid or lessen the adverse effects of such Force Majeure Event, as it may relate to the performance of each Party's respective obligations hereunder. In no event shall a Party's inability to pay any sums due hereunder or otherwise perform any of its financial obligations hereunder be independently deemed to be a Force Majeure Event. Until such Force Majeure Event is so resolved, mitigated or eliminated, or until expiration of the time period mutually agreed by the Parties, the Party so unable to perform its obligations shall not be deemed to be in default under or in breach of this Agreement; further provided that the Parties shall in any event be required to perform all other obligations hereunder which are reasonably capable of being performed during the continuance of such Force Majeure Event. In the event that the Parties do not agree upon the occurrence of a Force Majeure Event, then the matter shall be submitted to arbitration pursuant to the provisions of Section 4.3 hereof. Subject to the foregoing, a Force Majeure Event may include (a) the occurrence of any pandemic, epidemic or prevalent disease or illness with an actual or probable threat to human life, including, without limitation, atypical pneumonia or Severe Acute Respiratory Syndrome (SARS), or avian influenza, or (b) adherence to any travel restriction, warning or advisory issued in relation thereto by the Government of the United States, the World Health Organization (WHO) or the U.S. Centers for Disease Control (CDC), or (c) any quarantine or similar measure taken in relation thereto by any governmental authority to prevent the spread of any communicable disease, or (d) any unavailability of any resources or services resulting directly from any of the foregoing, or (e) impossibility to deliver Cytori Product(s) due to export/import restriction derived from a governmental regulation that would make the export/import act illegal. In the event that a Force Majeure Event continues for three (3) months or longer, either Party may terminate and cancel any and all outstanding Orders, regardless as to whether accepted by Cytori, by written notice to the other Party.

3.11 TRAINING.

3.11.1 Initial & Follow-up Training. Prior to launch of marketing and sales efforts by Lorem, Cytori shall conduct training for the designated and reasonably qualified Lorem staff or designees on how to set up, operate and use the Celution Products as contemplated to be used pursuant to the license granted herein. Lorem designated personnel shall also be trained in the installation, maintenance and basic field repairs of the Cytori Products, including software upgrades and troubleshooting. This training shall be conducted at least twice in the first year after the Effective Date at the Lorem designated facilities in China, Malaysia or in San Diego, CA or in licensed Territories as desired by Lorem. During the second year after the Effective Date, Cytori agrees to provide additional or refresher Cytori Product training from time to time as reasonably requested, provided such training shall occur in San Diego, CA or at such other location as mutually agreed by Cytori and Lorem.

After the first two years, Cytori shall make additional training available as reasonably required for a modest cost based fee, as it is the express expectation of the Parties that Lorem shall be responsible for training its own employees and its customers after the first two years, except in the case where new products are introduced by Cytori of the complexity that requires re-certification for all persons involved in the installation, maintenance or repair of the Cytori Products. In the Case of such new Cytori Products, Cytori shall make additional training available free of charge in locations as reasonably agreed.

3.11.2 Clinical Training and Case Support. During the first year after the Effective Date, Cytori shall also provide reasonable training to Lorem employees or designees as required to train competent and properly qualified medical personnel to utilize the Cytori Products clinically in the Fields of Use. In any event, Cytori will provide in person case support for no less than *** separate clinical cases within the first two years from the Effective Date, at times and locations as reasonably and mutually agreed. Cytori shall also collaborate with and assist Lorem in training initial Centers of Excellence in China, and in access to international guest surgeons experienced in various therapeutic fields of use for the Cytori Products.

3.12 REGULATORY.

3.12.1 Regulatory Matters. Lorem shall be responsible for obtaining all necessary government approvals, registrations, consents, licenses and permits of the Territory that are required for the marketing and sale of the Cytori Products in the Fields of Use of the Territory ("Approvals"), and for complying with any and all applicable statutory, administrative or regulatory requirements of the Territory for product labeling and packaging, product documentation such as traceability, samples, sales literature and records, and documentation for recalls including but not limited to product serial numbers for each product sold identifiable by account and date of sale, which documentation shall be maintained on a permanent basis by Lorem notwithstanding termination or expiration of this Agreement. Lorem shall also maintain records of all product registrations with any government agency or health authority, or any registration, approvals, or filing of this Agreement. Without limiting the generality of the foregoing:

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

(a) Lorem shall bear all costs, fees and expenses associated with obtaining regulatory approvals and for complying with laws of the Territory. Notwithstanding the forgoing, in the event and to the extent that Cytori has already obtained regulatory Approvals in the Territory, Lorem shall bear no expense for these or other Cytori efforts to obtain the same.

(b) Lorem shall promptly provide to Cytori, upon Cytori's request, such evidence that Cytori shall require, including, but not limited to, an opinion of any independent attorney licensed to practice law in the Territory confirming that all Approvals necessary to import and sell the Products in the Territory have been obtained and that Lorem's sales of the Products are in compliance with all Laws in the Territory. If such evidence is not received by Cytori, Cytori shall be entitled to hold shipment of the Products until such evidence is received.

(c) Notwithstanding the foregoing, and subject to the Lorem's ongoing commitment of Confidentiality (as specified in the Mutual NDA) for all regulatory information provided by Cytori, Cytori shall provide access to its regulatory files, the Cytori Products, and relevant clinical data as reasonable or necessary for Lorem in its regulatory activities. Cytori shall also from time to time provide reasonable regulatory counsel and advice from its internal regulatory team to aid Lorem's qualified regulatory personnel in the application and use of the Cytori regulatory materials.

3.13 COMPLIANCE WITH LAWS.

3.13.1 Corruption. Each party will comply with all applicable laws and regulations with respect to their activities contemplated herein. Each Party agrees that it will not knowingly assist or participate in any violation of laws or regulations applicable to Cytori or Lorem, including the United States Foreign Corrupt Practices Act and the UK Anti-Bribery Act, and any similar anti-bribery or anti-corruption laws applicable to its business activities. For purposes of clarity, each party represents and warrants that it will comply with all laws applicable to the conduct of business practices, including those that prohibit gratuities, inducements, or certain other payments; including, payments of money or anything of value offered, promised or paid, directly or indirectly, to any government official, or public or political officer, or other person to induce such person or official to use their influence with a government or instrumentality to obtain an improper business advantage for Cytori or Lorem in relation to this Agreement. Lorem acknowledges that Cytori is subject to certain United States laws, including the Foreign Corrupt Practices Act of 1977 and any of its amendments, which may apply to activities carried out on Cytori's behalf outside the United States of America. Neither Party will take nor omit to take any action if such act or omission would cause Cytori or Lorem to be in violation of any such laws. Each party shall maintain, and upon reasonable request provide to the other party, sufficient information to support its compliance with such laws, and to support the other parties responses to any investigation by a governmental authority. The parties acknowledge and agree that compliance with this Section 3.13.1 is of material importance to this contract, and that any breach of this Section may be considered grounds for termination of the Agreement.

3.13.2 United States Export Controls. Cytori's sale and delivery of Products to Lorem shall be subject in all respects to such laws and regulations of the United States of America (including, but are not limited to, those of the Export Administration Regulations of the U.S. Department of Commerce (the "EAR"), and the laws of the Territory (as applicable) which may restrict or require licenses for the export of Items from the United States (and/or the Territory) and their re-export from other countries) as shall from time to time govern the sale and delivery of goods abroad by persons subject to the jurisdiction of the Territory and the U.S. Lorem shall not directly or indirectly export, re-export or transship any of the Products, even though otherwise permitted by this Agreement or by subsequent authorization from Cytori, except as shall be permitted by the applicable laws in effect from time to time. Upon the reasonable request by Cytori, Lorem shall give written assurances against such export, re-export or transshipment.

3.14 QUALITY & PACKAGING.

3.14.1 Product Quality. Cytori and each of its Assignees shall be responsible for compliance with present and future applicable statutes, laws, ordinances and regulations of the United States and the European Economic Community now or hereafter in effect relating to the manufacture and quality of the Cytori Products (Celution Devices and Consumables). Furthermore, Cytori and each of its Assignees shall: (i) maintain and comply with inspection and process control systems with respect to the manufacture of Products as required by applicable law, and (ii) maintain a documented quality system that encompasses the following areas: how quality documents are generated and controlled, how manufacturing processes are controlled, how special or automated processes are validated, how suppliers are controlled, how test equipment is calibrated and controlled, handling of defective material, how corrective action processes are controlled, and how statistical process control is implemented, The ISO 13485:2003 Standard and the FDA Quality System Regulation (Code of Federal Regulations 21 CFR Part 820) should be referenced as examples of Quality System structure and discipline. Cytori agrees that it shall at all times use its best efforts to remain in compliance with all applicable Laws in the United States and European Economic Community applicable to a medical device manufacturer.

3.14.1 Product Packaging. Cytori agrees to cause the Cytori Products to be packed pursuant to its standard export procedure and its quality systems, which procedure and systems will be compliant with US & EU industry standards and all applicable US & EU laws and regulations. The above notwithstanding, Lorem shall be responsible for advising Cytori with respect to necessary compliance information sufficient to comply with local packaging regulations and other requirements in the Territory.

3.15 PATENT OWNERSHIP AND RIGHTS TO INVENTIONS.

3.15.1 No Ownership By Lorem. Lorem shall not be deemed by anything contained in this Agreement or done pursuant to this Agreement to acquire any right, title or interest in or to any Cytori Intellectual Property Rights, including its Patents, trade secrets or technology, or any patent now or hereafter covering or applicable to any Cytori Product, nor in or to any invention or improvement now or hereafter embodied in any Cytori Product, whether or not such invention or improvement is patentable under the laws of any country. "Cytori Material" shall include the Cytori Products, and any services or training provided by Cytori related to the use of the Cytori Products, Cytori Intellectual Property Rights, Cytori Regulatory Information and any other Cytori Confidential Information.

3.15.2 Inventions. Cytori and Lorem hereby agree that any discoveries, improvements, inventions, processes, techniques, know-how and data, whether or not patentable, made or conceived or reduced to practice or learned by Lorem and/or any of Lorem's Affiliates or sublicensees under this Agreement ("Lorem Party(ies)"), that modifies or incorporates the Cytori Materials (such discoveries, improvements, inventions, processes, techniques, know-how and data are collectively referred to as "Lorem Inventions") are hereby granted to and assigned perpetually and exclusively to Cytori world-wide, and such Lorem Inventions shall be included in the license to Lorem in Section 2.1 of this Agreement for use in the Territory without any additional fee or royalty. Lorem hereby agrees to promptly execute any required assignments or other documents now or hereafter reasonably necessary to perfect Cytori's ownership rights in this Agreement.

3.15.3 Invention Disclosure. Lorem shall disclose in writing to Cytori all Lorem Inventions that are directly related to the Cytori Materials, whether or not patentable, within thirty (30) days of identification or development or within thirty (30) days of Lorem's written receipt of same from any Lorem Party, as the case may be). Lorem, Cytori and the Lorem Parties shall cooperate to the extent reasonably necessary in the preparation, filing and prosecution of any patent applications.

3.16 ACCRUED LIABILITIES. The expiration or sooner termination of Section 3 of this Agreement for any cause shall not release any Party hereto from any liability which, at the time of such expiration or termination, has already accrued against such Party (or which thereafter may accrue against such Party in respect of any act or omission occurring prior to such expiration or termination), nor shall any such expiration or termination of this Agreement affect in any way the survival of any right, duty or obligation of any Party hereto which is expressly stated elsewhere in this Agreement to survive expiration or earlier termination hereof.

3.17 **EXAMINATION AND AUDIT OF LOREM BOOKS & RECORDS.** Lorem (a) shall maintain for at least five (5) years its books, records, contracts and accounts relating to the marketing and sale of the Products, including, without limitation, information concerning customer accounts, inventory levels, unit sales, historical Cytori Product sales prices, competitor information, market trends and strategies, and promotional activities (collectively, "Lorem Information"), and (b) shall permit examination thereof at all reasonable times by Cytori. Lorem shall allow representatives of Cytori at any reasonable time to (c) examine Lorem's place(s) of businesses and Lorem's inventory of the Products, and (d) audit all Lorem Information connected with the sale of Products. Lorem shall provide Cytori with copies of any documents requested by Cytori as a result of such examination or audit. In addition, Lorem's (and each of its subsidiaries) books and records shall be audited no less than annually by a professional, reputable and accredited audit firm such as KPMG LLP, and Cytori shall be provided full and unredacted copies of all audit reports generated by such firm within five (5) business days of their presentation to Lorem.

3.18 **TREATMENT OF CONFIDENTIAL INFORMATION.** All Confidential Information disclosed by one Party to another in the course of this Agreement shall be maintained confidential in accordance with the Mutual Nondisclosure Agreement executed between the Parties concurrently herewith. As such, the Confidential Information may not be used or disclosed by the receiving party except as necessary to perform its rights or responsibilities specified in this Agreement. Upon expiration or sooner termination of this Agreement, the Receiving Party shall immediately cease all use of the Disclosing Party's Confidential Information and shall, in accordance with Disclosing Party's reasonable written instructions, promptly return to Disclosing Party or destroy all Confidential Information of the Disclosing Party, including, without limitation, all copies (in electronic form or otherwise) in Receiving Party's possession and any notes or memoranda that contain Confidential Information of the Disclosing Party. The Receiving Party shall certify in a writing signed by an officer or director of the Receiving Party that all such Disclosing Party Confidential Information has been returned, deleted or destroyed.

3.19 **LIMITATION OF LIABILITY.**

TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL ANY PARTY BE LIABLE TO THE OTHER PARTY OR TO ANY THIRD PARTY FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES OF ANY NATURE (INCLUDING, BUT NOT LIMITED TO, DAMAGES FOR LOSS OF BUSINESS, LOSS OF PROFIT OR REVENUES, LOSS OF USE OF THE PRODUCTS OR ANY ASSOCIATED EQUIPMENT, COST OF CAPITAL, COST OF SUBSTITUTE PRODUCTS, FACILITIES OR SERVICE, DOWNTIME, PERSONAL PROFITS, BUSINESS INTERRUPTION, OR ANY OTHER PECUNIARY LOSS) ARISING OUT OF OR IN ANY WAY RELATED TO THE PARTIES' PERFORMANCE OR FAILURE TO PERFORM UNDER THIS AGREEMENT, WHETHER SUCH LIABILITY IS ASSERTED ON THE BASIS OF CONTRACT, TORT (INCLUDING NEGLIGENCE OR STRICT LIABILITY) OR OTHERWISE, EVEN IF THE OTHER PARTY HAS BEEN WARNED OF THE POSSIBILITY OF SUCH DAMAGES. EXCEPT TO THE EXTENT SPECIFICALLY PROVIDED OTHERWISE IN THIS AGREEMENT, ALL REMEDIES PROVIDED FOR HEREUNDER, INCLUDING, BUT NOT LIMITED TO, THE RIGHT TO TERMINATE THIS AGREEMENT AND ALL OF THE REMEDIES PROVIDED BY LAW (AND NOT EXCLUDED PURSUANT TO THE FOREGOING SENTENCE), SHALL BE DEEMED CUMULATIVE AND NON EXCLUSIVE.

4. MISCELLANEOUS PROVISIONS

- 4.1 Export Regulations. Each Party shall be responsible for observing and abiding by any and all export control laws and regulations (including, without limitation, any and all costs associated therewith) applicable to the Cytori Product(s).
- 4.2 Governing Law. This Agreement shall be governed in all respects by the laws of New York without regard to provisions regarding choice of laws.
- 4.3 Dispute Resolution. All disputes arising out of or in connection with this Agreement, or any relationship created by or in accordance with this Agreement, shall be finally settled under the Rules of the American Arbitration Association (the “**Rules**”) by three arbitrators. Judgment on the award rendered by the panel of arbitrators shall be binding upon the Parties and may be entered in any court having jurisdiction thereof. Lorem shall nominate one arbitrator and Cytori shall nominate one arbitrator. The arbitrators so nominated by Lorem and Cytori, respectively, shall jointly nominate the third arbitrator within fifteen (15) days following the confirmation of arbitrators nominated by Lorem and Cytori. If the arbitrators nominated by Lorem and Cytori cannot agree on the third arbitrator, then such third arbitrator shall be selected as provided in the Rules. The place of the arbitration and all hearings and meetings shall be San Diego, USA, unless the Parties to the arbitration otherwise agree. The arbitrators may order pre-hearing production or exchange of documentary evidence, and may require written submissions from the relevant Parties hereto, but may not otherwise order pre-hearing depositions or discovery. The arbitrators shall apply the laws of New York as set forth in Section 5.2; provided, however, that the Federal Arbitration Act shall govern. The language of the arbitral proceedings shall be English. The arbitrators shall not issue any award, grant any relief or take any action that is prohibited by or inconsistent with the provisions of this Agreement.

No arbitration pursuant to this Section 5.3 shall be commenced until the Party intending to request arbitration has first given thirty (30) days written notice of its intent to the other Party, and has offered to meet and confer with one or more responsible executives of such other Party in an effort to resolve the dispute(s) described in detail in such written notice. If one or more responsible executives of the other Party agree, within thirty (30) days after receipt of such written notice, to meet and confer with the requesting Party, then no arbitration shall be commenced until the Parties have met and conferred in an effort to resolve the dispute(s), or until sixty (60) days has elapsed from the date such written notice has been given.

- 4.4 CLAIMS & INDEMNIFICATION. Lorem shall promptly notify Cytori of any potential or actual litigation or governmental activity in the Territory relating to the Products or their use by Lorem of which Lorem becomes aware. Lorem shall provide such notice as soon as possible, but not to exceed five (5) business days from the time that Lorem learns of a threatened claim or litigation activity.
- (a) Indemnification by Lorem. Except to the extent Cytori is obligated to indemnify, defend and hold Lorem harmless hereunder, Lorem will indemnify, defend and hold harmless Cytori and its affiliates, officers, directors and employees (the "Cytori Indemnified Parties") from any claim, liability, loss, damage, lien, judgment, expense and cost (including reasonable attorneys' fees and other litigation expenses) with respect to any 3rd party claims against a Cytori Indemnified Party arising from: (a) Lorem's operations, or those of its sublicensees and/or customers, and any Lorem facilities; (b) Lorem' or any sublicensees or customers use of the Cytori Products outside the Fields of Use; (c) Lorem' and Lorem managed facilities failure to comply with applicable Laws in the Territory; or (d) the negligence or willful misconduct of Lorem, the Lorem managed facilities or subcontractors, or Lorem Indemnified Parties in the handling, storing, marketing, sale or disposal of the Cytori Products. Nothing in the foregoing shall obligate Lorem to indemnify Cytori to the extent a third party claim is the result of a material breach by Cytori of this Agreement, or to the extent the claim is one for which Cytori is obliged to indemnify Lorem hereunder (collectively, "Cytori Claims").
- (b) Indemnification by Cytori. Except to the extent Lorem is obligated to indemnify, defend and hold Cytori harmless hereunder, Cytori will indemnify, defend and hold harmless Lorem and its affiliates, officers, directors and employees (the "Lorem Indemnified Parties") from any claim, liability, loss, damage, lien, judgment, expense and cost (including reasonable attorneys' fees and other litigation expenses) with respect to any 3rd party claims against an Lorem Indemnified Party arising from: (a) any breach of Cytori's warranties set forth in this Agreement; or (b) products liability claims or the negligence or willful misconduct of Cytori or Cytori Indemnified Parties in the handling, labeling, manufacture, inspection, packaging, storage and delivery of Cytori Products to Lorem. Nothing in the foregoing shall obligate Cytori to indemnify Lorem to the extent any such claim is the result of a material breach by Lorem of Lorem' obligations under this Agreement, or to the extent the claim is one for which Lorem is obliged to indemnify Cytori hereunder. (collectively, "Lorem Claims").
- (c) Procedure. Indemnifying party shall have the right to control the defense of any claim for which indemnification is tendered provided it promptly assumes such defense and selects counsel reasonably acceptable to the party to be indemnified, and provided reasonable assurances with respect to such defense can be provided. The indemnified party shall cooperate in the defense and shall have the right to consent to any settlement of the claims provided that such consent may not be unreasonably withheld or delayed in the event that the proposed settlement fully releases the indemnified party from all Claims.

- 4.5 SUCCESSORS AND ASSIGNS. Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be fully binding upon, the successors, assigns, heirs, executors and administrators of the Parties hereto whose rights or obligations hereunder are affected by such amendments.
- 4.6 ENTIRE AGREEMENT. This Agreement and the attachments, schedules and exhibits hereto, which are hereby expressly incorporated herein by this reference, constitute the entire understanding and agreement between the Parties with regard to the subject matter hereof and thereof, and supersedes, cancels and annuls in its entirety any and all prior or contemporaneous agreements and understandings, express or implied, oral or written among them with respect thereto. No alteration, modification, interruption or amendment of this Agreement shall be binding upon the Parties unless in writing designated as an amendment hereto, and executed with equal formality by each of the Parties.
- 4.7 NOTICES. Except as otherwise expressly provided herein, all notices, requests, waivers and other communications made pursuant to this Agreement shall be in writing and shall be deemed to have been duly given (a) when hand delivered to the other Party; (b) when received, if sent by facsimile at the address and number set forth below, with a written confirmation copy of such facsimile sent the next business day in accordance with (c) below; (c) the second business day after deposit with a national overnight delivery service, postage prepaid, addressed to the other Party as set forth below, provided that the sending Party receives a confirmation of delivery from the delivery service provider; or (d) if earlier, when actually received.

To Cytori:	To Lorem:
3020 Callan Road, San Diego, CA 92121, U.S.A.	Level 12, 2 Queen Street, Melbourne 3000, Australia
Attn: Christopher J. Calhoun	Attn: Kian Thiam Lim
Fax: 858-458-0995	Fax: +613 9678 0088

- A Party may change or supplement its address set forth above, or may designate additional addresses, for purposes of this Section 4.6, by giving the other Party written notice of the new address in the manner set forth above.
- 4.8 AMENDMENTS AND WAIVERS. No term or provision of this Agreement may be amended, waived, discharged or terminated orally but only by an instrument in writing signed by the Party against whom the enforcement of such amendment, waiver, discharge or termination is sought. Any waiver shall be effective only in accordance with its express terms and conditions.

- 4.9 CUMULATIVE REMEDIES. Unless expressly so stated in this Agreement in respect of any particular right or remedy, the rights and remedies herein provided are cumulative and not exclusive of any rights or remedies provided by law.
- 4.10 TITLES AND SUBTITLES. The titles of the sections and subsections of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement.
- 4.11 RELATIONSHIP OF PARTIES. This Agreement shall not be deemed to constitute either Party, the agent, the partner, the licensee, the affiliate or the representative of the other Party, and neither Party shall represent to any third party that it has any such relationship or right of representation.
- 4.12 PRESS RELEASE. No public announcements or press releases shall be issued by either Party regarding this Agreement or any of the activities engaged in by the Parties or Lorem pursuant to this Agreement without the prior written approval of the other Party; provided, however, that either Party shall have the right to make such public disclosure as may be necessary or appropriate to comply with applicable securities or other laws.
- 4.13 COUNTERPARTS. This Agreement may be executed by facsimile signature in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.
- 4.14 SEVERABILITY. Should any provision of this Agreement be determined to be illegal or unenforceable, such determination shall not affect the remaining provisions of this Agreement.






IN WITNESS WHEREOF, the Parties have executed this Amended and Restated License/Supply Agreement as of the Effective Date.

CYTORI THERAPEUTICS, INC.	LOREM VASCULAR, PTY. LTD.
By: <u>/s/ Christopher J. Calhoun</u>	By: <u>/s/ Kian Thiam Lim</u>
Christopher J. Calhoun	Kian Thiam Lim
Title: CEO	Title: Director
<u>Date: January 30, 2014</u>	<u>Date: January 30, 2014</u>

LIST OF SCHEDULES

Schedule 1: Description of Cytori Products
Schedule 2: Initial Pricing
Schedule 3: Limited Warranty

SCHEDULE 1
DESCRIPTION OF CYTORI PRODUCTS

Product Name	Image	Description
Celution 800/IV Device		An automated, electromechanical device containing multilingual, interactive software that facilitates the extraction and concentration of ADRCs, using validated algorithms programmed into the device's software, standardizing tissue disaggregation, centrifugation and therapeutic- specific processes.
Celution 805/IV Consumable Set		A sterile, single-use set used with the Celution Device to process tissue and extract ADRCs within a closed system.
Celase Reagent		Celase® is a proprietary enzyme blend that releases ADRCs from the extracellular matrix of adipose tissue, optimized for use with the Celution device and consumable set. Celase is a sterile, pharmaceutical grade, mammalian-free reagent that is manufactured in compliance with Good Manufacturing Practices (GMP) standards.
Intravase Reagent or Reagent B		Intravase® is a sterile, GMP-grade secondary reagent used with the Celution System to prepare the Celution cell output for safe intravascular delivery. Intravase is a highly purified product to assure the lowest levels of impurities. Intravase is provided as a single-use unit which consists of a clear glass vial within a protected canister
Cytori 200/CK Convenience Kit		The Cytori 200/CK Procedure Pack contains all necessary components for a single Celution procedure, including ancillary products for tissue collection, tissue processing, and delivery. The ready-to-use components are single-use, minimizing the risk of contamination for patients, healthcare staffs, surgeons, and system operators.
Cytori 530/IS Tissue Collection Instrument Set		The Tissue Collection Instrument Set contains a collection of autoclavable components required for liposuction (200-360mL of tissue) under local anesthesia using a hand-held syringe.

CYTORI CELL/TISSUE BANK PRODUCTS- FOR FIELDS OF USE



COMMON PART NAME	TITLE/DESCRIPTION
---------------------	-------------------

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

**Related banking products not included that
must be purchased separately by
the customer:**

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

SCHEDULE 2**INITIAL PRICING****1. INITIAL PRICING FOR CHINA, HONG KONG, MALAYSIA:**

INTRAVASCULAR PRODUCTS	PRICES
Celution 800/IV Device	***
Celution 805/IV Consumable Set	***
Cytori 200/CK Convenience Kit	***
Cytori 530/IS Tissue Collection Instrument Set	***

NON-VASCULAR PRODUCTS	PRICES
Celution 800/CRS Device	***
Celution 805/CRS Consumable Set	***
Cytori 200/CK Convenience Kit	***
Cytori 530/IS Tissue Collection Instrument Set	***

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

2. INITIAL PRICING FOR AUSTRALIA & SINGAPORE:

INTRAVASCULAR PRODUCTS	PRICES
Celution 800/IV Device	***
Celution 805/IV Consumable Set (includes Convenience Kit)	***
Cytori 530/IS Tissue Collection Instrument Set	***

NON-VASCULAR PRODUCTS	PRICES
Celution 800/CRS Device	***
Celution 805/CRS Consumable Set (includes Convenience Kit)	***
Cytori 530/IS Tissue Collection Instrument Set	***

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

SCHEDULE 3

LIMITED WARRANTY

LIMITED WARRANTY. CYTORI Therapeutics, Inc. (CYTORI) warrants that the Celution Devices and Celution Consumable Products will operate substantially in conformance with CYTORI's published specifications and be free from defects in material and workmanship, when subjected to normal, proper and intended usage by properly trained personnel, for a period of one (1) year from the date of shipment to end user (or "Buyer"), but in no event longer than two (2) years from the original Delivery Date from Cytori, whichever occurs first (the "Warranty Period"). CYTORI agrees during the Warranty Period, provided it is promptly notified in writing upon the discovery of any defect and further provided that all costs of returning the defective Products to CYTORI are pre-paid by Buyer, to repair or replace, at CYTORI's option, defective Products so as to cause the same to operate in substantial conformance with said specifications. Replacement parts may be new or refurbished, at the election of CYTORI. All replaced parts shall become the property of CYTORI. Shipment to Buyer shall be paid for by CYTORI during the Warranty Period. Lamps, fuses, bulbs and other expendable items are expressly excluded from this limited warranty. Buyer shall not return a non-conforming or malfunctioning Product having a risk of causing biological hazard to Cytori. In such case, Buyer must retain such Product, and Contact Cytori for further assistance. In no event shall CYTORI have any obligation to make repairs, replacements or corrections required, in whole or in part, as the result of (i) normal wear and tear, (ii) accident, disaster or event of force majeure, (iii) misuse, fault or negligence of or by Buyer, (iv) use of the Products in a manner for which they were not designed, (v) causes external to the Products such as, but not limited to, power failure or electrical power surges, (vi) improper storage of the Products or (vii) use of the Products in combination with equipment or software not supplied by CYTORI. If CYTORI determines that Products for which Buyer has requested warranty services are not covered by the warranty hereunder, Buyer shall pay or reimburse CYTORI for all costs of investigating and responding to such request at CYTORI's then prevailing time and materials rates. CYTORI will provide repair services or replacement parts that are not covered by the warranty during the Warranty Period subject to Buyer's payment to CYTORI at CYTORI's then prevailing time and materials rates for such repairs. ANY DAMAGE CAUSED BY UNAUTHORIZED INSTALLATION, MAINTENANCE, REPAIR, SERVICE, RELOCATION OR ALTERATION TO OR OF, OR OTHER TAMPERING WITH, THE PRODUCTS PERFORMED BY ANY PERSON OR ENTITY OTHER THAN CYTORI (OR CYTORI'S CERTIFIED DESIGNEES) WITHOUT CYTORI'S PRIOR WRITTEN APPROVAL, OR DAMAGE CAUSED BY USE OF REPLACEMENT PARTS NOT SUPPLIED BY CYTORI, SHALL IMMEDIATELY VOID AND CANCEL ALL WARRANTIES WITH RESPECT TO SUCH DAMAGE